<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.63, http://www.edgar-online.com -->
<TITLE> SOLIGENIX, INC. (Form: 10-K, Received: 03/24/2016 07:34:01) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_RESULTS_OF_OPERATIONS **FIS_FINANCIAL_STATEMENTS **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_NAME_AND_TITLE **FIS_COMPENSATION **FIS_COMPENSATION_TABLE **FIS_OPTIONS_AGGREGATE **FIS_SECURITY_OWNERS **FIS_BENEFICIAL_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_SIGNATURES **FIS_BALANCE_SHEET **FIS_INCOME_STATEMENT **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_SUBSEQUENT_EVENTS **FIS_AUDITORS_OPINION FIS_EXHIBIT_10 FIS_EXHIBIT_10_2 FIS_EXHIBIT_21 **FIS_SUBSIDIARIES FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 FIS_EXHIBIT_32_2 **FIS_CERTIFICATION_4 ">
<META NAME="DETECTED PAGES" CONTENT="146">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="F10K2015_SOLIGENIXINC_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 2PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-SIZE: 12">
<B>
	UNITED STATES SECURITIES AND EXCHANGE
	COMMISSION
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 12">
<B>
	Washington,
	D.C. 20549
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 14">
<B>
	FORM
	10-K
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	(Mark One)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ANNUAL
	REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIESE EXCHANGE ACT OF 1934.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the Fiscal Year Ended
<B>
	December
	31, 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TRANSITION REPORT PURSUANT TO
	SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	For the transition period from ____________
	to ____________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	Commission File No. 000-16929
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 14">
<B>
	SOLIGENIX, INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	(Exact name of registrant as specified in its
	charter)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 49%; BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Delaware
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 49%; BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	41-1505029
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	(State or other jurisdiction of
<BR>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	incorporation or organization)
</P>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	(I.R.S. Employer
<BR>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	Identification Number)
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	29 EMMONS DRIVE, SUITE C-10
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	PRINCETON, NJ
</B>
</P>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	08540
</B>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(Address of principal executive offices)
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT; WIDTH: 25%">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; WIDTH: 50%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	(609) 538-8200
</B>
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT; WIDTH: 25%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	(Registrant&rsquo;s
	telephone number, including area code)
</TD>
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="3" STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	Securities registered under Section 12 (b) of
	the Exchange Act:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 49%; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Title
	of Each Class
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 49%; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Name
	of Each Exchange on Which Registered
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Common
	Stock, par value $.001 per share
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&#9;OTCQB
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	Securities registered under Section 12(g) of
	the Exchange Act:
<B>
	None
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&nbsp;&#9744;
	No&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&thorn;
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744;&nbsp;&nbsp;No
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&thorn;
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
	Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
	and (2) has been subject to such filing requirements for the past 90 days. Yes
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&thorn;
</FONT>
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS 2">
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No &#9744;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive
	Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the
	preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&thorn;
</FONT>
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS 2">
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No &#9744;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT">
	Indicate
	by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not
	be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference
	in Part III of this 10-K or any amendments to this Form 10-K.
<FONT STYLE="FONT-FAMILY: WINGDINGS 2">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&thorn;
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT">
	Indicate by check mark
	whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
	See the definition of &ldquo;large accelerated filer&rdquo;, &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
	in Rule 12b-2 of the Exchange Act. (Check one):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 26%; PADDING: 0PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Large
	accelerated filer &#9744;
</FONT>
</TD>
<TD STYLE="WIDTH: 20%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Accelerated
	filer &#9744;
</FONT>
</TD>
<TD STYLE="WIDTH: 26%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Non-accelerated
	filer &#9744;
</FONT>
</TD>
<TD STYLE="WIDTH: 28%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Smaller
	reporting company
<FONT STYLE="FONT-FAMILY: WINGDINGS 2">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&thorn;
</FONT>
</FONT>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
</FONT>
	&#9744;
<FONT STYLE="FONT-FAMILY: WINGDINGS 2">
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No &nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&thorn;
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS 2">
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: WINGDINGS 2">
	&nbsp;
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT">
	The aggregate market value
	of the common stock held by non-affiliates of the registrant was approximately $22,060,000 (assuming, for this purpose, that executive
	officers, directors and holders of 10% or more of the common stock are affiliates), based on the closing price of the registrant&rsquo;s
	common stock as reported on the Over-the-Counter Bulletin Board on March 18, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0PT 6PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT">
	As of March 18, 2016,
	31,269,522 shares of the registrant&rsquo;s Common Stock, par value $0.001 per share, were outstanding.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	DOCUMENTS
	INCORPORATED BY REFERENCE: None.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 2PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	SOLIGENIX, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	ANNUAL REPORT ON FORM 10-K
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	For the Year Ended December 31, 2015
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Table of Contents
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BACKGROUND-COLOR: WHITE; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; BORDER-BOTTOM: BLACK 1.5PT SOLID; WIDTH: 8%; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Item
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; BORDER-BOTTOM: BLACK 1.5PT SOLID; WIDTH: 82%; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Description
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; BORDER-BOTTOM: BLACK 1.5PT SOLID; WIDTH: 8%; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Page
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Part I
</B>
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Business
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1A.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Risk Factors
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	22
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1B.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Unresolved Staff Comments
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	38
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Properties
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	38
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Legal Proceedings
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	38
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Part II
</B>
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	39
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Selected Financial Data
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	39
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	7.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	40
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Financial Statements and Supplementary Data
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	46
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	9.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	47
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	9A.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Controls and Procedures
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	47
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	9B.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Other Information
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	48
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Part III
</B>
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Directors, Executive Officers and Corporate Governance
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	49
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	11.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Executive Compensation
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	54
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	57
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	13.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Certain Relationships and Related Transactions and Director Independence
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	59
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	14.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Principal Accountant Fees and Services
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	59
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Part IV
</B>
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	15.
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Exhibits and Financial Statement Schedules
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	60
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="3" STYLE="PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Signatures
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
	64
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD COLSPAN="3" STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated Financial Statements
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-1
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	PART I
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	Item 1. Business
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	This Annual Report on Form 10-K contains
	statements of a forward-looking nature relating to future events or our future financial performance. These statements are only
	predictions and actual events or results may differ materially. In evaluating such statements, you should carefully consider the
	various factors identified in this report that could cause actual results to differ materially from those indicated in any forward-looking
	statements, including those set forth in &ldquo;Risk Factors&rdquo; in this Annual Report on Form 10-K. See &ldquo;Cautionary Note
	Regarding Forward Looking Statements.&rdquo;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<U>
	Our Business Overview
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We are a late-stage biopharmaceutical company
	focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We maintain two
	active business segments: BioTherapeutics and Vaccines/BioDefense.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Our BioTherapeutics business segment is developing
	a first-in-class photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the
	treatment of cutaneous T-cell lymphoma (&ldquo;CTCL&rdquo;), proprietary formulations of oral beclomethasone 17,21-dipropionate
	(&ldquo;BDP&rdquo;) for the prevention/treatment of gastrointestinal (&ldquo;GI&rdquo;) disorders characterized by severe inflammation,
	including pediatric Crohn&rsquo;s disease (SGX203) and acute radiation enteritis (SGX201), and our novel innate defense regulator
	(&ldquo;IDR&rdquo;) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Our Vaccines/BioDefense business segment includes
	active development programs for RiVax&trade;, our ricin toxin vaccine candidate, OrbeShield
<SUP>
	&reg;,
</SUP>
	our GI acute radiation
	syndrome (&ldquo;GI ARS&rdquo;) therapeutic candidate and SGX943, our melioidosis therapeutic candidate. The development of our
	vaccine programs currently is supported by our heat stabilization technology, known as ThermoVax
<SUP>
	&reg;
</SUP>
	, under existing
	and on-going government contract funding. With the government contract from the National Institute of Allergy and Infectious Diseases
	(&ldquo;NIAID&rdquo;), we will attempt to advance the development of RiVax&trade; to protect against exposure to ricin toxin. We
	plan to use the funds received under our government contracts with the Biomedical Advanced Research and Development Authority (&ldquo;BARDA&rdquo;)
	and NIAID to advance the development of OrbeShield
<SUP>
	&reg;
</SUP>
	for the treatment of GI ARS.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	An outline for our business strategy follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Complete enrollment and report preliminary results in our pivotal Phase 3 clinical trial of SGX301
	for the treatment of CTCL;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Initiate a Phase 3 clinical trial of SGX203, for the treatment of pediatric Crohn&rsquo;s disease;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Continue to collect the long-term follow-up safety data from the SGX942 Phase 2 proof-of-concept
	study in the treatment of oral mucositis in head and neck cancer patients and publish the findings from this study;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Obtain FDA agreement on a pivotal Phase 2b/3 protocol of SGX942 in the treatment of oral mucositis
	in head and neck cancer patients;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Continue development of RiVax&trade; in combination with our ThermoVax
<SUP>
	&reg;
</SUP>
	technology,
	to develop new heat stable vaccines in biodefense and infectious diseases with the potential to collaborate and/or partner with
	other companies in these areas;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Advance the preclinical and manufacturing development of OrbeShield
<SUP>
	&reg;
</SUP>
	as a biodefense
	medical countermeasure for the treatment of GI ARS;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Continue to apply for and secure additional government funding for each of our BioTherapeutics
	and Vaccines/BioDefense programs through grants, contracts and/or procurements;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Acquire or in-license new clinical-stage compounds for development; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Explore other business development and merger/acquisition strategies.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<U>
	Corporate Information
</U>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We were incorporated in Delaware in 1987 under
	the name Biological Therapeutics, Inc. In 1987, the Company merged with Biological Therapeutics, Inc., a North Dakota corporation,
	pursuant to which we changed our name to &ldquo;Immunotherapeutics, Inc.&rdquo; We changed our name to &ldquo;Endorex Corp.&rdquo;
	in 1996, to &ldquo;Endorex Corporation&rdquo; in 1998, to &ldquo;DOR BioPharma, Inc.&rdquo; in 2001, and finally to &ldquo;Soligenix,
	Inc.&rdquo; in 2009. Our principal executive offices are located at 29 Emmons Drive, Suite C-10, Princeton, New Jersey 08540 and
	our telephone number is (609) 538-8200.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<U>
	Our Product Candidates in Development
</U>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The following tables summarize our product
	candidates under development:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: CENTER">
<U>
	BioTherapeutic Product Candidates
</U>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: CENTER">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 33%; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Soligenix Product Candidate
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 33%; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Therapeutic Indication
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 32%; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Stage of Development
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	SGX301
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	Cutaneous T-Cell Lymphoma
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	Phase 2 trial
	completed; demonstrated significantly higher response rate compared to placebo;
<BR>
	Phase 3 clinical trial initiated in the second half of 2015, with data expected in the second half of 2016
<BR>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-DECORATION: NONE; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	SGX942
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	Oral Mucositis in Head and Neck Cancer
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	Phase 2 trial initiated in the second half of 2013,
<BR>
	with positive preliminary results reported in the second half of 2015; seek to obtain FDA agreement on the Phase 2b/3 protocol in the second half of 2016
<BR>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-DECORATION: NONE; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	SGX203**
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	Pediatric Crohn&rsquo;s disease
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	Phase 1/2 clinical trial completed June 2013, efficacy data, pharmacokinetic (PK)/pharmacodynamic (PD) profile and safety confirmed;
<BR>
	Phase 3 clinical trial planned for the second half of 2016, with data expected in the first half of 2018
<BR>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	SGX201**
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	Acute Radiation Enteritis
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	Phase 1/2 clinical trial complete;
<BR>
	safety and preliminary efficacy demonstrated;
<BR>
	Phase 2 trial planned for the first half of 2017
<BR>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: CENTER">
<U>
	Vaccine Thermostability Platform**
</U>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: CENTER">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 33%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Soligenix Product
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Candidate
</B>
</P>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 33%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Indication
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 30%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Stage of Development
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ThermoVax
<SUP>
	&reg;
</SUP>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	Thermostability of aluminum
<BR>
	adjuvanted vaccines
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pre-clinical
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: CENTER">
<U>
	BioDefense Products**
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 33%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Soligenix Product Candidate
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 33%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Indication
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 32%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Stage of Development
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	RiVax&trade;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	Vaccine against
<BR>
	Ricin Toxin Poisoning
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	Phase 1B trial complete, safety and neutralizing antibodies for protection demonstrated;
<BR>
	Phase 1/2 trial planned for the second half of 2016
<BR>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	OrbeShield
<SUP>
	&reg;
</SUP>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	Therapeutic against GI ARS
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	Pre-clinical program initiated
<BR>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	SGX943
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	Melioidosis
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT; VERTICAL-ALIGN: TOP">
	Pre-clinical
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; WIDTH: 25%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	** Contingent upon continued government
	contract/grant funding or other funding source.
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<U>
	BioTherapeutics Overview
</U>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	SGX301 &ndash; for Treating Cutaneous
	T-Cell Lymphoma
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	SGX301 is a novel, first-in-class, photodynamic
	therapy that utilizes safe visible light for activation. The active ingredient in SGX301 is synthetic hypericin, a photosensitizer
	which is topically applied to skin lesions and then activated by fluorescent light 16 to 24 hours later. Hypericin is also found
	in several species of
<I>
	Hypericum
</I>
	plants, although the drug used in SGX301 is chemically synthesized by a proprietary manufacturing
	process and not extracted from plants. Importantly, hypericin is optimally activated with visible light thereby avoiding the negative
	consequences of ultraviolet light. Other light therapies using UVA light result in serious adverse effects including secondary
	skin cancers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Combined with photoactivation, in clinical
	trials hypericin has demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited
	growth of malignant T-cells isolated from CTCL patients. In both settings, it appears that the mode of action is an induction of
	cell death in a concentration as well as a light dose-dependent fashion. These effects appear to result, in part, from the generation
	of singlet oxygen during photoactivation of hypericin.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Hypericin is one of the most efficient known
	generators of singlet oxygen, the key component for phototherapy. The generation of singlet oxygen induces necrosis and apoptosis
	in adjacent cells. The use of topical hypericin coupled with directed visible light results in generation of singlet oxygen only
	at the treated site. We believe that the use of visible light (as opposed to cancer-causing ultraviolet light) is a major advance
	in photodynamic therapy. In a published Phase 2 clinical study in CTCL, after six weeks of twice weekly therapy, a majority of
	patients experienced a statistically significant improvement with topical hypericin treatment whereas the placebo was ineffective:
	58.3% compared to 8.3%, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	SGX301 has received orphan drug designation
	as well as Fast Track designation from the United States Food and Drug Administration (the &ldquo;FDA&rdquo;). The Orphan Drug
	Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and
	disorders. In addition to providing a seven year term of market exclusivity for SGX301 upon final FDA approval, orphan drug designation
	also positions us to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting
	clinical trials, waiver of FDA user fees for the potential submission of a New Drug Application (&ldquo;NDA&rdquo;) for SGX301,
	and certain tax credits. In addition, Fast Track is a designation that the FDA reserves for a drug intended to treat a serious
	or life-threatening condition and one that demonstrates the potential to address an unmet medical need for the condition. Fast
	Track designation is designed to facilitate the development and expedite the review of new drugs. For instance, should events warrant,
	we will be eligible to submit a NDA for SGX301 on a rolling basis, permitting the FDA to review sections of the NDA prior to receiving
	the complete submission. Additionally, NDAs for Fast Track development programs ordinarily will be eligible for priority review.
	SGX301 also was granted orphan drug designation from the European Medicines Agency Committee for Orphan Medical Products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We initiated our pivotal Phase 3 clinical study
	of SGX301 in the treatment of CTCL during December 2015 and anticipate data in the second half of 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	We estimate the potential worldwide market
	for SGX301 is in excess of $250 million for all applications, including the treatment of CTCL. This potential market information
	is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While we have determined
	this potential market size based on assumptions that we believe are reasonable, there are a number of factors that could cause
	our expectations to change or not be realized.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	Cutaneous T-Cell Lymphoma
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	CTCL is a class of non-Hodgkin&rsquo;s lymphoma
	(&ldquo;NHL&rdquo;), a type of cancer of the white blood cells that are an integral part of the immune system. Unlike most NHLs,
	which generally involve B-cell lymphocytes (involved in producing antibodies), CTCL is caused by an expansion of malignant T-cell
	lymphocytes (involved in cell-mediated immunity) normally programmed to migrate to the skin. These skin-trafficking malignant T-cells
	migrate to the skin, causing various lesions to appear that may change shape as the disease progresses, typically beginning as
	a rash and eventually forming plaques and tumors. Mycosis fungoides (&ldquo;MF&rdquo;) is the most common form of CTCL. It generally
	presents with skin involvement only, manifested as scaly, erythematous patches. Advanced disease with diffuse lymph node and visceral
	organ involvement is usually associated with a poorer response rate to standard therapies. A relatively uncommon sub-group of CTCL
	patients present with extensive skin involvement and circulating malignant cerebriform T-cells, referred to as S&eacute;zary syndrome.
	These patients have substantially graver prognoses than those with MF.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	CTCL mortality is related to stage of disease,
	with median survival generally ranging from about 12 years in the early stages to only 2.5 years when the disease has advanced.
	There is currently no FDA-approved drug for front-line treatment of early stage CTCL. Treatment of early-stage disease generally
	involves skin-directed therapies. One of the most common unapproved therapies used for early-stage disease is oral 5 or 8-methoxypsoralen
	(&ldquo;Psoralen&rdquo;) given with ultraviolet A (&ldquo;UVA&rdquo;) light, referred to as PUVA, which is approved for dermatological
	conditions such as disabling psoriasis not adequately responsive to other forms of therapy, idiopathic vitiligo and skin manifestations
	of CTCL in persons who have not been responsive to other forms of treatment. Psoralen is a mutagenic chemical that interferes with
	DNA causing mutations and other malignancies. Moreover, UVA is a carcinogenic light source that when combined with the Psoralen,
	results in serious adverse effects including secondary skin cancers; therefore, the FDA requires a Black Box warning for PUVA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	CTCL constitutes a rare group of NHLs, occurring
	in about 4% of the approximate 500,000 individuals living with NHL. We estimate, based upon review of historic published studies
	and reports and an interpolation of data on the incidence of CTCL, that it affects over 20,000 individuals in the U.S., with approximately
	2,800 new cases seen annually.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	SGX94
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	SGX94 is an innate defense regulator (&ldquo;IDR&rdquo;)
	that regulates the innate immune system to simultaneously reduce inflammation, eliminate infection and enhance tissue healing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	SGX94 is based on a new class of short, synthetic
	peptides known as IDRs that have a novel mechanism of action in that it is simultaneously anti-inflammatory and anti-infective.
	IDRs have no direct antibiotic activity but modulate host responses, increasing survival after infections with a broad range of
	bacterial Gram-negative and Gram-positive pathogens including both antibiotic sensitive and resistant strains, as well as accelerating
	resolution of tissue damage following exposure to a variety of agents including bacterial pathogens, trauma and chemo- or radiation-therapy.
	IDRs represent a novel approach to the control of infection and tissue damage via highly selective binding to an intracellular
	adaptor protein, sequestosome-1, also known as p62, which has a pivotal function in signal transduction during activation and control
	of the innate defense system. Preclinical data indicate that IDRs may be active in models of a wide range of therapeutic indications
	including life-threatening bacterial infections as well as the severe side-effects of chemo- and radiation-therapy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	SGX94 has demonstrated efficacy in numerous
	animal disease models including mucositis, colitis, skin infection and other bacterial infections and has been evaluated in a double-blind,
	placebo-controlled Phase 1 clinical trial in 84 healthy volunteers with both single ascending dose and multiple ascending dose
	components. SGX94 was shown to be safe and well-tolerated in all dose groups when administered by IV over 7 days and was consistent
	with safety results seen in pre-clinical studies. SGX94 is the subject of an open Investigational New Drug (&ldquo;IND&rdquo;)
	application which has been cleared by the FDA. We believe that market opportunities for SGX94 include mucositis, acute methicillin
	resistant
<I>
	Staphylococcus aureus
</I>
	(MRSA) bacterial infections, acinetobacter, melioidosis, acute radiation syndrome and as
	a vaccine adjuvant,&nbsp;with potential opportunities for non-dilutive funding to support the development.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	SGX942 &ndash; for Treating Oral
	Mucositis in Head and Neck Cancer
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	SGX942 is our product candidate containing
	our IDR technology platform, SGX94, targeting the treatment of oral mucositis in head and neck cancer patients. Oral mucositis
	in this patient population is an area of unmet medical need where there are currently no approved drug therapies. Accordingly,
	we received Fast Track designation for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in
	head and neck cancer patients from the FDA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We initiated a Phase 2 clinical study of SGX942
	in the treatment of oral mucositis in head and neck cancer patients in the second half of 2013. We completed enrollment in this
	trial in the second half of 2015 and in December 2015, released positive preliminary results. In this Phase 2 proof-of-concept
	clinical study that enrolled 111 patients, SGX942, at a dose of 1.5 mg/kg, successfully reduced the median duration of severe
	oral mucositis by 50%, from 18 days to 9 days (p=0.099) in all patients and by 67%, from 30 days to 10 days (p=0.040) in patients
	receiving the most aggressive chemoradiation therapy (CRT) for treatment of their head and neck cancer. In addition to identifying
	the optimal dose of 1.5 mg/kg, this study achieved all objectives, including a trend towards increased incidence of &ldquo;complete
	response&rdquo; of tumor at the one month follow up visit (47% in placebo vs. 63% in SGX942 at 1.5 mg/kg). Decreases in mortality
	and significant decreases in infection rate were also observed with SGX942 treatment, consistent with the preclinical results
	observed in animal models, and are being further evaluated. SGX942 was found to be generally safe and well tolerated, consistent
	with the safety profile observed in the prior Phase 1 study conducted in 84 healthy volunteers. Long-term follow-up evaluations
	are ongoing with final results expected in the fourth quarter of 2016. Data from this Phase 2 trial is expected to be submitted
	for future presentation and publication.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	We estimate the potential worldwide market
	for SGX942 is in excess of $500 million for all applications, including the treatment of oral mucositis. This potential market
	information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While we have
	determined this potential market size based on assumptions that we believe are reasonable, there are a number of factors that could
	cause our expectations to change or not be realized.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	Oral Mucositis
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	Mucositis is the clinical term for damage done
	to the mucosa by anticancer therapies. It can occur in any mucosal region, but is most commonly associated with the mouth, followed
	by the small intestine. We estimate, based upon our review of historic studies and reports, and an interpolation of data on the
	incidence of mucositis, that mucositis affects approximately 500,000 people in the U.S. per year and occurs in 40% of patients
	receiving chemotherapy. Mucositis can be severely debilitating and can lead to infection, sepsis, the need for parenteral nutrition
	and narcotic analgesia. The GI damage causes severe diarrhea. These symptoms can limit the doses and duration of cancer treatment,
	leading to sub-optimal treatment outcomes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The mechanisms of mucositis have been extensively
	studied and have been recently linked to the interaction of chemotherapy and/or radiation therapy with the innate defense system.
	Bacterial infection of the ulcerative lesions is regarded as a secondary consequence of dysregulated local inflammation triggered
	by therapy-induced cell death, rather than as the primary cause of the lesions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	We estimate, based upon our review of historic
	studies and reports, and an interpolation of data on the incidence of oral mucositis, that oral mucositis is a subpopulation of
	approximately 90,000 patients in the U.S., with&nbsp;a comparable number in Europe.&nbsp;Oral mucositis almost always occurs in
	patients with head and neck cancer treated with radiation therapy (greater than 80% incidence of severe mucositis) and is common
	in patients undergoing high dose chemotherapy and hematopoietic cell transplantation, where the incidence and severity of oral
	mucositis depends greatly on the nature of the conditioning regimen used for myeloablation.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	Oral BDP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	Oral BDP (beclomethasone 17,21-dipropionate)
	represents a first
<B>
	-
</B>
	of
<B>
	-
</B>
	its
<B>
	-
</B>
	kind oral, locally acting therapy tailored to treat GI inflammation. BDP has been
	marketed in the U.S. and worldwide since the early 1970s as the active pharmaceutical ingredient in a nasal spray and in a metered-dose
	inhaler for the treatment of patients with allergic rhinitis and asthma. Oral BDP is specifically formulated for oral administration
	as a single product consisting of two tablets. One tablet is intended to release BDP in the upper sections of the GI tract and
	the other tablet is intended to release BDP in the lower sections of the GI tract.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	Based on its pharmacological characteristics,
	oral BDP may have utility in treating other conditions of the gastrointestinal tract having an inflammatory component. We are planning
	to pursue development programs in the treatment of pediatric Crohn&rsquo;s disease, acute radiation enteritis and GI ARS pending
	further grant funding. We are also exploring the possibility of testing oral BDP for local inflammation associated with ulcerative
	colitis, among other indications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We are pursuing orphan drug designations for
	relevant indications as appropriate in both the U.S. and Europe. An orphan drug designation provides for seven years and ten years
	of market exclusivity upon approval in the U.S. and Europe, respectively.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	SGX203 &ndash;for Treating Pediatric
	Crohn&rsquo;s Disease
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	SGX203 is a two tablet delivery system of BDP
	specifically designed for oral use that allows for administration of immediate and delayed release BDP throughout the small bowel
	and the colon. The FDA has given SGX203 orphan drug designation as well as Fast Track designation for the treatment of pediatric
	Crohn's disease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We anticipate initiating a Phase 3 clinical
	study of SGX203 in the treatment of pediatric Crohn&rsquo;s disease in the second half of 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	We estimate the potential worldwide market
	for oral BDP is in excess of $500 million for all applications, including the treatment of pediatric Crohn&rsquo;s disease. This
	potential market information is a forward-looking statement, and investors are urged not to place undue reliance on this statement.
	While we have determined this potential market size based on assumptions that we believe are reasonable, there are a number of
	factors that could cause our expectations to change or not be realized.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT">
	Pediatric Crohn's Disease
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY">
	Crohn's disease causes inflammation of the
	GI tract. Crohn's disease can affect any area of the GI tract, from the mouth to the anus, but it most commonly affects the lower
	part of the small intestine, called the ileum. The swelling caused by the disease extends deep into the lining of the affected
	organ. The swelling can induce pain and can make the intestines empty frequently, resulting in diarrhea. Because the symptoms of
	Crohn's disease are similar to other intestinal disorders, such as irritable bowel syndrome and ulcerative colitis, it can be difficult
	to diagnose. People of Ashkenazi Jewish heritage have an increased risk of developing Crohn's disease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Crohn's disease can appear at any age, but
	it is most often diagnosed in adults in their 20s and 30s. However, approximately 30% of people with Crohn's disease develop symptoms
	before 20 years of age. We estimate, based upon our review of historic published studies and reports, and an interpolation of data
	on the incidence of Pediatric Crohn&rsquo;s disease, that Pediatric Crohn's disease is a subpopulation of approximately 80,000
	patients in the U.S. with a comparable number in Europe. Crohn&rsquo;s disease tends to be both severe and extensive in the pediatric
	population and a relatively high proportion (approximately 40%) of pediatric Crohn&rsquo;s patients have involvement of their upper
	gastrointestinal tract.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Crohn's disease presents special challenges
	for children and teens. In addition to bothersome and often painful symptoms, the disease can stunt growth, delay puberty, and
	weaken bones. Crohn's disease symptoms may sometimes prevent a child from participating in enjoyable activities. The emotional
	and psychological issues of living with a chronic disease can be especially difficult for young people.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	SGX201 &ndash;for Preventing Acute
	Radiation Enteritis
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	SGX201 is a delayed-release formulation
	of BDP specifically designed for oral use. In 2012, we completed a Phase 1/2 clinical trial testing SGX201 in prevention of acute
	radiation enteritis. Patients with rectal cancer scheduled to undergo concurrent radiation and chemotherapy prior to surgery were
	randomized to one of four dose groups. The objectives of the study were to evaluate the safety and maximal tolerated dose of escalating
	doses of SGX201, as well as the preliminary efficacy of SGX201 for prevention of signs and symptoms of acute radiation enteritis.
	The study demonstrated that oral administration of SGX201 was safe and well tolerated across all four dose groups. There was also
	evidence of a potential dose response with respect to diarrhea, nausea and vomiting and the assessment of enteritis according
	to National Cancer Institute Common Terminology Criteria for Adverse Events for selected gastrointestinal events. In addition,
	the incidence of diarrhea was lower than that seen in recent published historical control data in this patient population. This
	program was supported in part by a $500,000 two-year Small Business Innovation and Research (&ldquo;SBIR&rdquo;) grant awarded
	by the National Institutes of Health (&ldquo;NIH&rdquo;). We are currently working with our Radiation Enteritis medical advisory
	board in pursuing additional funding from the NIH to support the clinical development program.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We have received Fast Track designation from
	the FDA for SGX201 for acute radiation enteritis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We estimate the potential worldwide market
	for oral BDP is in excess of $500 million for all applications, including the treatment of acute radiation enteritis. This potential
	market information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While
	we have determined this potential market size based on assumptions that we believe are reasonable, there are a number of factors
	that could cause our expectations to change or not be realized.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Acute Radiation Enteritis
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	External radiation therapy is used to treat
	most types of cancer, including cancer of the bladder, uterine, cervix, rectum, prostate, and vagina. During delivery of treatment,
	some level of radiation will also be delivered to healthy tissue, including the bowel, leading to acute and chronic toxicities.
	The large and small bowels are very sensitive to radiation and the larger the dose of radiation the greater the damage to normal
	bowel tissue. Radiation enteritis is a condition in which the lining of the bowel becomes swollen and inflamed during or after
	radiation therapy to the abdomen, pelvis, or rectum. Most tumors in the abdomen and pelvis need large doses, and almost all patients
	receiving radiation to the abdomen, pelvis, or rectum will show signs of acute enteritis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Patients with acute enteritis may have nausea,
	vomiting, abdominal pain and bleeding, among other symptoms. Some patients may develop dehydration and require hospitalization.
	With diarrhea, the gastrointestinal tract does not function normally, and nutrients such as fat, lactose, bile salts, and vitamin
	B 12 are not well absorbed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Symptoms will usually resolve within two to
	six weeks after therapy has ceased. Radiation enteritis is often not a self-limited illness, as over 80% of patients who receive
	abdominal radiation therapy complain of a persistent change in bowel habits. Moreover, acute radiation injury increases the risk
	of development of chronic radiation enteropathy, and overall 5% to 15% of the patients who receive abdominal or pelvic irradiation
	will develop chronic radiation enteritis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We estimate, based upon our review of historic
	published studies and reports, and an interpolation of data on the treatment courses and incidence of cancers occurring in the
	abdominal and pelvic regions, there to be over 100,000 patients annually in the U.S., with a comparable number in Europe, who receive
	abdominal or pelvic external beam radiation treatment for cancer, and these patients are at risk of developing acute and chronic
	radiation enteritis.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Vaccines/BioDefense Overview
</U>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	ThermoVax
<SUP>
	&reg;
</SUP>
	&ndash;
	Thermostability Technology
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our thermostability technology, ThermoVax
<SUP>
	&reg;,
</SUP>
	is a novel method of rendering aluminum salt, (known colloquially as Alum), adjuvanted vaccines stable at elevated temperatures.
	Alum is the most widely employed adjuvant technology in the vaccine industry. The value of ThermoVax
<SUP>
	&reg;
</SUP>
	lies in its
	potential ability to eliminate the need for cold chain production, transportation, and storage for Alum adjuvanted vaccines. This
	would relieve companies of the high costs of producing and maintaining vaccines under refrigerated conditions. Based on historical
	reports from the World Health Organization and other scientific reports, we believe that a meaningful proportion of vaccine doses
	globally are wasted due to excursions from required cold chain temperature ranges. This is due to the fact that most Alum adjuvanted
	vaccines need to be maintained at between 2 and 8 degrees Celsius (&ldquo;C&rdquo;) and even brief excursions from this temperature
	range (especially below freezing) usually necessitates the destruction of the product or the initiation of costly stability programs
	specific for the vaccine lots in question. We believe that the savings realized from the elimination of cold chain costs and related
	product losses would significantly increase the profitability of vaccine products. We believe that elimination of the cold chain
	could further facilitate the use of these vaccines in the lesser developed parts of the world. ThermoVax
<SUP>
	&reg;
</SUP>
	has the
	potential to facilitate easier storage and distribution of strategic national stockpile vaccines in emergency settings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	ThermoVax
<SUP>
	&reg;
</SUP>
	development
	was supported pursuant to our $9.4 million NIAID grant enabling development of thermo-stable ricin (RiVax&trade;) and anthrax
	(VeloThrax
<SUP>
	&reg;
</SUP>
	) vaccines. Proof-of-concept preclinical studies with ThermoVax
<SUP>
	&reg;
</SUP>
	indicate that it is
	able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not
	withstand long temperature variations exceeding customary refrigerated storage conditions. These studies were conducted with our
	aluminum-adjuvanted ricin toxin vaccine, RiVax&trade; and our aluminum-adjuvanted anthrax vaccine, VeloThrax
<SUP>
	&reg;
</SUP>
	.
	Each vaccine was manufactured under precise lyophilization conditions using excipients that aid in maintaining native protein
	structure of the key antigen. When RiVax&trade; was kept at 40 degrees C (104 degrees Fahrenheit) for up to one year, all of the
	animals vaccinated with the lyophilized RiVax&trade; vaccine developed potent and high titer neutralizing antibodies. In contrast,
	animals that were vaccinated with the liquid RiVax&trade; vaccine kept at 40 degrees C did not develop neutralizing antibodies
	and were not protected against ricin exposure. The ricin A chain is extremely sensitive to temperature and rapidly loses the ability
	to induce neutralizing antibodies when exposed to temperatures higher than 8 degrees C. When VeloThrax
<SUP>
	&reg;
</SUP>
	was kept
	for up to 16 weeks at 70 degrees C, it was able to develop a potent antibody response, unlike the liquid formulation kept at the
	same temperature. Moreover, we have also demonstrated the compatibility of our thermostabilization technology with other secondary
	adjuvants such as TLR-4 agonists. Additionally, the University of Colorado conducted a study that demonstrated a heat stable vaccine
	formulation of a human papillomavirus (HPV) vaccine.&nbsp; The work was conducted by Drs. Randolph and Garcea and demonstrated
	the successful conversion of a commercial virus-like particle (VLP) based vaccine requiring cold chain storage to a subunit, alum-adjuvanted,
	vaccine which is stable at ambient temperatures.&nbsp; This work, funded by a University of Colorado Seed grant and the Specialized
	Program of Research Excellence (SPORE) in cervical cancer, is the first demonstration of the utility of ThermoVax
<SUP>
	&reg;
</SUP>
	technology for the development of a subunit based commercial vaccine.&nbsp; The HPV vaccine formulation was found to be stable
	for at least 12 weeks at 50 degrees C.&nbsp; In the study, mice immunized with the ThermoVax
<SUP>
	&reg;-
</SUP>
	stabilized HPV subunit
	vaccine were also found to achieve immune responses similar to the commercial HPV vaccine, Cervarix
<SUP>
	&reg;
</SUP>
	, as measured
	by either total antibody levels or neutralizing antibody levels.&nbsp; Moreover, whereas the immune responses to Cervarix
<SUP>
	&reg;
</SUP>
	were reduced after storage for 12 weeks at 50 degrees C, the ThermoVax
<SUP>
	&reg;
</SUP>
	formulated vaccine retained its efficacy.
	The results were published online in the European Journal of Pharmaceutics and Biopharmaceutic. See
<U>
	http://www.sciencedirect.com/science/article/pii/S0939641115002416)
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We also entered into a collaboration agreement
	with Axel Lehrer, PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine,
	University of Hawai
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	&#699;
</FONT>
	i at M&#257;noa and Hawaii Biotech, Inc. (&ldquo;HBI&rdquo;)
	to develop a heat stable subunit Ebola vaccine. Dr. Lehrer, a co-inventor of the Ebola vaccine with HBI, has shown proof of concept
	efficacy with subunit Ebola vaccines in non-human primates. The most advanced Ebola vaccines involve the use of vesicular stomatitis
	virus and adenovirus vectors &ndash; live, viral vectors which complicate the manufacturing, stability and storage requirements.
	Dr. Lehrer&rsquo;s vaccine candidate is based on highly purified recombinant protein antigens, circumventing many of these manufacturing
	difficulties. Dr. Lehrer and HBI have developed a robust manufacturing process for the required proteins. Application of ThermoVax
<SUP>
	&reg;
</SUP>
	may allow for a product that can avoid the need for cold chain distribution and storage, yielding a vaccine ideal for use in both
	the developed and developing world.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We intend to seek out potential partnerships
	with companies marketing FDA/ex-U.S. health authority approved Alum adjuvanted vaccines and currently developing Alum adjuvanted
	vaccines that are interested in eliminating the need for cold chain for their products. We believe that ThermoVax
<SUP>
	&reg;
</SUP>
	also will enable us to expand our vaccine development expertise beyond biodefense into the infectious disease space and also has
	the potential to allow for the development of multivalent vaccines (e.g., combination ricin-anthrax vaccine).
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	RiVax&trade;&nbsp;&ndash; Ricin
	Toxin Vaccine
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	RiVax&trade; is our proprietary vaccine candidate
	being developed to protect against exposure to ricin toxin, and if approved would be the first ricin vaccine.&nbsp;The immunogen
	in RiVax&trade; induces a protective immune response in animal models of ricin exposure and functionally active antibodies in humans.
	The immunogen consists of a genetically inactivated subunit ricin A chain that is enzymatically inactive and lacks residual toxicity
	of the holotoxin. RiVax&trade; has demonstrated statistically significant (p &lt; 0.0001) preclinical survival results in a lethal
	aerosol exposure non-human primate model (Roy et al, 2015, Thermostable ricin vaccine protects rhesus macaques against aerosolized
	ricin: Epitope-specific neutralizing antibodies correlate with protection, PNAS USA March 24, 2015), and has also been shown to
	be well tolerated and immunogenic in two Phase 1 clinical trials in healthy volunteers. Results of the first Phase 1 human trial
	of RiVax&trade; established that the immunogen was safe and induced antibodies that we believe may protect humans from ricin exposure.
	The antibodies generated from vaccination, concentrated and purified, were capable of conferring immunity passively to recipient
	animals, indicating that the vaccine was capable of inducing functionally active antibodies in humans. The outcome of this study
	was published in the Proceedings of the National Academy of Sciences (Vitetta et al., 2006, A Pilot Clinical Trial of a Recombinant
	Ricin Vaccine in Normal Humans, PNAS, 103:2268-2273). The second trial completed in September 2012, sponsored by University of
	Texas Southwestern Medical Center (&ldquo;UTSW&rdquo;), evaluated a more potent formulation of RiVax&trade; that contained an aluminum
	adjuvant (Alum). The results of the Phase 1B study indicated that Alum adjuvanted RiVax&trade; was safe and well tolerated, and
	induced greater ricin neutralizing antibody levels in humans than adjuvant-free RiVax&trade;. The outcomes of this second study
	were published in the
<I>
	Clinical and Vaccine Immunology
</I>
	(Vitetta et al., 2012, Recombinant Ricin Vaccine Phase 1B Clinical
	Trial, Clin. Vaccine Immunol. 10:1697-9). We have adapted the original manufacturing process for the immunogen contained in RiVax&trade;
	for large scale manufacturing and are further establishing correlates of the human immune response in non-human primates. We have
	initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology
	for the RiVax
<SUP>
	&trade;
</SUP>
	drug substance protein antigen.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The development of RiVax&trade; has been sponsored
	through a series of overlapping challenge grants, UC1, and cooperative grants, U01, from the NIH, granted to Soligenix and to UTSW
	where the vaccine originated. The second clinical trial was supported by a grant from the FDA&rsquo;s Office of Orphan Products
	to UTSW. To date, we and UTSW have collectively received approximately $25 million in grant funding from the NIH for the development
	of RiVax&trade;. In September 2014, we entered into a contract with the NIH for the development of RiVax&trade; that would provide
	up to an additional $24.7 million of funding in the aggregate if options to extend the contract are exercised by the NIH.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	RiVax&trade; has been granted orphan drug designation
	by the FDA for the prevention of ricin intoxication.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Assuming development efforts are successful
	for RiVax&trade;, we believe potential government procurement contract(s)&nbsp;could reach $200 million. This potential procurement
	contract information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While
	we have determined this potential procurement contract value based on assumptions that we believe are reasonable, there are a number
	of factors that could cause our expectations to change or not be realized.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Ricin Toxin
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Ricin toxin can be cheaply and easily produced,
	is stable over long periods of time, is toxic by several routes of exposure and thus has the potential to be used as a biological
	weapon against military and/or civilian targets. As a bioterrorism agent, ricin could be disseminated as an aerosol, by injection,
	or as a food supply contaminant. The potential use of ricin toxin as a biological weapon of mass destruction has been highlighted
	in a Federal Bureau of Investigations Bioterror report released in November 2007 titled
<I>
	Terrorism 2002-2005
</I>
	, which states
	that &ldquo;Ricin and the bacterial agent anthrax are emerging as the most prevalent agents involved in WMD investigations&rdquo;
	(http://www.fbi.gov/stats-services/publications/terrorism-2002-2005/terror02_05.pdf). In recent years, Al Qaeda in the Arabian
	Peninsula has threatened the use of ricin toxin to poison food and water supplies and in connection with explosive devices. Domestically,
	the threat from ricin remains a concern for security agencies. As recently as April 2013, letters addressed to the President, a
	U.S. Senator and a judge tested positive for ricin.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Center for Disease Control has classified
	ricin toxin as a Category B biological agent. Ricin works by first binding to glycoproteins found on the exterior of a cell, and
	then entering the cell and inhibiting protein synthesis leading to cell death. Once exposed to ricin toxin, there is no effective
	therapy available to reverse the course of the toxin. The recent ricin threat to government officials has heightened the awareness
	of this toxic threat. Currently, there is no FDA approved vaccine to protect against the possibility of ricin toxin being used
	in a terrorist attack, or its use as a weapon on the battlefield nor is there a known antidote for ricin toxin exposure.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	OrbeShield
<SUP>
	&reg;
</SUP>
	&ndash;for
	Treating GI Acute Radiation Syndrome
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	OrbeShield
<SUP>
	&reg;
</SUP>
	is an oral immediate
	and delayed release formulation of the topically active corticosteroid BDP and is being developed for the treatment of GI ARS.
	Corticosteroids are a widely used class of anti-inflammatory drugs.
<FONT STYLE="COLOR: RED">
</FONT>
	BDP is a corticosteroid with
	predominantly topical activity that is approved for use in asthma, psoriasis and allergic rhinitis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	OrbeShield
<SUP>
	&reg;
</SUP>
	has demonstrated
	positive preclinical results in a canine GI ARS model which indicate that dogs&nbsp;treated with OrbeShield
<SUP>
	&reg;
</SUP>
	demonstrated
	statistically significant (p=0.04) improvement in survival with dosing at either two hours or 24 hours after exposure to lethal
	doses of total body irradiation (&ldquo;TBI&rdquo;) when compared to control dogs. OrbeShield
<SUP>
	&reg;
</SUP>
	appears to significantly
	mitigate the damage to the GI epithelium caused by exposure to high doses of radiation using a well-established canine model of
	GI ARS.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The GI tract is highly sensitive to ionizing
	radiation and the destruction of epithelial tissue is one of the first effects of radiation exposure. The rapid loss of epithelial
	cells leads to inflammation and infection that are often the primary cause of death in acute radiation injury. This concept of
	GI damage also applies to the clinical setting of oncology, where high doses of radiation cannot be administered effectively to
	the abdomen because radiation is very toxic to the intestines. We are seeking to treat the same type of toxicity in our acute radiation
	enteritis clinical program with SGX201. As a result, we believe that OrbeShield
<SUP>
	&reg;
</SUP>
	has the potential to be a &ldquo;dual
	use&rdquo; compound, a desirable characteristic which is a specific priority of BARDA for ARS and other medical countermeasure
	indications. The FDA has cleared the IND application for OrbeShield
<SUP>
	&reg;
</SUP>
	for the mitigation of morbidity and mortality
	associated with GI ARS.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In September 2013, we received two government
	contracts from BARDA and NIAID for the advanced preclinical and manufacturing development of OrbeShield
<SUP>
	&reg;
</SUP>
	leading
	to FDA approval to treat GI ARS. The BARDA contract contains a two year base period with two contract options, exercisable by BARDA,
	for a total of five years and up to $26.3 million. The NIAID contract consists of a one year base period and two contract options,
	exercisable by NIAID, for a total of three years and up to $6.4 million. Previously, development of OrbeShield
<SUP>
	&reg;
</SUP>
	had been largely supported by a $1 million NIH grant to Soligenix&rsquo;s academic partner, the Fred Hutchinson Cancer Research
	Center. In July 2012, we received an SBIR grant from NIAID of approximately $600,000 to support further preclinical development
	of OrbeShield
<SUP>
	&reg;
</SUP>
	for the treatment of acute GI ARS. The FDA has given OrbeShield
<SUP>
	&reg;
</SUP>
	orphan drug designation
	and Fast Track designation for the prevention of death following a potentially lethal dose of total body irradiation during or
	after a radiation disaster.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Assuming development efforts are successful
	for OrbeShield
<SUP>
	&reg;
</SUP>
	, we believe potential government procurement contracts could reach as much as $450 million. This
	potential procurement contract information is a forward-looking statement, and investors are urged not to place undue reliance
	on this statement. While we have determined this potential procurement contract value based on assumptions that we believe are
	reasonable, there are a number of factors that could cause our expectations to change or not be realized.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	GI Acute Radiation Syndrome
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	ARS occurs after toxic radiation exposure and
	involves several organ systems, notably the bone marrow, the GI tract and, later, the lungs. In the event of a nuclear disaster
	or terrorist detonation of a nuclear bomb, casualties exposed to greater than 2 grays (&ldquo;Gy&rdquo;) of absorbed radiation
	are at high risk for development of clinically significant ARS. Exposure to high doses of radiation exceeding 10-12 Gy causes acute
	GI injury which can result in death. The GI tract is highly sensitive due to the continuous need for crypt stem cells and production
	of mucosal epithelium. The extent of injury to the bone marrow and the GI tract are the principal determinants of survival after
	exposure to TBI. Although the hematopoietic syndrome can be rescued by bone marrow transplantation or growth factor administration,
	there is no established treatment or preventive measure for the GI damage that occurs after high-dose radiation. As a result, we
	believe there is an urgent medical need for specific medical counter measures against the lethal pathophysiological manifestations
	of radiation-induced GI injury.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	SGX943 &ndash; for Treating Melioidosis
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	SGX943 uses the same active ingredient as SGX94
	and is being developed in preclinical studies as a potential treatment for melioidosis. Because SGX943 directly targets the innate
	immune system (and does not attempt to kill the bacteria directly), we believe it is particularly relevant for antibiotic-resistant
	bacteria. The bacteria which causes melioidosis,
<I>
	Burkholderia pseudomallei,
</I>
	is known to be resistant to most antibiotics
	and to require prolonged treatment with the few antibiotics that do work. In February 2014, we were awarded a one-year NIAID SBIR
	award of approximately $300,000 to further evaluate SGX943 as a potential treatment for melioidosis. Preclinical results to date
	have demonstrated that SGX943 treatment, in combination with standard of care antibiotics such as doxycycline, can statistically
	significantly enhance survival in a lethal murine pneumonic melioidosis model (p&lt; 0.001).
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Melioidosis
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Melioidosis is a potentially fatal infection
	caused by the Gram-negative bacillus,
<I>
	Burkholderia pseudomallei
</I>
	(&ldquo;Bp&rdquo;). Highly resistant to many antibiotics,
	Bp can cause an acute disease characterized by a fulminant pneumonia and a chronic condition that can recrudesce. There is no preventive
	vaccine or effective immunotherapy for melioidosis. We believe that there is an unmet medical need for improved prevention and
	therapy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Bp infection (melioidosis) is a major public
	health concern in the endemic regions of Southeast Asia and Northern Australia. In Northeast Thailand, which has the highest incidence
	of melioidosis, the mortality rate associated with Bp infection is over 40 percent, making it the third most common cause of death
	from infectious disease in that region after HIV/AIDS and tuberculosis. Bp activity is seen in Southeast Asia, South America, Africa,
	the Middle East, India, and Australia. The highest pockets of disease activity occur in Northern Australia and Northeast Thailand
	with increasing recognition of disease activity in coastal regions of India.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Beyond its public health significance, Bp and
	the closely-related
<I>
	Burkholderia mallei
</I>
	(&ldquo;Bm&rdquo;) are considered possible biological warfare agents by the DHHS
	because of the potential for widespread dissemination through aerosol. Bp like its relative Bm, the cause of Glanders, was studied
	by the U.S. as a potential biological warfare agent, but was never weaponized. It has been reported that the Soviet Union was also
	experimenting with Bp as a biological warfare agent. &nbsp;Both Bp and Bm have been designated high priority threats by the DHHS
	in its PHEMCE Strategy released in 2012 and are classified as Category B Priority Pathogens by NIAID.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Drug Approval Process
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The FDA and comparable regulatory agencies
	in state, local and foreign jurisdictions impose substantial requirements on the clinical development, manufacture and marketing
	of new drug and biologic products. The FDA, through regulations that implement the Federal Food, Drug, and Cosmetic Act, as amended,
	or FDCA, and other laws and comparable regulations for other agencies, regulate research and development activities and the testing,
	manufacture, labeling, storage, shipping, approval, recordkeeping, advertising, promotion, sale, export, import and distribution
	of such products. The regulatory approval process is generally lengthy, expensive and uncertain. Failure to comply with applicable
	FDA and other regulatory requirements can result in sanctions being imposed on us or the manufacturers of our products, including
	holds on clinical research, civil or criminal fines or other penalties, product recalls, or seizures, or total or partial suspension
	of production or injunctions, refusals to permit products to be imported into or exported out of the United States, refusals of
	the FDA to grant approval of drugs or to allow us to enter into government supply contracts, withdrawals of previously approved
	marketing applications and criminal prosecutions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Before human clinical testing in the U.S. of
	a new drug compound or biological product can commence, an Investigational New Drug, or IND, application is required to be submitted
	to the FDA. The IND application includes results of pre-clinical animal studies evaluating the safety and efficacy of the drug
	and a detailed description of the clinical investigations to be undertaken.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Clinical trials are normally done in three
	phases, although the phases may overlap. Phase 1 trials are smaller trials concerned primarily with metabolism and pharmacologic
	actions of the drug and with the safety of the product. Phase 2 trials are designed primarily to demonstrate effectiveness and
	safety in treating the disease or condition for which the product is indicated. These trials typically explore various doses and
	regimens. Phase 3 trials are expanded clinical trials intended to gather additional information on safety and effectiveness needed
	to clarify the product&rsquo;s benefit-risk relationship and generate information for proper labeling of the drug, among other
	things. The FDA receives reports on the progress of each phase of clinical testing and may require the modification, suspension
	or termination of clinical trials if an unwarranted risk is presented to patients. When data is required from long-term use of
	a drug following its approval and initial marketing, the FDA can require Phase 4, or post-marketing, studies to be conducted.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	With certain exceptions, once successful
	clinical testing is completed, the sponsor can submit a New Drug Application, or NDA, for approval of a drug, or a Biologic License
	Application, or BLA, for biologics such as vaccines, which will be reviewed, and if successful, approved by the FDA, allowing
	the product to be marketed. The process of completing clinical trials for a new drug is likely to take a number of years and require
	the expenditure of substantial resources. Furthermore, the FDA or any foreign health authority may not grant an approval on a
	timely basis, if at all. The FDA may deny the approval of an NDA or BLA, in its sole discretion, if it determines that its regulatory
	criteria have not been satisfied or may require additional testing or information. Among the conditions for marketing approval
	is the requirement that the prospective manufacturer&rsquo;s quality control and manufacturing procedures conform to good manufacturing
	practice regulations. In complying with standards contained in these regulations, manufacturers must continue to expend time,
	money and effort in the area of production, quality control and quality assurance to ensure full technical compliance. Manufacturing
	facilities, both foreign and domestic, also are subject to inspections by, or under the authority of, the FDA and by other federal,
	state, local or foreign agencies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Even after initial FDA or foreign health authority
	approval has been obtained, further studies, including Phase 4 post-marketing studies, may be required to provide additional data
	on safety and will be required to gain approval for the marketing of a product as a treatment for clinical indications other than
	those for which the product was initially tested. For certain drugs intended to treat serious, life-threatening conditions that
	show great promise in earlier testing, the FDA can also grant conditional approval. However, drug developers are required to study
	the drug further and verify clinical benefit as part of the conditional approval provision, and the FDA can revoke approval if
	later testing does not reproduce previous findings. The FDA may also condition approval of a product on the sponsor agreeing to
	certain mitigation strategies that can limit the unfettered marketing of a drug. Also, the FDA or foreign regulatory authority
	will require post-marketing reporting to monitor the side effects of the drug. Results of post-marketing programs may limit or
	expand the further marketing of the product. Further, if there are any modifications to the drug, including any change in indication,
	manufacturing process, labeling or manufacturing facility, an application seeking approval of such changes will likely be required
	to be submitted to the FDA or foreign regulatory authority.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In the U.S., the FDCA, the Public Health Service
	Act, the Federal Trade Commission Act, and other federal and state statutes and regulations govern, or influence the research,
	testing, manufacture, safety, labeling, storage, record keeping, approval, advertising and promotion of drug, biological, medical
	device and food products. Noncompliance with applicable requirements can result in, among other things, fines, recall or seizure
	of products, refusal to permit products to be imported into the U.S., refusal of the government to approve product approval applications
	or to allow the Company to enter into government supply contracts, withdrawal of previously approved applications and criminal
	prosecution. The FDA may also assess civil penalties for violations of the FDCA involving medical devices.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For biodefense development, such as with RiVax&trade;
	and OrbeShield
<SUP>
	&reg;
</SUP>
	, the FDA has instituted policies that are expected to result in shorter pathways to market. This
	potentially includes approval for commercial use utilizing the results of animal efficacy trials, rather than efficacy trials in
	humans. However, the Company will still have to establish that the vaccine and countermeasures it is developing are safe in humans
	at doses that are correlated with the beneficial effect in animals. Such clinical trials will also have to be completed in distinct
	populations that are subject to the countermeasures; for instance, the very young and the very old, and in pregnant women, if the
	countermeasure is to be licensed for civilian use. Other agencies will have an influence over the benefit-risk scenarios for deploying
	the countermeasures and in establishing the number of doses utilized in the Strategic National Stockpile. We may not be able to
	sufficiently demonstrate the animal correlation to the satisfaction of the FDA, as these correlates are difficult to establish
	and are often unclear. Invocation of the animal rule may raise issues of confidence in the model systems even if the models have
	been validated. For many of the biological threats, the animal models are not available and the Company may have to develop the
	animal models, a time-consuming research effort. There are few historical precedents, or recent precedents, for the development
	of new countermeasure for bioterrorism agents. Despite the animal rule, the FDA may require large clinical trials to establish
	safety and immunogenicity before licensure and it may require safety and immunogenicity trials in additional populations. Approval
	of biodefense products may be subject to post-marketing studies, and could be restricted in use in only certain populations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Vaccines are approved under the BLA process
	that exists under the Public Health Service Act. In addition to the greater technical challenges associated with developing biologics,
	the potential for generic competition is lower for a BLA product than a small molecule product subject to an NDA under the Federal
	Food, Drug and Cosmetic Act. Under the Patient Protection and Affordable Care Act enacted in 2010, a &ldquo;generic&rdquo; version
	of a biologic is known as a biosimilar and the barriers to entry &ndash; whether legal, scientific, or logistical &ndash; for a
	biosimilar version of a biologic approved under a BLA are higher.
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Orphan drug designation
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Under the Orphan Drug Act, the FDA may grant
	orphan drug designation to drugs or biologics intended to treat a rare disease or condition&mdash;generally a disease or condition
	that affects fewer than 200,000 individuals in the United States. Orphan drug designation must be requested before submitting an
	NDA or BLA. After the FDA grants orphan drug designation, the generic identity of the drug or biologic and its potential orphan
	use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the
	regulatory review and approval process. The first NDA or BLA applicant to receive FDA approval for a particular active ingredient
	to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the United
	States for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications
	to market the same drug or biologic for the same disease, except in limited circumstances, such as a showing of clinical superiority
	to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug or
	biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other
	benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA or BLA application user fee.
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Fast track designation and accelerated approval
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The FDA is required to facilitate the development,
	and expedite the review, of drugs or biologics that are intended for the treatment of a serious or life-threatening disease or
	condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the
	condition. Under the fast track program, the sponsor of a new drug or biologic candidate may request that the FDA designate the
	candidate for a specific indication as a fast track drug or biologic concurrent with, or after, the filing of the IND for the candidate.
	The FDA must determine if the drug or biologic candidate qualifies for fast track designation within 60 days of receipt of the
	sponsor's request. Unique to a fast track product, the FDA may initiate review of sections of a fast track product's NDA or BLA
	before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule
	for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA's time period goal
	for reviewing an application does not begin until the last section of the NDA or BLA is submitted. Additionally, the fast track
	designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the
	clinical trial process.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Any product submitted to the FDA for marketing,
	including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review,
	such as accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious or life-threatening
	illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means
	the FDA may approve the product based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a
	clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an
	effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence
	of the condition and the availability or lack of alternative treatments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In clinical trials, a surrogate endpoint is
	a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient
	feels, functions, or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A
	drug or biologic candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the
	completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required
	post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow the FDA to withdraw the drug or
	biologic from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations
	are subject to prior review by the FDA.
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Pediatric information
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Under the Pediatric Research Equity Act, or
	PREA, NDAs or BLAs or supplements to NDAs or BLAs must contain data to assess the safety and effectiveness of the drug for the
	claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation
	for which the drug is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless
	otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted.
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	False Claims Laws
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The federal False Claims Act prohibits, among
	other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval
	by, the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a
	false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act
	of 2009, a claim includes &ldquo;any request or demand&rdquo; for money or property presented to the US government.
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Anti-Kickback Laws
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The federal Anti-Kickback Statute prohibits,
	among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration,
	directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging
	for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs.
	The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted
	to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on
	the other.
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	United States Healthcare Reform
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Federal Physician Payments Sunshine Act and
	its implementing regulations require that certain manufacturers of drugs, devices, biological and medical supplies for which payment
	is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program (with certain exceptions) to report information
	related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities
	or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain
	ownership and investment interests held by physicians and their immediate family members.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition, we may be subject to data privacy
	and security regulation by both the federal government and the states in which we conduct our business. The Health Insurance Portability
	and Accountability Act, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH,
	and its implementing regulations, imposes certain requirements relating to the privacy, security and transmission of individually
	identifiable health information. Among other things, HITECH makes HIPAA&rsquo;s privacy and security standards directly applicable
	to &ldquo;business associates&rdquo;&mdash;independent contractors or agents of covered entities that receive or obtain protected
	health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of
	civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and possibly
	other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts
	to enforce the federal HIPAA laws and seek attorneys&rsquo; fees and costs associated with pursuing federal civil actions. In addition,
	state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other
	in significant ways and may not have the same effect, thus complicating compliance efforts.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Third-Party Suppliers and Manufacturers
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Drug substance and drug product manufacturing
	is outsourced to qualified suppliers. We do not have manufacturing capabilities/infrastructure and do not intend to develop the
	capacity to manufacture drug products substances. We have agreements with third-party manufacturers to supply bulk drug substances
	for our product candidates and with third parties to formulate, package and distribute our product candidates. Our employees include
	professionals with expertise in pharmaceutical manufacturing development, quality assurance and third party supplier management
	who oversee work conducted by third-party companies. We believe that we have on hand or can easily obtain sufficient amounts of
	product candidates to complete our currently contemplated clinical trials. All of the drug substances used in our product candidates
	currently are manufactured by single suppliers. While we have not experienced any supply disruptions, the number of manufacturers
	of the drug substances is limited. In the event it is necessary or advisable to acquire supplies from alternative suppliers, assuming
	commercially reasonable terms could be reached, the challenge would be the efficient transfer of technology and know-how from current
	manufactures to the new supplier. Formulation and distribution of our finished product candidates also currently are conducted
	by single suppliers but we believe that alternative sources for these services are readily available on commercially reasonable
	terms, subject to the efficient transfer of technology and know-how from current suppliers to the new supplier.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	All of the current agreements for the supply
	bulk drug substances for our product candidates and for the formulation or distribution of our product candidates relate solely
	to the development (including preclinical and clinical) of our product candidates. Under these contracts, our product candidates
	are manufactured upon our order of a specific quantity. In the event that we obtain marketing approval for a product candidate,
	we will qualify secondary suppliers for all key manufacturing activities supporting the marketing application.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Marketing and Collaboration
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We do not currently have any sales and marketing
	capability, other than to potentially market our biodefense vaccine products directly to government agencies. With respect to other
	commercialization efforts, we currently intend to seek distribution and other collaboration arrangements for the sales and marketing
	of any product candidate that is approved, while also evaluating the potential to commercialize on our own in orphan disease indications.
	From time to time, we have had and are having strategic discussions with potential collaboration partners for our biodefense vaccine
	product candidates, although no assurance can be given that we will be able to enter into one or more collaboration agreements
	for our product candidate on acceptable terms, if at all. We believe that both military and civilian health authorities of the
	U.S. and other countries will increase their stockpiling of therapeutics and vaccines to treat and prevent diseases and conditions
	that could ensue following a bioterrorism attack.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On December 20, 2012, we re-acquired the North
	American and European commercial rights to oral BDP through an amendment of our collaboration and supply agreement with Sigma-Tau
	Pharmaceuticals, Inc. (&ldquo;Sigma-Tau&rdquo;)
<FONT STYLE="COLOR: #333333">
	.
</FONT>
	The amendment requires us to make certain
	approval and commercialization milestone payments to Sigma-Tau which could reach up to $6 million. In addition, the Company has
	agreed to pay Sigma-Tau: (a) a royalty amount equal to 3% of all net sales of oral BDP made directly by the Company, and any third-party
	partner and/or their respective affiliates in the U.S., Canada, Mexico and in each country in the European Territory for the later
	to occur of: (i) a period of ten years from the first commercial sale of oral BDP in each country, or (ii) the expiration of the
	Company&rsquo;s patents and patent applications relating to oral BDP in such country (the &ldquo;Payment Period&rdquo;); and (b)
	15% of all up-front payments, milestone payments and any other consideration (exclusive of equity payments) received by the Company
	and/or a potential partner from the Company&rsquo;s and/or potential partner&rsquo;s licensees, distributors and agents for oral
	BDP in each relevant country in the territory, which amount will be paid on a product-by-product and a country-by-country basis
	for the Payment Period.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Competition
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our competitors are pharmaceutical and biotechnology
	companies, most of whom have considerably greater financial, technical, and marketing resources than we do. Universities and other
	research institutions, including the U.S. Army Medical Research Institute of Infectious Diseases, also compete in the development
	of treatment technologies, and we face competition from other companies to acquire rights to those technologies.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	SGX301 Competition
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The FDA has approved several treatments
	for later stages (IIB-IV) of CTCL and/or in conditions that are unresponsive to prior treatment. Two are targeted therapies (Targretin
<SUP>
	&reg;
</SUP>
	-caps
	and Ontak
<SUP>
	&reg;
</SUP>
	), two are histone deacetylases inhibitors (Zolina
<SUP>
	&reg;
</SUP>
	and Istodax
<SUP>
	&reg;
</SUP>
	) and the
	remaining two are topical therapies (Valchor
<SUP>
	&reg;
</SUP>
	and Targretin
<SUP>
	&reg;
</SUP>
	-gel). There are currently no FDA approved
	therapies for the treatment of front-line, early stage (I-IIA) CTCL; however certain topical chemotherapies and topical, radiation,
	photo and other therapies which are approved for indications other than CTCL are prescribed off-label for the treatment of early
	stage CTCL. These include psoralen combined with ultraviolet A (UVA) light therapy (&ldquo;PUVA&rdquo;); however, PUVA treatments
	are usually limited to three times per week and 200 times in total due to the potentially carcinogenic side effects. There are
	other drugs currently in development that may have the potential to be used in early stage (I-IIA) CTCL &ndash; one in phase 2
	(vorinostat) and others in phase 1. Vorinostat has been approved by the FDA to treat CTCL patients who have conditions that are
	unresponsive to other therapies. It currently is being studied in a phase 2 trial for the treatment of all stages of CTCL, with
	an estimated completion date for the phase 2 trial in September 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	SGX94/942 Competition
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Because SGX94 uses a novel mechanism of action
	in combating bacterial infections, there are no direct competitors at this time. Bacterial infections are routinely treated with
	antibiotics and SGX94 treatment is anticipated to be utilized primarily where antibiotics are insufficient (e.g., due to antibiotic
	resistance) or contra-indicated (e.g., in situations where the development of antibiotic resistance is a significant concern).
	Many groups are working on the antibiotic resistance problem and research into the innate immune system is intensifying, making
	emerging competition likely (from companies such as Celtaxsys Inc., Innaxon Therapeutics and Innate Pharma SA).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There is currently one drug approved for the
	treatment of oral mucositis in hematological cancer (palifermin). There are currently no approved drugs for treatment of oral mucositis
	in cancers with solid tumors (e.g., head and neck cancer). There are several drugs in clinical development for oral mucositis &ndash;
	one in Phase 3 (under development by Daewoong Pharmaceutical Co., Ltd), four in Phase 2 (under development by Cellceutix Corporation,
	BioAlliance Pharma S.A., Onexeo, and Alder Biopharmaceuticals Inc.) and one in Phase 1 (under development by ActoGenix N.V.). In
	addition, there are medical devices approved for the treatment of oral mucositis including MuGard, GelClair, Episil and Caphosol.
	These devices attempt to create a protective barrier around the oral ulceration.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Oral BDP Competition
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There are a number of approved treatments for
	Crohn&rsquo;s disease and additional compounds are in late-stage development.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Remicade (infliximab) and Humira (adalimumab)
	are currently approved for the treatment of pediatric Crohn&rsquo;s disease; however, both carry significant Black Box warnings
	in their labeling for increased risk of serious infection and malignancy, and therefore are approved for treatment of moderate
	to severe patients. There is one other marketed biologic, Tysabri (natalizumab), in a Phase 2 study for pediatric Crohn&rsquo;s.
	Entocort (enteric-coated budesonide) also has completed Phase 3 trials in pediatric Crohn&rsquo;s disease.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	ThermoVax
<SUP>
	&reg;
</SUP>
	Competition
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Multiple groups and companies are working to
	address the unmet need of vaccine thermostability using a variety of technologies. In addition, other organizations, such as the
	Bill and Melinda Gates Foundation and PATH, have programs designed to advance technologies to address this need.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Several stabilization technologies currently
	being developed involve mixing vaccine antigen +/- adjuvant with various proprietary excipients or co-factors that either serve
	to stabilize the vaccine or biological product in a liquid or dried (lyophilized) form.&nbsp;Examples of these approaches include
	the use of various plant-derived sugars and macromolecules being developed by companies such as Stabilitech Ltd. Variation Biotechnologies,
	Inc. (&ldquo;VBI&rdquo;) is developing a lipid system (resembling liposomes) to stabilize viral antigens, including virus-like
	particles (VLPs), and for potential application to a conventional influenza vaccine among others.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Other approaches involve process variations
	to freeze-dry live virus vaccines.&nbsp;For example, PaxVax, Inc. is seeking to employ a spray drying technology in concert with
	enteric coating to achieve formulations for room temperature stability of live virus vaccines using adenovirus vectors.&nbsp;VBI
	is seeking to utilize their proprietary stabilization technology for a number of vaccines (as a co-development service, similar
	to the business model being developed by Stabilitech Ltd.), whereas PaxVax is applying the technology to their own proprietary
	vaccine development programs. Stabilitech uses combinations of excipients, which include glassifying sugars similar to the ThermoVax
<SUP>
	&reg;
</SUP>
	technology, and variations in drying cycles during lyophilization, as does the ThermoVax
<SUP>
	&reg;
</SUP>
	technology.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Additionally, companies like Pharmathene, Inc.,
	Panacea Biotec Ltd., and Compass Biotech Inc. are developing proprietary vaccines with the application of some form of stabilization
	technology.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Vaccines/BioDefense Competition
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We face competition in the area of biodefense
	product development from various public and private companies, universities and governmental agencies, such as the U.S. Army, some
	of whom may have their own proprietary technologies which may directly compete with our technologies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The U.S. Army Medical Research Institute of
	Infectious Diseases, the DoD&rsquo;s lead laboratory for medical research to counter biological threats is also developing a ricin
	vaccine candidate, RVEc&trade;. RVEc&trade; has been shown to be fully protective in mice exposed to lethal doses of ricin toxin
	by the aerosol route. Further studies, in both rabbits and nonhuman primates, were conducted to evaluate RVEc&trade;&rsquo;s safety
	as well as its immunogenicity, with positive results observed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In the area of radiation-protective antidotes
	such as OrbeShield
<SUP>
	&reg;,
</SUP>
	various companies, such as Cleveland Biolabs, Inc., Aeolus Pharmaceuticals, Inc., Boulder Biotechnology,
	Inc., RxBio, Inc., Avaxia Biologics, Inc., Exponential Biotherapies Inc., Osiris Therapeutics, Inc., ImmuneRegen BioSciences, Inc.,
	Neumedicines, Inc., Cellerant Therapeutics, Inc., Onconova Therapeutics, Inc., Araim Pharmaceuticals, Inc., EVA Pharmaceuticals,
	Terapio Corporation, Cangene Corporation, Humanetics Corporation and the University of Arkansas Medical Sciences Center are developing
	biopharmaceutical products that may directly compete with OrbeShield
<SUP>
	&reg;,
</SUP>
	even though their approaches to such treatment
	are different.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	RxBio, Avaxia Biologics and the University
	of Arkansas have programs specifically for GI ARS. RxBio&rsquo;s Rx100 is a stem cell protectant designed as a single dose (oral
	or injection) which has shown promise in nonhuman primate studies. Avaxia is developing an orally delivered anti-TNF antibody as
	a treatment agent for exposure to radiation following a nuclear accident, attack or explosion. Pasireotide, a drug in development
	by Novartis for Cushing&rsquo;s disease, is being developed at the University of Arkansas to protect the intestine by reducing
	pancreatic secretions that exacerbate intestinal inflammation.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Patents and Other Proprietary Rights
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our goal is to obtain, maintain and enforce
	patent protection for our products, formulations, processes, methods and other proprietary technologies, preserve our trade secrets,
	and operate without infringing on the proprietary rights of other parties, both in the U.S. and in other countries. Our policy
	is to actively seek to obtain, where appropriate, the broadest intellectual property protection possible for our product candidates,
	proprietary information and proprietary technology through a combination of contractual arrangements and patents, both in the U.S.
	and elsewhere in the world.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We also depend upon the skills, knowledge and
	experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors, none
	of which is patentable. To help protect our proprietary knowledge and experience that is not patentable, and for inventions for
	which patents may be difficult to enforce, we rely on trade secret protection and confidentiality agreements to protect our interests.
	To this end, we require all employees, consultants, advisors and other contractors to enter into confidentiality agreements, which
	prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas,
	developments, discoveries and inventions important to our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We have issued U.S. patents 8,263,582 and 6,096,731
	that cover the use of oral BDP for treating inflammatory disorders of the gastrointestinal tract and the prevention and treatment
	of GI GVHD, respectively. U.S. patent numbers 8,263,582 and 6,096,731 are expected to expire in March 2022 and June 2018, respectively.
	We also have European patent EP 1392321 claiming the use of topically active corticosteroids in orally administered dosage forms
	that act concurrently to treat inflammation in the upper and lower gastrointestinal tract, as well as European patent EP 2242477
	claiming the use of orally ingested BDP for treatment of interstitial lung disease. European patents EP 1392321 and EP 2242477
	are expected to expire in March 2022 and January 2029.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The subject of U.S. patent application number
	12/633,631 filed December 8, 2009 and corresponding European patent application number 09836727.9 is the use of topically active
	BDP in radiation and chemotherapeutics injury. Additionally, we have numerous patent filings currently issued or pending in foreign
	jurisdictions covering this subject matter, including Australia, Canada, China, Hong Kong, Israel, India, Japan, South Korea and
	New Zealand.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	ThermoVax
<SUP>
	&reg;
</SUP>
	is the subject of
	U.S. patent 8,444,991 issued on May 21, 2013 titled &ldquo;Method of Preparing an Immunologically-Active Adjuvant-Bound Dried Vaccine
	Composition&rdquo; and also U.S. patent application number 13/474,661 filed May 17, 2012 titled &ldquo;Thermostable Vaccine Compositions
	and Methods of Preparing Same.&rdquo; The patent application and the corresponding foreign filings for both patents are pending
	and licensed to us by the University of Colorado (&ldquo;UC&rdquo;) and they address the use of adjuvants in conjunction with vaccines
	that are formulated to resist thermal inactivation. The license agreement covers thermostable vaccines for biodefense as well as
	other potential vaccine indications. &nbsp;U.S. patent 8,444,991 is expected to expire in December 2031.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	RiVax&trade; is the subject of three issued
	U.S. patent numbers 6,566,500, 6,960,652, and 7,829,668, all titled &ldquo;Compositions and methods for modifying toxic effects
	of proteinaceous compounds.&rdquo; This patent family includes composition of matter claims for the modified ricin toxin A chain
	which is the immunogen contained in RiVax&trade;, and issued in 2003, 2005 and 2010 respectively. The initial filing date of these
	patents is March 2000 and they are expected to expire in March 2020. The issued patents contain claims that describe alteration
	of sequences within the ricin A chain that affect vascular leak, one of the deadly toxicities caused by ricin toxin. Another U.S.
	patent number 7,175,848 titled &ldquo;Ricin A chain mutants lacking enzymatic activity as vaccines to protect against aerosolized
	ricin,&rdquo; was filed in October of 2000 and is expected to expire in October 2020.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In 2013, we expanded our patent portfolio to
	include innate defense regulation through the acquisition of the novel drug technology, known as SGX94. By binding to the pivotal
	regulatory protein p62, also known as sequestosome-1, SGX94 regulates the innate immune system to reduce inflammation, eliminate
	infection and enhance healing. As part of the acquisition, we acquired all rights, including composition of matter patents for
	SGX94 as well as other analogs and crystal structures of SGX94 with its protein target p62, including U.S. patent 8,124,721 and
	additional pending applications, both in the US and abroad. SGX94 was developed pursuant to discoveries made by Professors B. Brett
	Finlay and Robert Hancock of UBC.&nbsp; U.S. patent 8,124,721 is expected to expire in April 2028.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In 2014, we acquired a novel, first-in-class,
	photodynamic therapy that utilizes safe visible light for activation, which we refer to as SGX301. The active ingredient in SGX301
	is synthetic hypericin, a photosensitizer which is topically applied to skin lesions and then activated by fluorescent light 16
	to 24 hours later. As part of the acquisition, we acquired a license agreement relating to the use of photo-activated hypericin,
	composition of matter patent for SGX301 (U.S. patent 8,629,302) and additional issued and pending applications, both in the US
	and abroad. &nbsp;U.S. patent 8,629,302 is expected to expire in June 2032.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition to issued and pending patents,
	we also have &ldquo;Orphan Drug&rdquo; designations for SGX301 in the U.S. and the EU for CTCL, SGX203 in the U.S. for pediatric
	Crohn&rsquo;s disease, and OrbeShield
<SUP>
	&reg;
</SUP>
	in the U.S. for GI ARS, as well as for RiVax&trade; in the U.S. Our Orphan
	Drug designations provide for seven years of post-approval marketing exclusivity in the U.S. and ten years exclusivity in Europe.
	We have pending patent applications for this indication that, if granted, may extend our anticipated marketing exclusivity beyond
	the U.S. seven year or E.U. ten year post-approval exclusivity provided by Orphan Drug legislation.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Oral BDP License Agreement
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On November 24, 1998, the Company, known at
	the time as Enteron Pharmaceuticals, Inc. (&ldquo;Enteron&rdquo;) and George B. McDonald (&ldquo;Dr. McDonald&rdquo;) entered into
	an exclusive license agreement for the rights to intellectual property, including know-how, relating to oral BDP. The Company has
	an exclusive license to commercially exploit the covered products worldwide, subject to Dr.&nbsp;McDonald&rsquo;s right to make
	and use the technology for research purposes and the U.S. Government&rsquo;s right to use the technology for government purposes.
	Pursuant to the license agreement, as amended, the Company is required to (i) reimburse Dr. McDonald for certain out-of-pocket
	expenses incurred by Dr.&nbsp;McDonald in connection with the patent applications and issued patents, (ii) pay Dr.&nbsp;McDonald
	$400,000 upon approval by the FDA of the Company&rsquo;s first NDA incorporating oral BDP; (iii) pay Dr.&nbsp;McDonald royalty
	payments equal to 3% of net sales of the covered products and (iv) pay Dr. McDonald $400,000 in cash upon an approval of oral BDP
	by the European Medicines Agency.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Additionally, in the event that the Company
	sublicenses its rights under the license agreement, the Company will be required to pay Dr. McDonald 10% of any sublicense fees
	and royalty payments paid by the sublicense to the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The term of the license agreement expires upon
	the expiration of the licensed patent applications or patents. After seven years from the date of the agreement, Dr. McDonald has
	the right to terminate the license agreement in its entirety or to terminate exclusivity under the agreement if the Company or
	its sublicense has not commercialized or are not actively attempting to commercialize a covered product.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Additionally, the agreement terminates: (i)
	automatically upon the Company becoming insolvent; (ii) upon 30 days&rsquo; notice, if the Company breaches any obligation under
	the agreement without curing such breach during the notice period; and (iii) upon 90 days&rsquo; notice by the Company. After any
	termination, the Company will have the right to sell its inventory for a period not to exceed three months following the date of
	termination, subject to the payment of the amounts owed under the agreement.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	SGX94 License Agreements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On December 18, 2012, we announced the acquisition
	of a novel drug technology, known as SGX94, representing a novel approach to modulation of the innate immune system. SGX94 is an
	IDR that regulates the innate immune system to reduce inflammation, eliminate infection and enhance tissue healing by binding to
	the pivotal regulatory protein p62, also known as sequestosome-1. As part of the acquisition, Soligenix acquired all rights, including
	composition of matter patents, preclinical and Phase 1 clinical study datasets for SGX94. We also assumed a license agreement with
	UBC to advance the research and development of the SGX94 technology. The license agreement with UBC provides us with exclusive
	worldwide rights to manufacture, distribute, market sell and/or license or sublicense products derived or developed from this technology.
	Under the license agreement we are obligated to pay UBC (i) an annual license maintenance fee of CAN $1,000, and (ii) milestone
	payments which could reach up to CAN $1.2 million.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	ThermoVax
<SUP>
	&reg;
</SUP>
	License
	Agreement
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On September 1, 2009, we executed a worldwide
	exclusive option to license patent applications with the UC for ThermoVax
<SUP>
	&reg;
</SUP>
	which is the subject of U.S. patent number
	8,444,991 issued on May 21, 2013 titled &ldquo;Method of Preparing an Immunologically-Active Adjuvant-Bound Dried Vaccine Composition.&rdquo;
	This patent and its corresponding foreign filings are licensed to Soligenix by the UC and they address the use of adjuvants in
	conjunction with vaccines that are formulated to resist thermal inactivation. U.S. Patent 8,444,991 is expected to expire in December
	2031. The license agreement also covers thermostable vaccines for biodefense as well as other potential vaccine indications.&nbsp;In
	addition, Soligenix in conjunction with UC, filed domestic and foreign patent applications claiming priority back to a provisional
	application filed on May 17, 2011 titled: &ldquo;Thermostable Vaccine Compositions and Methods of Preparing Same.&rdquo;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	RiVax&trade; License Agreement
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In January 2003, we executed a worldwide exclusive
	option to license patent applications with UTSW for the nasal, pulmonary and oral uses of a non-toxic ricin vaccine. In June 2004,
	we entered into a license agreement with UTSW for the injectable rights to the ricin vaccine and, in October 2004, we negotiated
	the remaining oral rights to the ricin vaccine. To maintain this license we are obligated to pay $50,000 in annual license fees.
	Through this license, we have rights to the issued patent number 7,175,848 titled &ldquo;Ricin A chain mutants lacking enzymatic
	activity as vaccines to protect against aerosolized ricin.&rdquo; This patent includes methods of use and composition claims for
	RiVax&trade;.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	SGX301 License Agreement
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In September 2014, we acquired a worldwide
	exclusive license agreement with New York University and Yeda Research and Development Company Ltd. for the rights to a novel,
	first-in-class, photodynamic therapy that utilizes safe visible light for activation, which we refer to as SGX301. To maintain
	this license we are obligated to pay $25,000 in annual license fees. In addition, we will pay the licensors: (a) a royalty amount
	equal to 3% of all net sales of SGX301 made directly by us and/or any affiliates; (b) a royalty amount equal to 2.5% of all net
	sales of SGX301 made by our sublicensees, subject to stated maximums and (b) 20% of all payments, not based on net sales, received
	by us from our sublicensees. The exclusive license includes rights to several issued US patents, including U.S. patent numbers
	6,867,235 and 7,122,518, among other domestic and foreign patent applications. U.S. Patent numbers 6,867,235 and 7,122,518 are
	expected to expire in January 2020 and November 2023, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We acquired the license agreement for SGX301
	and related intangible assets, properties and rights pursuant to an asset purchase agreement with Hy Biopharma Inc. (&ldquo;Hy
	Biopharma&rdquo;). As consideration for the assets acquired, we paid $250,000 in cash and issued 1,849,113 shares of common stock
	with a market value of $3,750,000. Provided all future success-orientated milestones are attained, we will be required to make
	payments of up to $10.0 million, if and when achieved, payable in common stock of the Company.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Research and Development Expenditure
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We spent approximately $5.4 million and $9.1
	million in the years ended December 31, 2015 and 2014, respectively, on research and development. The amounts we spent on research
	and development per product during the years ended December 31, 2015, and 2014 are set forth in &ldquo;Management&rsquo;s Discussion
	and Analysis of Financial Condition and Results of Operations&rdquo; in this Annual Report on Form 10-K.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Employees
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As of December 31, 2015, we had 16 full-time
	employees, 8 of whom are MDs/PhDs.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Available Investor Information
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We file electronically with the Securities
	and Exchange Commission (&ldquo;SEC&rdquo;) our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on
	Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) of 15(d) of the Securities Exchange Act
	of 1934, as amended. We make available through our website, free of charge, copies of these reports as soon as reasonably practicable
	after we electronically file or furnish them to the SEC. Our website is located at http://www.soligenix.com. You can also request
	copies of such documents by contacting the company at (609) 538-8200 or sending an email to info@soligenix.com.
</P>
</EFX_BUSINESS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Item 1A. Risk factors
</B>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	An investment in our securities involves
	a high degree of risk. You should carefully consider the following information about these risks, together with the other information
	about these risks contained in this Annual Report, as well as the other information contained in this Annual Report generally,
	before deciding to buy our securities. Any of the risks we describe below could adversely affect our business, financial condition,
	operating results or prospects. The market prices for our securities could decline if one or more of these risks and uncertainties
	develop into actual events and you could lose all or part of your investment. Additional risks and uncertainties that we do not
	yet know of, or that we currently think are immaterial, may also impair our business operations. You should also refer to the other
	information contained in this Annual Report, including our financial statements and the related notes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<U>
	Risks Related to our Business
</U>
</B>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We have had significant losses
	and anticipate future losses; if additional funding cannot be obtained, we may reduce or discontinue our product development and
	commercialization efforts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We have experienced significant losses since
	inception and, at December 31, 2015, had an accumulated deficit of approximately $146.9 million. We expect to incur additional
	operating losses in the future and expect our cumulative losses to increase. As of December 31, 2015, we had approximately $4.9
	million in cash available. Based on our projected budgetary needs, funding from existing contracts and grants over the next two
	years and sales to the purchasers under our existing equity lines, we expect to be able to maintain the current level of our operations
	for at least the next 12 months.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We have sufficient funds through our existing
	biodefense grant facilities from the NIAID, a division of the NIH, and BARDA to finance our biodefense projects for the next six
	years. In September 2014, we entered into a contract with the NIH for the development of RiVax
<SUP>
	TM
</SUP>
	to protect against
	exposure to ricin toxin that would provide up to $24.7 million of funding in the aggregate if options to extend the contract are
	exercised by the NIH. In September 2013, we entered into contracts with the NIH and BARDA for the development of OrbeShield&reg;
	that would provide up to $32.7 million of funding in the aggregate if options to extend the contracts are exercised by BARDA and
	the NIH. In September 2009, we received a NIAID grant for approximately $9.4 million for the development of our biodefense programs.
	In July 2012, we received an additional SBIR grant from NIAID for $600,000 and in February 2014, we were awarded a one-year NIAID
	SBIR grant award of approximately $300,000 to further evaluate SGX943 as a treatment for melioidosis. Our biodefense grants have
	an overhead component that allows us an agency-approved percentage over our incurred costs. We estimate that the overhead component
	associated with our existing contracts and grants will fund some fixed costs for direct employees working on these contracts and
	grants as well as other administrative costs. As of December 2015, we have approximately $43.0 million in active contract funding.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our product candidates are positioned for or
	are currently in clinical trials, and we have not yet generated any significant revenues from sales or licensing of these product
	candidates. From inception through December 2015, we have expended approximately $66.2 million developing our current product candidates
	for pre-clinical research and development and clinical trials, and we currently expect to spend at least $12.9 million
<B>
</B>
	over
	the next 12 months in connection with the development of our therapeutic and vaccine products, licenses, employment agreements,
	and consulting agreements of which approximately $7.6 million will be reimbursed through our existing government contracts and
	grants. Unless and until we are able to generate sales or licensing revenue from one of our product candidates, we will require
	additional funding to meet these commitments, sustain our research and development efforts, provide for future clinical trials,
	and continue our operations. There can be no assurance we can raise such funds. If additional funds are raised through the issuance
	of equity securities, stockholders may experience dilution of their ownership interests, and the newly issued securities may have
	rights superior to those of the common stock. If additional funds are raised by the issuance of debt, we may be subject to limitations
	on our operations. If we cannot raise such additional funds, we may have to delay or stop some or all of our drug development programs.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If we are unable to develop our
	product candidates, our ability to generate revenues and viability as a company will be significantly impaired.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In order to generate revenues and profits,
	our organization must, along with corporate partners and collaborators, positively research, develop and commercialize our technologies
	or product candidates. Our current product candidates are in various stages of early clinical and pre-clinical development and
	will require significant further funding, research, development, pre-clinical and/or clinical testing, regulatory approval and
	commercialization, and are subject to the risks of failure inherent in the development of products based on innovative or novel
	technologies. Specifically, each of the following is possible with respect to any of our product candidates:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may not be able to maintain our current research and development schedules;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may be unable to secure procurement contracts on beneficial economic terms or at all from the
	U.S. government or others for our biodefense products;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may encounter problems in clinical trials; or
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the technology or product may be found to be ineffective or unsafe, or may fail to obtain marketing
	approval.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If any of the risks set forth above occur,
	or if we are unable to obtain the necessary regulatory approvals as discussed below, we may be unable to develop our technologies
	and product candidates and our business will be seriously harmed. Furthermore, for reasons including those set forth below, we
	may be unable to commercialize or receive royalties from the sale of any other technology we develop, even if it is shown to be
	effective, if:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	it is not economical or the market for the product does not develop or diminishes;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we are not able to enter into arrangements or collaborations to manufacture and/or market the product;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the product is not eligible for third-party reimbursement from government or private insurers;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	others hold proprietary rights that preclude us from commercializing the product;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we are not able to manufacture the product reliably;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	others have brought to market similar or superior products; or
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the product has undesirable or unintended side effects that prevent or limit its commercial use.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We expect a number of factors to
	cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We are a late-stage biopharmaceutical company.
	Our operations to date have been primarily limited to developing our technology and undertaking clinical studies and clinical trials
	of our product candidates in our two active business segments, BioTherapeutics and Vaccines/BioDefense. We have not yet obtained
	regulatory approvals for any of our product candidates. Consequently, any predictions made about our future success or viability
	may not be as accurate as they could be if we had commercialized products. Our financial condition has varied significantly in
	the past and will continue to fluctuate from quarter-to-quarter or year-to-year due to a variety of factors, many of which are
	beyond our control. Factors relating to our business that may contribute to these fluctuations include other factors described
	elsewhere in this Annual Report
<I>
</I>
	and also include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to obtain additional funding to develop our product candidates;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	delays in the commencement, enrollment and timing of clinical trials;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the success of our product candidates through all phases of clinical development;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	any delays in regulatory review and approval of product candidates in clinical development;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to obtain and maintain regulatory approval for our product candidates in the United
	States and foreign jurisdictions;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	potential side effects of our product candidates that could delay or prevent commercialization,
	limit the indications for any approved drug, require the establishment of risk evaluation and mitigation strategies, or cause an
	approved drug to be taken off the market;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our dependence on third-party contract manufacturing organizations (&ldquo;CMOs&rdquo;) to supply
	or manufacture our products;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our dependence on contract research organizations to conduct our clinical trials;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to establish or maintain collaborations, licensing or other arrangements;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	market acceptance of our product candidates;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to establish and maintain an effective sales and marketing infrastructure, either through
	the creation of a commercial infrastructure or through strategic collaborations;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	competition from existing products or new products that may emerge;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement
	for our products;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to discover and develop additional product candidates;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability and our licensors&rsquo; abilities to successfully obtain, maintain, defend and enforce
	intellectual property rights important to our business;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to attract and retain key personnel to manage our business effectively;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to build our finance infrastructure and improve our accounting systems and controls;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	potential product liability claims;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	potential liabilities associated with hazardous materials; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our ability to obtain and maintain adequate insurance policies.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Accordingly, the results of any quarterly or
	annual periods should not be relied upon as indications of future operating performance.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We have no approved products on
	the market and therefore do not expect to generate any revenues from product sales in the foreseeable future, if at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	To date, we have no approved product on the
	market and have not generated any significant product revenues. We have funded our operations primarily from sales of our securities
	and from government grants. We have not received, and do not expect to receive for at least the next several years, if at all,
	any revenues from the commercialization of our product candidates. To obtain revenues from sales of our product candidates, we
	must succeed, either alone or with third parties, in developing, obtaining regulatory approval for, manufacturing and marketing
	drugs with commercial potential or successfully obtain government procurement or stockpiling agreements. We may never succeed in
	these activities, and we may not generate sufficient revenues to continue our business operations or achieve profitability.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our business is subject to extensive
	governmental regulation, which can be costly, time consuming and subjects us to unanticipated delays.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our business is subject to very stringent federal,
	foreign, state and local government laws and regulations, including the Federal Food, Drug and Cosmetic Act, the Environmental
	Protection Act, the Occupational Safety and Health Act, and state and local counterparts to these acts. These laws and regulations
	may be amended, additional laws and regulations may be enacted, and the policies of the FDA and other regulatory agencies may change.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The regulatory process applicable to our products
	requires pre-clinical and clinical testing of any product to establish its safety and efficacy. This testing can take many years
	is uncertain as to outcome, and requires the expenditure of substantial capital and other resources. We estimate that the clinical
	trials of our product candidates that we have planned will take at least several years to complete. Furthermore, failure can occur
	at any stage of the trials, and we could encounter problems that cause us to abandon or repeat clinical trials. Favorable results
	in early studies or trials, if any, may not be repeated in later studies or trials. Even if our clinical trials are initiated and
	completed as planned, we cannot be certain that the results will support our product candidate claims. Success in preclinical testing,
	Phase 1 and Phase 2 clinical trials does not ensure that later Phase 2 or Phase 3 clinical trials will be successful. In addition,
	we, the FDA or other regulatory authorities may suspend clinical trials at any time if it appears that we are exposing participants
	to unacceptable health risks or the FDA or other regulatory authorities find deficiencies in our submissions or conduct of our
	trials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We may not be able to obtain, or we may experience
	difficulties and delays in obtaining, necessary domestic and foreign governmental clearances and approvals to market a product.
	Also, even if regulatory approval of a product is granted, that approval may entail limitations on the indicated uses for which
	the product may be marketed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Following any regulatory approval, a marketed
	product and its manufacturer are subject to continual regulatory review. Later discovery of problems with a product or manufacturer
	may result in restrictions on such product or manufacturer. These restrictions may include product recalls and suspension or withdrawal
	of the marketing approval for the product. Furthermore, the advertising, promotion and export, among other things, of a product
	are subject to extensive regulation by governmental authorities in the U.S. and other countries. If we fail to comply with applicable
	regulatory requirements, we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure
	of products, operating restrictions and/or criminal prosecution.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There may be unforeseen challenges
	in developing our biodefense products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	For development of biodefense vaccines and
	therapeutics, the FDA has instituted policies that are expected to result in accelerated approval. This includes approval for commercial
	use using the results of animal efficacy trials, rather than efficacy trials in humans, referred to as the Animal Rule. However,
	we will still have to establish that the vaccines we are developing are safe in humans at doses that are correlated with the beneficial
	effect in animals. Such clinical trials will also have to be completed in distinct populations that are subject to the countermeasures;
	for instance, the very young and the very old, and in pregnant women, if the countermeasure is to be licensed for civilian use.
	Other agencies will have an influence over the risk benefit scenarios for deploying the countermeasures and in establishing the
	number of doses utilized in the Strategic National Stockpile. We may not be able to sufficiently demonstrate the animal correlation
	to the satisfaction of the FDA, as these correlates are difficult to establish and are often unclear. Invocation of the Animal
	Rule may raise issues of confidence in the model systems even if the models have been validated. For many of the biological threats,
	the animal models are not available and we may have to develop the animal models, a time-consuming research effort. There are few
	historical precedents, or recent precedents, for the development of new countermeasure for bioterrorism agents. Despite the Animal
	Rule, the FDA may require large clinical trials to establish safety and immunogenicity before licensure and it may require safety
	and immunogenicity trials in additional populations. Approval of biodefense products may be subject to post-marketing studies,
	and could be restricted in use in only certain populations. The government&rsquo;s biodefense priorities can change, which could
	adversely affect the commercial opportunity for the products we are developing. Further, other countries have not, at this time,
	established criteria for review and approval of these types of products outside their normal review process, i.e., there is no
	Animal Rule equivalent, and consequently there can be no assurance that we will be able to make a submission for marketing approval
	in foreign countries based on such animal data.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Additionally, few facilities in the United
	States and internationally have the capability to test animals with anthrax or ricin, or otherwise assist us in qualifying the
	requisite animal models. We have to compete with other biodefense companies for access to this limited pool of highly specialized
	resources. We therefore may not be able to secure contracts to conduct the testing in a predictable timeframe or at all.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We are dependent on government
	funding, which is inherently uncertain, for the success of our biodefense operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We are subject to risks specifically associated
	with operating in the biodefense industry, which is a new and unproven business area. We do not anticipate that a significant commercial
	market will develop for our biodefense products. Because we anticipate that the principal potential purchasers of these products,
	as well as potential sources of research and development funds, will be the U.S. government and governmental agencies, the success
	of our biodefense division will be dependent in large part upon government spending decisions. The funding of government programs
	is dependent on budgetary limitations, congressional appropriations and administrative allotment of funds, all of which are inherently
	uncertain and may be affected by changes in U.S. government policies resulting from various political and military developments.
	Our receipt of government funding is also dependent on our ability to adhere to the terms and provisions of the original grant
	documents and other regulations. We can provide no assurance that we will receive or continue to receive funding for grants we
	have been awarded. The loss of government funds could have a material adverse effect on our ability to progress our biodefense
	business.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If the parties we depend on for
	supplying our drug substance raw materials and certain manufacturing-related services do not timely supply these products and services,
	it may delay or impair our ability to develop, manufacture and market our products. We do not have or anticipate having internal
	manufacturing capabilities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We rely on suppliers for our drug substance
	raw materials and third parties for certain manufacturing-related services to produce material that meets appropriate content,
	quality and stability standards, which material will be used in clinical trials of our products and, after approval, for commercial
	distribution. To succeed, clinical trials require adequate supplies of drug substance and drug product, which may be difficult
	or uneconomical to procure or manufacture. We and our suppliers and vendors may not be able to (i) produce our drug substance or
	drug product to appropriate standards for use in clinical studies, (ii) perform under any definitive manufacturing, supply or service
	agreements with us or (iii) remain in business for a sufficient time to be able to develop, produce, secure regulatory approval
	of and market our product candidates. If we do not maintain important manufacturing and service relationships, we may fail to find
	a replacement supplier or required vendor or develop our own manufacturing capabilities which could delay or impair our ability
	to obtain regulatory approval for our products and substantially increase our costs or deplete profit margins, if any. If we do
	find replacement manufacturers and vendors, we may not be able to enter into agreements with them on terms and conditions favorable
	to us and, there could be a substantial delay before a new facility could be qualified and registered with the FDA and foreign
	regulatory authorities.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The manufacturing of our products
	is a highly exacting process, and if we or one of our materials suppliers encounter problems manufacturing our products, our business
	could suffer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The FDA and foreign regulators require manufacturers
	to register manufacturing facilities. The FDA and foreign regulators also inspect these facilities to confirm compliance with current
	Good Manufacturing Practice (&ldquo;cGMP&rdquo;) or similar requirements that the FDA or foreign regulators establish. We, or our
	materials suppliers, may face manufacturing or quality control problems causing product production and shipment delays or a situation
	where we or the supplier may not be able to maintain compliance with the FDA&rsquo;s cGMP requirements, or those of foreign regulators,
	necessary to continue manufacturing our drug substance. Any failure to comply with cGMP requirements or other FDA or foreign regulatory
	requirements could adversely affect our clinical research activities and our ability to market and develop our products.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We may use our financial and human
	resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates
	that may be more profitable or for which there is a greater likelihood of success.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Because we have limited financial and human
	resources, we are currently focusing on the regulatory approval of certain product candidates. As a result, we may forego or delay
	pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential.
	Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.
	Our spending on existing and future product candidates for specific indications may not yield any commercially viable products.
	If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish
	valuable rights to that product candidate through strategic alliance, licensing or other royalty arrangements in cases in which
	it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate,
	or we may allocate internal resources to a product candidate in an area in which it would have been more advantageous to enter
	into a partnering arrangement.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Even if approved, our products
	will be subject to extensive post-approval regulation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Once a product is approved, numerous post-approval
	requirements apply. Among other things, the holder of an approved New Drug Application (&ldquo;NDA&rdquo;) is subject to periodic
	and other FDA monitoring and reporting obligations, including obligations to monitor and report adverse events and instances of
	the failure of a product to meet the specifications in the NDA. Application holders must submit new or supplemental applications
	and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Application holders
	must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Depending on the circumstances, failure to
	meet these post-approval requirements can result in criminal prosecution, fines, injunctions, recall or seizure of products, total
	or partial suspension of production, denial or withdrawal of pre-marketing product approvals, or refusal to allow us to enter into
	supply contracts, including government contracts. In addition, even if we comply with FDA and other requirements, new information
	regarding the safety or effectiveness of a product could lead the FDA to modify or withdraw product approval.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Even if we obtain regulatory approval
	to market our product candidates, our product candidates may not be accepted by the market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Even if the FDA approves one or more of our
	product candidates, physicians and patients may not accept it or use it. Even if physicians and patients would like to use our
	products, our products may not gain market acceptance among healthcare payors such as managed care formularies, insurance companies
	or government programs such as Medicare or Medicaid. Acceptance and use of our products will depend upon a number of factors including:
	perceptions by members of the health care community, including physicians, about the safety and effectiveness of our drug or device
	product; cost-effectiveness of our product relative to competing products; availability of reimbursement for our product from government
	or other healthcare payers; and effectiveness of marketing and distribution efforts by us and our licensees and distributors, if
	any.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The degree of market acceptance of any product
	that we develop will depend on a number of factors, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	cost-effectiveness;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the safety and effectiveness of our products, including any significant potential side effects,
	as compared to alternative products or treatment methods;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the timing of market entry as compared to competitive products;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
</FONT>
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	the rate of adoption of our products by doctors and nurses;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	product labeling or product insert required by the FDA for each of our products;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
</FONT>
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	reimbursement policies of government and third-party payors;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	effectiveness of our sales, marketing and distribution capabilities and the effectiveness of such
	capabilities of our collaborative partners, if any; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	unfavorable publicity concerning our products or any similar products.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 27; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our product candidates, if successfully developed,
	will compete with a number of products manufactured and marketed by major pharmaceutical companies, biotechnology companies and
	manufacturers of generic drugs. Our products may also compete with new products currently under development by others. Physicians,
	patients, third-party payors and the medical community may not accept and utilize any of our product candidates. If our products
	do not achieve market acceptance, we will not be able to generate significant revenues or become profitable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Because we expect sales of our current product
	candidates, if approved, to generate substantially all of our product revenues for the foreseeable future, the failure of these
	products to find market acceptance would harm our business and could require us to seek additional financing.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We do not have extensive sales
	and marketing experience and our lack of experience may restrict our success in commercializing some of our product candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We do not have extensive experience in marketing
	or selling pharmaceutical products whether in the U.S. or internationally. To obtain the expertise necessary to successfully market
	and sell any of our products, the development of our own commercial infrastructure and/or collaborative commercial arrangements
	and partnerships will be required. Our ability to make that investment and also execute our current operating plan is dependent
	on numerous factors, including, the performance of third party collaborators with whom we may contract.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our products, if approved, may
	not be commercially viable due to change in health care practice and third party reimbursement limitations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Recent initiatives to reduce the federal deficit
	and to change health care delivery are increasing cost-containment efforts. We anticipate that Congress, state legislatures and
	the private sector will continue to review and assess alternative benefits, controls on health care spending through limitations
	on the growth of private health insurance premiums and Medicare and Medicaid spending, price controls on pharmaceuticals, and other
	fundamental changes to the health care delivery system. Any changes of this type could negatively impact the commercial viability
	of our products, if approved. Our ability to successfully commercialize our product candidates, if they are approved, will depend
	in part on the extent to which appropriate reimbursement codes and authorized cost reimbursement levels of these products and related
	treatment are obtained from governmental authorities, private health insurers and other organizations, such as health maintenance
	organizations. In the absence of national Medicare coverage determination, local contractors that administer the Medicare program
	may make their own coverage decisions. Any of our product candidates, if approved and when commercially available, may not be included
	within the then current Medicare coverage determination or the coverage determination of state Medicaid programs, private insurance
	companies or other health care providers. In addition, third-party payers are increasingly challenging the necessity and prices
	charged for medical products, treatments and services.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our product candidates may cause
	serious adverse events or undesirable side effects which may delay or prevent marketing approval, or, if approval is received,
	require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Serious adverse events or undesirable side
	effects from any of our product candidates could arise either during clinical development or, if approved, after the approved product
	has been marketed. The results of future clinical trials may show that our product candidates cause serious adverse events or undesirable
	side effects, which could interrupt, delay or halt clinical trials, resulting in delay of, or failure to obtain, marketing approval
	from the FDA and other regulatory authorities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If any of our product candidates cause serious
	adverse events or undesirable side effects:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	regulatory authorities may impose a clinical hold which could result in substantial delays and
	adversely impact our ability to continue development of the product;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication
	or field alerts to physicians and pharmacies;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may be required to change the way the product is administered, conduct additional clinical trials
	or change the labeling of the product;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may be required to implement a risk minimization action plan, which could result in substantial
	cost increases and have a negative impact on our ability to commercialize the product;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may be required to limit the patients who can receive the product;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may be subject to limitations on how we promote the product;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	sales of the product may decrease significantly;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	regulatory authorities may require us to take our approved product off the market;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	we may be subject to litigation or product liability claims; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our reputation may suffer.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 28; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Any of these events could
	prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization
	costs and expenses, which in turn could delay or prevent us from generating significant revenues from the sale of our products.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Federal and/or state health care
	reform initiatives could negatively affect our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The availability of reimbursement by governmental
	and other third-party payers affects the market for any pharmaceutical product. These third-party payers continually attempt to
	contain or reduce the costs of healthcare. There have been a number of legislative and regulatory proposals to change the healthcare
	system and further proposals are likely. Medicare's policies may decrease the market for our products. Significant uncertainty
	exists with respect to the reimbursement status of newly approved healthcare products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition, third-party payers are increasingly
	challenging the price and cost-effectiveness of medical products and services. Once approved, we might not be able to sell our
	products profitably or recoup the value of our investment in product development if reimbursement is unavailable or limited in
	scope, particularly for product candidates addressing small patient populations. On July 15, 2008, the Medicare Improvements for
	Patients and Providers Act of 2008 became law with a number of Medicare and Medicaid reforms to establish a bundled Medicare payment
	rate that includes services and drug/labs that were separately billed at that time. Bundling initiatives that have been implemented
	in other healthcare settings have occasionally resulted in lower utilization of services that had not previously been a part of
	the bundled payment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition, in some foreign countries, the
	proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely
	from country to country. We expect that there will continue to be a number of U.S. federal and state proposals to implement governmental
	pricing controls. While we cannot predict whether such legislative or regulatory proposals will be adopted, the adoption of such
	proposals could have a material adverse effect on our business, financial condition and profitability.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We may not be able to retain rights
	licensed to us by third parties to commercialize key products or to develop the third party relationships we need to develop, manufacture
	and market our products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We currently rely on license agreements from
	New York University, Yeda Research and Development Company Ltd., the University of Texas Southwestern Medical Center, the University
	of British Columbia, Harvard University, the University of Colorado, and George B. McDonald, MD for the rights to commercialize
	key product candidates. We may not be able to retain the rights granted under these agreements or negotiate additional agreements
	on reasonable terms, if at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Furthermore, we currently have very limited
	product development capabilities and no manufacturing, marketing or sales capabilities. For us to research, develop and test our
	product candidates, we need to contract or partner with outside researchers, in most cases with or through those parties that did
	the original research and from whom we have licensed the technologies. If products are successfully developed and approved for
	commercialization, then we will need to enter into additional collaboration and other agreements with third parties to manufacture
	and market our products. We may not be able to induce the third parties to enter into these agreements, and, even if we are able
	to do so, the terms of these agreements may not be favorable to us. Our inability to enter into these agreements could delay or
	preclude the development, manufacture and/or marketing of some of our product candidates or could significantly increase the costs
	of doing so. In the future, we may grant to our development partners rights to license and commercialize pharmaceutical and related
	products developed under the agreements with them, and these rights may limit our flexibility in considering alternatives for the
	commercialization of these products. Furthermore, third-party manufacturers or suppliers may not be able to meet our needs with
	respect to timing, quantity and quality for the products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 29; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Additionally, if we do not enter into relationships
	with additional third parties for the marketing of our products, if and when they are approved and ready for commercialization,
	we would have to build our own sales force or enter into commercialization agreements with other companies. Development of an effective
	sales force in any part of the world would require significant financial resources, time and expertise. We may not be able to obtain
	the financing necessary to establish a sales force in a timely or cost effective manner, if at all, and any sales force we are
	able to establish may not be capable of generating demand for our product candidates, if they are approved.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We may suffer product and other
	liability claims; we maintain only limited product liability insurance, which may not be sufficient.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The clinical testing, manufacture and sale
	of our products involves an inherent risk that human subjects in clinical testing or consumers of our products may suffer serious
	bodily injury or death due to side effects, allergic reactions or other unintended negative reactions to our products. As a result,
	product and other liability claims may be brought against us. We currently have clinical trial and product liability insurance
	with limits of liability of $10 million, which may not be sufficient to cover our potential liabilities. Because liability insurance
	is expensive and difficult to obtain, we may not be able to maintain existing insurance or obtain additional liability insurance
	on acceptable terms or with adequate coverage against potential liabilities. Furthermore, if any claims are brought against us,
	even if we are fully covered by insurance, we may suffer harm such as adverse publicity.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We may use hazardous chemicals
	in our business. Potential claims relating to improper handling, storage or disposal of these chemicals could affect us and be
	time consuming and costly.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our research and development processes and/or
	those of our third party contractors may involve the controlled use of hazardous materials and chemicals. These hazardous chemicals
	are reagents and solvents typically found in a chemistry laboratory. Our operations also may produce hazardous waste products.
	Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials.
	While we attempt to comply with all environmental laws and regulations, including those relating to the outsourcing of the disposal
	of all hazardous chemicals and waste products, we cannot eliminate the risk of contamination from or discharge of hazardous materials
	and any resultant injury. In the event of such an accident, we could be held liable for any resulting damages and any liability
	could materially adversely affect our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Compliance with environmental laws and regulations
	may be expensive. Current or future environmental regulations may impair our research, development or production efforts. We might
	have to pay civil damages in the event of an improper or unauthorized release of, or exposure of individuals to, hazardous materials.
	We are not insured against these environmental risks.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We may agree to indemnify our collaborators
	in some circumstances against damages and other liabilities arising out of development activities or products produced in connection
	with these collaborations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition, the federal, state and local laws
	and regulations governing the use, manufacture, storage, handling and disposal of hazardous or radioactive materials and waste
	products may require us to incur substantial compliance costs that could materially adversely affect our business, financial condition
	and results of operations.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We may not be able to compete with
	our larger and better financed competitors in the biotechnology industry.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The biotechnology industry is intensely competitive,
	subject to rapid change and sensitive to new product introductions or enhancements. Most of our existing competitors have greater
	financial resources, larger technical staffs, and larger research budgets than we have, as well as greater experience in developing
	products and conducting clinical trials. Our competition is particularly intense in the gastroenterology and transplant areas and
	is also intense in the therapeutic area of inflammatory bowel diseases. We face intense competition in the biodefense area from
	various public and private companies and universities as well as governmental agencies, such as the U.S. Army, which may have their
	own proprietary technologies that may directly compete with our technologies. In addition, there may be other companies that are
	currently developing competitive technologies and products or that may in the future develop technologies and products that are
	comparable or superior to our technologies and products. We may not be able to compete with our existing and future competitors,
	which could lead to the failure of our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 30; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Additionally, if a competitor receives FDA
	approval before we do for a drug that is similar to one of our product candidates, FDA approval for our product candidate may be
	precluded or delayed due to periods of non-patent exclusivity and/or the listing with the FDA by the competitor of patents covering
	its newly-approved drug product. Periods of non-patent exclusivity for new versions of existing drugs such as our current product
	candidates can extend up to three and one-half years. See &ldquo;Business&mdash;The Drug Approval Process.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	These competitive factors could require us
	to conduct substantial new research and development activities to establish new product targets, which would be costly and time
	consuming. These activities would adversely affect our ability to commercialize products and achieve revenue and profits.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Competition and technological change
	may make our product candidates and technologies less attractive or obsolete.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We compete with established pharmaceutical
	and biotechnology companies that are pursuing other forms of treatment for the same indications we are pursuing and that have greater
	financial and other resources. Other companies may succeed in developing products earlier than us, obtaining FDA approval for products
	more rapidly, or developing products that are more effective than our product candidates. Research and development by others may
	render our technology or product candidates obsolete or noncompetitive, or result in treatments or cures superior to any therapy
	we develop. We face competition from companies that internally develop competing technology or acquire competing technology from
	universities and other research institutions. As these companies develop their technologies, they may develop competitive positions
	that may prevent, make futile, or limit our product commercialization efforts, which would result in a decrease in the revenue
	we would be able to derive from the sale of any products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	There can be no assurance that any of our product
	candidates will be accepted by the marketplace as readily as these or other competing treatments. Furthermore, if our competitors&rsquo;
	products are approved before ours, it could be more difficult for us to obtain approval from the FDA. Even if our products are
	successfully developed and approved for use by all governing regulatory bodies, there can be no assurance that physicians and patients
	will accept our product(s) as a treatment of choice.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Furthermore, the pharmaceutical research industry
	is diverse, complex, and rapidly changing. By its nature, the business risks associated therewith are numerous and significant.
	The effects of competition, intellectual property disputes, market acceptance, and FDA regulations preclude us from forecasting
	revenues or income with certainty or even confidence.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our business could be harmed if
	we fail to retain our current personnel or if they are unable to effectively run our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We currently have 19 employees and we depend
	upon these employees (in particular Dr. Christopher Schaber, our President and Chief Executive Officer) to manage the day-to-day
	activities of our business. Because we have such limited personnel, the loss of any of them or our inability to attract and retain
	other qualified employees in a timely manner would likely have a negative impact on our operations. We may be unable to effectively
	manage and operate our business, and our business may suffer, if we lose the services of our employees.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Instability and volatility in the
	financial markets could have a negative impact on our business, financial condition, results of operations, and cash flows.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	During recent years, there has been substantial
	volatility in financial markets due at least in part to the uncertainty with regard to the global economic environment. In addition,
	there has been substantial uncertainty in the capital markets and access to additional financing is uncertain. Moreover, customer
	spending habits may be adversely affected by current and future economic conditions. These conditions could have an adverse effect
	on our industry and business, including our financial condition, results of operations, and cash flows.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	To the extent that we do not generate sufficient
	cash from operations, we may need to issue stock or incur indebtedness to finance our plans for growth. Recent turmoil in the credit
	markets and the potential impact on the liquidity of major financial institutions may have an adverse effect on our ability to
	fund our business strategy through borrowings, under either existing or newly created instruments in the public or private markets
	on terms we believe to be reasonable, if at all.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 31; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Risks Related to our Intellectual Property
</U>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We may be unable to commercialize
	our products if we are unable to protect our proprietary rights, and we may be liable for significant costs and damages if we face
	a claim of intellectual property infringement by a third party.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our near and long term prospects depend in
	part on our ability to obtain and maintain patents, protect trade secrets and operate without infringing upon the proprietary rights
	of others. In the absence of patent and trade secret protection, competitors may adversely affect our business by independently
	developing and marketing substantially equivalent or superior products and technology, possibly at lower prices. We could also
	incur substantial costs in litigation and suffer diversion of attention of technical and management personnel if we are required
	to defend ourselves in intellectual property infringement suits brought by third parties, with or without merit, or if we are required
	to initiate litigation against others to protect or assert our intellectual property rights. Moreover, any such litigation may
	not be resolved in our favor.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Although we and our licensors have filed various
	patent applications covering the uses of our product candidates, patents may not be issued from the patent applications already
	filed or from applications that we might file in the future. Moreover, the patent position of companies in the pharmaceutical industry
	generally involves complex legal and factual questions, and recently has been the subject of much litigation. Any patents we own
	or license, now or in the future, may be challenged, invalidated or circumvented. To date, no consistent policy has been developed
	in the U.S. Patent and Trademark Office (the &ldquo;PTO&rdquo;) regarding the breadth of claims allowed in biotechnology patents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition, because patent applications in
	the U.S. are maintained in secrecy until patent applications publish or patents issue, and because publication of discoveries in
	the scientific or patent literature often lags behind actual discoveries, we cannot be certain that we and our licensors are the
	first creators of inventions covered by any licensed patent applications or patents or that we or they are the first to file. The
	PTO may commence interference proceedings involving patents or patent applications, in which the question of first inventorship
	is contested. Accordingly, the patents owned or licensed to us may not be valid or may not afford us protection against competitors
	with similar technology, and the patent applications licensed to us may not result in the issuance of patents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	It is also possible that our owned and licensed
	technologies may infringe on patents or other rights owned by others, and licenses to which may not be available to us. We may
	be unable to obtain a license under such patent on terms favorable to us, if at all. We may have to alter our products or processes,
	pay licensing fees or cease activities altogether because of patent rights of third parties.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition to the products for which we have
	patents or have filed patent applications, we rely upon unpatented proprietary technology and may not be able to meaningfully protect
	our rights with regard to that unpatented proprietary technology. Furthermore, to the extent that consultants, key employees or
	other third parties apply technological information developed by them or by others to any of our proposed projects, disputes may
	arise as to the proprietary rights to this information, which may not be resolved in our favor.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We may be involved in lawsuits
	to protect or enforce our patents, which could be expensive and time consuming.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The pharmaceutical industry has been characterized
	by extensive litigation regarding patents and other intellectual property rights, and companies have employed intellectual property
	litigation to gain a competitive advantage. We may become subject to infringement claims or litigation arising out of patents and
	pending applications of our competitors, or additional interference proceedings declared by the PTO to determine the priority of
	inventions. The defense and prosecution of intellectual property suits, PTO proceedings, and related legal and administrative proceedings
	are costly and time-consuming to pursue, and their outcome is uncertain. Litigation may be necessary to enforce our issued patents,
	to protect our trade secrets and know-how, or to determine the enforceability, scope, and validity of the proprietary rights of
	others. An adverse determination in litigation or interference proceedings to which we may become a party could subject us to significant
	liabilities, require us to obtain licenses from third parties, or restrict or prevent us from selling our products in certain markets.
	Although patent and intellectual property disputes might be settled through licensing or similar arrangements, the costs associated
	with such arrangements may be substantial and could include our paying large fixed payments and ongoing royalties. Furthermore,
	the necessary licenses may not be available on satisfactory terms or at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 32; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Competitors may infringe our patents, and we
	may file infringement claims to counter infringement or unauthorized use. This can be expensive, particularly for a company of
	our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid
	or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do
	not cover its technology. An adverse determination of any litigation or defense proceedings could put one or more of our patents
	at risk of being invalidated or interpreted narrowly.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Also, a third party may assert that our patents
	are invalid and/or unenforceable. There are no unresolved communications, allegations, complaints or threats of litigation related
	to the possibility that our patents are invalid or unenforceable. Any litigation or claims against us, whether or not merited,
	may result in substantial costs, place a significant strain on our financial resources, divert the attention of management and
	harm our reputation. An adverse decision in litigation could result in inadequate protection for our product candidates and/or
	reduce the value of any license agreements we have with third parties.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Interference proceedings brought before the
	PTO may be necessary to determine priority of invention with respect to our patents or patent applications. During an interference
	proceeding, it may be determined that we do not have priority of invention for one or more aspects in our patents or patent applications
	and could result in the invalidation in part or whole of a patent or could put a patent application at risk of not issuing. Even
	if successful, an interference proceeding may result in substantial costs and distraction to our management.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Furthermore, because of the substantial amount
	of discovery required in connection with intellectual property litigation or interference proceedings, there is a risk that some
	of our confidential information could be compromised by disclosure. In addition, there could be public announcements of the results
	of hearings, motions or other interim proceedings or developments. If investors perceive these results to be negative, the price
	of our common stock could be adversely affected.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If we infringe the rights of third
	parties we could be prevented from selling products, forced to pay damages, and defend against litigation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If our products, methods, processes and other
	technologies infringe the proprietary rights of other parties, we could incur substantial costs and we may have to: obtain licenses,
	which may not be available on commercially reasonable terms, if at all; abandon an infringing product candidate; redesign our products
	or processes to avoid infringement; stop using the subject matter claimed in the patents held by others; pay damages; and/or defend
	litigation or administrative proceedings which may be costly whether we win or lose, and which could result in a substantial diversion
	of our financial and management resources.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Risks Related to our Common Stock&nbsp;
</U>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our common stock price is highly
	volatile.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The market price of our common stock, like
	that of many other research and development public pharmaceutical and biotechnology companies, has been highly volatile and may
	continue to be so in the future due to a wide variety of factors, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	announcements by us or others of results of pre-clinical testing and clinical trials;
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	announcements of technological innovations, more important bio-threats or new commercial therapeutic
	products by us, our collaborative partners or our present or potential competitors;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our quarterly operating results and performance;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	developments or disputes concerning patents or other proprietary rights;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	acquisitions;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	litigation and government proceedings;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	adverse legislation;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	changes in government regulations;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	our available working capital;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	economic and other external factors; and
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	general market conditions.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 33; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Since January 1, 2015, the closing stock price
	of our common stock has fluctuated between a high of $2.50 per share to a low of $0.52 per share. On March 18, 2016, the last quoted
	sale price of our common stock as reported on the OTCQB was $0.82 per share. The fluctuation in the price of our common stock has
	sometimes been unrelated or disproportionate to our operating performance. In addition, potential dilutive effects of future sales
	of shares of common stock by the Company, as well as potential sale of common stock by the holders of warrants and options, could
	have an adverse effect on the market price of our shares.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our common stock trades on the
	Over-the-Counter Bulletin Board.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our common stock trades on the OTCQB securities
	market under the symbol &ldquo;SNGX.&rdquo; The OTCQB is a decentralized market regulated by the Financial Industry Regulatory
	Authority in which securities are traded via an electronic quotation system that serves more than 3,000 companies, but provides
	significantly less liquidity than national market systems such as the NYSE MKT. On the OTCQB, securities are traded by a network
	of brokers or dealers who carry inventories of securities to facilitate the buy and sell orders of investors, rather than providing
	the order matchmaking service seen in specialist exchanges. OTCQB securities include national, regional, and foreign equity issues.
	Companies traded on the OTCQB must be current in their reports filed with the SEC and other regulatory authorities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Since our common stock is not listed on a national
	exchange or market, the trading market for our common stock may become illiquid. Our common stock is subject to the penny stock
	rules of the SEC, which generally are applicable to equity securities with a price of less than $5.00 per share, other than securities
	registered on certain national securities exchanges provided that current price and volume information with respect to transactions
	in such securities is provided by the exchange or system. The penny stock rules require a broker-dealer, before a transaction in
	a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document prepared by the SEC that
	provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must
	provide the customer with bid and ask quotations for the penny stock, the compensation of the broker-dealer and its salesperson
	in the transaction and monthly account statements showing the market value of each penny stock held in the customer&rsquo;s account.
	In addition, the penny stock rules require that, before a transaction in a penny stock that is not otherwise exempt from such rules,
	the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and
	receive the purchaser&rsquo;s written agreement to the transaction. As a result of these requirements, our common stock could be
	priced at a lower price and our stockholders could find it more difficult to sell their shares.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Shareholders may suffer substantial
	dilution related to issued stock warrants and options.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As of December 31, 2015, we had a number of
	agreements or obligations that may result in dilution to investors. These include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	warrants to purchase a total of approximately 4,926,119 shares of our common stock at a current
	weighted average exercise price of approximately $0.74; and
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	options to purchase approximately 2,768,612 shares of our common stock at a current weighted average
	exercise price of approximately $2.13.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We also have an incentive compensation plan
	for our management, employees and consultants. We have granted, and expect to grant in the future, options to purchase shares of
	our common stock to our directors, employees and consultants. To the extent that warrants or options are exercised, our stockholders
	will experience dilution and our stock price may decrease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Additionally, the sale, or even the possibility
	of the sale, of the shares of common stock underlying these warrants and options could have an adverse effect on the market price
	for our securities or on our ability to obtain future financing.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 34; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Anti-takeover provisions in our
	stockholder rights plan and under Delaware law could make a third party acquisition of the Company difficult.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our stockholder rights plan contains provisions
	that could make it more difficult for a third party to acquire us, even if doing so might be deemed beneficial by our stockholders.
	These provisions could limit the price that investors might be willing to pay in the future for shares of our common stock. We
	are also subject to certain provisions of Delaware law that could delay, deter or prevent a change in control of the Company. The
	rights issued pursuant to our stockholder rights plan will become exercisable the tenth day after a person or group announces acquisition
	of 15% or more of our common stock or commences, or announces an intention to make, a tender or exchange offer the consummation
	of which would result in ownership by the person or group of 15% or more of our common stock. If the rights become exercisable,
	the holders of the rights (other than the person acquiring 15% or more of our common stock) will be entitled to acquire, in exchange
	for the rights&rsquo; exercise price, shares of our common stock or shares of any company in which we are merged, with a value
	equal to twice the rights&rsquo; exercise price.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our shares of common stock are
	thinly traded, so stockholders may be unable to sell at or near ask prices or at all if they need to sell shares to raise money
	or otherwise desire to liquidate their shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our common stock has from time to time been
	&ldquo;thinly-traded,&rdquo; meaning that the number of persons interested in purchasing our common stock at or near ask prices
	at any given time may be relatively small or non-existent. This situation is attributable to a number of factors, including the
	fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors and others
	in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons,
	they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase
	of our shares until such time as we become more seasoned and viable. As a consequence, there may be periods of several days or
	more when trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer which has a large and steady
	volume of trading activity that will generally support continuous sales without an adverse effect on share price. We cannot give
	stockholders any assurance that a broader or more active public trading market for our common shares will develop or be sustained,
	or that current trading levels will be sustained.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Since our common stock is not listed
	on a national securities exchange, U.S. holders of warrants may not be able to exercise their warrants without compliance with
	applicable state securities laws and the value of your warrants may be significantly reduced.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Since our securities are not listed for trading
	on a national exchange, the exercise of the warrants by U.S. holders may not be exempt from state securities laws. As a result,
	depending on the state of residence of a holder of the warrants, a U.S. holder may not be able to exercise its warrants unless
	we comply with any state securities law requirements necessary to permit such exercise or an exemption applies. Although we plan
	to use our reasonable efforts to assure that U.S. holders will be able to exercise their warrants under applicable state securities
	laws if no exemption exists, there is no assurance that we will be able to do so. As a result, your ability to exercise your warrants
	may be limited. The value of the warrants may be significantly reduced if U.S. holders are not able to exercise their warrants
	under applicable state securities laws.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our common stock is deemed to be
	a &ldquo;penny stock,&rdquo; which may make it more difficult for investors to sell their shares due to suitability requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our common stock is subject to Rule 15g-1 through
	15g-9 under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), which imposes certain sales practice
	requirements on broker-dealers which sell our common stock to persons other than established customers and &ldquo;accredited investors&rdquo;
	(generally, individuals with a net worth in excess of $1,000,000 or annual incomes exceeding $200,000 (or $300,000 together with
	their spouses)). For transactions covered by this rule, a broker-dealer must make a special suitability determination for the purchaser
	and have received the purchaser&rsquo;s written consent to the transaction prior to the sale. This rule adversely affects the ability
	of broker-dealers to sell our common stock and the ability of our stockholders to sell their shares of common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 35; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Additionally, our common stock is subject to
	the SEC regulations for &ldquo;penny stock.&rdquo; Penny stock includes any equity security that is not listed on a national exchange
	and has a market price of less than $5.00 per share, subject to certain exceptions. The regulations require that prior to any non-exempt
	buy/sell transaction in a penny stock, a disclosure schedule set forth by the SEC relating to the penny stock market must be delivered
	to the purchaser of such penny stock. This disclosure must include the amount of commissions payable to both the broker-dealer
	and the registered representative and current price quotations for the common stock. The regulations also require that monthly
	statements be sent to holders of penny stock that disclose recent price information for the penny stock and information of the
	limited market for penny stocks. These requirements adversely affect the market liquidity of our common stock.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We do not currently intend to pay
	dividends on our common stock in the foreseeable future, and consequently, our stockholders&rsquo; ability to achieve a return
	on their investment will depend on appreciation in the price of our common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We have never declared or paid cash dividends
	on our common stock and do not anticipate paying any cash dividends to holders of our common stock in the foreseeable future. Consequently,
	our stockholders must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize
	any future gains on their investments. There is no guarantee that shares of our common stock will appreciate in value or even maintain
	the price at which our stockholders have purchased their shares.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Upon dissolution of the Company,
	our stockholders may not recoup all or any portion of their investment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In the event of a liquidation, dissolution
	or winding-up of the Company, whether voluntary or involuntary, the proceeds and/or assets of the Company remaining after giving
	effect to such transaction, and the payment of all of our debts and liabilities will be distributed to the holders of common stock
	on a pro rata basis. There can be no assurance that we will have available assets to pay to the holders of common stock, or any
	amounts, upon such a liquidation, dissolution or winding-up of the Company. In this event, our stockholders could lose some or
	all of their investment.
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The sale or issuance of our common
	stock to Lincoln Park may cause dilution and the sale of the shares of common stock acquired by Lincoln Park, or the perception
	that such sales may occur, could cause the price of our common stock to fall.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On November 18, 2013, we entered into a purchase agreement (the
	&ldquo;2013 Purchase Agreement&rdquo;) with Lincoln Park Capital Fund, LLC (&ldquo;Lincoln Park&rdquo;), pursuant to which Lincoln
	Park has committed to purchase up to $10.6 million of our common stock.&nbsp; Concurrently with the execution of the 2013 Purchase
	Agreement, we issued 97,656 shares of our common stock to Lincoln Park as a partial fee for its commitment to purchase shares of
	our common stock under the 2013 Purchase Agreement and 285,714 shares of common stock for an aggregate price of $600,000. From
	November 18, 2013 through December 31, 2015, we sold 1,050,000 additional shares to Lincoln Park and issued 22,091 additional shares
	to Lincoln Park as additional commitment shares under the 2013 Purchase Agreement and received proceeds of $1,809,652. The shares
	that may be sold pursuant to the 2013 Purchase Agreement in the future may be sold by us to Lincoln Park at our discretion from
	time to time over the remaining term of approximately nine months from the date of this report.&nbsp; The purchase price for the
	shares that we may sell to Lincoln Park under the 2013 Purchase Agreement will fluctuate based on the price of our common stock.&nbsp;
	We generally have the right to control the timing and amount of any sales of our shares to Lincoln Park, except that, pursuant
	to the terms of the 2013 Purchase Agreement, we would be unable to sell shares to Lincoln Park if and when the closing sale price
	of our common stock is below $1.00 per share, subject to adjustment as set forth in the 2013 Purchase Agreement.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We entered into an additional purchase agreement (the &ldquo;2016
	Purchase Agreement&rdquo;) with Lincoln Park on March 22, 2016, with the intention that the 2016 Purchase Agreement will replace
	the 2013 Purchase Agreement once the registration statement registering the resale of the shares of common stock sold to Lincoln
	Park under the 2016 Purchase Agreement is declared effective by the SEC.&nbsp; Pursuant to the 2016 Purchase Agreement, Lincoln
	Park has committed to purchase up to $12 million of our common stock.&nbsp; Concurrently with the execution of the 2016 Purchase
	Agreement, we issued 100,000 shares of our common stock to Lincoln Park as a partial fee for its commitment to purchase shares
	of our common stock under the 2016 Purchase Agreement. The shares that may be sold pursuant to the 2016 Purchase Agreement may
	be sold by us to Lincoln Park at our sole discretion from time to time over the remaining term of approximately 36 months from
	the date the registration statement registering the resale of the shares of common stock sold to Lincoln Park under the 2016 Purchase
	Agreement is declared effective by the SEC.&nbsp; The purchase price for the shares that we may sell to Lincoln Park under the
	2016 Purchase Agreement will fluctuate based on the price of our common stock.&nbsp; We have the right to control the timing and
	amount of any sales of our shares to Lincoln Park, except that, pursuant to the terms of our agreements with Lincoln Park, we would
	be unable to sell shares to Lincoln Park that would cause Lincoln Park to beneficially own more than 4.99% of our issued and outstanding
	common stock.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: #1F497D">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: #1F497D">
</P>
<!-- FIELD: PAGE; SEQUENCE: 36; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; COLOR: #1F497D">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Depending on market liquidity at the time, sales of shares under
	the 2013 Purchase Agreement or the 2016 Purchase Agreement may cause the trading price of our common stock to fall.&nbsp; Additionally,
	further sales of our common stock, if any, to Lincoln Park under the 2013 Purchase Agreement or the 2016 Purchase Agreement will
	depend upon market conditions and other factors to be determined by us.&nbsp; Lincoln Park may ultimately purchase all, some or
	none of the shares of our common stock that may be sold pursuant to the 2013 Purchase Agreement or the 2016 Purchase Agreement
	and, after it has acquired shares, Lincoln Park may sell all, some or none of those shares.&nbsp; Therefore, sales to Lincoln Park
	by us could result in substantial dilution to the interests of other holders of our common stock.&nbsp; Additionally, the sale
	of a substantial number of shares of our common stock to Lincoln Park, or the anticipation of such sales, could make it more difficult
	for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect
	sales.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The issuance of our common stock
	pursuant to the terms of the asset purchase agreement with Hy Biopharma Inc. may cause dilution and the issuance of such shares
	of common stock, or the perception that such issuances may occur, could cause the price of our common stock to fall.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On April 1, 2014, we entered into an option
	agreement pursuant to which Hy Biopharma Inc. granted us an option to purchase certain assets, properties and rights (the &ldquo;Hypericin
	Assets&rdquo;) related to the development of Hy Biopharma&rsquo;s synthetic hypericin product candidate for the treatment of CTCL,
	which we refer to as SGX301, from Hy Biopharma. In exchange for the option, we paid $50,000 in cash and issued 43,067 shares of
	common stock in the aggregate to Hy Biopharma and its assignees. We subsequently exercised the option, and on September 3, 2014,
	we entered into an asset purchase agreement with Hy Biopharma, pursuant to which we purchased the Hypericin Assets. Pursuant to
	the purchase agreement, we paid $250,000 in cash and issued 1,849,113 shares of common stock in the aggregate to Hy Biopharma and
	its assignees, and may issue up to an aggregate of $10 million worth of our common stock (subject to a cap equal to 19.99% of our
	issued and outstanding common stock) in the aggregate upon attainment of specified milestones. Also on September 3, 2014, we entered
	into the Registration Rights Agreement with Hy Biopharma, pursuant to which we have filed a registration statement with the SEC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The number of shares that we may issue under
	the purchase agreement will fluctuate based on the market price of our common stock.&nbsp;&nbsp;Depending on market liquidity at
	the time, the issuance of such shares may cause the trading price of our common stock to fall.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We may ultimately issue all, some or none of
	the additional shares of our common stock that may be issued pursuant to the purchase agreement. We are required to register any
	shares issued pursuant to the purchase agreement for resale under the Securities Act. After any such shares are registered, the
	holders will be able to sell all, some or none of those shares.&nbsp;&nbsp;Therefore, issuances by us under the purchase agreement
	could result in substantial dilution to the interests of other holders of our common stock.&nbsp;&nbsp;Additionally, the issuance
	of a substantial number of shares of our common stock pursuant to the purchase agreement, or the anticipation of such issuances,
	could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we
	might otherwise wish to effect sales.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 37; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_RISK_FACTORS>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Item 1B. Unresolved Staff Comments
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	None.
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Item 2. Properties
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We currently lease approximately 5,200 square
	feet of office space at 29 Emmons Drive, Suite C-10, Princeton, New Jersey 08540. This office space currently serves as our corporate
	headquarters. In December 2014, we entered into a lease agreement through May 31, 2018 for existing and expanded office space.
	The rent for the first 12 months was approximately $12,300 per month, or approximately $20.85 per square foot. The rent increased
	to approximately $12,375 per month, or approximately $20.95 per square foot, for the next 12 months, and thereafter to approximately
	$12,460 per month, or approximately $21.13 per square foot for the remainder of the lease. Our office space is sufficient to satisfy
	our current needs.
</P>
</EFX_PROPERTIES>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Item 3. Legal Proceedings
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	From time to time, we are a party to claims
	and legal proceedings arising in the ordinary course of business. Our management evaluates our exposure to these claims and proceedings
	individually and in the aggregate and allocates additional monies for potential losses on such litigation if it is possible to
	estimate the amount of loss and if the amount of the loss is probable.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 38; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_LEGAL_PROCEEDINGS>
</EFX_PART_I>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	PART II
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Item 5. Market for Registrant&rsquo;s Common Equity,
	Related Stockholder Matters and Issuer Purchases of Equity Securities
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Our common stock is quoted on the OTCQB under
	the symbol &ldquo;SNGX.&rdquo; The following table sets forth for the periods indicated, the high and low sales prices per share
	of our common stock as reported by the OTCQB.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Price Range
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Period
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	High
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Low
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Year Ended December 31, 2014:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	First Quarter
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2.50
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1.75
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Second Quarter
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2.29
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1.65
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Third Quarter
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2.25
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1.67
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Fourth Quarter
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2.09
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	0.91
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Year Ended December 31, 2015:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	First Quarter
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2.30
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	0.98
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Second Quarter
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2.95
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1.36
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Third Quarter
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2.48
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	0.91
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Fourth Quarter
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1.44
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	0.44
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Year Ending December 31, 2016:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-LEFT: 10PT">
	First Quarter (through March 18, 2016)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	[1.25]
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	[0.62]
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	On March 18, 2016, the last reported price
	of our common stock quoted on the OTCQB was $0.82 per share. The OTCQB prices set forth above represent inter-dealer quotations,
	without adjustment for retail mark-up, mark-down or commission, and may not represent the prices of actual transactions.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Transfer Agent
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Shares of our common stock are issued in registered
	form.&nbsp;&nbsp;American Stock Transfer &amp; Trust Company, LLC, 6201 15
<SUP>
	th
</SUP>
	&nbsp;Avenue, Brooklyn, NY 11219 (Telephone:
	(718) 921-8200; Facsimile: (718) 765-8719) is the registrar and transfer agent for shares of our common stock.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Holders of Common Stock
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As of March 18, 2016, there were 404 holders
	of record of our common stock. As of such date, 31,268,522 shares of our common stock were issued and outstanding.
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Dividends
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We have never declared nor paid any cash dividends,
	and currently intend to retain all our cash and any earnings for use in our business and, therefore, do not anticipate paying any
	cash dividends in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of the Board
	of Directors and will be dependent upon our consolidated financial condition, results of operations, capital requirements and such
	other factors as the Board of Directors deems relevant.
</P>
</EFX_MARKET>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Item 6. Selected Financial Data
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 39; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_FINANCIAL_DATA>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item
	7. Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Cautionary
	Note Regarding Forward-Looking Statements &ndash; Industry Data and Market Information
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	This
	Annual Report on Form 10-K contains forward-looking statements that reflect our current expectations about our future results,
	performance, prospects and opportunities. These forward-looking statements are subject to significant risks, uncertainties, and
	other factors, including those identified in &ldquo;Risk Factors&rdquo; above, which may cause actual results to differ materially
	from those expressed in, or implied by, any forward-looking statements. The forward-looking statements within this Form 10-K may
	be identified by words such as &ldquo;believes,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo;
	&ldquo;may,&rdquo; &ldquo;would,&rdquo; &ldquo;will&rdquo; and other similar expressions. However, these words are not the exclusive
	means of identifying these statements. In addition, any statements that refer to expectations, projections or other characterizations
	of future events or circumstances are forward-looking statements. Except as expressly required by the federal securities laws,
	we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances occurring
	subsequent to the filing of this Form 10-K with the SEC or for any other reason. You should carefully review and consider the
	various disclosures we make in this report and our other reports filed with the SEC that attempt to advise interested parties
	of the risks, uncertainties and other factors that may affect our business.
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Our
	Business Overview
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We were incorporated in Delaware in
	1987. We are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where
	there is an unmet medical need. We maintain two active business segments: BioTherapeutics and Vaccines/BioDefense.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Our BioTherapeutics business segment
	is developing a first-in-class photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible
	light for the treatment of cutaneous T-cell lymphoma (&ldquo;CTCL&rdquo;), proprietary formulations of oral beclomethasone 17,21-dipropionate
	(&ldquo;BDP&rdquo;) for the prevention/treatment of gastrointestinal (&ldquo;GI&rdquo;) disorders characterized by severe inflammation,
	including pediatric Crohn&rsquo;s disease (SGX203) and acute radiation enteritis (SGX201), and our novel innate defense regulator
	(&ldquo;IDR&rdquo;) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Our Vaccines/BioDefense business segment
	includes active development programs for RiVax&trade;, our ricin toxin vaccine candidate, OrbeShield
<SUP>
	&reg;,
</SUP>
	our GI acute
	radiation syndrome (&ldquo;GI ARS&rdquo;) therapeutic candidate and SGX943, our melioidosis therapeutic candidate. The development
	of our vaccine programs currently is supported by our heat stabilization technology, known as ThermoVax
<SUP>
	&reg;
</SUP>
	, under
	existing and on-going government contract funding. With the government contract from the National Institute of Allergy and Infectious
	Diseases (&ldquo;NIAID&rdquo;), we will attempt to advance the development of RiVax&trade; to protect against exposure to ricin
	toxin. We plan to use the funds received under our government contracts with the Biomedical Advanced Research and Development Authority
	(&ldquo;BARDA&rdquo;) and NIAID to advance the development of OrbeShield
<SUP>
	&reg;
</SUP>
	for the treatment of GI ARS.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	An outline for our business strategy
	follows:
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Complete
	enrollment and report preliminary results in our pivotal Phase 3 clinical trial of SGX301
	for the treatment of CTCL;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Initiate
	a Phase 3 clinical trial of SGX203, for the treatment of pediatric Crohn&rsquo;s disease;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Continue
	to collect the long-term follow-up safety data from the SGX942 Phase 2 proof-of-concept
	study in the treatment of oral mucositis in head and neck cancer patients and publish
	the findings from the SGX942 Phase 2 proof-of-concept study in the treatment of oral
	mucositis in head and neck cancer patients;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Obtain
	FDA agreement on a pivotal Phase 2b/3 protocol of SGX942 in the treatment of oral mucositis
	in head and neck cancer patients;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Continue
	development of RiVax&trade; in combination with our ThermoVax&reg; technology, to develop
	new heat stable vaccines in biodefense and infectious diseases with the potential to
	collaborate and/or partner with other companies in these areas;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Advance the preclinical and manufacturing
	development of OrbeShield&reg; as a biodefense medical countermeasure for the treatment of GI ARS;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Continue to apply for and secure additional
	government funding for each of our BioTherapeutics and Vaccines/BioDefense programs through grants, contracts and/or procurements;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Acquire or in-license new clinical-stage
	compounds for development; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Explore other business development
	and merger/acquisition strategies.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 40; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Critical
	Accounting Policies
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements,
	which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial
	statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses, and
	related disclosure of contingent assets and liabilities. We evaluate these estimates and judgments on an on-going basis.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Intangible
	Assets
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	One of the most significant estimates
	or judgments that we make is whether to capitalize or expense patent and license costs. We make this judgment based on whether
	the technology has alternative future uses, as defined in Financial Accounting Standards Board (&ldquo;FASB&rdquo;) Accounting
	Standards Codification (&ldquo;ASC&rdquo;) 730,
<I>
	Research and Development
</I>
	. Based on this consideration, we capitalized payments
	made to legal firms that are engaged in filing and protecting rights to intellectual property for our current product candidates
	in both the domestic and international markets. We believe that patent rights are one of our most valuable assets. Patents and
	patent applications are key components of intellectual property, especially in the early stage of product development, as their
	purchase and maintenance gives us access to key product development rights from our academic and industry partners. These rights
	can also be sold or sub-licensed as part of our strategy to partner our product candidates at each stage of development as the
	intangible assets have alternative future use. The legal costs incurred for these patents consist of work associated with filing
	new patents designed to protect, preserve and maintain our rights, and perhaps to extend the lives of the patents. We capitalize
	such costs and amortize intangibles on a straight-line basis over their expected useful life &ndash; generally a period of 11 to
	16 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	These
	intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may
	not be recoverable or if the underlying program is no longer being pursued. If the sum of the expected undiscounted cash flows
	is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair
	value and carrying value of the related asset or group of assets.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Fair
	Value of Financial Instruments
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	FASB
	ASC 820 &mdash;
<I>
	Fair Value Measurements and Disclosures,
</I>
	defines fair value as the price that would be received to sell
	an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC
	820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement
	purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to us on December
	31, 2015. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that
	could be realized on disposition of the financial instruments.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	FASB
	ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable
	or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market
	assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
	(Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	three levels of the fair value hierarchy are as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Level
	1 &mdash; Quoted prices in active markets for identical assets or liabilities that the
	reporting entity has the ability to access at the measurement date. Level 1 primarily
	consists of financial instruments whose value is based on quoted market prices such as
	exchange-traded instruments and listed equities.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Level
	2 &mdash; Inputs other than quoted prices included within Level 1 that are observable
	for the asset or liability, either directly or indirectly. Level 2 includes financial
	instruments that are valued using models or other valuation methodologies. These models
	consider various assumptions, including volatility factors, current market prices and
	contractual prices for the underlying financial instruments. Substantially all of these
	assumptions are observable in the marketplace, can be derived from observable data or
	are supported by observable levels at which transactions are executed in the marketplace.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Level
	3 &mdash; Unobservable inputs for the asset or liability. Financial instruments are considered
	Level 3 when their fair values are determined using pricing models, discounted cash flows
	or similar techniques and at least one significant model assumption or input is unobservable.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 41; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The carrying amounts reported in the
	consolidated balance sheet for cash and cash equivalents, contract and grants receivable, accounts payable and accrued compensation
	approximate their fair value based on the short-term maturity of these instruments. We recognize all derivative financial instruments
	as assets or liabilities in the financial statements and measure them at fair value with changes in fair value reflected as current
	period income or loss unless the derivatives qualify as hedges. As a result, certain warrants issued in connection with our June
	2013 offering were accounted for as derivatives.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<U>
	Revenue Recognition
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Our revenues are primarily generated
	from government contracts and grants. The revenue from government contracts and grants is based upon subcontractor costs and internal
	costs incurred that are specifically covered by the contracts and grants, plus a facilities and administrative rate that provides
	funding for overhead expenses and management fees. These revenues are recognized when expenses have been incurred by subcontractors
	or when we incur reimbursable internal expenses that are related to the government contracts and grants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<U>
	Research and Development Costs
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Research and development costs are charged
	to expense when incurred in accordance with FASB ASC 730,
<I>
	Research and Development
</I>
	. Research and development includes costs
	such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials,
	salaries, share-based compensation, employee benefits, equipment depreciation and allocation of various corporate costs. Purchased
	in-process research and development expense represents the value assigned or paid for acquired research and development for which
	there is no alternative future use as of the date of acquisition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Accounting
	for Warrants
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	considered FASB ASC 815,
<I>
	Evaluating Whether an Instrument is Considered Indexed to an Entity&rsquo;s Own Stock
</I>
	, which provides
	guidance for determining whether an equity-linked financial instrument (or embedded feature) issued by an entity is indexed to
	the entity&rsquo;s stock and therefore, qualifying for the first part of the scope exception in paragraph 815-10-15. We evaluated
	the provisions in our outstanding warrants and determined that warrants issued in connection with our June 2013 registered public
	offering contain provisions that protect holders from a decline in the issue price of our common stock (or &ldquo;down-round&rdquo;
	provisions) and contain net settlement provisions. Consequently, these warrants are recognized as liabilities at their fair value
	on the date of grant and remeasured at fair value on each reporting date. All other warrants issued were indexed to our own stock
	and therefore are accounted for as equity instruments for 2015 and 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Share-Based
	Compensation
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Stock options are issued with an exercise price
	equal to the market price on the date of grant. Stock options issued to directors upon re-election vest quarterly for a period
	of one year (new director issuances are fully vested upon issuance). Stock options issued to employees vest 25% on the grant date,
	then 25% each subsequent year for a period of three years. Stock options vest over each three-month period from the date of issuance
	to the end of the three year period. These options have a ten year life for as long as the individuals remain employees or directors.
	In general, when an employee or director terminates their position the options will expire within three months, unless otherwise
	extended by the Board.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	From time to time, we issue restricted shares
	of our common stock to vendors and consultants as compensation for services performed. Typically these instruments vest upon issuance
	and therefore the entire stock compensation expense is recognized upon issuance to the vendors and/or consultants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Share-based compensation expense for options,
	warrants and shares of common stock granted to non-employees has been determined in accordance with FASB ASC 505-50,
<I>
	Equity-Based
	Payments to Non-Employees
</I>
	, and represents the fair value of the consideration received, or the fair value of the equity instruments
	issued, whichever may be more reliably measured. For options that vest over future periods, the fair value of options granted to
	non-employees is amortized as the options vest.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 42; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The weighted average fair value of each option
	grant made during 2015 and 2014 was estimated on the date of each grant using the Black-Scholes option pricing model and amortized
	ratably over the option vesting periods, which approximates the service period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<U>
	Income Taxes
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Deferred tax assets and liabilities are recognized
	for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets
	and liabilities and their respective tax bases. A valuation allowance is established when it is more likely than not that all or
	a portion of a deferred tax asset will not be realized. A review of all available positive and negative evidence is considered,
	including the Company&rsquo;s current and past performance, the market environment in which the Company operates, the utilization
	of past tax credits, and the length of carryback and carryforward periods.&nbsp;Deferred tax assets and liabilities are measured
	utilizing tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered
	or settled. No current or deferred income taxes have been provided through December 31, 2015 due to the net operating losses incurred
	by the Company since its inception. The Company recognizes accrued interest and penalties associated with uncertain tax positions,
	if any, as part of income tax expense. There were no tax related interest and penalties recorded for 2015 and 2014. Additionally,
	the Company has not recorded an asset for unrecognized tax benefits or a liability for uncertain tax positions at December 31,
	2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<U>
	Earnings Per Share
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Basic earnings per share (&ldquo;EPS&rdquo;)
	excludes dilution and is computed by dividing income (loss) available to common stockholders by the weighted-average number of
	common shares outstanding for the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts
	to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in
	the earnings of the entity. Since there is a significant number of options and warrants outstanding, fluctuations in the actual
	market price can have a variety of results for each period presented.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<U>
	Use of Estimates and Assumptions
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The preparation of financial statements in
	conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions such
	as the fair value of warrants and stock options and the useful life of intangibles that affect the reported amounts in the financial
	statements and accompanying notes. Actual results could differ from those estimates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<U>
	Material Changes in Results of Operations
</U>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Year Ended December 31, 2015 Compared
	to 2014
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	For the year ended December 31, 2015, we had
	a net loss of $7,831,230 as compared to a net loss of $6,706,972 for the prior year, representing an increased loss of $1,124,258
	or 17%. Included in the net loss for December 31, 2015 is a non-cash expense of $1,201,870 versus a non-cash gain of $3,436,195
	for December 31, 2014 which represents the change in the fair value of the warrant liability related to warrants issued in connection
	with our registered public offering in June 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	For the year ended December 31, 2015 and 2014,
	revenues and associated costs relate to government contracts and grants awarded in support of the development of ThermoVax
<SUP>
	&reg;
</SUP>
	,
	RiVax&trade; GI-ARS and OrbeShield
<SUP>
	&reg;
</SUP>
	in GI ARS. For the year ended December 31, 2015, we had revenues of $8,768,390
	as compared to $7,043,016 for the prior year, representing an increase of $1,725,374 or 24%. The increase in revenues was a result
	of research and development activities performed under our government contracts associated with OrbeShield
<SUP>
	&reg;
</SUP>
	and
	RiVax&trade;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We incurred costs related to contract and grant
	revenues in the year ended December 31, 2015 and 2014 of $6,882,204 and $5,313,855, respectively, representing an increase of $1,568,349
	or 30%. These costs primarily relate to payments made to subcontractors and allocated employee costs in connection with research
	performed pursuant to contracts and grants. The fluctuations are due to the development activity performed on the contracts and
	grants discussed above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 43; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Our gross profit for the year ended December
	31, 2015 was $1,886,186 as compared to $1,729,161 for the prior year, representing an increase of $157,025 or 9%. This increase
	is due primarily to the increased activity in our OrbeShield
<SUP>
	&reg;
</SUP>
	and RiVax&trade; contracts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Research and development, including acquired
	in-process research and development costs, decreased by $3,686,696 or 41%, to $5,399,839 for the year ended December 31, 2015 as
	compared to $9,086,535 for the prior year. This decrease is primarily related to the 2014 acquisition of Hypericin, SGX 301, for
	which we issued common stock with a value of $3,750,000 and paid cash of $250,000 which was recognized as acquired in-process research
	and development expense. During 2015, we also completed the Phase 2 clinical trial with SGX942 for patients suffering from oral
	mucositis associated with their CRT for head and neck cancer and in December 2015, initiated the pivotal Phase 3 clinical trial
	of SGX301 for the treatment of CTCL.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	General and administrative expenses increased
	by $192,648 or 6%, to $3,596,623 for the year ended December 31, 2015, as compared to $3,403,975 for the prior year. This increase
	is primarily related to an increase in outside professional services.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Other income (expense) for the year ended December
	31, 2015 was $(1,209,887) as compared to $3,437,505 for the prior year. The change is primarily related to non-cash expense of
	$(1,201,870) which represents the change in the fair value of the warrant liability related to warrants issued in connection with
	our June 2013 registered public offering for the year ended December 31, 2015 as compared to non-cash income of $3,436,195 from
	the change for the year ended December 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	The State of New Jersey&rsquo;s Technology
	Business Tax Certificate Program allows certain high technology and biotechnology companies to sell unused net operating loss (&ldquo;NOL&rdquo;)
	carryforwards to other New Jersey-based corporate taxpayers. In accordance with this program, during the year ended December 31,
	2015, we sold New Jersey NOL carryforwards, resulting in the recognition of $488,933 of income tax benefit, net of transaction
	costs as compared to $616,872 for the year ended December 31, 2014. There can be no assurance as to the continuation or magnitude
	of this program in future years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Business Segments
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We maintain two active business segments for
	the year ended December 31, 2015 and December 31, 2014: Vaccines/BioDefense and BioTherapeutics.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Revenues for the Vaccines/BioDefense business
	segment for the year ended December 31, 2015 were $8,754,418 as compared to $6,756,388 for the year ended December 31, 2014, representing
	an increase of $1,998,030 or 30%. This increase in revenues was a result of our OrbeShield
<SUP>
	&reg;
</SUP>
	and RiVax&trade; contracts.
	Revenues for the BioTherapeutics business segment for the year ended December 31, 2015 were $13,972 as compared to $286,628 for
	the year ended December 31, 2014, representing a decrease of $272,656 or 95%. This decrease is primarily related to work performed
	under our oral mucositis grant which expired in early 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Income from operations for the Vaccines/BioDefense
	business segment for the year ended December 31, 2015 was $1,263,709 as compared to $807,164 for the year ended December 31, 2014.
	Income from operations is primarily attributable to our gross margins related to our government contracts. Loss from operations
	for the BioTherapeutics business segment for the year ended December 31, 2015 was $4,487,988 as compared to $7,674,381 for the
	year ended December 31, 2014, representing a decrease of $3,186,393. This decreased loss is due primarily to the 2014 acquisition
	of Hypericin, SGX 301, for which we issued common stock with a value of $3,750,000 and paid cash of $250,000 which was recognized
	as acquired in-process research and development expense, offset by expenses in 2015 related to the Phase 2 clinical trial with
	SGX942 for patients suffering from oral mucositis associated with their CRT for head and neck cancer and the initiation of the
	pivotal Phase 3 clinical trial of SGX301 for the treatment of CTCL.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Amortization and depreciation expense for the
	Vaccines/BioDefense business segment for the year ended December 31, 2015 was $39,925 as compared to $39,625 for the year ended
	December 31, 2014. Amortization and depreciation expense for the BioTherapeutics business segment for the year ended December 31,
	2015 was $199,661 as compared to $199,196 for the year ended December 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 44; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<U>
	Financial Condition and Liquidity
</U>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Cash and Working Capital
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	As of December 31, 2015, we had cash and cash
	equivalents of $4,921,545 as compared to $5,525,094 as of December 31, 2014, representing a decrease of $603,549 or 11%. As of
	December 31, 2015, we had working capital of $2,179,694 which excludes a non-cash warrant liability of $2,434,101 as compared to
	working capital of $3,174,214 as of December 31, 2014, representing a decrease of $994,520 or 31%. The decrease in working capital
	was primarily the result of expenditures in 2015 related to support the completion of our Phase 2 clinical trial of SGX942 and
	the initiation of the pivotal Phase 3 clinical trial of SGX301 for the treatment of CTCL offset by $4,804,857 in various financing
	activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Based on our current rate of cash outflows,
	cash on hand, proceeds from government contract and grant programs,&nbsp;proceeds available from our equity lines and proceeds
	from the State of New Jersey Technology Business Tax Certificate Transfer Program, management believes that its current cash will
	be sufficient to meet the anticipated cash needs for working capital and capital expenditures for at least the next twelve months.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Our plans with respect to our liquidity management
	include, but are not limited to, the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	We
	have up to $43.0 million in active government contract funding still available to support
	our associated research programs through 2016 and beyond. We plan to submit additional
	contract and grant applications for further support of these programs with various funding
	agencies.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	We
	have continued to use equity instruments to provide a portion of the compensation due
	to vendors and collaboration partners and expect to continue to do so for the foreseeable
	future.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	We
	will pursue NOL sales in the state of New Jersey pursuant to our Technology Business
	Tax Certificate Transfer Program. Based on the receipt of $488,933 in proceeds from the
	sale of NJ NOL in 2015, we expect to participate in this program during 2016 and beyond;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	We
	have an aggregate of $20.2 million available from equity facilities through 2019; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	We
	may seek additional capital in the private and/or public equity markets, pursue government
	contracts and grants as well as business development activities to continue our operations,&nbsp;respond
	to competitive pressures, develop new products and services, and to support new strategic
	partnerships.&nbsp;We are currently evaluating additional equity financing opportunities
	on an ongoing basis and may execute them when appropriate. However, there can be no assurances
	that we can consummate such a transaction, or consummate a transaction at favorable pricing.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Expenditures
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Under our budget and based upon our existing product development
	agreements and license agreements pursuant to letters of intent and option agreements, we expect our total research and development
	expenditures for the next 12 months to be approximately $12.9 million before any grant reimbursements, of which $5.3 million relates
	to the BioTherapeutics business and $7.6 million relates to the Vaccines/BioDefense business.&nbsp;We anticipate contract reimbursements
	in the next 12 months of approximately $7.6 million to offset research and development expenses in the Vaccines/BioDefense business
	segment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	table below details our costs for research and development by program and amounts reimbursed for the years ended December 31,
	2015 and 2014:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	Research &amp; Development Expenses
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Oral BDP
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	74,543
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	561,655
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	RiVax&trade; &amp; ThermoVax
<SUP>
	&reg;
</SUP>
	&nbsp;&nbsp;Vaccines
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	622,908
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	846,870
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 10PT">
	SGX94
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,216,632
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,820,807
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 10PT">
	SGX943/101
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: RIGHT">
	10,671
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: RIGHT">
	19,378
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 10PT">
	SGX301
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	2,141,175
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	4,369,585
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 10PT">
	Other
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	333,910
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	468,240
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 4PT; PADDING-LEFT: 20PT">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	5,399,839
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	9,086,535
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	Reimbursed under Government Contracts and Grants
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	OrbeShield
<SUP>
	&reg;
</SUP>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	5,240,377
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	4,100,663
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	RiVax&trade; &amp;
	ThermoVax
<SUP>
	&reg;
</SUP>
	Vaccines
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,557,082
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	930,573
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 10PT">
	Other
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	84,745
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	282,619
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 20PT">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	6,882,204
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	5,313,855
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; PADDING-LEFT: 30PT">
	Grand Total
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	12,282,043
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	14,400,390
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 45; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Contractual
	Obligations
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	We have commitments of approximately
	$500,000 at December 31, 2015 for several licensing agreements with consultants and universities. Additionally, we have collaboration
	and license agreements, which upon clinical or commercialization success, may require the payment of milestones of up to $7.9 million
	and/or royalties up to 6% of net sales of covered products, if and when achieved. However, there can be no assurance that clinical
	or commercialization success will occur.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In December 2014, we entered into a
	lease agreement through May 31, 2018 for existing and expanded office space. The rent for the first 12 months was approximately
	$12,300 per month, or approximately $20.85 per square foot. This rent increased to approximately $12,375 per month, or approximately
	$20.95 per square foot, for the next 12 months, and thereafter will increase to approximately $12,460 per month, or approximately
	$21.13 per square foot for the remainder of the lease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On September 3, 2014, we entered into
	an asset purchase agreement with Hy Biopharma, Inc. (&ldquo;Hy Biopharma&rdquo;) pursuant to which we acquired certain intangible
	assets, properties and rights of Hy Biopharma related to the development of Hy BioPharma&rsquo;s synthetic hypericin product. As
	consideration for the assets acquired, we paid $250,000 in cash and issued 1,849,113 shares of common stock with a fair value based
	on our stock price on the date of grant of $3,750,000. These amounts were charged to research and development expense during the
	third quarter of 2014 as the assets will be used in our research and development activities and do not have alternative future
	use pursuant to generally accepted accounting principles in the United States. Provided all future success-oriented milestones
	are attained, we will be required to make additional payments of up to $10.0 million, if and when achieved. Payments will be payable
	in restricted securities of the Company; provided that Hy BioPharma&rsquo;s ownership of our securities is not to exceed 19.9%
	of our outstanding stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In February 2007, our Board of Directors
	authorized the issuance of 50,000 shares to Dr. Schaber immediately prior to the completion of a transaction, or series or a combination
	of related transactions negotiated by our Board of Directors whereby, directly or indirectly, a majority of our capital stock or
	a majority of our assets are transferred from us and/or our stockholders to a third party. Dr. Schaber&rsquo;s amended employment
	agreement includes our obligation to issue such shares if such event occurs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Employees
	with employment contracts have severance agreements that will provide separation benefits from the Company if they are involuntarily
	separated from employment.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As a result
	of the above agreements, we have future contractual obligations over the next five years as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT/10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
<U>
	Year
</U>
</B>
</P>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Research and Development
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT/10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
<U STYLE="TEXT-DECORATION: NONE">
	Property and
</U>
</B>
</P>
<P STYLE="FONT: 10PT/10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
<U STYLE="TEXT-DECORATION: NONE">
	Other Leases
</U>
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT/10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT/10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
<U>
	Total
</U>
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; TEXT-ALIGN: CENTER; PADDING-LEFT: 5.4PT">
	2016
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	100,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	157,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	257,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-LEFT: 5.4PT">
	2017
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	151,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	251,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-LEFT: 5.4PT">
	2018
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	52,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	152,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-LEFT: 5.4PT">
	2019
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 5.4PT">
	2020
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	100,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	100,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 4PT; PADDING-LEFT: 5.4PT">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	500,000
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	360,000
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	860,000
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
</EFX_RESULTS_OF_OPERATIONS>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item
	8. Financial Statements and Supplementary Data
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	information required by this Item 8 is contained on pages F-1 through F-22 of this Annual Report on Form 10-K and is incorporated
	herein by reference.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 46; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_FINANCIAL_STATEMENTS>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item
	9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	None.
</FONT>
</P>
</EFX_ACCOUNTING_CHANGES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item
	9A. Controls and Procedures
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Evaluation
	of Disclosure Controls and Procedures
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Disclosure
	controls and procedures are the Company&rsquo;s controls and other procedures that are designed to ensure that information required
	to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
	Act&rdquo;) is recorded, processed, summarized and reported within the time periods specified in the SEC&rsquo;s rules and forms.
	Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required
	to be disclosed by us in the reports that we file under the Exchange Act is accumulated and communicated to our management, including
	our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required
	disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can only provide
	reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the possible
	controls and procedures.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	management has evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness
	of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as
	of the end of the period covered by this report. Based upon that evaluation, our management, including our principal executive
	officer and principal financial officer, has concluded that, as of the end of the period covered by this report, the Company&rsquo;s
	disclosure controls and procedures were effective at the reasonable assurance level.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 47; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Management&rsquo;s
	Annual Report on Internal Control over Financial Reporting
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Company
	management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control
	over financial reporting is a process designed by, or under the supervision of, our principal executive and principal financial
	officers and effected by the Company&rsquo;s Board of Directors, management and other personnel to provide reasonable assurance
	regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
	with generally accepted accounting principles and includes those policies and procedures that:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	pertain
	to the maintenance of records that in reasonable detail accurately and fairly reflect
	the transactions and dispositions of the assets of the Company;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	provide
	reasonable assurance that transactions are recorded as necessary to permit preparation
	of financial statements in accordance with generally accepted accounting principles,
	and that receipts and expenditures of the Company are being made only in accordance with
	authorizations of management and directors of the Company; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	provide
	reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
	use or disposition of the Company&rsquo;s assets that could have a material effect on
	the financial statements.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Because
	of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any
	evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes
	in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Management
	assessed the effectiveness of the Company&rsquo;s internal control over financial reporting as of December 31, 2015. In making
	this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission
	(&ldquo;COSO&rdquo;) in
<I>
	Internal Control-Integrated
</I>
<I>
	Framework, 2013
</I>
	.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Based
	on our assessment, management has concluded that, as of December 31, 2015, the Company&rsquo;s internal control over financial
	reporting is effective.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Changes
	in Internal Control over Financial Reporting
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	There
	were no changes in the Company&rsquo;s internal control over financial reporting identified in connection with the evaluation
	of such internal control that occurred during the Company&rsquo;s last fiscal quarter that have materially affected, or are reasonably
	likely to materially affect, the Company&rsquo;s internal control over financial reporting.
</FONT>
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item
	9B. Other Information
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY">
	On March 22, 2016, we entered into a
	purchase agreement with Lincoln Park Capital Fund, LLC (&ldquo;Lincoln Park&rdquo;), pursuant to which Lincoln Park has agreed
	to purchase up to $12 million of shares of our common stock from us, from time to time and subject to certain limitations. Also
	on March 22, 2016, we entered into a Registration Rights Agreement (the &ldquo;Registration Rights Agreement&rdquo;) with Lincoln
	Park, pursuant to which we agreed to file with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) a registration
	statement (the &ldquo;Registration Statement&rdquo;) to register for resale under the Securities Act of 1933, as amended (the &ldquo;Securities
	Act&rdquo;), the shares of our common stock that have been or may be issued to Lincoln Park under the Purchase Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY">
	After the SEC has declared the Registration
	Statement effective, we have the right at our sole discretion, over a 36-month period, to sell up to $12 million of shares of our
	common stock to Lincoln Park in amounts up to $750,000 per sale, provided certain conditions in the Purchase Agreement are met.
	In addition, we may direct Lincoln Park to purchase additional shares in accordance with the terms of the Purchase Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY">
	If, and/or when, we sell stock, we will
	control the timing and amount of sales, if any, of our common stock to Lincoln Park under the Purchase Agreement; provided that
	in no event will such shares be sold to Lincoln Park where such sale would result in Lincoln Park&rsquo;s beneficial ownership
	exceeding 4.99% of the then outstanding shares of our common stock. The purchase price of the shares related to the $12 million
	of funding will be based on prevailing market prices of our common stock, calculated using the formula set forth in the Purchase
	Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY">
	In consideration for entering into the
	Purchase Agreement, we issued to Lincoln Park 100,000 shares of our common stock as a commitment fee and will issue up to 500,000
	additional shares pro rata, when and if, Lincoln Park purchases at our request the $12 million commitment. We may terminate the
	Purchase Agreement at any time at our discretion without any cost to us. The proceeds we receive pursuant to the Purchase Agreement
	are expected to be used to further develop our product candidates and for general corporate purposes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 12PT; TEXT-ALIGN: JUSTIFY">
	The securities issued pursuant to the
	Purchase Agreement were exempt from registration pursuant to the provisions of Section 4(a)(2) of the Securities Act and Rule
	506 of Regulation D promulgated thereunder. Lincoln Park represented to us that it is an &ldquo;accredited investor&rdquo; as
	defined in Rule 501(a) of Regulation D promulgated under the Securities Act; is knowledgeable, sophisticated and experienced in
	making investment decisions of this kind; and received adequate information about us or had adequate access to information about
	us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 48; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	PART
	III
</B>
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item
	10. Directors, Executive Officers and Corporate Governance
</B>
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	table below contains information regarding the current members of the Board of Directors and executive officers. The ages of individuals
	are provided as of March 18, 2016:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Name
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Age
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Position
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Christopher J. Schaber,
</B>
</FONT>
<B>
<FONT STYLE="FONT-SIZE: 10PT">
	PhD
</FONT>
</B>
<FONT STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
</FONT>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: CENTER">
	49
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT">
	Chairman of the Board, Chief Executive Officer and President
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Keith L. Brownlie, CPA
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	63
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Marco M. Brughera, DVM
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	60
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Gregg A. Lapointe, CPA
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	57
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Robert J. Rubin, MD
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	70
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Jerome B. Zeldis, MD, PhD
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	65
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Director
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Oreola Donini, PhD
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	44
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Chief Scientific Officer and Senior Vice President
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Richard Straube, MD
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	64
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Chief Medical Officer and Senior Vice President
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	Joseph M. Warusz, CPA
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; VERTICAL-ALIGN: TOP">
	59
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Vice President of Finance, Acting Chief Financial Officer and Corporate Secretary
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Christopher
	J. Schaber, PhD
</B>
	has over 26 years of experience in the pharmaceutical and biotechnology industry. Dr. Schaber has been our
	President and Chief Executive Officer and a director since August 2006. He was appointed Chairman of the Board on October 8, 2009.
	He also serves on the board of directors of the Biotechnology Council of New Jersey (&ldquo;BioNJ&rdquo;) since January
	2009 and the Alliance for Biosecurity since October 2014, and has been a member of the corporate councils of both the National
	Organization for Rare Diseases (&ldquo;NORD&rdquo;) and the American Society for Blood and Marrow Transplantation (&ldquo;ASBMT&rdquo;)
	since October 2009 and July 2009, respectively. Prior to joining Soligenix, Dr. Schaber served from 1998 to 2006 as Executive
	Vice President and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development
	and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution,
	pre-clinical and clinical research, and medical affairs, as well as coordination of commercial launch preparation activities.
	From 1996 to 1998, Dr. Schaber was a co-founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance
	and Drug Development. From 1994 to 1996, Dr. Schaber was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairs
	and Operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions with The Liposome
	Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories. Dr. Schaber received his BA degree from Western
	Maryland College, his MS degree in Pharmaceutics from Temple University School of Pharmacy and his PhD degree in Pharmaceutical
	Sciences from the Union Graduate School.&nbsp;Dr. Schaber was selected to serve as a member of our Board of Directors because
	of his extensive experience in drug development and pharmaceutical operations, including his experience as an executive senior
	officer with our Company and Discovery Laboratories, Inc., and as a member of the board of directors of BioNJ; because of his
	proven ability to raise funds and provide access to capital; and because of his advanced degrees in science and business.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Keith
	L. Brownlie, CPA
</B>
	has been a director since June 2011. Mr. Brownlie currently serves on the Board of Directors of Rxi Pharmaceuticals
	Corporation, a publicly traded biotechnology company involved in the research and development of RNAi products for the diagnosis,
	prevention and treatment of human diseases, a position he has held since June 2012. From July 2013 until December 2014, Mr. Brownlie
	served on the Board of Directors of Cancer Genetics, Inc., a publicly traded, early stage diagnostics company. Mr. Brownlie served
	as a member of the Board of Directors of Epicept Corporation, a publicly traded, specialty pharmaceutical company focused on the
	clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain, from April 2011 to
	August 2013 when Epicept Corporation merged with Immune Pharmaceuticals, Inc. From 1974 to 2010, Mr. Brownlie worked with the
	accounting firm of Ernst &amp; Young LLP where he served as audit partner for numerous public companies and was the Life Sciences
	Industry Leader for the New York metro area. Mr. Brownlie received a BS in Accounting from Lehigh University and is a Certified
	Public Accountant in the state of New Jersey. Mr. Brownlie co-founded the New Jersey Entrepreneur of the Year Program and was
	Vice President and Trustee of the New Jersey Society of CPAs. In addition, he served as accounting advisor to the board of the
	Biotechnology Council of New Jersey. Mr. Brownlie was selected to serve as a member of our Board of Directors because of his vast
	experience as an audit partner for numerous public companies and as a director of publicly traded specialty pharmaceutical and
	biotechnology companies.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 49; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Marco Maria Brughera, DVM
</B>
	joined the
	Board of Directors in October 2013. He is the Global Head of the Rare Disease Business Unit for Sigma-Tau Finanziaria S.p.A. Group.
	He currently serves as President in Sigma-Tau Pharmaceuticals, Inc. and in Sigma-Tau Research Switzerland S.A. and as Chief Executive
	Officer in Sigma-Tau Rare Disease Ltd. From December 2011 through January 2014, Dr. Brughera served on the Board of Directors of
	Gentium S.p.A., a publicly traded biopharmaceutical company. From January 2011 through October 2012, Dr. Brughera held several
	other positions with the Sigma-Tau Group, including Corporate Research and Development Managing Director of Sigma-Tau Industrie
	Farmaceutiche Riunite S.p.A. From 2004 to 2010, Dr. Brughera served as the Vice President of Preclinical Development at Nerviano
	Medical Sciences S.r.l. (&ldquo;NMS Group&rdquo;), a pharmaceutical oncology-focused integrated discovery and development company.
	He also served as the Managing Director at Accelera, S.r.l., an independent contract research organization affiliated with the
	NMS Group. From 1999 to 2004, Dr. Brughera held several senior level positions in the areas of discovery and development toxicology
	with Pharmacia Corporation and Pfizer, Inc. Prior to 1999, he held various positions at Pharmacia &amp; Upjohn Company, Inc., and
	Farmitalia Carlo Erba S.p.A., an Italian pharmaceutical company. Dr. Brughera earned his degree in veterinary medicine from the
	University of Milan and is a European Registered Toxicologist.&nbsp;&nbsp;Pursuant to our February 11, 2009 stock purchase agreement
	with Sigma-Tau Pharmaceuticals, Inc., we were required to use our best efforts to secure the election of a Sigma-Tau designee to
	our Board of Directors until such time as Sigma-Tau beneficially owned less than 10% of our issued and outstanding shares of Common
	Stock.&nbsp; As of March 18, 2016, Sigma Tau beneficially owned 9.7% of our outstanding Common Stock, and our obligation with respect
	to the election of a Sigma-Tau designee to our Board of Directors has expired.&nbsp;&nbsp;In view of Dr. Brughera&rsquo;s background
	in the areas of drug discovery and development and his experience as an executive officer and a director in the pharmaceutical
	industry, the Nominating Committee accepted Dr. Brughera as Sigma-Tau&rsquo;s designee for election to the Board of Directors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	Gregg Lapointe, CPA, MBA
</B>
	has
	been a director since March 2009. Mr. Lapointe is currently CEO of Cerium Pharmaceuticals, Inc. and serves on the Board of Directors
	of SciClone Pharmaceuticals, Inc., Raptor Pharmaceuticals, Inc., ImmunoCellular Therapeutics Ltd. and the Board of Trustees of
	the Keck Graduate Institute of Applied Life Sciences. He has previously served on the Board of Directors of the Pharmaceuticals
	Research and Manufacturers of America (PhRMA) and Questcor Pharmaceuticals, Inc. He previously served in varying roles for Sigma-Tau
	Pharmaceuticals, Inc., a private biopharmaceutical company, from September 2001 through February 2012, including Chief Operating
	Officer from November 2003 to April 2008 and Chief Executive Officer from April 2008 to February 2012. From May, 1996 to August
	2001, he served as Vice President of Operations and Vice President, Controller of AstenJohnson, Inc. (formerly JWI Inc.). Prior
	to that, Mr. Lapointe spent several years in the Canadian medical products industry in both distribution and manufacturing. Mr.
	Lapointe began his career at Price Waterhouse. Mr. Lapointe received his B.A. degree in Commerce from Concordia University in Montreal,
	Canada, a graduate diploma in Accountancy from McGill University and his M.B.A. degree from Duke University. He is a C.P.A. in
	the state of Illinois. Mr. Lapointe was selected to serve as a member of our Board of Directors because of his significant experience
	in the areas of global strategic planning and implementation, business development, corporate finance, and acquisitions, and his
	experience as an executive officer and board member in the pharmaceutical and medical products industries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Robert
	J. Rubin, MD
</B>
	has been a director since October 2009. Dr. Rubin was a clinical professor of medicine at Georgetown University
	from 1995 until 2012 when he was appointed a Distinguished Professor of Medicine. From 1987 to 2001, he was president of the Lewin
	Group (purchased by Quintiles Transnational Corp. in 1996), an international health policy and management consulting firm. From
	1994 to 1996, Dr. Rubin served as Medical Director of ValueRx, a pharmaceutical benefits company. From 1992 to 1996, Dr. Rubin
	served as President of Lewin-VHI, a health care consulting company. From 1987 to 1992, he served as President of Lewin-ICF, a
	health care consulting company. From 1984 to 1987, Dr. Rubin served as a principal of ICF, Inc., a health care consulting company.
	From 1981 to 1984, Dr. Rubin served as the Assistant Secretary for Planning and Evaluation at the Department of Health and Human
	Services and as an Assistant Surgeon General in the United States Public Health Service. Dr. Rubin has served on the Board of
	BioTelemetry, Inc. (formerly known as CardioNet, Inc.) since 2007. He is a board certified nephrologist and internist. Dr. Rubin
	received an undergraduate degree in Political Science from Williams College and his medical degree from Cornell University Medical
	College. Dr. Rubin was selected to serve as a member of our Board of Directors because of his vast experience in the health care
	industry, including his experience as a nephrologist, internist, clinical professor of medicine and Assistant Surgeon General,
	and his business experience in the pharmaceutical industry.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 50; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Jerome
	B. Zeldis, MD, PhD
</B>
	has been a director since June 2011. Dr. Zeldis is currently Chief Executive Officer of Celgene Global
	Health and Chief Medical Officer of Celgene Corporation, a publicly traded, fully integrated biopharmaceutical company, where
	he has been employed since 1997. From September 1994 to February 1997, Dr. Zeldis worked at Sandoz Research Institute and the
	Janssen Research Institute in both clinical research and medical development. He has been a board member of several
	biotechnology companies and is currently on the boards of the NJ Chapter of the Arthritis Foundation, the Castleman&rsquo;s
	Disease Organization and PTC Therapeutics, Inc. and Alliqua, Inc. Additionally, he has served as Assistant Professor of
	Medicine at the Harvard Medical School (from July 1987 to September 1988), Associate Professor of Medicine at University of
	California, Davis from (September 1988 to September 1994), Clinical Associate Professor of Medicine at Cornell Medical School
	(January 1995 to December 2003) and Professor of Clinical Medicine at the Robert Wood Johnson Medical School (July 1998 to
	June 2010). Dr. Zeldis received a BA and an MS from Brown University, and an MD, and a PhD in Molecular Biophysics and
	Biochemistry from Yale University. Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and in
	Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. Dr. Zeldis was selected to serve as a
	member of our Board of Directors because of his experience as an executive officer of a publicly traded biopharmaceutical
	company and in clinical research and medical development, and his experience in the health care industry, including his
	experience as an internist, gastroenterologist and professor of medicine.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Oreola
	Donini, PhD
</B>
	, has been with our company since August 15, 2013 and is currently our Chief Scientific Officer and Senior Vice
	President, a position she has held since December 5, 2014. Dr. Donini served as our Vice President of Preclinical Research and
	Development from August 15, 2013 until December 4, 2014. She has more than 15 years&rsquo; experience in drug discovery and preclinical
	development with start-up biotechnology companies. From 2012 to 2013, Dr. Donini worked with ESSA Pharma Inc. as Vice President
	Research and Development. From 2004 to 2013, Dr. Donini worked with Inimex Pharmaceuticals Inc., (&ldquo;Inimex&rdquo;), lastly
	as Senior Director of Preclinical R&amp;D from 2007-2013. Prior to joining Inimex, she worked with Kinetek Pharmaceuticals Inc.,
	developing therapies for infectious disease, cancer and cancer supportive care. Dr. Donini is a co-inventor and leader of the
	Company&rsquo;s SGX94 innate defense regulator technology, developed by Inimex and subsequently acquired by the Company. She was
	responsible for overseeing the manufacturing and preclinical testing of SGX94, which demonstrated efficacy in combating bacterial
	infections and mitigating the effects of tissue damage due to trauma, infection, radiation and/or chemotherapy treatment. These
	preclinical studies resulted in a successful Phase 1 clinical study and clearance of Phase 2 protocols for oral mucositis in head
	and neck cancer and acute bacterial skin and skin structure infections. While with ESSA Pharma Inc. as the Vice President of Research
	and Development, Dr. Donini led the preclinical testing of a novel N-terminal domain inhibitor of the androgen receptor for the
	treatment of prostate cancer. While with Kinetek Pharmaceuticals Inc., her work related to the discovery of novel kinase and phosphatase
	inhibitors for the treatment of cancer. Dr. Donini received her PhD from Queen&rsquo;s University in Kinston, Ontario, Canada
	and completed her post-doctoral work at the University of California, San Francisco. Her research has spanned drug discovery,
	preclinical development, manufacturing and clinical development in infectious disease, cancer and cancer supportive care.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Richard
	Straube, MD
</B>
	has been with our company since January 2014 and is currently our Senior Vice President and Chief Medical Officer.
	Dr. Straube is a board-certified pediatrician with 35 years&rsquo; experience in both academia and industry, including clinical
	research experience in host-response modulation.&nbsp;From 2009 until joining our company, he was Chief Medical Officer of Stealth
	Peptides Incorporated, a privately-held, clinical stage, biopharmaceutical company.&nbsp;Prior to joining the Company, Dr. Straube
	served from 1988 to 1993 in various capacities, including most recently as Senior Director, Infectious Diseases and Immunology,
	Clinical Research, for Centocor, Inc., a privately-held biopharmaceutical company focused on developing monoclonal antibody-based
	diagnostics.&nbsp;&nbsp;While at Centocor, Inc., Dr. Straube was responsible for the initial anti-cytokine and anti-endotoxin
	programs targeted at ameliorating inappropriate host responses to infectious and immunologic challenges. Programs that he managed
	at Centocor, Inc. include assessments of immunomodulation using monoclonal removal of inciting molecular triggers, removal of
	internal immune-messengers, augmentation of normal host defenses, and maintenance of normal sub-cellular function in the face
	of injury.&nbsp;&nbsp;From 1993 to 1995, Dr. Straube was Director of Medical Affairs at T-cell Sciences, Inc., a privately-held
	biotechnology company.&nbsp;&nbsp;From 1995 to 1997, he was Director of Clinical Investigations of the Pharmaceutical Products
	Division of Ohmeda Corp., a privately-held biopharmaceutical company.&nbsp;&nbsp;He served from 1998 to 2007 as Executive Vice
	President of Research and Development and Chief Scientific Officer at INO Therapeutics LLC, a privately-held biotherapeutics company,
	where he was responsible for the clinical trials and subsequent approval of inhaled nitric oxide for the treatment of persistent
	pulmonary hypertension of the newborn.&nbsp;&nbsp;From 2007 to 2009, Dr. Straube was the Chief Medical Officer at Critical Biologics
	Corporation, a privately-held biotechnology company.&nbsp;&nbsp;Dr. Straube received his medical degree and residency training
	at the University of Chicago, completed a joint adult and pediatrician infectious diseases fellowship at the University of California,
	San Diego (&ldquo;UCSD&rdquo;), and as a Milbank Scholar completed training in clinical trial design at the London School of Hygiene
	and Tropical Medicine.&nbsp;&nbsp;While on the faculty at the UCSD Medical Center, his research focused on interventional studies
	for serious viral infections.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 51; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Joseph
	M. Warusz, CPA
</B>
	has been with the company since June 2011 and is currently our Vice President of Finance and Acting Chief Financial
	Officer, a position he has held since February 2012. He has more than 30 years of financial management experience in public and
	private life science companies as well as large pharma. Prior to joining Soligenix on June 1, 2011 as Vice President of Administration
	and Controller, he held senior financial positions with Amicus Therapeutics, Inc. from 2004 to 2005, Orchid Cellmark, Inc. from
	2000 to 2004, and NexMed, Inc. from 1998 to 1999. From 2005 to 2011, Mr. Warusz performed consulting assignments at Ardea BioSciences,
	Inc., NovaDel Pharma, Inc. and Melior Discovery, all R&amp;D-focused companies in the biotechnology and specialty pharmaceuticals
	arenas. Prior to 1998, Mr. Warusz also held management positions in financial analysis, accounting, reporting and auditing at
	Bristol-Myers Squibb and Peat Marwick Main &amp; Company. He received his BS in accounting and MBA in finance at Drexel University
	and is a Certified Public Accountant.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Board
	Leadership Structure
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 18PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Our
	Board of Directors believes that Dr. Schaber&rsquo;s service as both the Chairman of our Board of Directors and our Chief Executive
	Officer is in the best interest of our Company and our stockholders. Dr. Schaber possesses detailed and in-depth knowledge of
	the issues, opportunities and challenges facing our Company and our business and, therefore, is best positioned to develop agendas
	that ensure that the Board of Directors&rsquo; time and attention are focused on the most important matters. His combined role
	enables decisive leadership, ensures clear accountability, and enhances our ability to communicate our message and strategy clearly
	and consistently to our stockholders, employees, and collaborative partners.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Messrs.
	Brownlie and Lapointe, Dr. Rubin, and Dr. Zeldis are independent and the Board of Directors believes that the independent directors
	provide effective oversight of management. Moreover, in addition to feedback provided during the course of meetings of the Board
	of Directors, the independent directors hold executive sessions. Following an executive session of independent directors, the
	independent directors&rsquo; report back to the full Board of Directors regarding any specific feedback or issues, provide the
	Chairman with input regarding agenda items for Board of Directors and Committee meetings, and coordinate with the Chairman regarding
	information to be provided to the independent directors in performing their duties. The Board of Directors believes that this
	approach appropriately and effectively complements the combined Chairman/Chief Executive Officer structure.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Although
	the Company believes that the combination of the Chairman and Chief Executive Officer roles is appropriate under the current circumstances,
	our corporate governance guidelines do not establish this approach as a policy, and the Board of Directors may determine that
	it is more appropriate to separate the roles in the future.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Section
	16(a) Beneficial Ownership Reporting Compliance
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	We
	are required to identify each person who was an officer, director or beneficial owner of more than 10% of our registered equity
	securities during our most recent fiscal year and who failed to file on a timely basis reports required by Section 16(a) of the
	Exchange Act.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	To
	our knowledge, based solely on review of these filings and written representations from the certain reporting persons, we believe
	that during the year ended December 31, 2015, our officers, directors and significant stockholders have timely filed the appropriate
	form under Section 16(a) of the Exchange Act.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 52; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Committees
	of the Board of Directors
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Our
	Board of Directors has the following three committees: (1)&nbsp;Compensation, (2)&nbsp;Audit and (3)&nbsp;Nominating and Corporate
	Governance. Our Board of Directors has adopted a written charter for each of these committees, which are available on our website
	at www.soligenix.com under the &ldquo;Investors&rdquo; section.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 25%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Director
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Audit
</B>
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Committee
</B>
</FONT>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Compensation
</B>
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Committee
</B>
</FONT>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Nominating
	and
</B>
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Corporate Governance
</B>
</FONT>
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Committee
</B>
</FONT>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Keith
	L. Brownlie, CPA
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/24/0001213900-16-011833_IMAGE_001.JPG" ALT="">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/24/0001213900-16-011833_IMAGE_002.JPG" ALT="">
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Marco
	M. Brughera, DVM
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/24/0001213900-16-011833_IMAGE_002.JPG" ALT="">
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Gregg
	A. Lapointe, CPA
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/24/0001213900-16-011833_IMAGE_002.JPG" ALT="" STYLE="WIDTH: 12PX; HEIGHT: 18PX">
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/24/0001213900-16-011833_IMAGE_002.JPG" ALT="">
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Robert
	J. Rubin, MD
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/24/0001213900-16-011833_IMAGE_002.JPG" ALT="">
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/24/0001213900-16-011833_IMAGE_001.JPG" ALT="">
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Jerome
	B. Zeldis, MD, PhD
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/24/0001213900-16-011833_IMAGE_002.JPG" ALT="">
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/24/0001213900-16-011833_IMAGE_001.JPG" ALT="">
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/24/0001213900-16-011833_IMAGE_001.JPG" ALT="">
	&ndash; Committee Chair
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/24/0001213900-16-011833_IMAGE_002.JPG" ALT="" STYLE="WIDTH: 12PX; HEIGHT: 18PX">
	&ndash; Member
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Audit
	Committee
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Our
	Board of Directors has an Audit Committee, which is comprised of Mr. Brownlie (Chair), Mr. Lapointe and Dr. Rubin.&nbsp;&nbsp;The
	Audit Committee assists our Board of Directors in monitoring the financial reporting process, the internal control structure and
	the independent registered public accountants. Its primary duties are to serve as an independent and objective party to monitor
	the financial reporting process and internal control system, to review and appraise the audit effort of the independent registered
	public accountants and to provide an open avenue of communication among the independent registered public accountants, financial
	and senior management, and our Board of Directors.&nbsp;&nbsp;Our Board of Directors has determined that Mr. Brownlie, Mr. Lapointe
	and Dr. Rubin are &ldquo;independent&rdquo; directors, within the meaning of applicable listing standards of Nasdaq and the Exchange
	Act and the rules and regulations thereunder.&nbsp;&nbsp;Our Board of Directors has also determined that the members of the Audit
	Committee are qualified to serve on the committee and have the experience and knowledge to perform the duties required of the
	committee and that Mr. Brownlie qualifies as an &ldquo;audit committee financial expert&rdquo; as that term is defined in the
	applicable regulations of the Exchange Act.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Compensation Committee
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Our Board of Directors has a Compensation
	Committee, which is comprised of Dr. Rubin (Chair), Dr. Brughera and Dr. Zeldis. The Compensation Committee is responsible for
	reviewing and approving the executive compensation program, assessing executive performance, setting salary, making grants of annual
	incentive compensation and approving certain employment agreements. Our Board of Directors has determined that Dr. Rubin and Dr.
	Zeldis are &ldquo;independent&rdquo; directors within the meaning of applicable listing standards of The NASDAQ Stock Market LLC
	(&ldquo;Nasdaq&rdquo;) and the Exchange Act and the rules and regulations thereunder. Our Board of Directors reviewed Dr. Brughera&rsquo;s
	relationship as the Global Head of the Rare Disease Franchise for Sigma-Tau SpA., an affiliate of Sigma-Tau Pharmaceuticals, Inc.,
	which owns approximately 9.4% of the issued and outstanding shares of our common stock. Our Board of Directors determined that
	Dr. Brughera&rsquo;s position with Sigma-Tau Spa. would not impair his ability to exercise independent judgment.&nbsp;&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Nominating and Corporate
	Governance Committee
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Our Board of Directors has a Nominating
	and Corporate Governance Committee (&ldquo;Nominating Committee&rdquo;), which is comprised of Dr. Zeldis (Chair), Mr. Brownlie
	and Mr. Lapointe. The Nominating Committee makes recommendations to the Board of Directors regarding the size and composition of
	our Board of Directors, establishes procedures for the nomination process, identifies and recommends candidates for election to
	our Board of Directors. Our Board of Directors has determined that Dr. Zeldis, Mr. Brownlie and Mr. Lapointe are &ldquo;independent&rdquo;
	directors, as such term is defined by the applicable Nasdaq listing standards.&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 53; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Code
	of Ethics
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	have adopted a code of ethics that applies to all of our executive officers and senior financial officers (including our chief
	executive officer, chief financial officer, chief accounting officer and any person performing similar functions). A copy of our
	code of ethics is publicly available on our website at www.soligenix.com under the &ldquo;Investors&rdquo; section. If
	we make any substantive amendments to our code of ethics or grant any waiver, including any implicit waiver, from a provision
	of the code to our chief executive officer, chief financial officer or chief accounting officer, we will disclose the nature of
	such amendment or waiver in a Current Report on Form 8-K.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Diversity
	Considerations in Identifying Director Nominees
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	We
	do not have a formal diversity policy or set of guidelines in selecting and appointing directors that comprise our Board of Directors.
	However, when making recommendations to our Board of Directors regarding the size and composition of our Board of Directors, our
	Nominating Committee does consider each individual director&rsquo;s qualifications, skills, business experience and capacity to
	serve as a director and the diversity of these attributes for the Board of Directors as a whole.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Compensation
	Committee Interlocks and Insider Participation
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	No
	member of our Compensation Committee is or has at any time during the past year been one of our officers or employees. None of
	our executive officers currently serves or in the past year has served as a member of the Board of Directors or Compensation Committee
	of any entity that has one or more executive officers serving on our Board of Directors or Compensation Committee.
</FONT>
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item
	11. Executive Compensation
</B>
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Summary
	Compensation
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	following table contains information concerning the compensation paid during each of the two years ended December 31, 2015 to
	our Chief Executive Officer and each of the two other most highly compensated executive officers during 2015 (collectively, the
	&ldquo;Named Executive Officers&rdquo;).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_COMPENSATION_TABLE>
<A NAME="FIS_COMPENSATION_TABLE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Summary
	Compensation
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-INDENT: 0">
	Name
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-INDENT: 0">
	Position
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Year
</TD>
<TD STYLE="PADDING: 0; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-INDENT: 0">
	Salary
</TD>
<TD STYLE="PADDING: 0; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-INDENT: 0">
	Bonus
</TD>
<TD STYLE="PADDING: 0; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-INDENT: 0">
	Option Awards
</TD>
<TD STYLE="PADDING: 0; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-INDENT: 0">
	All Other Compensation
</TD>
<TD STYLE="PADDING: 0; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-INDENT: 0">
	Total
</TD>
<TD STYLE="PADDING: 0; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 16%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Christopher
	J.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	CEO &amp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: CENTER; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2015
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	424,360
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	101,846
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	158,200
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	36,201
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	720,607
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<B>
	Schaber
<SUP>
	1
</SUP>
</B>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	President
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2014
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	412,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	115,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	150,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	29,580
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	706,580
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Joseph
	M.
</B>
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	VP &amp; Acting
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	196,730
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	38,362
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	62,150
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	24,676
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	321,918
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<B>
	Warusz
<SUP>
	2
</SUP>
</B>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	CFO
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2014
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	191,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	41,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	67,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	21,197
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	320,697
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Richard
	C.
</B>
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	CMO &amp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2015
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	309,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	58,401
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	79,100
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	25,656
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	472,157
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<B>
	Straube
<SUP>
	3
</SUP>
</B>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
	Senior VP
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2014
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	300,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	62,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	276,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	21,328
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	659,328
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_COMPENSATION_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.2PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -7.2PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.2PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -7.2PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.2PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -7.2PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 0; TEXT-INDENT: 0; WIDTH: 2%">
<SUP>
	1
</SUP>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 0; TEXT-INDENT: 0">
	Dr. Schaber deferred the payment of his
<FONT STYLE="COLOR: WINDOWTEXT">
	2015
</FONT>
	bonus of $101,846 until January 15, 2016.
	Option award figures include the value of common stock option awards at grant date as calculated under FASB ASC 718. Other compensation
	represents health insurance costs paid by the Company.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 0; TEXT-INDENT: 0">
<SUP>
	2
</SUP>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 0; TEXT-INDENT: 0">
	Mr. Warusz deferred the payment of his 2015 bonus of $38,362 until January 15, 2016. Option award figures include the value of
	common stock option awards at grant date as calculated under FASB ASC 718. Other compensation represents health insurance costs
	paid by the Company.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-LEFT: 0; TEXT-INDENT: 0">
<SUP>
	3
</SUP>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-LEFT: 0; TEXT-INDENT: 0">
	Dr. Straube joined the Company on January 1, 2014. He deferred the payment of his 2015 bonus of
	$58,401 until January 15, 2016. Option award figures include the value of common stock option awards at grant date as calculated
	under FASB ASC 718. Other compensation represents health insurance costs paid by the Company.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.2PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -7.2PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.2PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -7.2PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 54; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 7.2PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -7.2PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Employment
	and Severance Agreements
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	August 2006, we entered into a three-year employment agreement with Christopher J. Schaber, PhD. Pursuant to this employment agreement
	we agreed to pay Dr. Schaber a base salary of $300,000 per year and a minimum annual bonus of $100,000. Dr. Schaber&rsquo;s employment
	agreement was renewed in December 27, 2007 for an additional term of three years. We agreed to issue him options to purchase 125,000
	shares of our common stock, with one third immediately vesting and the remainder vesting over three years. Upon termination without
	&ldquo;Just Cause&rdquo; as defined by this agreement, we would pay Dr. Schaber nine months of severance, as well as any accrued
	bonuses, accrued vacation, and we would provide health insurance and life insurance benefits for Dr. Schaber and his dependents.
	No unvested options shall vest beyond the termination date. Dr. Schaber&rsquo;s monetary compensation (base salary of $300,000
	and bonus of $100,000) remained unchanged from 2006 with the 2007 renewal. Upon a change in control of the Company due to merger
	or acquisition, all of Dr. Schaber&rsquo;s options shall become fully vested, and be exercisable for a period of five years after
	such change in control (unless they would have expired sooner pursuant to their terms). In the event of his death during the term
	of the agreement, all of his unvested options shall immediately vest and remain exercisable for the remainder of their term and
	become the property of Dr. Schaber&rsquo;s immediate family. Dr. Schaber&rsquo;s employment agreement automatically renewed in
	December 2013 for an additional term of three years.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	On June 22, 2011, the Compensation Committee
	eliminated his fixed minimum annual bonus payable and revised it to an annual targeted bonus of 40% of his annual base salary.
	On December 4, 2013, the Compensation Committee approved an increase in salary for Dr. Schaber to $412,000. On December 4, 2014,
	the Compensation Committee approved an increase in salary for Dr. Schaber to $424,360. On December 10, 2015, the Compensation Committee
	approved an increase in salary for Dr. Schaber to $434,969.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In May 2011, we entered into a one-year
	employment agreement with Mr. Joseph M. Warusz, our Acting Chief Financial Officer, Vice President Finance and Chief Accounting
	Officer. Pursuant to the agreement, we have agreed to pay Mr. Warusz $175,000 per year and a targeted annual bonus of 30% of base
	salary. We also agreed to issue him options to purchase 40,000 shares of our common stock with one-third immediately vesting and
	the remainder vesting over three years. Upon termination without &ldquo;Just Cause&rdquo;, as defined in Mr. Warusz&rsquo;s employment
	agreement, we would pay Mr. Warusz three months of severance, accrued bonuses and vacation, and health insurance benefits. No unvested
	options vest beyond the termination date. On December 6, 2012, the Compensation Committee approved an increase in the targeted
	annual bonus to 35%. On December 4, 2013, the Compensation Committee approved an increase in salary for Mr. Warusz to $191,000.
	On December 4, 2014, the Compensation Committee approved an increase in salary for Mr. Warusz to $196,730. On December 10, 2015,
	the Compensation Committee approved an increase in salary for Mr. Warusz to $201,648.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In December 2014, we entered into a
	one-year employment agreement with Richard C. Straube, MD, our Chief Medical Officer and Senior Vice President. Pursuant to the
	agreement, we have agreed to pay Dr. Straube $300,000 per year and a targeted annual bonus of 30% of base salary. We also agreed
	to issue him options to purchase 100,000 shares of our common stock with one-third immediately vesting and the remainder vesting
	over three years. Upon termination without &ldquo;Just Cause&rdquo;, as defined in Dr. Straube&rsquo;s employment agreement, we
	would pay Dr. Straube three months of severance, accrued bonuses and vacation, and health insurance benefits. No unvested options
	vest beyond the termination date. On December 4, 2014, the Compensation Committee approved an increase in salary for Dr. Straube
	to $309,000. On December 10, 2015, the Compensation Committee approved an increase in salary for Dr. Straube to $316,725.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	February 2007, our Board of Directors authorized the issuance of 50,000 shares to Dr. Schaber immediately prior to the completion
	of a transaction, or series or a combination of related transactions negotiated by our Board of Directors whereby, directly or
	indirectly, a majority of our capital stock or a majority of our assets are transferred from the Company and/or our stockholders
	to a third party. The amended agreement with Dr. Schaber includes our obligation to issue such shares to him if such event occurs.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 55; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Outstanding
	Equity Awards at Fiscal Year-End
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 18PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	following table contains information concerning unexercised options, stock that has not vested, and equity incentive plan awards
	for the Named Executive Officers outstanding at December&nbsp;31, 2015. We have never issued Stock Appreciation Rights.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_OPTIONS_AGGREGATE>
<A NAME="FIS_OPTIONS_AGGREGATE"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="6" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Number
	of Securities
</B>
<BR>
<B>
	Underlying Unexercised
</B>
<BR>
<B>
	Options
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(#)
</B>
</FONT>
</P>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Equity
	Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Option
	Exercise Price
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Option
	Expiration
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Name
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Exercisable
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Unexercisable
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Options
	(#)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	($)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Date
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Christopher J. Schaber
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	125,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5.40
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8/28/2016
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	45,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	9.40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8/9/2017
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	140,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1.20
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12/17/2018
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	110,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.64
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6/30/2020
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	112,185
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	0.64
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11/30/2021
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	130,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	0.68
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12/04/2022
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	75,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	25,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	25,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2.01
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12/04/2023
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	50,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	50,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	50,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12/04/2024
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	35,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	105,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	105,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1.13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12/30/2025
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Richard C. Straube
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	68,750
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31,250
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31,250
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2.01
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1/06/2024
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	25,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	25,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	25,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12/04/2024
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	17,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	52,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	52,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1.13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12/30/2025
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Joseph M. Warusz
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	40,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.10
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5/30/2021
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	25,310
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	0.64
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11/30/2021
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	55,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	0.68
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12/04/2022
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	33,754
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11,246
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11,246
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2.01
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12/04/2023
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	22,502
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	22,498
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	22,498
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12/04/2024
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	13,750
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	41,250
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	41,250
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1.13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12/30/2025
</TD>
</TR>
</TABLE>
</EFX_OPTIONS_AGGREGATE>
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Compensation
	of Directors
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	following table contains information concerning the compensation of the non-employee directors during the fiscal year ended December
	31, 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Name
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-DECORATION: NONE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Fees Earned
<U STYLE="TEXT-DECORATION: NONE">
	Paid in Cash
<SUP>
	1
</SUP>
</U>
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U STYLE="TEXT-DECORATION: NONE">
	Option Awards
<SUP>
	2
</SUP>
</U>
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; TEXT-DECORATION: NONE; TEXT-ALIGN: LEFT">
	Keith Brownlie
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	55,500
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	30,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	85,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Marco Brughera
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	40,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	30,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	70,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Gregg A. Lapointe
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	47,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	30,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	77,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Robert J. Rubin
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	52,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	30,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	82,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Jerome B. Zeldis
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	50,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	30,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	80,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0; WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<SUP>
	1
</SUP>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Directors
	who are compensated as full-time employees receive no additional compensation for service
	on our Board of Directors. Each independent director who is not a full-time employee
	is paid $35,000 annually, on a prorated basis, for their service on our Board of Directors,
	the chairman of our&nbsp;Audit Committee is paid $15,000 annually, on a prorated basis,
	and the chairmen of our&nbsp;Compensation and Nominating Committees will be paid $10,000
	annually, on a prorated basis. Additionally, Audit Committee members are paid $7,500
	annually and Compensation and Nominating Committee members are paid $5,000 annually.
	This compensation is paid quarterly.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0; WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<SUP>
	2
</SUP>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	We
	maintain a stock option grant program pursuant to the nonqualified stock option plan,
	whereby members of our Board of Directors or its committees who are not full-time employees
	receive an initial grant of fully vested options to purchase 15,000 shares of common
	stock. Upon re-election to the Board, each Board member will receive stock options with
	a value of $30,000, calculated using the closing price of the common stock on the trading
	day prior to the date of the annual meeting of the Company&rsquo;s stockholders, which
	vest at the rate of 25% per quarter, commencing with the first quarter after each annual
	meeting of stockholders.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 9PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.9PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 9PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.9PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 56; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 9PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -9.9PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Stock
	Ownership Policy
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	April 2012, our Board of Directors adopted a stock ownership policy applicable to our non-employee directors to strengthen the
	link between director and stockholder interests. Pursuant to the stock ownership policy, each non-employee director is required
	to hold a minimum ownership position in the common stock equal to the annual cash compensation paid for service on the Board of
	Directors, exclusive of cash compensation paid for service as a chair or member of any committees of the Board of Directors.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Stock
	counted toward the ownership requirement includes common stock held by the director, unvested and vested restricted stock, and
	all shares of common stock beneficially owned by the director held in a trust and by a spouse and/or minor children of the director.
	The policy provides that the ownership requirement must be attained within three years after the later of June 21, 2012 and the
	date a director is first elected or appointed to the Board of Directors. To monitor progress toward meeting the requirement, the
	Nominating Committee will review director ownership levels at the end of March of each year. Non-employee directors are prohibited
	from selling any shares of common stock unless such director is in compliance with the stock ownership policy. A copy of our director
	compensation and stock ownership policy is publicly available on our website at www.soligenix.com under the &ldquo;Investors&rdquo;
	section.
</FONT>
</P>
</EFX_COMPENSATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item
	12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</B>
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	table below provides information regarding the beneficial ownership of the common stock as of March 18, 2016, of (1) each person
	or entity who owns beneficially 5% or more of the shares of our outstanding common stock, (2) each of our directors, (3) each
	of the Named Executive Officers, and (4) our directors and officers as a group. Except as otherwise indicated, and subject to
	applicable community property laws, we believe the persons named in the table have sole voting and investment power with respect
	to all shares of common stock held by them.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Beneficial
	Ownership
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 12PT ARIAL, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Name of Beneficial Owner
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Shares
	of Common&nbsp;Stock Beneficially Owned
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	Percent
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	of Class
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Randall J. Kirk (1)
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,867,816
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	20.34
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	NRM VII Holdings I, LLC (1)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	5,833,333
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	17.27
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Paolo Cavazza (2)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	3,379,950
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	10.66
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Sigma-Tau Pharmaceuticals, Inc (2)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	3,068,461
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	9.70
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Intrexon Corporation (1)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,034,483
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	3.31
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Christopher J. Schaber (3)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	941,298
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2.93
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Keith Brownlie (4)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	115,208
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	*
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Marco Brughera (5)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	43,600
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	*
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Gregg A. Lapointe&nbsp;(6)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	151,493
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	*
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Robert J. Rubin (7)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	111,158
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	*
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Jerry Zeldis (8)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	126,041
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	*
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Joseph Warusz (9)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	217,294
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	*
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Richard Straube (10)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	131,250
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	*
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Oreola Donini (11)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	140,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	*
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	All directors and executive officers as a group (9 persons)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,977,342
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6.00
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; WIDTH: 15%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On June 26, 2013, Randal J. Kirk, on his own behalf and on behalf of Third Security, LLC, NYM VII
	Holdings I, LLC and Intrexon Corporation, filed Amendment No. 1 to Schedule 13D with the Securities and Exchange Commission (the
	&ldquo;SEC&rdquo;), which amends the Schedule 13D filed May 9, 2013 with the SEC (as amended, &ldquo;Schedule 13D&rdquo;).&nbsp;&nbsp;The
	Schedule 13D states that Mr. Kirk is Senior Managing Director of, and controls, Third Security, LLC, which is the Manager of an
	affiliate that manages NRM VII Holdings I, LLC, and that Mr. Kirk serves as the Chairman and Chief Executive Officer of Intrexon
	Corporation.&nbsp;&nbsp;The Schedule 13D indicates that (a) Mr. Kirk, Third Security, LLC and NRM VII Holdings I, LLC have sole
	voting and dispositive power with respect to 3,333,333 shares of Common Stock and warrants to purchase 2,500,000 shares of Common
	Stock exercisable within 60 days of March 18, 2016 held by NRM VII Holdings I, LLC, and (b) Mr. Kirk and Intrexon Corporation have
	shared voting and dispositive power with respect to 1,034,483 shares of Common Stock held by Intrexon Corporation.&nbsp;&nbsp;The
	address of the principal business office of Mr. Kirk is 2875 South Ocean Boulevard, Suite 214, Palm Beach, Florida 33480.&nbsp;&nbsp;The
	address of the principal business office of NRM VII Holdings I, LLC is c/o Third Security, LLC, 1881 Grove Avenue, Redford, Virginia
	24141.&nbsp;&nbsp;The address of the principal business office of Intrexon Corporation is 20358 Seneca Meadows Parkway, Germantown,
	Maryland 20876.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 57; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	On
	May 16, 2013, Paolo Cavazza, on his own behalf and on behalf of Sigma Tau Finanziaria S.p.A., Sigma-Tau International S.A., Sigma-Tau
	America S.A. and Sigma-Tau Pharmaceuticals, Inc., filed Amendment No. 4 to Schedule 13D with the SEC, which amends the Schedule
	13D filed with the SEC on February 20, 2009 as amended by Amendment No. 1 filed with the SEC on October 2, 2009, Amendment No.
	2 filed with the SEC on June 28, 2010 and Amendment No. 3 filed with the SEC on January 2, 2013 (the &ldquo;Schedule 13D&rdquo;).&nbsp;&nbsp;The
	Schedule 13D indicates that (a) Mr. Cavazza has sole voting and dispositive power with respect to (i) 59,539 shares held by Mr.
	Paolo Cavazza and (ii) 164,146 shares of common stock and warrants to purchase 87,804 shares held by SINAF SA, and (b) Mr. Cavazza,
	Sigma-Tau Finanziaria S.p.A., Sigma-Tau International S.A., Sigma-Tau America S.A. and Sigma-Tau Pharmaceuticals, Inc. have shared
	voting and dispositive power with respect to 2,711,392 shares of common stock and warrants to purchase 357,069 shares of common
	stock exercisable within 60 days of the date of March 18, 2016 held by Sigma-Tau Pharmaceuticals, Inc. Sigma-Tau Pharmaceuticals,
	Inc. is a direct wholly-owned subsidiary of Sigma-Tau Finanziaria S.p.A. Mr. Paolo Cavazza directly and indirectly owns 37,2% of
	Sigma-Tau Finanziaria S.p.A. SINAF SA is a wholly owned subsidiary of Aptafin S.p.A., which is owned by Mr. Paolo Cavazza and members
	of his family.&nbsp;&nbsp;Mr. Paolo Cavazza&rsquo;s address is Via Tesserte, 10, Lugano, Switzerland. The business address of Sigma-Tau
	Finanziaria S.p.A. is Via Sudafrica, 20, Rome, Italy 00144.&nbsp;&nbsp;&nbsp;The business address of Sigma-Tau Pharmaceuticals,
	Inc. is 9841 Washingtonian Boulevard, Suite 500, Gaithersburg, Maryland 20878.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	(3)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Includes 92,904 shares of common stock owned
	by Dr. Schaber, options to purchase 843,435 shares of common stock exercisable within 60 days of March 18, 2016, and warrants to
	purchase 4,959 shares of common stock exercisable within 60 days of March 18, 2015. The address of Dr. Schaber is c/o Soligenix,
	29 Emmons Drive, Suite C-10, Princeton, New Jersey 08540.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	(4)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Includes 50,000 shares of common stock and options to purchase 65,208 shares of common stock exercisable
	within 60 days of the March 18, 2016 . The address of Mr. Brownlie is c/o Soligenix, 29 Emmons Drive, Suite C-10, Princeton, New
	Jersey 08540.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	(5)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Includes 7,500 shares of common stock and options to purchase 36,100 shares of common stock owned
	by Dr. Brughera exercisable within 60 days of March 18, 2016. The address of Dr. Brughera is c/o Soligenix, 29 Emmons Drive, Suite
	C-10, Princeton, New Jersey 08540.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	(6)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Includes 73,781 shares of common stock and options to purchase 77,712 shares of common stock exercisable
	within 60 days of March 18, 2016, . The address of Mr. Lapointe is c/o Soligenix, 29 Emmons Drive, Suite C-10, Princeton, New Jersey
	08540.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	(7)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Includes 12,195 shares of common stock and options to purchase 98,962 shares of common stock exercisable
	within 60 days of March 18, 2016. The address of Dr. Rubin is c/o Soligenix, 29 Emmons Drive, Suite C-10, Princeton, New Jersey
	08540.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	(8)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Includes 69,166 shares of common stock and options to purchase 56,875 shares of common stock exercisable
	within 60 days of March 18, 2016 . The address of Dr. Zeldis is c/o Soligenix, 29 Emmons Drive, Suite C-10, Princeton, New Jersey
	08540.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	(9)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Includes 12,955 shares of common stock, options to purchase 199,380 shares of common stock owned
	by Mr. Warusz exercisable within 60 days of March 18, 2016 and warrants to purchase 4,959 shares of Common Stock exercisable within
	60 days of March 18, 2016. The address of Mr. Warusz is c/o Soligenix, 29 Emmons Drive, Suite C-10, Princeton, New Jersey 08540.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	(10)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Includes options to purchase 131,250 shares of common stock exercisable within 60 days of March
	18, 2016. The address of Dr. Straube is c/o Soligenix, 29 Emmons Drive, Suite C-10, Princeton, New Jersey 08540.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
	(11)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Includes options to purchase 90,000 shares of common stock owned by Dr. Donini exercisable within
	60 days of March 18, 2016 and warrants to purchase 50,000 shares of common stock exercisable within 60 days of March 18, 2016.
	The address of Dr. Donini is c/o Soligenix, 29 Emmons Drive, Suite C-10, Princeton, New Jersey 08540.
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-ALIGN: JUSTIFY">
	* Indicates less than 1%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-ALIGN: JUSTIFY">
	** Beneficial ownership is determined
	in accordance with the rules of the SEC. Shares of common stock subject to options or warrants currently exercisable or exercisable
	within 60 days of March 18, 2016 are deemed outstanding for computing the percentage ownership of the stockholder holding the options
	or warrants, but are not deemed outstanding for computing the percentage ownership of any other stockholder. Percentage of ownership
	is based on 31,269,522 shares of common stock outstanding as of March 18, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.25IN; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 58; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Equity
	Compensation Plan Information
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In December 2005, our Board of Directors
	approved the 2005 Equity Incentive Plan, which was approved by stockholders on December 29, 2005. In September 2013, our stockholders
	approved an amendment to the 2005 Equity Incentive Plan to increase the maximum number of shares of our common stock available
	for issuance under the plan by 1,250,000 shares, bringing the total shares reserved for issuance under the plan to 3,000,000 shares.
	In April 2015, our Board of Directors approved the 2015 Equity Incentive Plan, which was approved by stockholders on June 18,
	2015. A maximum of 3,000,000 shares of our common stock are available for issuance under the 2015 Equity Incentive Plan. The following
	table provides information, as of December 31, 2015 with respect to options outstanding under our 2005 Equity Incentive Plan and
	our 2015 Equity Incentive Plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Plan
	Category
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Number
	of Securities
<BR>
	to be Issued upon Exercise of Outstanding Options, Warrants and Rights
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Weighted-Average
	Exercise Price of Outstanding Options, Warrants and Rights
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Number
	of Securities Remaining Available for Future Issuance Under Equity Compensation Plans
<BR>
	(excluding securities reflected
	in the first column)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 52%; TEXT-ALIGN: LEFT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Equity
	compensation plans approved by security holders
<SUP>
	1
</SUP>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2,768,612
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2.13
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2,523,000
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Equity compensation
	plans not approved by security holders
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	-
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2,768,612
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2.13
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2,523,000
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; WIDTH: 15%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<SUP>
	1
</SUP>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0; WIDTH: 98%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Includes our 2005 Equity Incentive Plan and our 2015 Equity Incentive Plan. Our 2005 Plan expired in 2015
	and thus no securities remain available for future issuance under that plan.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_SECURITY_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item
	13. Certain Relationships and Related Transactions and Director Independence
</B>
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Related
	Party Transactions
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Other
	than the employment agreements and compensation paid to our directors, we did not engage in any transactions with related parties
	since January 1, 2015. For a discussion of our employment agreements and compensation paid to our directors, see &ldquo;Item 11.
	Executive Compensation.&rdquo;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Director
	Independence
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Board of Directors has determined that Keith Brownlie, Gregg Lapointe, Dr. Robert Rubin and Dr. Jerome Zeldis are &ldquo;independent&rdquo;
	as such term is defined by the applicable listing standards of Nasdaq. Our Board of Directors based this determination primarily
	on a review of the responses of the Directors to questionnaires regarding their employment, affiliations and family and other
	relationships.
</FONT>
</P>
</EFX_OFFICER_TRANSACTIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item
	14. Principal Accountant Fees and Services
</B>
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	following table highlights the aggregate fees billed during each of the two years ended December 31, 2015 by EisnerAmper LLP.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 12PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; TEXT-ALIGN: JUSTIFY">
	Audit fees
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	167,365
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	173,503
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Tax fees
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,536
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1.5PT">
	Other fees
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	27,500
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	11,993
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 4PT">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	204,865
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	196,032
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Other
	Fees
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Our
	principal accountants did not bill us for any services or products other than as reported above in this Item 14 during each of
	the two years. Other services include billing for an IT security assessment project that commenced during the year ended December
	31, 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Pre-Approval
	Policies and Procedures
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	audit committee has adopted a policy that requires advance approval of all audit services and permitted non-audit services to
	be provided by the independent auditor as required by the Exchange Act. The audit committee must approve the permitted service
	before the independent auditor is engaged to perform it. The audit committee approved all of the services described above in accordance
	with its pre-approval policies and procedures.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 59; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Part
	IV
</B>
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Item
	15. Exhibits and Financial Statements Schedules
</B>
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 0.3IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	a.
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(1)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated Financial Statements:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.3IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	financial statements required to be filed by Item 8 of this Annual Report on Form 10-K and filed in this Item 15, are as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 14.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 14.4PT; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 0.3IN; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD>
	Consolidated Balance Sheets as of December 31, 2015 and 2014
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: CENTER">
	F-2
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Consolidated Statements of Operations for the Years Ended December 31, 2015 and 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	F-3
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Consolidated Statements of Shareholders&rsquo; Deficiency for the Years Ended December 31, 2015 and 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	F-4
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Consolidated Statements of Cash Flows for the Years Ended December 31, 2015 and 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	F-5
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Notes to Consolidated Financial Statements
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	F-6
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	Report of Independent Registered Public Accounting Firm
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	F-22
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 14.4PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.3IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(2)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Financial Statement Schedules
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.3IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Schedules
	are omitted because they are not applicable, or are not required, or because the information is included in the consolidated financial
	statements and notes thereto.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.3IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(3)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Exhibits:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; WIDTH: 10%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2.1
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY; WIDTH: 90%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Agreement and Plan of Merger, dated May 10, 2006 by and among the Company, Corporate Technology Development, Inc., Enteron Pharmaceuticals, Inc. and CTD Acquisition, Inc. (incorporated by reference to Exhibit 2.1 included in our Registration Statement on Form SB-2 (File No. 333-133975) filed on May 10, 2006).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3.1
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 included in our current report on Form 8-K filed on June 22, 2012).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3.2
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	By-laws (incorporated by reference to Exhibit 3.1 included in our Quarterly Report on Form 10-QSB, as amended, for the fiscal quarter ended June 30, 2003).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.1
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Rights Agreement dated June 22, 2007, between the Company and American Stock Transfer &amp; Trust Company, as Rights Agent (incorporated by reference to Exhibit 4.1 included in our current report on Form 8-K filed on June 22, 2007).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.2
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Right Certificate (incorporated by reference to Exhibit 4.2 included in our current report on Form 8-K filed on June 22, 2007).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.3
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Warrant issued to each investor in the January 2009 private placement (incorporated by reference to Exhibit 4.18 included in our Registration Statement on Form S-1 (File No. 333-149239) filed on February 14, 2008).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.4
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Warrant issued to each investor in the September 2009 private placement (incorporated by reference to Exhibit 10.2 included in our current report on Form 8-K filed on September 29, 2009).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.5
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Warrant dated April 19, 2010, issued to Fusion Capital Fund II, LLC (incorporated by reference to Exhibit 4.10 included in our Post-Effective Amendment to Registration Statement on Form S-1 filed on April 20, 2010).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.6
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Common Stock Purchase Warrant issued to each investor in the June 2010 private placement (incorporated by reference to Exhibit 10.2 included in our current report on Form 8-K filed on June 18, 2010).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.7
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Warrant dated December 20, 2012 and issued to Sigma-Tau to purchase 357,069 shares of the Company&rsquo;s common stock (incorporated by reference to Exhibit 10.2 of our current report on Form 8-K filed on December 27, 2012).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.8
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Warrant dated December 20, 2012 and issued to SINAF S.A. to purchase 87,804 shares of the Company&rsquo;s common stock (incorporated by reference to Exhibit 10.3 of our current report on Form 8-K filed on December 27, 2012).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.9
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-DECORATION: NONE; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Warrant dated December 20, 2012 and issued to McDonald to purchase 280,000 shares of the Company&rsquo;s common stock (incorporated by reference to Exhibit 10.6 of our current report on Form 8-K filed on December 27, 2012).
<STRIKE>
</STRIKE>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 60; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; WIDTH: 10%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.10
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY; WIDTH: 90%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Common Stock Purchase Warrant issued to each investor in the June 2013 registered public offering (incorporated by reference to Exhibit 10.3 included in our current report on Form 8-K filed on June 24, 2013).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.11
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Warrant issued to Maxim Group LLC (incorporated by reference to Exhibit 10.4 included in our current report on Form 8-K filed on June 24, 2013).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.12
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Warrant to Purchase Common Stock issued to each investor in the December 2014 registered public offering (incorporated by reference to Exhibit 4.12 included in our Registration Statement on Form S-1 (File No. 333-199761) filed on December 17, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.13
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Warrant to Purchase Common Stock issued to Roth Capital Partners, LLC (incorporated by reference to Exhibit 4.13 included in our Registration Statement on Form S-1 (File No. 333-199761) filed on December 17, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.1
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	License Agreement between the Company and the University of Texas Southwestern Medical Center (incorporated by reference to Exhibit 10.9 included in our Annual Report on Form 10-KSB filed March 30, 2004, as amended, for the fiscal year ended December 31, 2004).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.2
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	License Agreement between the Company and Thomas Jefferson University (incorporated by reference to Exhibit 10.9 included in our Annual Report on Form 10-KSB, as amended, for the fiscal year ended December 31, 2004).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.3
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	License Agreement between the Company and the University of Texas Medical Branch (incorporated by reference to Exhibit 10.10 included in our Annual Report on Form 10-KSB, as amended, for the fiscal year ended December 31, 2004).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.4
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consulting Agreement between the Company and Lance Simpson of Thomas Jefferson University. (incorporated by reference to Exhibit 10.43 included in our Annual Report on Form 10-KSB as amended for the fiscal year ended December 31, 2002).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.5
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2005 Equity Incentive Plan, as amended on September 25, 2013 (incorporated by reference to Exhibit 10.1 included in our current report on Form 8-K filed on September 30, 2013). **
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.6
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form S-8 Registration of Stock Options Plan dated December 30, 2005 (incorporated by reference to our registration statement on Form S-8 filed on December 30, 2005).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.7
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Letter of Intent dated January 3, 2007 by and between the Company and Sigma-Tau Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 included in our current report on Form 8-K filed on January 4, 2007).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.8
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Employment Agreement dated December 27, 2007, between Christopher J. Schaber, PhD and the Company (incorporated by reference to Exhibit 10.30 included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2008). **
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	10.9
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Exclusive License Agreement dated November 24, 1998, between Enteron Pharmaceuticals, Inc. and George B. McDonald, MD and amendments (incorporated by reference to Exhibit 10.42 included in our Registration Statement on Form S-1 (File No. 333
<B>
	-
</B>
	157322) filed on February 13, 2009).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: LEFT">
	10.10
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Collaboration and Supply Agreement dated February 11, 2009, between the Company and Sigma-Tau Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.43 included in our Registration Statement on Form S-1 (File No. 333
<B>
	-
</B>
	157322) filed on February 13, 2009). &dagger;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.11
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Employment Agreement dated as of May 31, 2011, between Joseph M. Warusz and the Company (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on May 31, 2011).**
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.12
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	First Amendment to Employment Agreement dated as of July 12, 2011, between the Company and Christopher J. Schaber, PhD (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on July 14, 2011).**
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.13
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amendment to the Collaboration and Supply Agreement dated July 26, 2011, between Sigma-Tau Pharmaceuticals, Inc. and the Company (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on July 28, 2011).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.14
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amendment to the Exclusive License Agreement dated as of July 26, 2011, between George McDonald, MD and the Company (incorporated by reference to Exhibit 10.2 of our current report on Form 8-K filed on July 28, 2011).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.15
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amendment No. 2 to the Collaboration and Supply Agreement between the Company, Enteron and Sigma-Tau dated as of December 20, 2012 (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on December 27, 2012). &dagger;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 61; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.16
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amendment to Exclusive License Agreement dated as of December 20, 2012 between Enteron and McDonald (incorporated by reference to Exhibit 10.4 of our current report on Form 8-K filed on December 27, 2012).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.17
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amendment to Consulting Agreement dated as of December 20, 2012 between Enteron and McDonald (incorporated by reference to Exhibit 10.5 of our current report on Form 8-K filed on December 27, 2012).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0; PADDING-LEFT: 0; PADDING-BOTTOM: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.18
</FONT>
</TD>
<TD STYLE="WIDTH: 90%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Contract HHSO100201300023C dated September 18, 2013 between the Company and the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on September 24, 2013). &dagger;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.19
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Contract HHSN272201300030C dated September 24, 2013 by and between the Company and the National Institutes of Health (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on September 30, 2013). &dagger;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.20
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Purchase Agreement dated as of November 18, 2013 between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on November 21, 2013).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.21
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Registration Rights Agreement dated as of November 18, 2013 between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.2 of our current report on Form 8-K filed on November 21, 2013)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.22
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Employment Agreement dated as of January 6, 2014 between the Company and Richard Straube, M.D. (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on January 8, 2014). **
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.23
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Asset Purchase Agreement dated September 3, 2014 between the Company and Hy Biopharma, Inc. (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on September 5, 2014). &dagger;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.24
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Registration Rights Agreement dated September 3, 2014 between the Company and Hy Biopharma, Inc. (incorporated by reference to Exhibit 10.2 of our current report on Form 8-K filed on September 5, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.25
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Contract HHSN272201400039C dated September 17, 2014 by and between the Company and the National Institutes of Health (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on September 23, 2014). &dagger;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.26
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Lease Agreement dated November 21,
	2014, between the Company and CPP II, LLC. (incorporated by reference to Exhibit 10.42 of our annual report on Form
	10-K for the year ended December 31, 2014).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; WIDTH: 10%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.27
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; WIDTH: 90%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2015 Equity Incentive Plan, as amended on June 9, 2015 (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on June 19, 2015).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.28
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Equity Purchase Agreement dated as of July 29, 2015 between the Company and Kodiak Capital Group, LLC, Kingsbrook Opportunities Master Fund LP and River North Equity, LLC (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on July 31, 2015).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.29
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Registration Rights Agreement dated as of July 29, 2015 between the Company and Kodiak Capital Group, LLC, Kingsbrook Opportunities Master Fund LP and River North Equity, LLC (incorporated by reference to Exhibit 10.2 of our current report on Form 8-K filed on July 31, 2015).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.30
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Promissory Note dated as of July 29, 2015 made by the Company in favor of Kodiak Capital Group, LLC, Kingsbrook Opportunities Master Fund LP and River North Equity, LLC (incorporated by reference to Exhibit 10.3 of our current report on Form 8-K filed on July 31, 2015).
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.31
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Purchase Agreement dated as of March 22, 2016 between the Company and Lincoln Park Capital Fund, LLC. *
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.32
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Registration Rights Agreement dated as of March 22, 2016&nbsp;&nbsp;between the Company and Lincoln Park Capital Fund, LLC. *
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 62; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0; WIDTH: 10%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	21.1
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0; WIDTH: 90%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Subsidiaries
	of the Company. *
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	23.1
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consent
	of EisnerAmper LLP. *
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31.1
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification
	of the Chief Executive Officer pursuant to Exchange Act rule 13(a)-14(a) (under Section 302 of the Sarbanes-Oxley Act of 2002).
	*
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31.2&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification
	of the Chief Financial Officer pursuant to Exchange Act rule 13(a)-14(a) (under Section 302 of the Sarbanes-Oxley Act of 2002).
	*
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	32.1&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification
	of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	32.2&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification
	of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; WIDTH: 15%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 6%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	*
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	**
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&dagger;
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 94%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0; TEXT-INDENT: 0">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Filed
	herewith.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Indicates
	management contract or compensatory plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Portions
	of this exhibit have been omitted pursuant to a request for confidential treatment.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 63; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_EXHIBITS>
</EFX_PART_IV>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	SIGNATURES
</B>
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,
	thereunto duly authorized.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	SOLIGENIX, INC.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; WIDTH: 60%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; WIDTH: 4%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; WIDTH: 36%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0 0 1.5PT; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	By:
</B>
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 0; BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING-LEFT: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;/s/
	Christopher J. Schaber
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Christopher J. Schaber, PhD
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Chief Executive Officer and
	President
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Date:
	March 24, 2016
</FONT>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in
	the capacities indicated and on the dates indicated.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 35%; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Name
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Capacity
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 17%; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Date
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 0; BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING-LEFT: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT/12.5PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	/s/
	Christopher J. Schaber
</B>
</FONT>
</P>
</TD>
<TD STYLE="PADDING: 0 0 1.5PT; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
</P>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Chairman
	of the Board, Chief Executive
</FONT>
</TD>
<TD STYLE="PADDING: 0 0 1.5PT; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	March
	24, 2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-BOTTOM: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Christopher
	J. Schaber, PhD
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT/12.5PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Officer
	and President
</FONT>
</P>
<P STYLE="FONT: 10PT/12.5PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(principal
	executive officer)
</FONT>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-BOTTOM: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 0; BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING-LEFT: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT/12.5PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	/s/
	Keith L. Brownlie
</B>
</FONT>
</P>
</TD>
<TD STYLE="PADDING: 0 0 1.5PT; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Director
</FONT>
</TD>
<TD STYLE="PADDING: 0 0 1.5PT; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	March
	24, 2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Keith
	L. Brownlie, CPA
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 0; BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING-LEFT: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	/s/
	Marco Brughera
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0 0 1.5PT; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Director
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0 0 1.5PT; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-TOP: 0; PADDING-RIGHT: 0; PADDING-LEFT: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	March
	24, 2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Marco
	Brughera, DVM
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 0; BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING-LEFT: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT/12.5PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	/s/
	Gregg A. Lapointe
</B>
</FONT>
</P>
</TD>
<TD STYLE="PADDING: 0 0 1.5PT; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0 0 1.5PT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Director
</FONT>
</TD>
<TD STYLE="PADDING: 0 0 1.5PT; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0 0 1.5PT; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	March&nbsp;24,
	2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Gregg
	A. Lapointe, CPA
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 0; BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING-LEFT: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT/12.5PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	/s/
	Robert J. Rubin
</B>
</FONT>
</P>
</TD>
<TD STYLE="PADDING: 0 0 1.5PT; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0 0 1.5PT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Director
</FONT>
</TD>
<TD STYLE="PADDING: 0 0 1.5PT; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0 0 1.5PT; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	March
	24, 2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Robert
	J. Rubin, MD
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 0; BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING-LEFT: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT/12.5PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	/s/
	Jerome B. Zeldis
</B>
</FONT>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0 0 1.5PT; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0 0 1.5PT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Director
</FONT>
</TD>
<TD STYLE="PADDING: 0 0 1.5PT; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0 0 1.5PT; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	March&nbsp;&nbsp;24,
	2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Jerome
	Zeldis, MD, PhD
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-TOP: 0; PADDING-RIGHT: 0; BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING-LEFT: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT/12.5PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	/s/
	Joseph M. Warusz
</B>
</FONT>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0 0 1.5PT; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING: 0 0 1.5PT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Vice
	President of Finance, Acting Chief
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0 0 1.5PT; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0 0 1.5PT; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	March&nbsp;&nbsp;24,
	2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Joseph
	M. Warusz, CPA
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING: 0; TEXT-INDENT: 0; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING: 0; TEXT-INDENT: 0; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT/12.5PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Financial
	Officer and Corporate Secretary
</FONT>
</P>
<P STYLE="FONT: 10PT/12.5PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(principal
	accounting officer)
</FONT>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 64; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	SOLIGENIX,
	INC. AND SUBSIDIARIES
<BR>
	CONSOLIDATED FINANCIAL STATEMENTS
<BR>
<BR>
	Table of Contents
</B>
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT 0PT 1.5PT; TEXT-INDENT: 0PT; WIDTH: 90%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-TOP: 0PT; PADDING-RIGHT: 0PT; BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING-LEFT: 5.4PT; TEXT-ALIGN: CENTER; WIDTH: 10%">
<B>
	Page
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT 0PT 0PT 5.4PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated
	Balance Sheets as of December 31, 2015 and 2014
</FONT>
</P>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT 0PT 0PT 5.4PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-2
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT 0PT 0PT 5.4PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated
	Statements of Operations for the Years Ended December 31, 2015 and 2014
</FONT>
</P>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT 0PT 0PT 5.4PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-3
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT 0PT 0PT 5.4PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated
	Statements of Changes in Shareholders&rsquo; Deficiency for the Years Ended December 31, 2015 and 2014
</FONT>
</P>
</TD>
<TD STYLE="PADDING: 0PT 0PT 0PT 5.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-4
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0PT 0PT 0PT 5.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated
	Statements of Cash Flows for the Years Ended December 31, 2015 and 2014
</FONT>
</P>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT 0PT 0PT 5.4PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-5
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT 0PT 0PT 5.4PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Notes
	to Consolidated Financial Statements
</FONT>
</P>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT 0PT 0PT 5.4PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-6
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT 0PT 0PT 5.4PT; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 0PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Report
	of Independent Registered Public Accounting Firm
</FONT>
</P>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT 0PT 0PT 5.4PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-22
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 65; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_SIGNATURES>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Soligenix,
	Inc. and Subsidiaries
<BR>
	Consolidated Balance Sheets
<BR>
	As of December 31,
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Assets
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Current assets:
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,921,545
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	5,525,094
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Contracts and grants receivable
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,985,212
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	794,767
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 10PT">
	Prepaid expenses
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	244,267
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	172,928
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Total current assets
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	7,151,024
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,492,789
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Office furniture and equipment, net
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	47,366
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	51,510
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	Intangible assets, net
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	188,732
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	409,949
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT">
	Total assets
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	7,387,122
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,954,248
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Liabilities and shareholders&rsquo; deficiency
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Current liabilities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accounts payable
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,379,936
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	3,003,545
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Notes payable
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	292,719
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Warrant liability
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,434,101
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	3,789,562
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 10PT">
	Accrued compensation
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	298,675
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	315,030
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	Total current liabilities
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	7,405,431
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	7,108,137
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Commitments and contingencies
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Shareholders&rsquo; deficiency:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Preferred stock, 350,000 shares authorized; none issued or outstanding
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Common stock, $.001 par value; 50,000,000 shares authorized; 31,269,522 and 23,936,568 shares issued and outstanding in 2015 and 2014, respectively
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	31,270
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	23,937
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Additional paid-in capital
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	146,828,000
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	138,868,523
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 10PT">
	Accumulated deficit
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(146,877,579
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(139,046,349
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	Total shareholders&rsquo; deficiency
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(18,309
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(153,889
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT">
	Total liabilities and shareholders&rsquo; deficiency
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	7,387,122
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,954,248
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	accompanying notes are an integral part of these consolidated financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 66; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Soligenix,
	Inc. and Subsidiaries
<BR>
	Consolidated Statements of Operations
<BR>
	For the Years Ended December 31,
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Revenues:
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Grant revenue
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	127,042
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	1,497,548
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Contract revenue
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	8,641,348
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	5,545,468
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Total revenues
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	8,768,390
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,043,016
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Cost of&nbsp;&nbsp;revenues
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(6,882,204
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	(5,313,855
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Gross profit
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	1,886,186
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	1,729,161
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Operating expenses:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Research and development
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	5,399,839
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,086,535
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Acquired in-process research and development
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,000,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	General and administrative
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	3,596,623
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	3,403,975
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Total operating expenses
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	8,996,462
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	12,490,510
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Loss from operations
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(7,110,276
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	(10,761,349
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Other income (expense):
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Change in fair value of warrant liability
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,201,870
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,436,195
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Interest income (expense), net
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(8,017
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	1,310
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Total other income (expense)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(1,209,887
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	3,437,505
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Net loss before income taxes
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(8,320,163
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7,323,844
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Income tax benefit
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	488,933
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	616,872
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Net loss
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(7,831,230
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	(6,706,972
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Basic&nbsp;net loss per share
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(0.30
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	(0.32
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Diluted&nbsp;net loss per share
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(0.30
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	(0.43
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Basic&nbsp;weighted average common shares outstanding
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	26,065,765
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	20,638,421
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Diluted&nbsp;weighted average common shares outstanding
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	26,065,765
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	23,584,944
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	accompanying notes are an integral part of these consolidated financial statements.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 67; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Soligenix,
	Inc. and Subsidiaries
<BR>
	Consolidated Statements of Changes in Shareholders&rsquo; Deficiency
<BR>
	For the Years Ended December 31, 2015 and 2014
</B>
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Common Stock
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	Additional Paid&ndash;In
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	Accumulated
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Shares
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Par Value
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Capital
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Deficit
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 40%; FONT-WEIGHT: BOLD; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; PADDING-BOTTOM: 4PT">
	Balance, December 31, 2013
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	19,626,439
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	19,626
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	130,549,930
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	(132,339,377
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	(1,769,821
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	&nbsp;Issuance of common stock pursuant to Lincoln Park Equity line
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	230,743
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	231
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	470,244
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	470,475
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Issuance of common stock to vendors
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	121,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	121
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	255,919
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	256,040
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Issuance of shares from exercise of stock options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36,672
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	28,041
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	28,078
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Reclassification of warrant liability upon partial exercise of warrants issued in unit offering
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,055,490
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,055,490
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Fair value of common stock warrants issued to vendors
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,775
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,775
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Issuance of common stock to collaboration partner
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	43,067
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	43
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	99,959
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100,002
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Shares issued in connection with acquisition of in-process research and development
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,849,113
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,849
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,748,151
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,750,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Issuance of common stock from cashless exercise of warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	143,004
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	143
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(143
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Share-based compensation expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	720,150
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	720,150
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Common stock issued in unit offering, net of offering costs of $344,808
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,886,530
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,887
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,936,007
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,937,894
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	(6,706,972
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	(6,706,972
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; PADDING-BOTTOM: 4PT">
	Balance, December 31, 2014
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	23,936,568
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	23,937
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	138,868,523
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	(139,046,349
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	(153,889
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	&nbsp;Issuance of common stock pursuant to Lincoln Park Equity line
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	841,348
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	842
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,338,335
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,339,177
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Issuance of common stock pursuant to Equity Line Purchase Agreement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,545,770
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,546
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,495,454
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,500,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Stock issuance cost associated with Equity Line Purchase Agreement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(453,162
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(453,162
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Issuance of common stock to vendors
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	166,282
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	166
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	232,046
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	232,212
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Issuance of shares from exercise of stock options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	33,125
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	33
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,217
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,250
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Issuance of shares for exercise of warrants
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,746,429
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,746
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,115,775
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,117,521
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Reclassification of warrant liability upon partial exercise of warrants issued in unit offering
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,557,331
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,557,331
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Share-based compensation expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	654,481
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	654,481
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Net loss
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	(7,831,230
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	(7,831,230
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Balance, December 31, 2015
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	31,269,522
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	31,270
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	146,828,000
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(146,877,579
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(18,309
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	accompanying notes are an integral part of these consolidated financial statements.
<B>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 68; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
	&nbsp;
</FONT>
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Soligenix,
	Inc. and Subsidiaries
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Consolidated
	Statements of Cash Flows
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	For
	the Years Ended December 31,
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Operating activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Net loss
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(7,831,230
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(6,706,972
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Adjustments to reconcile net loss to net cash used in operating activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Amortization and depreciation
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	247,458
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	245,787
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Charge for common stock issued for collaboration agreement
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	100,002
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Common stock issued in exchange for services
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	232,212
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	256,040
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Issuance of common stock for acquisition of in-process research and development
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,000,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Warrants issued to vendor
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,775
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Amortization of discount on debt
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	10,648
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Share-based compensation
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	654,481
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	720,150
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Change in fair value of warrant liability
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,201,870
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(3,436,195
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Change in operating assets and liabilities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Contracts and grants&nbsp;receivable
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(1,190,445
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	72,319
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Taxes receivable
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	750,356
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Prepaid expenses
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(71,339
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(37,537
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Accounts payable
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,376,391
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,483,255
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Accrued compensation
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(16,354
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	81,291
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 30PT">
	Total adjustments and change in operating assets and liabilities
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,444,922
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,240,243
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Net cash used in operating activities
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(5,386,308
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(2,466,729
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Investing activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Payments for acquisition of in-process research and development
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(250,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Purchases of furniture and office equipment
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(22,098
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(50,866
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Net cash used in investing activities
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(22,098
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(300,866
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Financing activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Net proceeds from sale of units containing common stock and warrants
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,937,894
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Net proceeds from issuance of common stock pursuant to the equity lines
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	3,839,177
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	470,475
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Stock issuance cost associated with equity line purchase agreement
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(171,091
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Proceeds from exercise of options and warrants
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,136,771
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	28,078
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Net cash provided by financing activities
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,804,857
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,436,447
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Net decrease in cash and cash equivalents
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(603,549
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(331,148
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Cash and cash equivalents at beginning of period
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	5,525,094
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	5,856,242
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Cash and cash equivalents at end of period
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	4,921,545
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	5,525,094
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Supplemental disclosure of non cash investing and financing activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Notes payable issued in connection with Equity Purchase Agreement
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	282,071
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Reclassification of warrant liability to additional paid-in capital upon partial exercise of warrants issued in unit offering
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,557,331
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,055,490
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Supplemental information:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: -10PT; PADDING-LEFT: 20PT">
	Cash paid for state income taxes
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	7,542
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	6,994
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	accompanying notes are an integral part of these consolidated financial statements.
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 69; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Soligenix,
	Inc. and Subsidiaries
</B>
<BR>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<B>
	Notes to Consolidated Financial Statements
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Note
	1. Nature of Business
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Basis
	of Presentation
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Soligenix,
	Inc. (the &ldquo;Company&rdquo;) is a late-stage biopharmaceutical company focused on developing and commercializing products
	to treat rare diseases where there is an unmet medical need. The Company maintains two active business segments: BioTherapeutics
	and Vaccines/BioDefense.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company&rsquo;s BioTherapeutics business segment is developing a first-in-class photodynamic therapy (SGX301) utilizing safe visible
	light for the treatment of cutaneous T-cell lymphoma (&ldquo;CTCL&rdquo;), proprietary formulations of oral beclomethasone 17,21-dipropionate
	(&ldquo;BDP&rdquo;) for the prevention/treatment of gastrointestinal (&ldquo;GI&rdquo;) disorders characterized by severe inflammation,
	including pediatric Crohn&rsquo;s disease (SGX203) and acute radiation enteritis (SGX201), and it&rsquo;s novel innate defense
	regulator (&ldquo;IDR&rdquo;) technology (SGX942) for the treatment of oral mucositis in head and neck cancer.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company&rsquo;s Vaccines/BioDefense business segment includes active development programs for RiVax&trade;, its ricin toxin vaccine
	candidate, VeloThrax&trade;, an anthrax vaccine candidate, OrbeShield&trade;, a GI acute radiation syndrome (&ldquo;GI ARS&rdquo;)
	therapeutic candidate and SGX943, a melioidosis therapeutic candidate. The development of the vaccine programs currently supported
	by the heat stabilization technology, known as ThermoVax&trade;, under existing and on-going government contract funding. With
	the government contract from the National Institute of Allergy and Infectious Diseases (&ldquo;NIAID&rdquo;), the Company will
	attempt to advance the development of RiVax&trade; to protect against exposure to ricin toxin. The Company plans to use the funds
	received under the government contracts with the Biomedical Advanced Research and Development Authority (&ldquo;BARDA&rdquo;)
	and NIAID to advance the development of OrbeShield&trade; for the treatment of GI ARS.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company generates revenues under government grants primarily from the National Institutes of Health (the &ldquo;NIH&rdquo;) and
	government contracts from BARDA and NIAID.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company is subject to risks common to companies in the biotechnology industry including, but not limited to, development of new
	technological innovations, dependence on key personnel, protections of proprietary technology, compliance with the United States
	Food and Drug Administration (the U.S. &ldquo;FDA&rdquo;) regulations, litigation, and product liability.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Liquidity
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	As
	of December 31, 2015, the Company had cash and cash equivalents of $4,921,545 as compared to $5,525,094 as of December 31, 2014,
	representing a decrease of $603,549 or 11%. The decrease in cash was primarily due to net cash used in operations of $5,386,308
	partially offset by cash provided by financing activities of $4,804,857. As of December 31, 2015, the Company had working capital
	of $2,179,694, which excludes a non-cash warrant liability of $2,434,101, as compared to working capital of $3,174,214 as of December
	31, 2014, representing a decrease of $994,520 or 31%. The decrease in working capital was primarily the result of expenditures
	to support the completion of the Phase 2 clinical trial of SGX942 and the initiation of the pivotal Phase 3 clinical trial of
	SGX301 for the treatment of CTCL offset by the $4,804,857 in various financing activities.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Based
	on the Company&rsquo;s current rate of cash outflows, cash on hand, proceeds from its government contract and grant programs,&nbsp;availability
	of funds from equity lines and proceeds from the state of New Jersey Technology Business Tax Certificate Transfer Program, management
	believes that its current cash will be sufficient to meet the anticipated cash needs for working capital and capital expenditures
	for at least the next twelve months.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 70; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Management&rsquo;s
	business plan can be outlined as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Complete
	enrollment and report preliminary results in the pivotal Phase 3 clinical trial of SGX301 for the treatment of CTCL;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Initiate
	a Phase 3 clinical trial of oral BDP, known as SGX203, for the treatment of pediatric Crohn&rsquo;s disease;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Continue
	to collect the long-term follow-up safety data from the SGX942 Phase 2 proof-of-concept study in the treatment of oral mucositis
	in head and neck cancer patients and publish the findings from this study;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Obtain
	FDA agreement on a pivotal Phase 2b/3 protocol of SGX942 in the treatment of oral mucositis in head and neck cancer patients;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Continue
	development of RiVax&trade; in combination with ThermoVax&reg; technology to develop new heat stable vaccines in biodefense
	and infectious diseases with the potential to collaborate and/or partner with other companies in these areas;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Advance
	the preclinical and manufacturing development of OrbeShield&trade; as a biodefense medical countermeasure for the treatment
	of GI ARS;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Continue
	to apply for and secure additional government funding for each of our BioTherapeutics and Vaccines/BioDefense programs through
	grants, contracts and/or procurements;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Acquire
	or in-license new clinical-stage compounds for development; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Explore
	other business development and merger/acquisition strategies.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company&rsquo;s plans with respect to its liquidity management include, but are not limited to the following:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company has up to $43.0 million in active government contract funding still available to support its associated research programs
	through 2016 and beyond. The Company plans to submit additional contract and grant applications for further support of its
	programs with various funding agencies;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company has continued to use equity instruments to provide a portion of the compensation due to vendors and collaboration
	partners and expects to continue to do so for the foreseeable future;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company will pursue Net Operating Loss (&ldquo;NOL&rdquo;) sales in the state of New Jersey pursuant to its Technology Business
	Tax Certificate Transfer Program. Based on the receipt of $488,933 in proceeds of the sale of NJ NOL in 2015, the Company
	expects to participate in the program during 2016 and beyond;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company has an aggregate of $20.2 million available from equity facilities through 2019; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company may seek additional capital in the private and/or public equity markets, pursue government contracts and grants as
	well as business development activities to continue its operations,&nbsp;respond to competitive pressures, develop new products
	and services, and to support new strategic partnerships.&nbsp;The Company is currently evaluating additional equity financing
	opportunities on an ongoing basis and may execute them when appropriate. However, there can be no assurances that the Company
	can consummate such a transaction, or consummate a transaction at favorable pricing.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Note
	2. Summary of Significant Accounting Policies
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Principles
	of Consolidation
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	consolidated financial statements include Soligenix, Inc., and its wholly and majority owned subsidiaries. All significant intercompany
	accounts and transactions have been eliminated as a result of consolidation.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Operating
	Segments
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Operating
	segments are defined as components of an enterprise about which separate financial information is available that is evaluated
	on a regular basis by the chief operating decision maker, or decision making group, in deciding how to allocate resources to an
	individual segment and in assessing the performance of the segment. The Company divides its operations into two operating segments:
	BioTherapeutics and Vaccines/BioDefense.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 71; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Cash
	and Cash Equivalents
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Contracts
	and Grants Receivable
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Contracts
	and grants receivable consist of unbilled amounts due from various grants from the NIH and contracts from BARDA and NIAID, an
	institute of NIH, for costs incurred prior to the period end under reimbursement contracts. The amounts were billed to the respective
	governmental agencies in the month subsequent to period end and collected shortly thereafter. Accordingly, no allowance for doubtful
	amounts has been established. If amounts become uncollectible, they are charged to operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Intangible
	Assets
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	One
	of the most significant estimates or judgments that the Company makes is whether to capitalize or expense patent and license costs.
	The Company makes this judgment based on whether the technology has alternative future uses, as defined in Financial Accounting
	Standards Board (&ldquo;FASB&rdquo;) Accounting Standards Codification (&ldquo;ASC&rdquo;) 730,
<I>
	Research and Development
</I>
	.
	Based on this consideration, the Company capitalizes payments made to legal firms that are engaged in filing and protecting rights
	to intellectual property and rights for its current products in both the domestic and international markets. The Company believes
	that patent rights are one of its most valuable assets. Patents and patent applications are a key component of intellectual property,
	especially in the early stage of product development, as their purchase and maintenance gives the Company access to key product
	development rights from Soligenix&rsquo;s academic and industry partners. These rights can also be sold or sub-licensed as part
	of its strategy to partner its products at each stage of development as the intangible assets have alternative future use. The
	legal costs incurred for these patents consist of work associated with filing new patents designed to protect, preserve and maintain
	the Company&rsquo;s rights, and perhaps extend the lives of the patents. The Company capitalizes such costs and amortizes intangibles
	on a straight-line basis over their expected useful life &ndash; generally a period of 11 to 16 years.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	These
	intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may
	not be recoverable or if the underlying program is no longer being pursued. If the sum of the expected undiscounted cash flows
	is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair
	value and carrying value of the related asset or group of assets. No such write downs have occurred during the years ended December
	31, 2015 and 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company did not capitalize any patent related costs during the years ended December 31, 2015 or 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Impairment
	of Long-Lived Assets
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Office
	furniture and equipment and intangible assets are evaluated and reviewed for impairment whenever events or changes in circumstances
	indicate that the carrying amount may not be recoverable. The Company recognizes impairment of long-lived assets in the event
	the net book value of such assets exceeds the estimated future undiscounted cash flows attributable to such assets. If the sum
	of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized
	for the difference between the fair value and the carrying value of the related asset or group of assets. Such analyses necessarily
	involve significant judgment.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company did not record any impairment of long-lived assets for the years ended December 31, 2015 or 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Fair
	Value of Financial Instruments
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	FASB
	ASC 820 &mdash;
<I>
	Fair Value Measurements and Disclosures,
</I>
	defines fair value as the price that would be received to sell
	an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC
	820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement
	purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company
	on December 31, 2015. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the
	amounts that could be realized on disposition of the financial instruments.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 72; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	FASB
	ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable
	or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market
	assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
	(Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	three levels of the fair value hierarchy are as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Level
	1 &mdash; Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to
	access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market
	prices such as exchange-traded instruments and listed equities.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Level
	2 &mdash; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly
	or indirectly. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These
	models consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying
	financial instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from observable
	data or are supported by observable levels at which transactions are executed in the marketplace.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Level
	3 &mdash; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values
	are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption
	or input is unobservable.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	carrying amounts reported in the consolidated balance sheet for cash and cash equivalents, contracts and grants receivable, accounts
	payable, notes payable and accrued compensation approximate their fair value based on the short-term maturity of these instruments.
	The Company recognizes all derivative financial instruments as assets or liabilities in the financial statements and measures
	them at fair value with changes in fair value reflected as current period income or loss unless the derivatives qualify as hedges.
	As a result, certain warrants issued in connection with the Company&rsquo;s June 2013 registered public offering were accounted
	for as derivatives. See Note 5,
<I>
	Warrant Liability
</I>
	.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Revenue
	Recognition
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company&rsquo;s revenues are primarily generated from government contracts and grants. The revenue from government contracts and
	grants is based upon subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants,
	plus a facilities and administrative rate that provides funding for overhead expenses and management fees. These revenues are
	recognized when expenses have been incurred by subcontractors or when the Company incurs reimbursable internal expenses that are
	related to the government contracts and grants.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Research
	and Development Costs
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Research
	and development costs are charged to expense when incurred in accordance with FASB ASC 730,
<I>
	Research and Development
</I>
	. Research
	and development includes costs such as clinical trial expenses, contracted research and license agreement fees with no alternative
	future use, supplies and materials, salaries, share-based compensation, employee benefits, equipment depreciation and allocation
	of various corporate costs. Purchased in-process research and development expense represents the value assigned or paid for acquired
	research and development for which there is no alternative future use as of the date of acquisition.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 73; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Accounting
	for Warrants
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company considered FASB ASC 815,
<I>
	Evaluating Whether an Instrument is Considered Indexed to an Entity&rsquo;s Own Stock
</I>
	,
	which provides guidance for determining whether an equity-linked financial instrument (or embedded feature) issued by an entity
	is indexed to the entity&rsquo;s stock, and, therefore, qualifying for the first part of the scope exception in paragraph 815-10-15.
	The Company evaluated the provisions in its outstanding warrants and determined that warrants issued in connection with the Company&rsquo;s
	June 2013 registered public offering contains provisions that protect holders from a decline in the issue price of the Company&rsquo;s
	common stock (or &ldquo;down-round&rdquo; provisions) and contain net settlement provisions. Consequently, these warrants are
	recognized as liabilities at their fair value on the date of grant and remeasured at fair value on each reporting date. All other
	warrants issued were indexed to the Company&rsquo;s stock and therefore are accounted for as equity instruments for 2015 and 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Share-Based
	Compensation
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Stock
	options are issued with an exercise price equal to the market price on the date of grant. Stock options issued to directors upon
	re-election vest quarterly for a period of one year (new director issuances are fully vested upon issuance). Stock options issued
	to employees vest 25% on the grant date, then 25% each subsequent year for a period of three years. Stock options vest over each
	three-month period from the date of issuance to the end of the three year period. These options have a ten year life for as long
	as the individuals remain employees or directors. In general, when an employee or director terminates their position, the options
	will expire within three months, unless otherwise extended by the Board.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	From
	time to time, the Company issues restricted shares of common stock to vendors and consultants as compensation for services performed.
	Typically these instruments vest upon issuance and therefore the entire share-based compensation expense is recognized upon issuance
	to the vendors and/or consultants.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Share-based
	compensation expense for options, warrants and shares of common stock granted to non-employees has been determined in accordance
	with and FASB ASC 505-50,
<I>
	Equity-Based Payments to Non-Employees
</I>
	, and represents the fair value of the consideration received,
	or the fair value of the equity instruments issued, whichever may be more reliably measured. For options that vest over future
	periods, the fair value of options granted to non-employees is amortized as the options vest. The fair value is remeasured each
	reporting period until performance is complete.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	For
	the year ended December 31, 2015 the Company issued 605,340 stock options at a weighted average exercise price of $1.19 per share.
	The fair value of options issued during the years ended December 31, 2015 and 2014 was estimated to be $1.22 and $1.48 per share,
	respectively, using the Black-Scholes option-pricing model and the following assumptions:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	a
	dividend yield of 0%;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	an
	expected life of 4 years;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	volatilities
	ranging from 121% - 141% and 128% - 165% for 2015 and 2014, respectively;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	forfeitures
	at a rate of 12%; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	risk-free
	interest rates ranging from .98% to 1.53% and 1.05% to 1.43% for 2015 and 2014, respectively.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	weighted average fair value of each option grant made during 2015 and 2014 was estimated on the date of each grant using the Black-Scholes
	option pricing model and amortized ratably over the option vesting periods, which approximates the service period.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 74; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Income
	Taxes
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	Deferred tax assets and
	liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying
	amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is established when it is more
	likely than not that all or a portion of a deferred tax asset will not be realized. A review of all available positive and negative
	evidence is considered, including the Company&rsquo;s current and past performance, the market environment in which the Company
	operates, the utilization of past tax credits, and the length of carryback and carryforward periods.&nbsp;Deferred tax assets
	and liabilities are measured utilizing tax rates expected to apply to taxable income in the years in which those temporary differences
	are expected to be recovered or settled. The Company recognizes accrued interest and penalties associated with uncertain tax positions,
	if any, as part of income tax expense. There were no tax related interest and penalties recorded for 2015 and 2014. Additionally,
	the Company has not recorded an asset for unrecognized tax benefits or a liability for uncertain tax positions at December 31,
	2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Earnings
	Per Share
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Basic
	earnings per share (&ldquo;EPS&rdquo;) excludes dilution and is computed by dividing income (loss) available to common stockholders
	by the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that could
	occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the
	issuance of common stock that shared in the earnings of the entity. Since there is a significant number of options and warrants
	outstanding, fluctuations in the actual market price can have a variety of results for each period presented.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	For the Year Ended
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	For the Year Ended
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	December&nbsp;31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	December&nbsp;31, 2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	Numerator:
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Net loss for basic earnings per share
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(7,831,230
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	(6,706,972
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less change in fair value of warrant liability
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	3,436,195
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Net loss for diluted earnings per share
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	(7,831,230
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10,143,167
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Denominator:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Weighted-average basic common shares outstanding
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	26,065,765
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,638,421
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Assumed conversion of dilutive securities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock purchase warrants
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,946,523
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Denominator for diluted earnings per share &ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	adjusted weighted-average shares
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	26,065,765
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,584,944
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Basic net loss per share
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	($
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	0.30
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	($
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	0.32
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Diluted net loss per share
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	($
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	0.30
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	($
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	0.43
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	following table summarizes potentially dilutive adjustments to the weighted average number of common shares which were excluded
	from the calculation because their effect would be anti-dilutive.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	For the Year Ended
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	For the Year Ended
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	December&nbsp;31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	December&nbsp;31, 2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Common stock purchase warrants
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	4,926,119
</TD>
<TD STYLE="WIDTH: 1%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	2,546,143
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Stock options
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2,768,612
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	2,488,279
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Total
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	7,694,731
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	5,034,422
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Shares
	issuable upon the exercise of options and warrants outstanding at December 31, 2015 and 2014 were 2,768,612 and 2,488,279 shares
	issuable upon the exercise of options, and 4,926,119 and 7,269,500 shares issuable upon the exercise of warrants, respectively.
	The weighted average exercise price of the Company&rsquo;s stock options and warrants outstanding at December 31, 2015 were $2.13
	and $0.74 per share, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Use
	of Estimates and Assumptions
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management
	to make estimates and assumptions such as the fair value of warrants and stock options and the useful life of intangibles that
	affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 75; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Recently
	Issued Accounting Pronouncements
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	August 2014, FASB issued Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2014-15, &ldquo;
<I>
	Presentation of Financial Statements
	- Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern.&rdquo;
</I>
	The amendments in this ASU are intended to define management&rsquo;s responsibility to evaluate whether there is substantial
	doubt about an entity&rsquo;s ability to continue as a going concern and to provide related footnote disclosures. Specifically,
	this ASU provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date
	that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt
	is alleviated as a result of consideration of management&rsquo;s plans and requires an express statement and other disclosures
	when substantial doubt is not alleviated. The new standard will be effective for annual periods ending after December 15, 2016,
	and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact the adoption of
	this standard will have on the Company's consolidated financial statements and disclosures.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: #252525">
	In
	February 2016, the FASB issued ASU No. 2016-02, &ldquo;
<I>
	Leases
</I>
	&rdquo; (topic 842)
<I>
	.
</I>
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	FASB issued this update to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities
	on the balance sheet and disclosing key information about leasing arrangements.
<FONT STYLE="COLOR: #252525">
	The updated guidance
	is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. Early
	adoption of the update is permitted.&nbsp;
</FONT>
	The Company
<FONT STYLE="COLOR: #252525">
	&nbsp;
</FONT>
	is evaluating the impact
	of
<FONT STYLE="COLOR: #252525">
	&nbsp;
</FONT>
	the adoption of this update on our consolidated financial statements and related disclosures.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Note
	3. Intangible Assets
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	following is a summary of intangible assets which consists of licenses and patents:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Weighted Average Remaining Amortization Period (Years)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Cost
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Accumulated Amortization
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Net Book Value
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	December 31, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 52%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	Licenses
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: CENTER">
	3.8
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	462,234
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	333,732
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	128,502
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	Patents
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	1.1
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	1,893,185
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	1,832,955
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	60,230
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 20PT">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	1.9
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	2,355,419
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	2,166,687
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	188,732
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	December 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	Licenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	4.7
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	462,234
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	306,495
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	155,739
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	Patents
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	1.9
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	1,893,185
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	1,638,975
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	254,210
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 20PT">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT">
	2.6
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	2,355,419
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	1,945,470
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	409,949
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amortization
	expense was $221,217 and $222,563 in 2015 and 2014, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Based
	on the balance of licenses and patents at December 31, 2015, the annual amortization expense for each of the succeeding four years
	is expected to approximate as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Year
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Amortization Expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 88%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	2016
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	61,800
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	2017
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	61,800
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	2018
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37,300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	2019
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	27,832
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 76; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	License
	fees and royalty payments are expensed annually as incurred, as the Company does not attribute any future benefits of such payments.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Note
	4. Notes Payable
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	On
	July 29, 2015, the Company entered into equity purchase agreements (the &ldquo;Equity Line Purchase Agreements&rdquo;) and registration
	rights agreements with certain accredited institutional investors. Under the Equity Line Purchase Agreements, the investors have
	agreed to purchase from the Company up to an aggregate of $10 million worth of shares of common stock, from time to time.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	consideration for entering into the Equity Line Purchase Agreements, the Company issued to the investors promissory notes having
	an aggregate principal amount of $300,000, which were recorded as stock issuance costs. The promissory notes are payable by April
	15, 2016, with an issuance date present value of $282,071. The promissory notes did not include terms for interest, therefore
	the interest was imputed at 9%. Total discount amortization of $10,648 was recorded as interest expense for the year ended December
	31, 2015. The discount is being accreted over the term of the promissory notes using the effective interest rate method.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Note
	5. Warrant Liability
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Warrants
	issued in connection with the Company&rsquo;s June 2013 registered public offering contain provisions that protect holders from
	a decline in the issue price of its common stock (or &ldquo;down-round&rdquo; provision) and contain net settlement provisions.
	As a result, the Company accounts for these warrants as liabilities instead of equity instruments. Down-round provisions reduce
	the exercise or conversion price of a warrant if the Company issues equity shares for a price that is lower than the exercise
	or conversion price of the warrants. Net settlement provisions allow the holder of the warrant to surrender shares underlying
	the warrant equal to the exercise price as payment of its exercise price, instead of exercising the warrant by paying cash. The
	Company evaluates whether warrants to acquire its common stock contain provisions that protect holders from declines in the stock
	price or otherwise could result in modification of the exercise price and/or shares to be issued under the respective warrant
	agreements based on a variable that is not an input to the fair value of a &ldquo;fixed for fixed&rdquo; option. As a result of
	the Company&rsquo;s December 2014 registered public unit offering, the exercise price of warrants outstanding in connection with
	the public offering completed in June 2013 was adjusted to $0.61 per share. As a result of the Company&rsquo;s December 2015 drawdown
	on the Equity Line Purchase Agreement, the exercise price of warrants outstanding in connection with the public offering completed
	in June 2013 was adjusted to $0.51 per share.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company recognized these warrants as liabilities at their fair value on the date of grant and remeasures them to fair value on
	each reporting date.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company recognized an initial warrant liability for the warrants issued in connection with the registered public offering completed
	in June 2013 totaling $4,827,788, which was based on the June 25, 2013 closing price of a share of the Company&rsquo;s common
	stock as reported on OTC Markets of $0.96. During the year ended December 31, 2014, 143,004 shares of common were issued upon
	586,081 warrants exercised on a cashless basis. On January 22, 2014, 250,000 warrants were exercised and on August 19, 2014, 336,081
	warrants were exercised. The fair value of the warrants exercised in 2014, or $1,055,490 was reclassified from warrant liability
	to additional paid-in capital on the respective exercise dates. During the year ended December 31, 2015, 1,686,429 warrants were
	exercised. The fair value of the warrants exercised in 2015, or $2,557,331 was reclassified from warrant liability to additional
	paid-in capital on the respective exercise dates. On December 31, 2015, the closing price of the Company&rsquo;s common stock
	as reported on OTC Markets was $1.13. Due to the fluctuations in the market value of the Company&rsquo;s common stock from December&nbsp;31,
	2014 through December 31, 2015, the Company recognized a non-cash expense of $1,201,870 for the change in the fair value of the
	warrant liability for 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 77; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	assumptions used in connection with the valuation of warrants issued, using the binomial method, were as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Initial Measurement June 25, 2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	December 31, 2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	December&nbsp;&nbsp;31, 2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Exercised During 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 40%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Number of shares underlying the warrants
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	5,416,851
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	5,309,438
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	4,723,357
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	1,686,429
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	3,036,925
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Exercise price
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.65
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.65
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.61
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.61
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.51
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Volatility
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	140
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	135
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	128
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	117-119%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	98
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Risk-free interest rate
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.49
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.75
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.38
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	.81-1.06%
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.19
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Expected dividend yield
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Expected warrant life (years)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.0
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3.01-3.33
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.48
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Stock price
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.96
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.80
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.98
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1.69-$2.22
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.13
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Recurring
	Level 3 Activity and Reconciliation
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	The
	table below provides a reconciliation of the beginning and ending balances for the liability measured at fair value using
	significant unobservable inputs (Level 3). The table reflects losses for the year ended December 31, 2015 for the financial
	liability categorized as Level 3 as of December 31, 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Fair
	Value Measurements Using Significant Unobservable Inputs (Level 3):
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	December&nbsp;31, 2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Decrease from Warrants Exercised in 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Increase in Fair Value
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	December&nbsp;31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 52%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT">
	Warrant liability
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,789,562
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(2,557,331
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,201,870
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,434,101
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Note
	6. Income Taxes
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	income tax benefit consisted of the following for the years ended December 31, 2015 and December 31, 2014:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Federal
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 76%; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	State
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	(488,933
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	(616,872
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Income tax benefit
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	(488,933
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	(616,872
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	significant components of the Company&rsquo;s deferred tax assets and liabilities at December 31, 2015 and 2014 are as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Net operating loss carry forwards
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	31,216,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	29,594,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Orphan drug and research and development credit carry forwards
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,909,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,556,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Equity based compensation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,923,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,049,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Intangibles
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	2,090,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	2,140,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Total
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	40,138,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37,339,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Valuation allowance
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	(40,138,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	(37,339,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Net deferred tax assets
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 78; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company has gross NOLs at December 31, 2015 of approximately $90,891,000 for federal tax purposes and approximately $5,273,000
	of New Jersey NOL carry forwards remaining after the sale of unused net operating loss carry forwards, portions of which will
	begin to expire in 2018. In addition, the Company has $4,909,000 of various tax credits which expire from 2018 to 2034. The Company
	may be able to utilize its NOLs to reduce future federal and state income tax liabilities. However, these NOLs are subject to
	various limitations under Internal Revenue Code (&ldquo;IRC&rdquo;) Section 382. IRC Section 382 limits the use of NOLs to the
	extent there has been an ownership change of more than 50 percentage points. In addition, the NOL carry forwards are subject to
	examination by the taxing authority and could be adjusted or disallowed due to such exams. Although the Company has not undergone
	an IRC Section 382 analysis, it is likely that the utilization of the NOLs may be substantially limited.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company and one or more of its subsidiaries files income tax returns in the U.S. Federal jurisdiction, and various state and local
	jurisdictions. During the years ended December 31, 2015 and 2014, in accordance with the State of New Jersey&rsquo;s Technology
	Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused net operating
	loss carryforwards to other New Jersey-based corporate taxpayers, the Company sold New Jersey net operating loss carryforwards,
	resulting in the recognition of $488,933 and $616,872 of income tax benefit, net of transaction costs, respectively. There can
	be no assurance as to the continuation or magnitude of this program in the future.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Reconciliations
	of the difference between income tax benefit computed at the federal and state statutory tax rates and the provision for income
	tax benefit for the years ended December 31, 2015 and 2014 were as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Income tax loss at federal statutory rate
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	(34.00
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	(34.00
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	State tax benefits, plus sale of NJ NOLs, net of federal benefit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(6.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(6.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	Subtotal
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(40.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(40.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 0PT">
	Valuation allowance
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	34.12
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	31.58
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT; PADDING-BOTTOM: 4PT">
	Income tax benefit
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	(5.88
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT">
	)%
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 4PT DOUBLE">
	(8.42
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT">
	)%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Note
	7. Shareholders&rsquo; Deficiency
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Preferred
	Stock
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company has 350,000 shares of preferred stock authorized, none of which are issued or outstanding.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Common
	Stock
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	following items represent transactions in the Company&rsquo;s common stock for the year ended December 31, 2015:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	February 2015, the Company issued 701,786 shares of common stock in connection with the exercise of stock warrants;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	March 2015, the Company issued 482,000 shares of common stock in connection with the exercise of stock warrants;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	March 2015, the Company issued 153,010 shares of common stock pursuant to the Lincoln Park facility;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	April 2015, the Company issued 356,786 shares of common stock in connection with the exercise of stock warrants;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	April 2015, the Company issued 8,125 shares of common stock in connection with the exercise of stock options;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	May 2015, the Company issued 76,364 shares of common stock pursuant to the Lincoln Park facility;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	June 2015, the Company issued 384,237 shares of common stock pursuant to the Lincoln Park facility;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	June 2015, the Company issued 198,714 shares of common stock in connection with the exercise of stock warrants;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	July 2015, the Company issued 7,143 shares of common stock in connection with the exercise of stock warrants;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 79; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	September 2015, the Company issued 609,535 shares of common stock pursuant to an Equity Line Purchase Agreement;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	September 2015, the Company issued 25,000 shares of common stock in connection with the exercise of stock options;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	October 2015, the Company issued 151,843 shares of common stock pursuant to the Lincoln Park facility;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	November 2015, the Company issued 75,894 shares of common stock pursuant to the Lincoln Park facility;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	December 2015, the Company issued 3,936,235 shares of common stock pursuant to an Equity Line Purchase Agreement;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9679;
</FONT>
</TD>
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	nine separate transactions, the Company issued 166,282 fully vested shares of common stock as partial consideration for services
	performed.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The following items represent transactions in the Company&rsquo;s common stock for the year ended December 31, 2014:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	January 2014, the Company issued 77,889 shares of common stock in connection with the cashless exercise of 250,000 stock warrants;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	March 2014, the Company issued 76,932 shares of common stock pursuant to the Lincoln Park facility;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	April 2014, the Company issued 76,907 shares of common stock pursuant to the Lincoln Park facility;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	May 2014, the Company issued 43,067 shares of common stock upon the execution of an agreement to evaluate specific oncology
	technology;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	May 2014, the Company issued 29,172 shares of common stock upon the exercise of vested stock options;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	July 2014, the Company issued 76,904 shares of common stock pursuant to the Lincoln Park facility;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	July 2014, the Company issued 7,500 shares of common stock upon the exercise of vested stock options;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	August 2014, the Company issued 65,115 shares of common stock with the cashless exercise of 336,081 stock warrants;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	September 2014, the Company issued 1,849,113 shares of common stock in connection with the Hy BioPharma Acquisition of in
	process research and development.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	December 2014, the Company issued 1,886,530 shares of common stock and 1,169,318 warrants pursuant to a registered direct
	unit offering of common stock and warrants. The Company received net proceeds of $1,937,894 from this offering.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	four separate transactions, the Company issued 121,000 shares of common stock as partial consideration for services performed.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Equity
	Line Purchase Agreement
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	On
	July 29, 2015, the Company entered into the Equity Line Purchase Agreements and a registration rights agreements with accredited
	institutional investors, Kodiak Capital Group, LLC (&ldquo;Kodiak Capital&rdquo;), Kingsbrook Opportunities Master Fund LP (&ldquo;Kingsbrook&rdquo;)
	and River North Equity, LLC (&ldquo;River North&rdquo; and, together with Kodiak Capital and Kingsbrook, the &ldquo;Investors&rdquo;).
	Under the Equity Line Purchase Agreements, the Investors agreed to purchase from the Company up to an aggregate of $10 million
	worth of shares of common stock, from time to time. In accordance with the registration rights agreements, the Company has filed
	with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) a registration statement to register for resale under
	the Securities Act of 1933, as amended, the shares of common stock that may be issued to the Investors under the Equity Line Purchase
	Agreements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	From
	the date that the SEC declared the registration statement effective, in August 2015, until December 31, 2016, the Company has
	the right to sell up to $5 million, $4 million and $1 million worth of shares of common stock to Kodiak Capital, Kingsbrook and
	River North, respectively. The Company will control the timing and amount of future sales, if any, of common stock to the Investors
	under the Equity Line Purchase Agreements. The purchase price of the shares will be equal to eighty percent (80%) of the lowest
	daily volume weighted average price of the common stock for any trading day during the five consecutive trading days immediately
	following the date of the Company&rsquo;s notice to the Investors requesting the purchase. There is no minimum amount that the
	Company may require the Investors to purchase at any one time. The Company may not require the Investors to purchase more than
	$3 million worth of shares of common stock during any seven day period and may not require any of the Investors to purchase shares
	of common stock if such purchase would result in such Investor&rsquo;s beneficial ownership exceeding 9.99% of the outstanding
	common stock.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 80; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Equity Line Purchase Agreements contain customary representations, warranties, covenants, closing conditions, and indemnification
	and termination provisions. Each of the Investors has covenanted not to cause or engage in any manner whatsoever any direct or
	indirect short selling of the common stock.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	consideration for entering into the Equity Line Purchase Agreements, the Company issued to each of the Investors a promissory
	note having a principal amount equal to 3% of the total amount committed by such Investor. The principal amount due under the
	promissory notes does not accrue interest and is payable by April 15, 2016 (see Note 4).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Equity Line Purchase Agreements may be terminated by the Company at any time at its discretion without any cost to the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	initial drawdown under the Equity Line Purchase Agreements was $500,000 offset by issuance cost of $453,162, which is included
	in the Consolidated Statements of Changes in Shareholders&rsquo; Deficiency. Issuance costs include professional fees, 3% commitment
	fee (promissory notes payable by April 15, 2016) and SEC filing fees.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	December 2015, a second drawdown was made, whereby under the Equity Line Purchase Agreements, the Company issued 3,936,235 shares
	of common stock receiving proceeds of $2,000,000.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	On
	March 7, 2016, in accordance with the terms of the Equity Line Purchase Agreements, the Company exercised its right to terminate
	the Purchase Agreements upon written notice to the Investors. The Company did not incur any penalties as a result of this termination.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Equity
	Line
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	November 2013, the Company entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC (&ldquo;Lincoln
	Park&rdquo;). The Lincoln Park equity facility allows the Company to require Lincoln Park to purchase up to 75,000 shares (&ldquo;Regular
	Purchase&rdquo;) of the Company&rsquo;s common stock every two business days, up to an aggregate of $10.6 million over approximately
	a 36-month period depending on certain conditions, including the quoted market price of the Company&rsquo;s common stock on such
	date. The purchase price for the Regular Purchase shall be equal to the lesser of (i) the lowest sale price of the common shares
	during the purchase date, or (ii) the average of the three lowest closing sale prices of common shares during the twelve business
	days prior to the purchase date. Each Regular Purchase shall not exceed $750,000. Furthermore, for each additional purchase by
	Lincoln Park, additional commitment shares in commensurate amounts up to a total of 122,070 shares will be issued based upon the
	relative proportion of the aggregate amount of $10.0 million. The Regular Purchase amount may be increased up to 100,000 shares
	of common stock if the closing price of the common shares is not below $2.50. In addition to the Regular Purchase and provided
	that the closing price of the common shares is not below $1.50 on the purchase date, the Company in its sole discretion may direct
	Lincoln Park on each purchase date to purchase on the next stock trading day (&ldquo;Accelerate Purchase Date&rdquo;) additional
	shares of Company stock up to the lesser of (i) two times the number of shares purchased following a Regular Purchase or (ii)
	30% of the trading volume of shares traded on the Accelerated Purchase Date as a price equal to the lesser of the closing sale
	price on the Accelerated Purchase Date or 95% of the Accelerated Purchase Date&rsquo;s volume weighted average price.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	During the year ended December
	31, 2014, in three separate transactions, the Company sold 225,000 shares of common stock and issued 5,743 commitment shares receiving
	net proceeds of $470,475. During the year ended December 31, 2015, in nine separate transactions, the Company sold 825,000 shares
	of common stock and issued 16,348 commitment shares receiving net proceeds of $1,339,177.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 81; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Note
	8. Stock Option Plans and Warrants to Purchase Common Stock
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Stock
	Option Plans
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Amended and Restated 2005 Equity Incentive Plan was replaced by the 2015 Equity Incentive Plan (&ldquo;2015 Plan&rdquo;), approved
	in June 2015, and is divided into four separate equity programs:
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1)
</FONT>
</TD>
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the
	Discretionary Option Grant Program, under which eligible persons may, at the discretion of the Plan Administrator, be granted
	options to purchase shares of common stock,
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2)
</FONT>
</TD>
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the
	Salary Investment Option Grant Program, under which eligible employees may elect to have a portion of their base salary invested
	each year in options to purchase shares of common stock,
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3)
</FONT>
</TD>
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the
	Automatic Option Grant Program, under which eligible nonemployee Board members will automatically receive options at periodic
	intervals to purchase shares of common stock, and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4)
</FONT>
</TD>
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the
	Director Fee Option Grant Program, under which non-employee Board members may elect to have all, or any portion, of their
	annual retainer fee otherwise payable in cash applied to a special option grant.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	2005 Equity Incentive Plan (&ldquo;2005 Plan&rdquo;) also was divided into four separate equity programs:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1)
</FONT>
</TD>
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the
	Discretionary Option Grant Program, under which eligible persons may, at the discretion of the Plan Administrator, be issued
	common stock or granted options to purchase shares of common stock,
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2)
</FONT>
</TD>
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the
	Salary Investment Option Grant Program, under which eligible employees may elect to have a portion of their base salary invested
	each year in options to purchase shares of common stock,
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3)
</FONT>
</TD>
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the
	Automatic Option Grant Program, under which eligible nonemployee Board members will automatically receive options at periodic
	intervals to purchase shares of common stock, and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 24PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 24PX; PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4)
</FONT>
</TD>
<TD STYLE="PADDING: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the
	Director Fee Option Grant Program, under which non-employee Board members may elect to have all, or any portion, of their
	annual retainer fee otherwise payable in cash applied to a special option grant.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	addition, under the 2005 Plan, the Board may elect to pay certain consultants, directors, and employees in common stock. The 2005
	Plan was amended in September 2007 to increase the number of options available under the plan to 1,000,000, in 2010 to increase
	the number of shares under the plan to 1,750,000 and again in 2013 to increase the number shares available under the plan to 3,000,000.
	The 2015 Plan was approved in June 2015 with 3,000,000 shares available under the plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	table below accounts only for transactions occurring as part of the 2015 Plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	Shares available for grant at plan approval
</TD>
<TD STYLE="WIDTH: 1%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,000,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="WIDTH: 1%; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	&nbsp;&nbsp;Options granted
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(477,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT">
	Shares available for grant at end of year
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,523,000
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	total option activity for the amended 2005 Plan and the 2015 Plan for the years ended December 31, 2015 and 2014 was as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Options
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<B>
	Weighted Average
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<B>
	Options Exercise Price
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT">
	Balance at December 31, 2013
</TD>
<TD STYLE="WIDTH: 1%; FONT-FAMILY: TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,051,511
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-FAMILY: TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2.63
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	&nbsp;&nbsp;Granted
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	637,495
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1.79
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	&nbsp;&nbsp;Exercised
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(36,672
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	0.77
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	&nbsp;&nbsp;Forfeited
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(164,055
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3.13
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT">
	Balance at December 31, 2014
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,488,279
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2.40
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	&nbsp;&nbsp;Granted
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	605,340
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1.19
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	&nbsp;&nbsp;Exercised
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(33,125
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	0.58
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	&nbsp;&nbsp;Forfeited
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(291,882
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3.13
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT">
	Balance at December 31, 2015
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,768,612
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2.13
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 82; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	As
	of December 31, 2015, there were 2,082,199 options exercisable with a weighted average exercise price of $2.33, a weighted average
	remaining contractual term of 7.28 years and an intrinsic value of $256,347. The intrinsic value of options exercised during the
	years ended December 31, 2015 and 2014 was $18,181 and $47,241, respectively. As of December 31, 2015, there were 2,768,612 options
	outstanding and expected to vest with a weighted average exercise price of $2.13, weighted average remaining term of 7.28 years
	and an intrinsic value of $257,369. The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference
	between the closing price of our common stock on the last trading day on December 31, 2015 and the exercise price, multiplied
	by the number of in-the-money options) what would have been received by the option holders had all option holders exercised their
	options on December 31, 2015. This amount changes based on the fair market value of our common stock.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company awarded 605,340 and 637,495 stock options&nbsp;to new employees and existing Board members during the years ended 2015
	and 2014, respectively. During the year ended 2015, under the 2005 Equity Incentive Plan, 29,000 option grants were issued to
	employees and 99,340 option grants were issued to Board members, and under the 2015 Equity Incentive Plan 477,000 option grants
	were issued to employees.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	weighted-average exercise price, by price range, for outstanding options to purchase common stock at December 31, 2015 was:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<B>
	Price
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<B>
	Range
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<B>
	Weighted Average Remaining
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<B>
	Contractual Life in Years
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<B>
	Outstanding
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<B>
	Options
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<B>
	Exercisable
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<B>
	Options
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
	$0.30-$2.20
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	8.03
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	2,170,838
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	1,484,425
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
	$2.26-$4.10
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.36
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	174,774
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	174,774
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT">
	$4.64-$9.40
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	3.22
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	423,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	423,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	7.28
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	2,768,612
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	2,082,199
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company&rsquo;s share-based compensation expense for the years ended December 31, 2015 and 2014 was recognized as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Share-based Compensation
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	Research and Development
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	260,204
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	308,847
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT">
	General and Administrative
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	394,277
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	411,303
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 4PT">
	Total
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	654,481
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	720,150
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	At
	December 31, 2015, the total compensation cost for stock options not yet recognized was approximately $773,197 and will be expensed
	over the next three years.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Warrants
	to Purchase Common Stock
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Warrant
	activity for the years ended December 31, 2015 and 2014 was as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-FAMILY: CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Warrants
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Weighted Average
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	Warrant Exercise Price
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	Balance at December 31, 2013
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	8,156,526
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	2.17
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	&nbsp;&nbsp;Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,169,318
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.48
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	&nbsp;&nbsp;Exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(586,081
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.65
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT">
	&nbsp;&nbsp;Expired
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	(1,470,263
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	3.49
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	Balance at December 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,269,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	&nbsp;&nbsp;Exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,746,429
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.64
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT">
	&nbsp;&nbsp;Expired
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	(596,952
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	5.59
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT">
	Balance at December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	4,926,119
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	0.74
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 83; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	weighted-average remaining life, by price range, for outstanding warrants at December 31, 2015 was:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<B>
	Price
</B>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<B>
	Range
</B>
</P>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Weighted Average Remaining Contractual Life in Years
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<B>
	Outstanding
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<B>
	Warrants
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Exercisable Warrants
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
	$.51-$0.53
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	2.4
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	3,811,801
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	3,811,801
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT">
	$1.48-$2.05
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	4.0
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	1,114,318
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; TEXT-ALIGN: RIGHT">
	1,114,318
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	2.7
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	4,926,119
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; TEXT-ALIGN: RIGHT">
	4,926,119
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Note
	9. Concentrations
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	At
	December 31, 2015 and 2014, the Company had deposits in major financial institutions that exceeded the amount under protection
	by the Securities Investor Protection Corporation (&ldquo;SIPC&rdquo;). Currently, the Company is covered up to $1,000,000 by
	the SIPC and at times maintains cash balances in excess of the SIPC coverage.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Note
	10. Commitments and Contingencies
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company has commitments of approximately $500,000 at December 31, 2015 for several licensing agreements with consultants and universities.
	Additionally, the Company has collaboration and license agreements, which upon clinical or commercialization success, may require
	the payment of milestones of up to $7.9 million and/or royalties up to 6% of net sales of covered products, if and when achieved.
	However, there can be no assurance that clinical or commercialization success will occur. As of December 31, 2015 no milestones
	or royalty payments have been paid or accrued.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	December 2014, the Company entered into a lease agreement through May 31, 2018 for existing and expanded office space. The rent
	for the first 12 months was approximately $12,300 per month, or approximately $20.85 per square foot. This rent increased to approximately
	$12,375 per month, or approximately $20.95 per square foot, for the next 12 months and will increase to approximately $12,460
	per month, or approximately $21.13 per square foot for the remainder of the lease. The Company paid rent expense in the amount
	of $142,935 and $94,400 for 2015 and 2014, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	On
	September 3, 2014, the Company entered into an asset purchase agreement with Hy Biopharma, Inc. (&ldquo;Hy Biopharma&rdquo;) pursuant
	to which the Company acquired certain intangible assets, properties and rights of Hy Biopharma related to the development of Hy
	BioPharma&rsquo;s synthetic hypericin product. As consideration for the assets acquired, the Company paid $250,000 in cash and
	issued 1,849,113 shares of common stock with a fair value based on the Company&rsquo;s stock price on the date of grant of $3,750,000.
	These amounts were charged to research and development expense during the third quarter of 2014 as the assets will be used in
	the Company&rsquo;s research and development activities and do not have alternative future use pursuant to generally accepted
	accounting principles in the United States. Provided all future success-oriented milestones are attained, the Company will be
	required to make additional payments of up to $10.0 million, if and when achieved. Payments will be payable in restricted securities
	of the Company provided that Hy BioPharma&rsquo;s ownership is not to exceed 19.9% of the Company&rsquo;s outstanding stock. As
	of December 31, 2015, no milestone payments have been paid or accrued.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	February 2007, the Company&rsquo;s Board of Directors authorized the issuance of 50,000 shares of the Company&rsquo;s common stock
	to Dr. Schaber immediately prior to the completion of a transaction, or series or a combination of related transactions, negotiated
	by its Board of Directors whereby, directly or indirectly, a majority of its capital stock or a majority of its assets are transferred
	from the Company and/or its stockholders to a third party. Dr. Schaber&rsquo;s amended employment agreement includes the Company&rsquo;s
	obligation to issue such shares if such event occurs.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	As
	a result of the above agreements, the Company has future contractual obligations over the next five years as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Year
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Research and Development
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Property and Other Leases
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	2016
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	100,000
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	157,000
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	257,000
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	2017
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	100,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	151,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	251,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	2018
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	100,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	52,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	152,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	2019
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	100,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	100,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT">
	2020
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	100,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	-
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	100,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT">
	Total
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	500,000
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	360,000
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	860,000
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 84; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Note
	11. Operating Segments
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company maintains two active operating segments:&nbsp;BioTherapeutics and Vaccines/BioDefense.&nbsp;Each segment includes an element
	of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support
	functions generic to both operating segments.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	For the Years Ended December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Revenues
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	Vaccines/BioDefense
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	8,754,418
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	6,756,388
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	BioTherapeutics
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	13,972
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	286,628
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT; PADDING-LEFT: 20PT">
	Total
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	8,768,390
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	7,043,016
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	Income (Loss) from Operations
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	Vaccines/BioDefense
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,263,709
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	807,164
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	BioTherapeutics
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(4,487,988
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(7,674,381
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	Corporate
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(3,885,997
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(3,894,132
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT; PADDING-LEFT: 20PT">
	Total
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(7,110,276
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(10,761,349
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	Amortization and Depreciation Expense
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	Vaccines/BioDefense
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	39,925
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	39,625
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	BioTherapeutics
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	199,661
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	199,196
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	Corporate
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	7,872
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	6,966
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT; PADDING-LEFT: 20PT">
	Total
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	247,458
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	245,787
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	Other Income (Expense), Net
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	Corporate
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(1,209,887
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,437,505
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	Share-Based Compensation
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	Vaccines/BioDefense
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	111,960
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	114,920
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	BioTherapeutics
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	148,244
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	193,926
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.5PT; TEXT-INDENT: 0PT; PADDING-LEFT: 10PT">
	Corporate
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	394,277
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	411,304
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PT; TEXT-INDENT: 0PT; PADDING-LEFT: 20PT">
	Total
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	654,481
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	720,150
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	As of December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE">
	Identifiable Assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-DECORATION: NONE; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-DECORATION: NONE; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; PADDING-LEFT: 10PT">
	Vaccines/BioDefense
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: RIGHT">
	2,123,676
</TD>
<TD STYLE="WIDTH: 1%; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: RIGHT">
	1,025,220
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; PADDING-LEFT: 10PT">
	BioTherapeutics
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: RIGHT">
	76,183
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: RIGHT">
	204,308
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; PADDING-BOTTOM: 1.5PT; PADDING-LEFT: 10PT">
	Corporate
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: RIGHT">
	5,187,263
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: RIGHT">
	5,724,720
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; PADDING-BOTTOM: 4PT; PADDING-LEFT: 20PT">
	Total
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: RIGHT">
	7,387,122
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; PADDING-BOTTOM: 4PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 4PT DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: RIGHT">
	6,954,248
</TD>
<TD STYLE="PADDING-BOTTOM: 4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-DECORATION: NONE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&nbsp;
</P>
<EFX_SUBSEQUENT_EVENTS>
<A NAME="FIS_SUBSEQUENT_EVENTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Note
	12. Subsequent Events
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company entered into a purchase agreement with Lincoln Park on March 22, 2016 pursuant to which Lincoln Park has committed to
	purchase up to $12 million of the Company&rsquo;s common stock.&nbsp;&nbsp;Concurrently with the execution of the purchase agreement,
	the Company issued 100,000 shares of its common stock to Lincoln Park as a partial fee for its commitment to purchase shares of
	the Company&rsquo;s common stock under the purchase agreement. The shares that may be sold pursuant to the purchase agreement
	may be sold by the Company to Lincoln Park at the Company&rsquo;s discretion from time to time over the remaining term of approximately
	36 months, once the registration statement registering the resale of the shares of common stock sold to Lincoln Park under the
	purchase agreement is declared effective by the SEC.&nbsp;&nbsp;The purchase price for the shares that the Company may sell to
	Lincoln Park under the purchase agreement will fluctuate based on the price of the Company&rsquo;s common stock.&nbsp;&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company has the right to control the timing and amount of any sales of its shares to Lincoln Park, except that, pursuant to the
	terms of the agreements with Lincoln Park, the Company would be unable to sell shares to Lincoln Park that would cause Lincoln
	Park to beneficially own more than 4.99% of the Company&rsquo;s issued and outstanding common stock.&nbsp;&nbsp;Sales of the Company&rsquo;s
	common stock, if any, to Lincoln Park will depend upon market conditions and other factors to be determined by the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 85; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</P>
</DIV>
</EFX_SUBSEQUENT_EVENTS>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	REPORT
	OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Board of Directors and Shareholders
<BR>
	Soligenix, Inc.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	We
	have audited the accompanying consolidated balance sheets of Soligenix, Inc. and subsidiaries (the &ldquo;Company&rdquo;) as of
	December 31, 2015 and 2014, and the related consolidated statements of operations, shareholders&rsquo; deficiency, and cash flows
	for each of the years then ended. The financial statements are the responsibility of the Company&rsquo;s management. Our responsibility
	is to express an opinion on these financial statements based on our audits.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	We
	conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
	standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are
	free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control
	over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing
	audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness
	of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining,
	on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing
	the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement
	presentation. We believe that our audits provide a reasonable basis for our opinion.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In
	our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position
	of Soligenix, Inc. and subsidiaries as of December 31, 2015 and 2014, and the consolidated results of their operations and their
	cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States
	of America.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/
	EisnerAmper LLP
</FONT>
<BR>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Philadelphia, PA
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	March 24, 2016
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	F-22
</FONT>
</P>
</EFX_AUDITORS_OPINION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage87"></A>
<A NAME="F10K2015EX10XXXI_SOLIGENIX_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10"></A>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	EXHIBIT 10.31
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PURCHASE
	AGREEMENT
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PURCHASE
	AGREEMENT
</B>
	(the &ldquo;
<U>
	Agreement
</U>
	&rdquo;), dated as of March 22, 2016, by and between
<B>
	SOLIGENIX, INC.
</B>
	, a Delaware
	corporation (the &ldquo;
<U>
	Company
</U>
	&rdquo;), and
<B>
	LINCOLN PARK CAPITAL FUND, LLC
</B>
	, an Illinois limited liability company
	(the &ldquo;
<U>
	Investor
</U>
	&rdquo;).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	WHEREAS:
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 45.8PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 45.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Subject
	to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to
	buy from the Company, up to Twelve Million Dollars ($12,000,000) of the Company's common stock, par value $0.001 per share (the
	&quot;
<U>
	Common Stock
</U>
	&quot;). The shares of Common Stock to be purchased hereunder are referred to herein as the &quot;
<U>
	Purchase
	Shares
</U>
	.&quot;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9;NOW
	THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration,
	the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	1.&#9;CERTAIN
	DEFINITIONS.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	For
	purposes of this Agreement, the following terms shall have the following meanings:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9;(a)&#9;&ldquo;
<U>
	Accelerated
	Purchase Share Amount
</U>
	&rdquo; means, with respect to any Accelerated Purchase made pursuant to
<U>
	Section 2(b)
</U>
	hereof,
	the number of Purchase Shares directed by the Company to be purchased by the Investor on an Accelerated Purchase Notice, which
	number of Purchase Shares shall not exceed the lesser of (i) 300% of the number of Purchase Shares directed by the Company to
	be purchased by the Investor pursuant to the corresponding Regular Purchase Notice for the corresponding Regular Purchase referred
	to in
<U>
	Section 2(b)
</U>
	hereof (subject to the Purchase Share limitations contained in
<U>
	Section 2(a)
</U>
	hereof) and (ii)
	the Accelerated Purchase Share Percentage multiplied by the trading volume of the Common Stock on the Principal Market during
	normal trading hours on the Accelerated Purchase Date.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(b)&#9;&ldquo;
<U>
	Accelerated
	Purchase Date
</U>
	&rdquo; means, with respect to any Accelerated Purchase made pursuant to
<U>
	Section 2(b)
</U>
	hereof, the Business
	Day immediately following the applicable Purchase Date with respect to the corresponding Regular Purchase referred to in
<U>
	Section
	2(b)
</U>
	hereof.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(c)&#9;&ldquo;
<U>
	Accelerated
	Purchase Notice
</U>
	&rdquo; means, with respect to any Accelerated Purchase made pursuant to
<U>
	Section 2(b)
</U>
	hereof, an irrevocable
	written notice from the Company to the Investor directing the Investor to buy a specified Accelerated Purchase Share Amount on
	the applicable Accelerated Purchase Date pursuant to
<U>
	Section 2(b)
</U>
	hereof at the applicable Accelerated Purchase Price.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(d)&#9;&ldquo;
<U>
	Accelerated
	Purchase Share Percentage
</U>
	&rdquo; means, with respect to any Accelerated Purchase made pursuant to
<U>
	Section 2(b)
</U>
	hereof,
	0.30.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(e)&#9;&ldquo;
<U>
	Accelerated
	Purchase Price
</U>
	&rdquo; means, with respect to any particular Accelerated Purchase made pursuant to Section 2(b) hereof, the
	lower of (i) ninety-five percent (95%) of the VWAP during (A) the entire trading day on the Accelerated Purchase Date, if the
	volume of shares of Common Stock traded on the Principal Market on the Accelerated Purchase Date has not exceeded the Accelerated
	Purchase Share Volume Maximum, or (B) the portion of the trading day of the Accelerated Purchase Date (calculated starting at
	the beginning of normal trading hours) until such time at which the volume of shares of Common Stock traded on the Principal Market
	has exceeded the Accelerated Purchase Share Volume Maximum or (ii) the Closing Sale Price on the Accelerated Purchase Date (to
	be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other
	similar transaction).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(f)&#9;&ldquo;
<U>
	Accelerated
	Purchase Share Volume Maximum
</U>
	&rdquo; means the number of shares of Common Stock traded on the Principal Market during normal
	trading hours on the Accelerated Purchase Date equal to (i) the amount of shares of Common Stock properly directed by the Company
	to be purchased on the Accelerated Purchase Notice, divided by (ii) the Accelerated Purchase Share Percentage (to be appropriately
	adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9;(g)
	&#9; &ldquo;
<U>
	Available Amount
</U>
	&rdquo; means, initially, Twelve Million Dollars ($12,000,000) in the aggregate, which amount
	shall be reduced by the Purchase Amount each time the Investor purchases shares of Common Stock pursuant to
<U>
	Section 2
</U>
	hereof.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(h)&#9;&ldquo;
<U>
	Bankruptcy
	Law
</U>
	&rdquo; means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(i)&#9;&ldquo;
<U>
	Business
	Day
</U>
	&rdquo; means any day on which the Principal Market is open for trading, including any day on which the Principal Market
	is open for trading for a period of time less than the customary time.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(j)&#9;&ldquo;
<U>
	Closing
	Sale Price
</U>
	&rdquo; means, for any security as of any date, the last closing sale price for such security on the Principal Market
	as reported by the Principal Market.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9;(k)&#9;&ldquo;
<U>
	Confidential
	Information
</U>
	&rdquo; means any information disclosed by either party to the other party, either directly or indirectly, in writing,
	orally or by inspection of tangible objects (including, without limitation, documents, prototypes, samples, plant and equipment),
	which is designated as &quot;Confidential,&quot; &quot;Proprietary&quot; or some similar designation. Information communicated
	orally shall be considered Confidential Information if such information is confirmed in writing as being Confidential Information
	within ten (10) Business Days after the initial disclosure. Confidential Information may also include information disclosed to
	a disclosing party by third parties. Confidential Information shall not, however, include any information which (i) was publicly
	known and made generally available in the public domain prior to the time of disclosure by the disclosing party; (ii) becomes
	publicly known and made generally available after disclosure by the disclosing party to the receiving party through no action
	or inaction of the receiving party; (iii) is already in the possession of the receiving party at the time of disclosure by the
	disclosing party as shown by the receiving party&rsquo;s files and records immediately prior to the time of disclosure; (iv) is
	obtained by the receiving party from a third party without a breach of such third party&rsquo;s obligations of confidentiality;
	(v) is independently developed by the receiving party without use of or reference to the disclosing party&rsquo;s Confidential
	Information, as shown by documents and other competent evidence in the receiving party&rsquo;s possession; or (vi) is required
	by law to be disclosed by the receiving party, provided that the receiving party gives the disclosing party prompt written notice
	of such requirement prior to such disclosure and assistance in obtaining an order protecting the information from public disclosure.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(l)&#9;&ldquo;
<U>
	Custodian
</U>
	&rdquo;
	means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(m)&#9;&ldquo;
<U>
	DTC
</U>
	&rdquo;
	means The Depository Trust Company, or any successor performing substantially the same function for the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(n)&#9;&ldquo;
<U>
	DWAC
	Shares
</U>
	&rdquo; means shares of Common Stock that are (i) issued in electronic form, (ii) freely tradable and transferable and
	without restriction on resale and (iii) timely credited by the Company to the Investor&rsquo;s or its designee&rsquo;s specified
	Deposit/Withdrawal at Custodian (DWAC) account with DTC under its Fast Automated Securities Transfer (FAST) Program, or any similar
	program hereafter adopted by DTC performing substantially the same function.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(o)
	&#9;&ldquo;
<U>
	Exchange Act
</U>
	&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
	thereunder.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(p)&#9;&ldquo;
<U>
	Material
	Adverse Effect
</U>
	&rdquo; means any material adverse effect on (i)&nbsp;the enforceability of any Transaction Document, (ii)&nbsp;the
	results of operations, assets, business or financial condition of the Company and its Subsidiaries, taken as a whole, other than
	any material adverse effect that resulted exclusively from (A)&nbsp;any change in the United States or foreign economies or securities
	or financial markets in general that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole,
	(B)&nbsp;any change that generally affects the industry in which the Company and its Subsidiaries operate that does not have a
	disproportionate effect on the Company and its Subsidiaries, taken as a whole, (C)&nbsp;any change arising in connection with
	earthquakes, hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any
	such hostilities, acts of war, sabotage or terrorism or military actions existing as of the date hereof, (D)&nbsp;any action taken
	by the Investor, its affiliates or its or their successors and assigns with respect to the transactions contemplated by this Agreement,
	(E)&nbsp;the effect of any change in applicable laws or accounting rules that does not have a disproportionate effect on the Company
	and its Subsidiaries, taken as a whole, or (F)&nbsp;any change resulting from compliance with terms of this Agreement or the consummation
	of the transactions contemplated by this Agreement, or (iii)&nbsp;the Company&rsquo;s ability to perform in any material respect
	on a timely basis its obligations under any Transaction Document to be performed as of the date of determination.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(q)&#9;&ldquo;
<U>
	Maturity
	Date
</U>
	&rdquo; means the first day of the month immediately following the thirty-six (36) month anniversary of the Commencement
	Date.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(r)&#9;&ldquo;
<U>
	PEA
	Period
</U>
	&rdquo; means the period commencing at 9:30 a.m., Eastern time, on the twentieth (20
<SUP>
	th
</SUP>
	) Business Day immediately
	prior to the filing of any post-effective amendment to the Registration Statement (as defined herein) or New Registration Statement
	(as such term is defined in the Registration Rights Agreement), and ending at 9:30 a.m., Eastern time, on the Business Day immediately
	following, the effective date of any post-effective amendment to the Registration Statement (as defined herein) or New Registration
	Statement (as such term is defined in the Registration Rights Agreement).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(s)&#9;&ldquo;
<U>
	Person
</U>
	&rdquo;
	means an individual or entity including but not limited to any limited liability company, a partnership, a joint venture, a corporation,
	a trust, an unincorporated organization and a government or any department or agency thereof.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(t)&#9;&ldquo;
<U>
	Principal
	Market
</U>
	&rdquo; means the OTCQB operated by the OTC Markets Group, Inc. (or any nationally recognized successor thereto); provided,
	however, that in the event the Company&rsquo;s Common Stock is ever listed or traded on The NASDAQ Capital Market, The NASDAQ
	Global Market, The NASDAQ Global Select Market, the New York Stock Exchange, the NYSE MKT, the NYSE Arca, the OTC Bulletin Board
	or the OTCQX operated by the OTC Markets Group, Inc. (or any nationally recognized successor to any of the foregoing), then the
	&ldquo;Principal Market&rdquo; shall mean such other market or exchange on which the Company&rsquo;s Common Stock is then listed
	or traded.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage90"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(u)&#9;&ldquo;
<U>
	Purchase
	Amount
</U>
	&rdquo; means, with respect to any Regular Purchase or any Accelerated Purchase made hereunder, the portion of the Available
	Amount to be purchased by the Investor pursuant to
<U>
	Section 2
</U>
	hereof.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(v)&#9;&ldquo;
<U>
	Purchase
	Date
</U>
	&rdquo; means, with respect to any Regular Purchase made pursuant to
<U>
	Section 2(a)
</U>
	hereof, the Business Day on which
	the Investor receives by 5:00 p.m., Eastern time, of such Business Day a valid Regular Purchase Notice that the Investor is to
	buy Purchase Shares pursuant to
<U>
	Section 2(a)
</U>
	hereof.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(w)&#9;&ldquo;
<U>
	Purchase
	Price
</U>
	&rdquo; means, with respect to any Regular Purchase made pursuant to
<U>
	Section 2(a) hereof
</U>
	, the lower of: (i) the
	lowest Sale Price on the applicable Purchase Date and (ii) the arithmetic average of the three (3) lowest Closing Sale Prices
	for the Common Stock during the twelve (12) consecutive Business Days ending on the Business Day immediately preceding such Purchase
	Date (in each case, to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other
	similar transaction that occurs on or after the date of this Agreement).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(x)&#9;&ldquo;
<U>
	Regular
	Purchase Notice
</U>
	&rdquo; means, with respect to any Regular Purchase pursuant to
<U>
	Section 2(a)
</U>
	hereof, an irrevocable
	written notice from the Company to the Investor directing the Investor to buy such applicable amount of Purchase Shares at the
	applicable Purchase Price as specified by the Company therein on the Purchase Date.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(y)&#9;&ldquo;
<U>
	Sale
	Price
</U>
	&rdquo; means any trade price for the shares of Common Stock on the Principal Market as reported by the Principal Market.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(z)&#9;&ldquo;
<U>
	SEC
</U>
	&rdquo;
	means the U.S. Securities and Exchange Commission.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(aa)&#9;&ldquo;
<U>
	Securities
</U>
	&rdquo;
	means, collectively, the Purchase Shares and the Commitment Shares.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(bb)&#9;&ldquo;
<U>
	Securities
	Act
</U>
	&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(cc)&#9;&ldquo;
<U>
	Subsidiary
</U>
	&rdquo;
	means any Person the Company wholly-owns or controls, or in which the Company, directly or indirectly, owns a majority of the
	voting stock or similar voting interest, in each case that would be disclosable pursuant to Item 601(b)(21) of Regulation S-K
	promulgated under the Securities Act.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(dd)&#9;&ldquo;
<U>
	Transaction
	Documents
</U>
	&rdquo; means, collectively, this Agreement and the schedules and exhibits hereto, the Registration Rights Agreement
	and the schedules and exhibits thereto, and each of the other agreements, documents, certificates and instruments entered into
	or furnished by the parties hereto in connection with the transactions contemplated hereby and thereby.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(ee)
	&ldquo;
<U>
	Transfer Agent
</U>
	&rdquo; means American Stock Transfer &amp; Trust Co., or such other Person who is then serving as
	the transfer agent for the Company in respect of the Common Stock.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(ff)&#9;&ldquo;
<U>
	VWAP
</U>
	&rdquo;
	means in respect of an applicable Accelerated Purchase Date, the volume weighted average price of the Common Stock on the Principal
	Market, as reported on the Principal Market.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage91"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2.
	PURCHASE OF COMMON STOCK.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 45.8PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Subject
	to the terms and conditions set forth in this Agreement, the Company has the right to sell to the Investor, and the Investor has
	the obligation to purchase from the Company, Purchase Shares as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)&#9;
<U>
	Commencement
	of Regular Sales of Common Stock
</U>
	. Upon the satisfaction of the conditions set forth in
<U>
	Sections 7
</U>
	and
<U>
	8
</U>
	hereof
	(the &ldquo;
<U>
	Commencement
</U>
	&rdquo; and the date of satisfaction of such conditions the &ldquo;
<U>
	Commencement Date
</U>
	&rdquo;)
	and thereafter, the Company shall have the right, but not the obligation, to direct the Investor, by its delivery to the Investor
	of a Regular Purchase Notice from time to time, to purchase up to One Hundred Thousand (100,000) Purchase Shares (each such purchase
	a &ldquo;
<U>
	Regular Purchase
</U>
	&rdquo;), at the Purchase Price on the Purchase Date;
<U>
	provided
</U>
	,
<U>
	however
</U>
	, that (i)
	the Regular Purchase may be increased to up to One Hundred Fifty Thousand (150,000) Purchase Shares, provided that the Closing
	Sale Price of the Common Stock is not below $1.00 on the Purchase Date, (ii) the Regular Purchase may be increased to up to Two
	Hundred Thousand (200,000) Purchase Shares, provided that the Closing Sale Price of the Common Stock is not below $1.50 on the
	Purchase Date, and (iii) the Regular Purchase may be increased to up to Two Hundred Fifty Thousand (250,000) Purchase Shares,
	provided that the Closing Sale Price of the Common Stock is not below $2.00 on the Purchase Date (all of which share and dollar
	amounts shall be appropriately adjusted for any reorganization, recapitalization, non-cash dividend (excluding dividends of rights
	and shares of capital stock issuable upon exercise of such rights), stock split or other similar transaction);
<U>
	provided
</U>
	,
<U>
	further
</U>
	,
<U>
	however
</U>
	, that the Investor&rsquo;s committed obligation under any single Regular Purchase shall not exceed
	Seven Hundred Fifty Thousand Dollars ($750,000). If the Company delivers any Regular Purchase Notice for a Purchase Amount in
	excess of the limitations contained in the immediately preceding sentence, such Regular Purchase Notice shall be void
<I>
	ab initio
</I>
	to the extent of the amount by which the amount of Purchase Shares set forth in such Regular Purchase Notice exceeds the amount
	of Purchase Shares which the Company is permitted to include in such Purchase Notice in accordance herewith, and the Investor
	shall have no obligation to purchase such excess Purchase Shares in respect of such Regular Purchase Notice; provided that the
	Investor shall remain obligated to purchase the amount of Purchase Shares which the Company is permitted to include in such Regular
	Purchase Notice. The Company may deliver multiple Regular Purchase Notices to the Investor so long as at least one (1) Business
	Day has passed since the most recent Regular Purchase was completed. Notwithstanding the foregoing, the Company shall not deliver
	any Regular Purchase Notices during the PEA Period.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(b)&#9;
<U>
	Accelerated
	Purchases
</U>
	. Subject to the terms and conditions of this Agreement, in addition to purchases of Purchase Shares as described
	in
<U>
	Section 2(a)
</U>
	above, the Company shall also have the right, but not the obligation, to direct the Investor by the Company&rsquo;s
	delivery to the Investor of an Accelerated Purchase Notice from time to time, and the Investor thereupon shall have the obligation,
	to buy Purchase Shares at the Accelerated Purchase Price on the Accelerated Purchase Date in an amount equal to the Accelerated
	Purchase Share Amount (each such purchase, an &ldquo;
<U>
	Accelerated Purchase
</U>
	&rdquo;). The Company may deliver an Accelerated
	Purchase Notice to the Investor only on a Purchase Date on which the Company also properly submitted a Regular Purchase Notice
	for a Regular Purchase and the Closing Sale Price is not below $0.75 (to be appropriately adjusted for any reorganization, recapitalization,
	non-cash dividend, stock split or other similar transaction and, effective upon the consummation of any such reorganization, recapitalization,
	non-cash dividend, stock split or other similar transaction, the Closing Sale Price is not below the
<U>
	lower
</U>
	of (i) the adjusted
	price and (ii) $0.75). If the Company delivers any Accelerated Purchase Notice for an Accelerated Purchase Share Amount in excess
	of the limitations contained in the definition of Accelerated Purchase Share Amount, such Accelerated Purchase Notice shall be
	void
<I>
	ab initio
</I>
	to the extent of the amount by which the number of Purchase Shares set forth in such Accelerated Purchase
	Notice exceeds the Accelerated Purchase Share Amount which the Company is permitted to include in such Accelerated Purchase Notice
	in accordance herewith (which shall be confirmed in an Accelerated Purchase Confirmation (defined below)), and the Investor shall
	have no obligation to purchase such excess Purchase Shares in respect of such Accelerated Purchase Notice; provided that the Investor
	shall remain obligated to purchase the Accelerated Purchase Share Amount which the Company is permitted to include in such Accelerated
	Purchase Notice. Upon completion of each Accelerated Purchase Date, the Accelerated Purchase Share Amount and the applicable Accelerated
	Purchase Price shall be set forth on a confirmation of the Accelerated Purchase to be provided to the Company by the Investor
	(an &ldquo;
<U>
	Accelerated Purchase Confirmation
</U>
	&rdquo;).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage92"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(c)&#9;
<U>
	Payment for Purchase Shares.
</U>
	For each Regular Purchase, the Investor shall pay to the Company an amount equal to the Purchase
	Amount with respect to such Regular Purchase as full payment for such Purchase Shares via wire transfer of immediately available
	funds on the same Business Day that the Investor receives such Purchase Shares, if such Purchase Shares are received by the Investor
	before 1:00 p.m., Eastern time, or, if such Purchase Shares are received by the Investor after 1:00 p.m., Eastern time, the next
	Business Day. For each Accelerated Purchase, the Investor shall pay to the Company an amount equal to the Purchase Amount with
	respect to such Accelerated Purchase as full payment for such Purchase Shares via wire transfer of immediately available funds
	on the third Business Day following the date that the Investor receives such Purchase Shares. If the Company or the Transfer Agent
	shall fail for any reason or for no reason to electronically transfer any Purchase Shares as DWAC Shares in respect of a Regular
	Purchase or Accelerated Purchase (as applicable) within five (5) Business Days following the receipt by the Company of the Purchase
	Price or Accelerated Purchase Price, respectively, therefor in compliance with this
<U>
	Section 2(c)
</U>
	, and if on or after such
	Business Day the Investor purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction
	of a sale by the Investor of such Purchase Shares that the Investor anticipated receiving from the Company in respect of such
	Regular Purchase or Accelerated Purchase (as applicable), then the Company shall, within five (5) Business Days after the Investor&rsquo;s
	request, either (i) pay cash to the Investor in an amount equal to the Investor&rsquo;s total purchase price (including brokerage
	commissions, if any) for the shares of Common Stock so purchased (the &ldquo;
<U>
	Cover Price
</U>
	&rdquo;), at which point the Company&rsquo;s
	obligation to deliver such Purchase Shares as DWAC Shares shall terminate, or (ii) promptly honor its obligation to deliver to
	the Investor such Purchase Shares as DWAC Shares and pay cash to the Investor in an amount equal to the excess (if any) of the
	Cover Price over the total Purchase Price for such Regular Purchase plus the total Accelerated Purchase Price for such Accelerated
	Purchase (as applicable). The Company shall not issue any fraction of a share of Common Stock upon any Regular Purchase or Accelerated
	Purchase. If the issuance would result in the issuance of a fraction of a share of Common Stock, the Company shall round such
	fraction of a share of Common Stock up or down to the nearest whole share. All payments made under this Agreement shall be made
	in lawful money of the United States of America or wire transfer of immediately available funds to such account as the Company
	may from time to time designate by written notice in accordance with the provisions of this Agreement. Whenever any amount expressed
	to be due by the terms of this Agreement is due on any day that is not a Business Day, the same shall instead be due on the next
	succeeding day that is a Business Day.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(d)&#9;
<U>
	Beneficial
	Ownership Limitation.
</U>
	Notwithstanding anything to the contrary contained in this Agreement, the Company shall not&nbsp;issue
	or sell, and the Investor shall not&nbsp;purchase or acquire, any shares of Common Stock under this Agreement&nbsp;which, when
	aggregated with all other shares of Common Stock then beneficially owned by the Investor and its affiliates (as calculated pursuant
	to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in the beneficial ownership by the&nbsp;Investor
	and its affiliates&nbsp;of more than&nbsp;4.99% of the then issued and outstanding shares of Common Stock (the &ldquo;
<U>
	Beneficial
	Ownership Limitation
</U>
	&rdquo;). Upon the written or oral request of the Investor, the Company shall promptly (but not later
	than 24 hours) confirm orally or in writing to the Investor the number of shares of Common Stock then outstanding. The Investor
	and the Company shall each cooperate in good faith in the determinations required hereby and the application hereof. The Investor&rsquo;s
	written certification to the Company of the applicability of the Beneficial Ownership Limitation, and the resulting effect thereof
	hereunder at any time, shall be conclusive with respect to the applicability thereof and such result absent manifest error.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	3.&#9;INVESTOR'S
	REPRESENTATIONS AND WARRANTIES.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Investor represents and warrants to the Company that as of the date hereof and as of the Commencement Date:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)&#9;
<U>
	Investment
	Purpose
</U>
	. &nbsp;The Investor is acquiring the Securities as principal for its own account and not with a view to or for distributing
	or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, will
	not distribute any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct
	or indirect arrangement or understandings with any other Persons to distribute or regarding the distribution of such Securities
	in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting the Investor&rsquo;s
	right to sell the Securities at any time pursuant to the Registration Statement described herein or otherwise in compliance with
	applicable federal and state securities laws).&nbsp;&nbsp;The Investor is acquiring the Securities hereunder in the ordinary course
	of its business.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9;(b)&#9;
<U>
	Accredited
	Investor Status
</U>
	. The Investor is an &quot;accredited investor&quot; as that term is defined in Rule 501(a)(3) of Regulation
	D promulgated under the Securities Act.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(c)&#9;
<U>
	Reliance
	on Exemptions
</U>
	. The Investor understands that the Securities may be offered and sold to it in reliance on specific exemptions
	from the registration requirements of United States federal and state securities laws and that the Company is relying in part
	upon the truth and accuracy of, and the Investor's compliance with, the representations, warranties, agreements, acknowledgments
	and understandings of the Investor set forth herein in order to determine the availability of such exemptions and the eligibility
	of the Investor to acquire the Securities.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(d)&#9;
<U>
	Information
</U>
	.
	The Investor understands that its investment in the Securities involves a high degree of risk. The Investor (i) is able to bear
	the economic risk of an investment in the Securities including a total loss thereof, (ii) has such knowledge and experience in
	financial and business matters that it is capable of evaluating the merits and risks of the proposed investment in the Securities
	and (iii) has had an opportunity to ask questions of and receive answers from the officers of the Company concerning the financial
	condition and business of the Company and others matters related to an investment in the Securities. Neither such inquiries nor
	any other due diligence investigations conducted by the Investor or its representatives shall modify, amend or affect the Investor's
	right to rely on the Company's representations and warranties contained in Section 4 below. The Investor has sought such accounting,
	legal and tax advice as it has considered necessary to make an informed investment decision with respect to its acquisition of
	the Securities.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(e)&#9;
<U>
	No
	Governmental Review
</U>
	. The Investor understands that no U.S. federal or state agency or any other government or governmental
	agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of an investment
	in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(f)&#9;
<U>
	Transfer
	or Sale
</U>
	. The Investor understands that (i) the Securities may not be offered for sale, sold, assigned or transferred unless
	(A) registered pursuant to the Securities Act or (B) an exemption exists permitting such Securities to be sold, assigned or transferred
	without such registration; (ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the
	terms of Rule 144 and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller
	(or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities Act)
	may require compliance with some other exemption under the Securities Act or the rules and regulations of the SEC thereunder.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage94"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(g)&#9;
<U>
	Validity;
	Enforcement
</U>
	. This Agreement has been duly and validly authorized, executed and delivered on behalf of the Investor and is
	a valid and binding agreement of the Investor enforceable against the Investor in accordance with its terms, subject as to enforceability
	to general principles of equity and to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar
	laws relating to, or affecting generally, the enforcement of applicable creditors' rights and remedies.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(h)&#9;
<U>
	Residency
</U>
	.
	The Investor is a resident of the State of Illinois.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(i)&#9;
<U>
	No
	Short Selling
</U>
	. The Investor represents and warrants to the Company that at no time prior to the date of this Agreement has
	any of the Investor, its agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly,
	any (i) &quot;short sale&quot; (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Common Stock
	or (ii) hedging transaction, which establishes a net short position with respect to the Common Stock.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	4.&#9;REPRESENTATIONS
	AND WARRANTIES OF THE COMPANY.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company represents and warrants to the Investor that as of the date hereof and as of the Commencement Date:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)&#9;
<U>
	Organization
	and Qualification
</U>
	. The Company and each of its Subsidiaries is an entity duly incorporated or otherwise organized, validly
	existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite corporate
	power and authority to own and use its properties and assets and to carry on its business as currently conducted.&nbsp;&nbsp;Neither
	the Company nor any of its Subsidiaries is in violation or default of any of the provisions of its respective certificate or articles
	of incorporation, bylaws or other organizational or charter documents.&nbsp;&nbsp;Each of the Company and its Subsidiaries is
	duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which
	the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be
	so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in a Material Adverse
	Effect and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit
	or curtail such power and authority or qualification. The Company has no Subsidiaries except as set forth on
<U>
	Schedule 4(a)
</U>
	hereof.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(b)&#9;
<U>
	Authorization;
	Enforcement; Validity
</U>
	. (i) The Company has the requisite corporate power and authority to enter into and perform its obligations
	under this Agreement, the Registration Rights Agreement and each of the other Transaction Documents, and to issue the Securities
	in accordance with the terms hereof and thereof, (ii) the execution and delivery of the Transaction Documents by the Company and
	the consummation by it of the transactions contemplated hereby and thereby, including without limitation, the issuance of the
	Commitment Shares (as defined below in
<U>
	Section 5(e)
</U>
	) and the reservation for issuance and the issuance of the Purchase
	Shares issuable under this Agreement, have been duly authorized by the Company's Board of Directors and no further consent or
	authorization is required by the Company, its Board of Directors or its stockholders, (iii) this Agreement has been, and each
	other Transaction Document shall be on the Commencement Date, duly executed and delivered by the Company and (iv) this Agreement
	constitutes, and each other Transaction Document upon its execution on behalf of the Company, shall constitute, the valid and
	binding obligations of the Company enforceable against the Company in accordance with their terms, except as such enforceability
	may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or
	similar laws relating to, or affecting generally, the enforcement of creditors' rights and remedies. The Board of Directors of
	the Company has approved the resolutions (the &ldquo;
<U>
	Signing Resolutions
</U>
	&rdquo;) substantially in the form as set forth
	as
<U>
	Exhibit C
</U>
	attached hereto to authorize this Agreement and the transactions contemplated hereby. The Signing Resolutions
	are valid, in full force and effect and have not been modified or supplemented in any respect. The Company has delivered to the
	Investor a true and correct copy of a unanimous written consent adopting the Signing Resolutions executed by all of the members
	of the Board of Directors of the Company. Except as set forth in this Agreement, no other approvals or consents of the Company&rsquo;s
	Board of Directors, any authorized committee thereof, and/or stockholders is necessary under applicable laws and the Company&rsquo;s
	Restated Certificate of Incorporation and/or Bylaws to authorize the execution and delivery of this Agreement or any of the transactions
	contemplated hereby, including, but not limited to, the issuance of the Commitment Shares and the issuance of the Purchase Shares.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage95"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(c)&#9;
<U>
	Capitalization
</U>
	.
	As of the date hereof, the authorized capital stock of the Company is set forth in
<U>
	Schedule 4(c)
</U>
	hereof. Except as disclosed
	in the SEC Documents (as defined below), (i) no shares of the Company's capital stock are subject to preemptive rights or any
	other similar rights or any liens or encumbrances suffered or permitted by the Company, (ii) there are no outstanding debt securities,
	(iii) there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever
	relating to, or securities or rights convertible into, any shares of capital stock of the Company or any of its Subsidiaries,
	or contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound
	to issue additional shares of capital stock of the Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe
	to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, any shares of capital
	stock of the Company or any of its Subsidiaries, (iv) there are no agreements or arrangements under which the Company or any of
	its Subsidiaries is obligated to register the sale of any of their securities under the Securities Act (except the Registration
	Rights Agreement), (v) there are no outstanding securities or instruments of the Company or any of its Subsidiaries which contain
	any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company
	or any of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries, (vi) there are
	no securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities
	as described in this Agreement and (vii) the Company does not have any stock appreciation rights or &quot;phantom stock&quot;
	plans or agreements or any similar plan or agreement. The Company has furnished to the Investor true and correct copies of the
	Company's Restated Certificate of Incorporation, as amended and as in effect on the date hereof (the &quot;
<U>
	Certificate of Incorporation
</U>
	&quot;),
	and the Company's Bylaws, as amended and as in effect on the date hereof (the &quot;
<U>
	Bylaws
</U>
	&quot;), and summaries of the
	terms of all securities convertible into or exercisable for Common Stock, if any, and copies of any documents containing the material
	rights of the holders thereof in respect thereto.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(d)&#9;
<U>
	Issuance
	of Securities
</U>
	. Upon issuance and payment therefor in accordance with the terms and conditions of this Agreement, the Purchase
	Shares shall be validly issued, fully paid and nonassessable and free from all taxes, liens, charges, restrictions, rights of
	first refusal and preemptive rights with respect to the issue thereof, with the holders being entitled to all rights accorded
	to a holder of Common Stock. Upon issuance in accordance with the terms and conditions of this Agreement, the Commitment Shares
	(as defined below in
<U>
	Section 5(e)
</U>
	) shall be validly issued, fully paid and nonassessable and free from all taxes, liens,
	charges, restrictions, rights of first refusal and preemptive rights with respect to the issue thereof, with the holders being
	entitled to all rights accorded to a holder of Common Stock. 5,000,000 shares of Common Stock have been duly authorized and reserved
	for issuance upon purchase under this Agreement as Purchase Shares. 500,000 shares of Common Stock (subject to equitable adjustment
	for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction) have been duly authorized
	and reserved for issuance as Additional Commitment Shares in accordance with this Agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage96"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(e)&#9;
<U>
	No
	Conflicts
</U>
	. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the
	Company of the transactions contemplated hereby and thereby (including, without limitation, the reservation for issuance and issuance
	of the Purchase Shares and the Commitment Shares) will not (i) result in a violation of the Certificate of Incorporation, any
	Certificate of Designations, Preferences and Rights of any outstanding series of preferred stock of the Company or the Bylaws
	or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default)
	under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument
	to which the Company or any of its Subsidiaries is a party, or result in a violation of any law, rule, regulation, order, judgment
	or decree (including federal and state securities laws and regulations and the rules and regulations of the Principal Market applicable
	to the Company or any of its Subsidiaries) or by which any property or asset of the Company or any of its Subsidiaries is bound
	or affected, except in the case of conflicts, defaults, terminations, amendments, accelerations, cancellations and violations
	under clause (ii), which could not reasonably be expected to result in a Material Adverse Effect. Neither the Company nor its
	Subsidiaries is in violation of any term of or in default under its Certificate of Incorporation, any Certificate of Designation,
	Preferences and Rights of any outstanding series of preferred stock of the Company or Bylaws or their organizational charter or
	bylaws, respectively. Neither the Company nor any of its Subsidiaries is in violation of any term of or is in default under any
	material contract, agreement, mortgage, indebtedness, indenture, instrument, judgment, decree or order or any statute, rule or
	regulation applicable to the Company or its Subsidiaries, except for possible conflicts, defaults, terminations or amendments
	that could not reasonably be expected to have a Material Adverse Effect. The business of the Company and its Subsidiaries is not
	being conducted, and shall not be conducted, in violation of any law, ordinance, regulation of any governmental entity, except
	for possible violations, the sanctions for which either individually or in the aggregate could not reasonably be expected to have
	a Material Adverse Effect. Except as specifically contemplated by this Agreement and as required under the Securities Act or applicable
	state securities laws and the rules and regulations of the Principal Market, the Company is not required to obtain any consent,
	authorization or order of, or make any filing or registration with, any court or governmental agency or any regulatory or self-regulatory
	agency in order for it to execute, deliver or perform any of its obligations under or contemplated by the Transaction Documents
	in accordance with the terms hereof or thereof. Except as set forth elsewhere in this Agreement, all consents, authorizations,
	orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence shall be obtained
	or effected on or prior to the Commencement Date. Since one year prior to the date hereof, the Company has not received nor delivered
	any notices or correspondence from or to the Principal Market. The Principal Market has not commenced any delisting proceedings
	against the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(f)&#9;
<U>
	SEC
	Documents; Financial Statements
</U>
	. The Company has filed all reports, schedules, forms, statements and other documents required
	to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof,
	for the twelve months preceding the date hereof (or such shorter period as the Company was required by law or regulation to file
	such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being
	collectively referred to herein as the &ldquo;
<U>
	SEC Documents
</U>
	&rdquo;) on a timely basis or has received a valid extension
	of such time of filing and has filed any such SEC Documents prior to the expiration of any such extension.&nbsp;&nbsp;As of their
	respective dates and to the best of the Company&rsquo;s knowledge, the SEC Documents complied in all material respects with the
	requirements of the Securities Act and the Exchange Act, as applicable. None of the SEC Documents, when filed, contained any untrue
	statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the
	statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements of
	the Company included in the SEC Documents comply in all material respects with applicable accounting requirements and the rules
	and regulations of the SEC with respect thereto as in effect at the time of filing.&nbsp;&nbsp;Such financial statements have
	been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the
	periods involved (&ldquo;
<U>
	GAAP
</U>
	&rdquo;), except as may be otherwise specified in such financial statements or the notes thereto
	and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material
	respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results
	of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial,
	year-end audit adjustments. Except as set forth in the SEC Documents, the Company has received no notices or correspondence from
	the SEC for the one year preceding the date hereof
<B>
	.
</B>
	The SEC has not commenced any enforcement proceedings against the Company
	or any of its Subsidiaries.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage97"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(g)&#9;
<U>
	Absence
	of Certain Changes
</U>
	. Except as disclosed in the SEC Documents, since December 31, 2014, there has been no material adverse
	change in the business, properties, operations, financial condition or results of operations of the Company or its Subsidiaries.
	The Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to any Bankruptcy
	Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate
	involuntary bankruptcy
<B>
</B>
	or insolvency proceedings. The Company is financially solvent and is generally able to pay its debts
	as they become due.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(h)&#9;
<U>
	Absence
	of Litigation
</U>
	. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government
	agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries, threatened
	against or affecting the Company, the Common Stock or any of the Company's or its Subsidiaries' officers or directors in their
	capacities as such, which could reasonably be expected to have a Material Adverse Effect.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(i)&#9;
<U>
	Acknowledgment
	Regarding Investor's Status
</U>
	. The Company acknowledges and agrees that the Investor is acting solely in the capacity of arm's
	length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further
	acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with
	respect to the Transaction Documents and the transactions contemplated hereby and thereby and any advice given by the Investor
	or any of its representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby
	and thereby is merely incidental to the Investor's purchase of the Securities. The Company further represents to the Investor
	that the Company's decision to enter into the Transaction Documents has been based solely on the independent evaluation by the
	Company and its representatives and advisors.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(j)&#9;
<U>
	No
	General Solicitation; No Integrated Offering
</U>
	. Neither the Company, nor any of its affiliates, nor any Person acting on its
	or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under
	the Securities Act) in connection with the offer or sale of the Securities. Neither the Company, nor or any of its affiliates,
	nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers
	to buy any security, under circumstances that would require registration of the offer and sale of any of the Securities under
	the Securities Act, whether through integration with prior offerings or otherwise, or cause this offering of the Securities to
	be integrated with prior offerings by the Company in a manner that would require stockholder approval pursuant to the rules of
	the Principal Market on which any of the securities of the Company are listed or designated. The issuance and sale of the Securities
	hereunder does not contravene the rules and regulations of the Principal Market.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage98"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(k)&#9;
<U>
	Intellectual
	Property Rights
</U>
	. The Company and its Subsidiaries own or possess adequate rights or licenses to use all material trademarks,
	trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses,
	approvals, governmental authorizations, trade secrets and rights necessary to conduct their respective businesses as now conducted.
	None of the Company's material trademarks, trade names, service marks, service mark registrations, service names, patents, patent
	rights, copyrights, inventions, licenses, approvals, government authorizations, trade secrets or other intellectual property rights
	have expired or terminated, or, by the terms and conditions thereof, could expire or terminate within two years from the date
	of this Agreement. The Company and its Subsidiaries do not have any knowledge of any infringement by the Company or its Subsidiaries
	of any material trademark, trade name rights, patents, patent rights, copyrights, inventions, licenses, service names, service
	marks, service mark registrations, trade secret or other similar rights of others, or of any such development of similar or identical
	trade secrets or technical information by others, and there is no claim, action or proceeding being made or brought against, or
	to the Company's knowledge, being threatened against, the Company or its Subsidiaries regarding trademark, trade name, patents,
	patent rights, invention, copyright, license, service names, service marks, service mark registrations, trade secret or other
	infringement, which could reasonably be expected to have a Material Adverse Effect.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(l)&#9;
<U>
	Environmental
	Laws
</U>
	. The Company and its Subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local
	laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or
	wastes, pollutants or contaminants (&ldquo;
<U>
	Environmental Laws
</U>
	&rdquo;), (ii) have received all permits, licenses or other
	approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance
	with all terms and conditions of any such permit, license or approval, except where, in each of the three foregoing clauses, the
	failure to so comply could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(m)&#9;
<U>
	Title
</U>
	.
	The Company and its Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and
	marketable title in all personal property owned by them that is material to the business of the Company and its Subsidiaries,
	in each case free and clear of all liens, encumbrances and defects (&ldquo;
<U>
	Liens
</U>
	&rdquo;) and, except for Liens as do not
	materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such
	property by the Company and its Subsidiaries and Liens for the payment of federal, state or other taxes, the payment of which
	is neither delinquent nor subject to penalties.&nbsp;&nbsp;Any real property and facilities held under lease by the Company and
	its Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and its Subsidiaries are
	in compliance with such exceptions as are not material and do not interfere with the use made and proposed to be made of such
	property and buildings by the Company and its Subsidiaries.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(n)&#9;
<U>
	Insurance
</U>
	.
	The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and
	risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company
	and its Subsidiaries are engaged. Neither the Company nor any such Subsidiary has been refused any insurance coverage sought or
	applied for and neither the Company nor any such Subsidiary has any reason to believe that it will not be able to renew its existing
	insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to
	continue its business at a cost that would not materially and adversely affect the condition, financial or otherwise, or the earnings,
	business or operations of the Company and its Subsidiaries, taken as a whole.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(o)&#9;
<U>
	Regulatory
	Permits
</U>
	. The Company and its Subsidiaries possess all material certificates, authorizations and permits issued by the appropriate
	federal, state or foreign regulatory authorities necessary to conduct their respective businesses, and neither the Company nor
	any such Subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate,
	authorization or permit.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage99"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(p)&#9;
<U>
	Tax
	Status
</U>
	. The Company and each of its Subsidiaries has made or filed all federal and state income and all other material tax
	returns, reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent that the
	Company and each of its Subsidiaries has set aside on its books provisions reasonably adequate for the payment of all unpaid and
	unreported taxes) and has paid all taxes and other governmental assessments and charges that are material in amount, shown or
	determined to be due on such returns, reports and declarations, except those being contested in good faith and has set aside on
	its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns,
	reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any
	jurisdiction, and the officers of the Company know of no basis for any such claim.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(q)&#9;
<U>
	Transactions
	With Affiliates
</U>
	. &nbsp;Except as set forth in the SEC Documents, none of the officers or directors of the Company and, to
	the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company or
	any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement
	providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise
	requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which
	any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each
	case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for
	expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock
	option plan of the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(r)&#9;
<U>
	Application
	of Takeover Protections
</U>
	. The Company and its board of directors have taken or will take prior to the Commencement Date all
	necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including
	any distribution under a rights agreement) or other similar anti-takeover provision under the Certificate of Incorporation or
	the laws of the state of its incorporation which is or could become applicable to the Investor as a result of the transactions
	contemplated by this Agreement, including, without limitation, the Company's issuance of the Securities and the Investor's ownership
	of the Securities.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(s)&#9;&nbsp;
<U>
	Disclosure
</U>
	.&nbsp;&nbsp;Except
	with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents that will be timely
	publicly disclosed by the Company, the Company confirms that neither it nor any other Person acting on its behalf has provided
	the Investor or its agents or counsel with any information that it believes constitutes or might constitute material, non-public
	information which is not otherwise disclosed in the Registration Statement or the SEC Documents.&nbsp;&nbsp;&nbsp;The Company
	understands and confirms that the Investor will rely on the foregoing representation in effecting purchases and sales of securities
	of the Company.&nbsp;&nbsp;All of the disclosure furnished by or on behalf of the Company to the Investor regarding the Company,
	its business and the transactions contemplated hereby, including the disclosure schedules to this Agreement, is true and correct
	and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
	statements made therein, in light of the circumstances under which they were made, not misleading. The press releases disseminated
	by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement
	of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements
	therein, in light of the circumstances under which they were made and when made, not misleading.&nbsp;&nbsp;The Company acknowledges
	and agrees that the Investor neither makes nor has made any representations or warranties with respect to the transactions contemplated
	hereby other than those specifically set forth in Section 3 hereof.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage100"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(t)&#9;
<U>
	Foreign
	Corrupt Practices
</U>
	. &nbsp;Neither the Company, nor to the knowledge of the Company, any agent or other Person acting on behalf
	of the Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful
	expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials
	or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully
	any contribution made by the Company (or made by any Person acting on its behalf of which the Company is aware) which is in violation
	of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9;(u)&#9;
<U>
	DTC
	Eligibility
</U>
	. The Company, through the Transfer Agent, currently participates in the DTC Fast Automated Securities Transfer
	(FAST) Program and the Common Stock can be transferred electronically to third parties via the DTC Fast Automated Securities Transfer
	(FAST) Program.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(v)&#9;
<U>
	Sarbanes-Oxley
</U>
	.
	The Company is in compliance with all provisions of the Sarbanes-Oxley Act of 2002, as amended, which are applicable to it as
	of the date hereof, except where the failure to be in compliance is not reasonably likely to result in a Material Adverse Effect.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(w)&#9;
<U>
	Certain
	Fees
</U>
	. Except as disclosed on
<U>
	Schedule 4(w)
</U>
	, no brokerage or finder&rsquo;s fees or commissions are or will be payable
	by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person
	with respect to the transactions contemplated by the Transaction Documents. Except as disclosed on
<U>
	Schedule 4(w)
</U>
	, the Investor
	shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees
	of a type contemplated in this
<U>
	Section 4(w)
</U>
	that may be due in connection with the transactions contemplated by the Transaction
	Documents.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(x)&#9;
<U>
	Investment
	Company
</U>
	. The Company is not, and immediately after receipt of payment for the Securities will not be, an &ldquo;investment
	company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(y)&#9;
<U>
	Listing
	and Maintenance Requirements
</U>
	. The Common Stock is registered pursuant to Section&nbsp;12(g) of the Exchange Act, and the Company
	has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the
	Common Stock pursuant to the Exchange Act nor has the Company received any notification that the SEC is currently contemplating
	terminating such registration. The Company has not, in the twelve (12) months preceding the date hereof, received any notice from
	any Person to the effect that the Company is not in compliance with the listing or maintenance requirements of the Principal Market.
	The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all
	such listing and maintenance requirements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(z)&#9;
<U>
	Accountants
</U>
	.
	The Company&rsquo;s accountants are set forth in the SEC Documents and, to the knowledge of the Company, such accountants are
	an independent registered public accounting firm as required by the Securities Act.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(aa)&#9;
<U>
	No
	Market Manipulation
</U>
	.&nbsp;The Company has not, and to its knowledge no Person acting on its behalf has, (i)&nbsp;taken, directly
	or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of
	the Company to facilitate the sale or resale of any of the Securities, (ii)&nbsp;sold, bid for, purchased, or, paid any compensation
	for soliciting purchases of, any of the Securities, or (iii)&nbsp;paid or agreed to pay to any Person any compensation for soliciting
	another to purchase any other securities of the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(bb)&#9;
<U>
	Shell
	Company Status
</U>
	. The Company is not currently, and has never been, an issuer identified in Rule 144(i)(1) under the Securities
	Act.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage101"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(cc)&#9;
<U>
	No
	Disqualification Events
</U>
	. None of the Company, any of its predecessors, any affiliated issuer, any director, executive officer,
	other officer of the Company participating in the offering contemplated hereby, any beneficial owner of 20% or more of the Company's
	outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule
	405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an &ldquo;
<U>
	Issuer Covered
	Person
</U>
	&rdquo;) is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications described in Rule 506(d)(1)(i) to (viii)
	under the Securities Act (a &ldquo;
<U>
	Disqualification Event
</U>
	&rdquo;), except for a Disqualification Event covered by Rule
	506(d)(2) or (d)(3) under the Securities Act. The Company has exercised reasonable care to determine whether any Issuer Covered
	Person is subject to a Disqualification Event.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	5.&#9;COVENANTS.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)&#9;
<U>
	Filing
	of Current Report and Registration Statement
</U>
	. The Company agrees that it shall, within the time required under the Exchange
	Act, file with the SEC a report on Form 8-K relating to the transactions contemplated by, and describing the material terms and
	conditions of, the Transaction Documents (the &ldquo;
<U>
	Current Report
</U>
	&rdquo;). The Company shall also file with the SEC,
	within thirty (30) calendar days from the date hereof, a new registration statement (the &ldquo;
<U>
	Registration Statement
</U>
	&rdquo;)
	covering only the resale of the Purchase Shares and the Commitment Shares in accordance with the terms of the Registration Rights
	Agreement between the Company and the Investor, dated as of the date hereof (the &ldquo;
<U>
	Registration Rights Agreement
</U>
	&rdquo;).
	The Company shall permit the Investor to review and comment upon the final pre-filing draft version of the Current Report at least
	two (2) Business Days prior to its filing with the SEC, and the Company shall give due consideration to all such comments. The
	Investor shall use its reasonable best efforts to comment upon the final pre-filing draft version of the Current Report within
	one (1) Business Day from the date the Investor receives it from the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(b)&#9;
<U>
	Blue
	Sky
</U>
	. The Company shall take all such action, if any, as is reasonably necessary in order to obtain an exemption for or to
	register or qualify (i) the issuance of the Commitment Shares and the sale of the Purchase Shares to the Investor under this Agreement
	and (ii) any subsequent resale of all Commitment Shares and all Purchase Shares by the Investor, in each case, under applicable
	securities or &ldquo;Blue Sky&rdquo; laws of the states of the United States in such states as is reasonably requested by the
	Investor from time to time, and shall provide evidence of any such action so taken to the Investor.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(c)&#9;
<U>
	Listing/DTC
</U>
	.
	The Company shall promptly secure the listing of all of the Purchase Shares and Commitment Shares to be issued to the Investor
	hereunder on the Principal Market (subject to official notice of issuance) and upon each other national securities exchange or
	automated quotation system, if any, upon which the Common Stock is then listed, and shall use reasonable best efforts to maintain,
	so long as any shares of Common Stock shall be so listed, such listing of all such Securities from time to time issuable hereunder.
	The Company shall use reasonable best efforts to maintain the listing of the Common Stock on the Principal Market and shall comply
	in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules and regulations of
	the Principal Market. Neither the Company nor any of its Subsidiaries shall take any action that would reasonably be expected
	to result in the delisting or suspension of the Common Stock on the Principal Market. The Company shall promptly, and in no event
	later than the following Business Day, provide to the Investor copies of any notices it receives from the Principal Market regarding
	the continued eligibility of the Common Stock for listing on the Principal Market; provided, however, that the Company shall not
	be required to provide the Investor copies of any such notice that the Company reasonably believes constitutes material non-public
	information and the Company would not be required to publicly disclose such notice in any report or statement filed with the SEC
	under the Exchange Act (including on Form 8-K) or the Securities Act. The Company shall pay all fees and expenses in connection
	with satisfying its obligations under this
<U>
	Section 5(c)
</U>
	. The Company shall take all action necessary to ensure that its
	Common Stock can be transferred electronically as DWAC Shares.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage102"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(d)&#9;
<U>
	Prohibition
	of Short Sales and Hedging Transactions
</U>
	. The Investor agrees that beginning on the date of this Agreement and ending on the
	date of termination of this Agreement as provided in Section 11, the Investor and its agents, representatives and affiliates shall
	not in any manner whatsoever enter into or effect, directly or indirectly, any (i) &ldquo;short sale&rdquo; (as such term is defined
	in Rule 200 of Regulation SHO of the Exchange Act) of the Common Stock or (ii) hedging transaction, which establishes a net short
	position with respect to the Common Stock.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(e)&#9;
<U>
	Issuance
	of Commitment Shares
</U>
	. In consideration for the Investor&rsquo;s execution and delivery of this Agreement, the Company shall
	cause to be issued to the Investor a total of 100,000 shares of Common Stock (the &ldquo;
<U>
	Initial Commitment Shares
</U>
	&rdquo;)
	immediately upon the execution of this Agreement and shall deliver to the Transfer Agent the Irrevocable Transfer Agent Instructions
	with respect to the issuance of such Initial Commitment Shares. The Company shall cause to be issued to the Investor up to 500,000
	shares of Common Stock (the &ldquo;
<U>
	Additional Commitment Shares
</U>
	&rdquo; and, collectively with the Initial Commitment Shares,
	the &ldquo;
<U>
	Commitment Shares
</U>
	&rdquo;), as follows: in connection with each purchase of Purchase Shares hereunder, the Company
	shall issue to the Investor a number of shares of Common Stock equal to the product of (i) 500,000 and (y) the Purchase Amount
	Fraction. The &ldquo;
<U>
	Purchase Amount Fraction
</U>
	&rdquo; shall mean a fraction, the numerator of which is the Purchase Amount
	purchased by the Investor with respect to such purchase of Purchase Shares and the denominator of which is Twelve Million Dollars
	($12,000,000). The Additional Commitment Shares shall be equitably adjusted for any reorganization, recapitalization, non-cash
	dividend, stock split or other similar transaction. For the avoidance of doubt, (1) all of the Initial Commitment Shares shall
	be fully earned as of the date of this Agreement, whether or not the Commencement shall occur or any Purchase Shares are purchased
	by the Investor under this Agreement and irrespective of any subsequent termination of this Agreement and (2) the Additional Commitment
	Shares shall be fully earned as of the date of their issuance pursuant to this Agreement, irrespective of any subsequent termination
	of this Agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(f)&#9;
<U>
	Due
	Diligence; Non-Public Information
</U>
	. The Investor shall have the right, from time to time as the Investor may reasonably deem
	appropriate, to perform reasonable due diligence on the Company during normal business hours. The Company and its officers and
	employees shall provide information and reasonably cooperate with the Investor in connection with any reasonable request by the
	Investor related to the Investor's due diligence of the Company. Each party hereto agrees not to disclose any Confidential Information
	of the other party to any third party and shall not use the Confidential Information for any purpose other than in connection
	with, or in furtherance of, the transactions contemplated hereby. Each party hereto acknowledges that the Confidential Information
	shall remain the property of the disclosing party and agrees that it shall take all reasonable measures to protect the secrecy
	of any Confidential Information disclosed by the other party. The Company confirms that neither it nor any other Person acting
	on its behalf shall provide the Investor or its agents or counsel with any information that constitutes or might constitute material,
	non-public information, unless a simultaneous public announcement thereof is made by the Company in the manner contemplated by
	Regulation FD. In the event of a breach of the foregoing covenant by the Company or any Person acting on its behalf (as determined
	in the reasonable good faith judgment of the Investor), in addition to any other remedy provided herein or in the other Transaction
	Documents, the Investor shall have the right to make a public disclosure, in the form of a press release, public advertisement
	or otherwise, of such material, non-public information without the prior approval by the Company; provided the Investor shall
	have first provided notice to the Company that it believes it has received information that constitutes material, non-public information,
	the Company shall have at least 24 hours to respond to such notice, and thereafter the Investor shall have provided a draft final
	version of such press release, public advertisement or otherwise at least 24 hours prior to the Investor&rsquo;s intended public
	disclosure, and the Investor shall have incorporated any reasonable comments made by the Company on such draft press release,
	and the Company shall have failed to publicly disclose such material, non-public information prior to such disclosure by the Investor.
	The Investor shall not have any liability to the Company, any of its Subsidiaries, or any of their respective directors, officers,
	employees, stockholders or agents, for any such disclosure. The Company understands and confirms that the Investor shall be relying
	on the foregoing covenants in effecting transactions in securities of the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage103"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(g)
	&#9;
<U>
	Purchase Records
</U>
	. The Investor and the Company shall each maintain records showing the remaining Available Amount at
	any given time and the dates and Purchase Amounts for each Regular Purchase and Accelerated Purchase or shall use such other method,
	reasonably satisfactory to the Investor and the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(h)
	&#9;
<U>
	Taxes.
</U>
	The Company shall pay any and all transfer, stamp or similar taxes that may be payable with respect to the
	issuance and delivery of any shares of Common Stock to the Investor made under this Agreement.
<B>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(i)&#9;
<U>
	Use
	of Proceeds
</U>
	. The Company will use the net proceeds from the offering as described in the Registration Statement or the SEC
	Documents.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(j)&#9;
<U>
	Other
	Transactions
</U>
	. The Company shall not enter into, announce or recommend to its stockholders any agreement, plan, arrangement
	or transaction in or of which the terms thereof would restrict, materially delay, conflict with or impair the ability or right
	of the Company to perform its obligations under the Transaction Documents, including, without limitation, the obligation of the
	Company to deliver the Purchase Shares and the Commitment Shares to the Investor in accordance with the terms of the Transaction
	Documents.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(k)&#9;
<U>
	Integration
</U>
	.
	From and after the date of this Agreement, neither the Company, nor or any of its affiliates will, and the Company shall use its
	reasonable best efforts to ensure that no Person acting on their behalf will, directly or indirectly, make any offers or sales
	of any security or solicit any offers to buy any security, under circumstances that would require registration of the offer and
	sale of any of the Securities under the Securities Act.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage104"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(l)&#9;
<U>
	Limitation
	on Variable Rate Transactions and Continuous Offerings.
</U>
	From and after the date of this Agreement until the earlier of (i)
	the six-month anniversary of the date of this Agreement (irrespective of any earlier termination of this Agreement) and (ii) a
	Change-in-Control, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the
	Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a
	Variable Rate Transaction, other than in connection with an Exempt Issuance. From and after the date of this Agreement until the
	earlier of (i) the 24-month anniversary of the date of this Agreement (irrespective of any earlier termination of this Agreement)
	and (ii) a Change-in-Control, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance
	by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) in a
	Continuous Offering, other than in connection with an Exempt Issuance. &ldquo;
<U>
	Common Stock Equivalents
</U>
	&rdquo; means any
	securities of the Company or its Subsidiaries which entitle the holder thereof to acquire at any time Common Stock, including,
	without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into
	or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. &ldquo;
<U>
	Variable Rate
	Transaction
</U>
	&rdquo; means a transaction in which the Company issues or sells any debt or equity securities that are convertible
	into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock or Common Stock Equivalents
	either (i) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading
	prices of or quotations for the Common Stock at any time after the initial issuance of such debt or equity securities, or (ii)
	with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of
	such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business
	of the Company or the market for the Common Stock (including, without limitation, any &ldquo;full ratchet&rdquo; or &ldquo;weighted
	average&rdquo; anti-dilution provisions). A &ldquo;
<U>
	Continuous Offering
</U>
	&rdquo; means a transaction in which the Company
	enters into any agreement, including, but not limited to, an &ldquo;equity line of credit&rdquo;, &ldquo;at-the-market offering&rdquo;
	or other continuous offering or similar offering of Common Stock or Common Stock Equivalents, whereby the Company may sell Common
	Stock or Common Stock Equivalents at a future determined price. &ldquo;
<U>
	Exempt Issuance
</U>
	&rdquo; means the issuance of (a)
	Common Stock or options to employees, officers, directors or vendors of the Company pursuant to any stock or option plan duly
	adopted for such purpose, by the Board of Directors or a majority of the members of a committee of directors established for such
	purpose, (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities
	exercisable or exchangeable for or convertible into Common Stock issued and outstanding on the date of this Agreement, provided
	that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease
	the exercise price, exchange price or conversion price of such securities, (c) securities issued pursuant to acquisitions or strategic
	transactions approved by the Board of Directors or a majority of the members of a committee of directors established for such
	purpose, which acquisitions or strategic transactions can have a Variable Rate Transaction component, provided that any such issuance
	shall only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company
	or an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in
	addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily
	for the purpose of raising capital or to an entity whose primary business is investing in securities; and (d) Common Stock issued
	and sold pursuant to an &ldquo;at-the-market offering&rdquo; of Common Stock through a registered broker-dealer. &ldquo;
<U>
	Change-in-Control
</U>
	&rdquo;
	means any one or more of the following: (i) the Company shall, directly or indirectly, in one or more related transactions, (1)
	consolidate or merge with or into (whether or not the Company is the surviving corporation) another Person, with the result that
	the holders of the Company&rsquo;s capital stock immediately prior to such consolidation or merger together beneficially own less
	than 50% of the outstanding voting power of the surviving or resulting corporation, or (2) sell, lease, license, assign, transfer,
	convey or otherwise dispose of all or substantially all of the properties or assets of the Company to another Person, or (3) consummate
	a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
	spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding shares
	of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated
	or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)
	or (ii) the consummation of any purchase, tender or exchange offer by any Person or &ldquo;group&rdquo; (as such term is used
	for purposes of Sections 13(d) and 14(d) of the Exchange Act), whereby such Person or group is or shall become the &ldquo;beneficial
	owner&rdquo; (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of 50% of the aggregate ordinary voting
	power represented by issued and outstanding Common Stock (not including any shares of Common Stock held by the Person or Persons
	making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender or exchange offer).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage105"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	6.&#9;TRANSFER
	AGENT INSTRUCTIONS.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
	On the date of this Agreement, the Company shall issue irrevocable instructions to the Transfer Agent substantially in the
	form attached hereto as
<B>
<U>
	Exhibit E
</U>
</B>
	to issue the Initial Commitment Shares in accordance with the terms of this
	Agreement (the &ldquo;
<U>
	Irrevocable Transfer Agent Instructions
</U>
	&rdquo;). The certificate(s) representing the Initial
	Commitment Shares, except as set forth below, shall bear the following restrictive legend (the &ldquo;
<U>
	Restrictive
	Legend
</U>
	&rdquo;):
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 36PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 36PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	THE
	SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE
	STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR
	ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
	OR APPLICABLE STATE SECURITIES LAWS, UNLESS SOLD PURSUANT TO: (1) RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (2)
	AN OPINION OF HOLDER&rsquo;S COUNSEL, IN A CUSTOMARY FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE
	SECURITIES LAWS.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
	On the earlier of (i) the Commencement Date and (ii) such time that the Investor shall request, provided all conditions of
	Rule 144 under the Securities Act are met, the Company shall, no later than one (1) Business Day following the delivery by
	the Investor to the Company or the Transfer Agent of one or more legended certificates representing the Initial Commitment
	Shares (which certificates the Investor shall promptly deliver on or prior to the first to occur of the events described in
	clauses (i) and (ii) of this sentence), as directed by the Investor, issue and deliver (or cause to be issued and delivered)
	to the Investor, as requested by the Investor, either: (A) a certificate representing such Initial Commitment Shares that is
	free from all restrictive and other legends or (B) a number of shares of Common Stock equal to the number of Initial
	Commitment Shares represented by the certificate(s) so delivered by the Investor as DWAC Shares. The Company shall take all
	actions to carry out the intent and accomplish the purposes of the immediately preceding sentence, including, without
	limitation, delivering all such legal opinions, consents, certificates, resolutions and instructions to the Transfer Agent,
	and any successor transfer agent of the Company, as may be requested from time to time by the Investor or necessary or
	desirable to carry out the intent and accomplish the purposes of the immediately preceding sentence. On the Commencement
	Date, the Company shall issue to the Transfer Agent, and any subsequent transfer agent, (i) irrevocable instructions in the
	form substantially similar to those used by the Investor in substantially similar transactions (the &ldquo;
<U>
	Commencement
	Irrevocable Transfer Agent Instructions
</U>
	&rdquo;) and (ii) the notice of effectiveness of the Registration Statement in the
	form attached as an exhibit to the Registration Rights Agreement (the &ldquo;
<U>
	Notice of Effectiveness of
	Registration Statement
</U>
	&rdquo;), in each case to issue the Initial Commitment Shares, the Additional Commitment Shares and
	the Purchase Shares in accordance with the terms of this Agreement and the Registration Rights Agreement. All Purchase Shares
	and Additional Commitment Shares to be issued from and after Commencement to or for the benefit of the Investor pursuant to
	this Agreement shall be issued only as DWAC Shares. The Company represents and warrants to the Investor that, while this
	Agreement is effective, no instruction other than the Commencement Irrevocable Transfer Agent Instructions and the Notice of
	Effectiveness of Registration Statement referred to in this
<U>
	Section 6(b)
</U>
	will be given by the Company to the Transfer
	Agent with respect to the Initial Commitment Shares, the Additional Commitment Shares or the Purchase Shares from and after
	Commencement, and the Initial Commitment Shares, the Additional Commitment Shares and the Purchase Shares covered by the
	Registration Statement shall otherwise be freely transferable on the books and records of the Company. The Company agrees
	that if the Company fails to fully comply with the provisions of this
<U>
	Section 6(b)
</U>
	within five (5) Business Days of
	the Investor providing the deliveries referred to above, the Company shall, at the Investor&rsquo;s written instruction,
	purchase such shares of Common Stock containing the Restrictive Legend from the Investor at the greater of the (i) Purchase
	Price or Accelerated Purchase Price paid for such shares of Common Stock (as applicable) and (ii) the Closing Sale Price of
	the Common Stock on the date of the Investor&rsquo;s written instruction.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage106"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	7.
	CONDITIONS TO THE COMPANY'S RIGHT TO COMMENCES SALES OF SHARES OF COMMON STOCK.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	right of the Company hereunder to commence sales of the Purchase Shares on the Commencement Date is subject to the satisfaction
	of each of the following conditions:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)&#9;The
	Investor shall have executed each of the Transaction Documents and delivered the same to the Company;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(b)&#9;The
	Registration Statement covering the resale of the Commitment Shares
<B>
</B>
	and Purchase Shares shall have been declared effective
	under the Securities Act by the SEC and no stop order with respect to the Registration Statement shall be pending or threatened
	by the SEC; and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(c)&#9;The
	representations and warranties of the Investor shall be true and correct in all material respects as of the date hereof and as
	of the Commencement Date as though made at that time.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	8.
</B>
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	CONDITIONS TO THE INVESTOR'S OBLIGATION TO PURCHASE SHARES OF COMMON STOCK.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	obligation of the Investor to buy Purchase Shares under this Agreement is subject to the satisfaction of each of the following
	conditions on or prior to the Commencement Date and, once such conditions have been initially satisfied, there shall not be any
	ongoing obligation to satisfy such conditions after the Commencement has occurred:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)&#9;The
	Company shall have executed each of the Transaction Documents and delivered the same to the Investor;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9;(b)&#9;The
	Company shall have issued or caused to be issued to the Investor (i) one or more certificates representing the Initial Commitment
	Shares free from all restrictive and other legends or (ii) a number of shares of Common Stock equal to the number of Initial Commitment
	Shares as DWAC Shares, in each case in accordance with
<U>
	Section 6(b)
</U>
	;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
	The Common Stock shall be listed or quoted on the Principal Market, trading in the Common Stock shall not have been within
	the last 365 days suspended by the SEC or the Principal Market, and all Securities to be issued by the Company to the
	Investor pursuant to this Agreement shall have been approved for listing or quotation on the Principal Market in accordance
	with the applicable rules and regulations of the Principal Market, subject only to official notice of issuance;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(d)&#9;The
	Investor shall have received the opinions of the Company's legal counsel dated as of the Commencement Date substantially in the
	form of
<B>
<U>
	Exhibit A
</U>
</B>
	attached hereto;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(e)&#9;The
	representations and warranties of the Company shall be true and correct in all material respects (except to the extent that any
	of such representations and warranties is already qualified as to materiality in Section 4 above, in which case, such representations
	and warranties shall be true and correct without further qualification) as of the date hereof and as of the Commencement Date
	as though made at that time (except for representations and warranties that speak as of a specific date, which shall be true and
	correct as of such date) and the Company shall have performed, satisfied and complied with the covenants, agreements and conditions
	required by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the Commencement
	Date. The Investor shall have received a certificate, executed by the CEO, President or CFO of the Company, dated as of the Commencement
	Date, to the foregoing effect in the form attached hereto as
<B>
<U>
	Exhibit B
</U>
</B>
	;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage107"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(f)&#9;The
	Board of Directors of the Company shall have adopted resolutions in the form attached hereto as
<B>
<U>
	Exhibit C
</U>
</B>
	which
	shall be in full force and effect without any amendment or supplement thereto as of the Commencement Date;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(g)&#9;As
	of the Commencement Date, the Company shall have reserved out of its authorized and unissued Common Stock, (i) solely for the
	purpose of effecting purchases of Purchase Shares hereunder, 5,000,000 shares of Common Stock, and (ii) solely for the purpose
	of effecting the issuance of Additional Commitment Shares hereunder, 500,000 shares of Common Stock;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(h)&#9;The
	Commencement Irrevocable Transfer Agent Instructions and the Notice of Effectiveness of Registration Statement each shall have
	been delivered to and acknowledged in writing by the Company and the Company's Transfer Agent (or any successor transfer agent);
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(i)&#9;The
	Company shall have delivered to the Investor a certificate evidencing the incorporation and good standing of the Company in the
	State of Delaware issued by the Secretary of State of the State of Delaware as of a date within ten (10) Business Days of the
	Commencement Date;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(j)&#9;The
	Company shall have delivered to the Investor a certified copy of the Certificate of Incorporation as certified by the Secretary
	of State of the State of Delaware within ten (10) Business Days of the Commencement Date;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(k)&#9;The
	Company shall have delivered to the Investor a secretary's certificate executed by the Secretary of the Company, dated as of the
	Commencement Date, in the form attached hereto as
<B>
<U>
	Exhibit D
</U>
</B>
	;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(l)&#9;The
	Registration Statement covering the resale of the Commitment Shares
<B>
</B>
	and Purchase Shares shall have been declared effective
	under the Securities Act by the SEC and no stop order with respect to the Registration Statement shall be pending or threatened
	by the SEC. The Company shall have prepared and filed with the SEC, not later than one (1) Business Day after the effective date
	of the Registration Statement, a final and complete prospectus (the preliminary form of which shall be included in the Registration
	Statement) and shall have delivered to the Investor a true and complete copy thereof. Such prospectus shall be current and available
	for the resale by the Investor of all of the Securities covered thereby. The Current Report shall have been filed with the SEC,
	as required pursuant to
<U>
	Section 5(a)
</U>
	. All reports, schedules, registrations, forms, statements, information and other documents
	required to have been filed by the Company with the SEC at or prior to the Commencement Date pursuant to the reporting requirements
	of the Exchange Act shall have been filed with the SEC within the applicable time periods prescribed for such filings under the
	Exchange Act;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(m)&#9;No
	Event of Default has occurred, or any event which, after notice and/or lapse of time, would become an Event of Default has occurred;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(n)&#9;All
	federal, state and local governmental laws, rules and regulations applicable to the transactions contemplated by the Transaction
	Documents and necessary for the execution, delivery and performance of the Transaction Documents and the consummation of the transactions
	contemplated thereby in accordance with the terms thereof shall have been complied with, and all consents, authorizations and
	orders of, and all filings and registrations with, all federal, state and local courts or governmental agencies and all federal,
	state and local regulatory or self-regulatory agencies necessary for the execution, delivery and performance of the Transaction
	Documents and the consummation of the transactions contemplated thereby in accordance with the terms thereof shall have been obtained
	or made, including, without limitation, in each case those required under the Securities Act, the Exchange Act, applicable state
	securities or &ldquo;Blue Sky&rdquo; laws or applicable rules and regulations of the Principal Market, or otherwise required by
	the SEC, the Principal Market or any state securities regulators;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage108"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(o)&#9;No
	statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed
	by any federal, state, local or foreign court or governmental authority of competent jurisdiction which prohibits the consummation
	of or which would materially modify or delay any of the transactions contemplated by the Transaction Documents; and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(p)&#9;No
	action, suit or proceeding before any federal, state, local or foreign arbitrator or any court or governmental authority of competent
	jurisdiction shall have been commenced or threatened, and no inquiry or investigation by any federal, state, local or foreign
	governmental authority of competent jurisdiction shall have been commenced or threatened, against the Company, or any of the officers,
	directors or affiliates of the Company, seeking to restrain, prevent or change the transactions contemplated by the Transaction
	Documents, or seeking material damages in connection with such transactions.
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	9.
</B>
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	INDEMNIFICATION.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	consideration of the Investor's execution and delivery of the Transaction Documents and acquiring the Securities hereunder and
	in addition to all of the Company's other obligations under the Transaction Documents, the Company shall defend, protect, indemnify
	and hold harmless the Investor and all of its affiliates, stockholders, officers, directors, employees and direct or indirect
	investors and any of the foregoing Person's agents or other representatives (including, without limitation, those retained in
	connection with the transactions contemplated by this Agreement) (collectively, the &quot;
<U>
	Indemnitees
</U>
	&quot;) from and against
	any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in
	connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification hereunder
	is sought), and including reasonable attorneys' fees and disbursements (the &quot;
<U>
	Indemnified Liabilities
</U>
	&quot;), incurred
	by any Indemnitee as a result of, or arising out of, or relating to (a) any misrepresentation or breach of any representation
	or warranty made by the Company in the Transaction Documents or any other certificate, instrument or document contemplated hereby
	or thereby, (b) any breach of any covenant, agreement or obligation of the Company contained in the Transaction Documents or any
	other certificate, instrument or document contemplated hereby or thereby, or (c) any cause of action, suit or claim brought or
	made against such Indemnitee and arising out of or resulting from the execution, delivery, performance or enforcement of the Transaction
	Documents or any other certificate, instrument or document contemplated hereby or thereby, other than, in the case of clause (c),
	with respect to Indemnified Liabilities which directly and primarily result from the fraud, gross negligence or willful misconduct
	of an Indemnitee. The indemnity in this Section 9 shall not apply to amounts paid in settlement of any claim if such settlement
	is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or
	delayed. To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make
	the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable
	law. Payment under this indemnification shall be made within thirty (30) days from the date Investor makes written request for
	it. A certificate containing reasonable detail as to the amount of such indemnification submitted to the Company by Investor shall
	be conclusive evidence, absent manifest error, of the amount due from the Company to Investor. If any action shall be brought
	against any Indemnitee in respect of which indemnity may be sought pursuant to this Agreement, such Indemnitee shall promptly
	notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing
	reasonably acceptable to the Indemnitee. Any Indemnitee shall have the right to employ separate counsel in any such action and
	participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnitee, except
	to the extent that (i)&nbsp;the employment thereof has been specifically authorized by the Company in writing, (ii)&nbsp;the Company
	has failed after a reasonable period of time to assume such defense and to employ counsel or (iii)&nbsp;in such action there is,
	in the reasonable opinion of such separate counsel, a material conflict on any material issue between the position of the Company
	and the position of such Indemnitee, in which case the Company shall be responsible for the reasonable fees and expenses of no
	more than one such separate counsel.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage109"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	10.&#9;EVENTS
	OF DEFAULT.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	An
	&quot;
<U>
	Event of Default
</U>
	&quot; shall be deemed to have occurred at any time as any of the following events occurs:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)&#9;the
	effectiveness of a registration statement registering the resale of the Securities lapses for any reason (including, without limitation,
	the issuance of a stop order or similar order) or such registration statement (or the prospectus forming a part thereof) is unavailable
	to the Investor for resale of any or all of the Securities to be issued to the Investor under the Transaction Documents, and such
	lapse or unavailability continues for a period of ten (10) consecutive Business Days or for more than an aggregate of thirty (30)
	Business Days in any 365-day period, but excluding a lapse or unavailability where (i) the Company terminates a registration statement
	after the Investor has confirmed in writing that all of the Securities covered thereby have been resold or (ii) the Company supersedes
	one registration statement with another registration statement, including (without limitation) by terminating a prior registration
	statement when it is effectively replaced with a new registration statement covering Securities (provided in the case of this
	clause (ii) that all of the Securities covered by the superseded (or terminated) registration statement that have not theretofore
	been resold are included in the superseding (or new) registration statement);
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(b)&#9;the
	suspension of the Common Stock from trading on the Principal Market for a period of one (1) Business Day, provided that the Company
	may not direct the Investor to purchase any shares of Common Stock during any such suspension;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(c)&#9;the
	delisting of the Common Stock from the OTCQB operated by the OTC Markets Group, Inc., provided, however, that the Common Stock
	is not immediately thereafter trading on the New York Stock Exchange, the NYSE MKT, the NYSE Arca, The NASDAQ Capital Market,
	The NASDAQ Global Market, The NASDAQ Global Select Market, the OTC Bulletin Board or the OTCQX operated by the OTC Markets Group,
	Inc. (or nationally recognized successor to any of the foregoing);
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(d)&#9;the
	failure for any reason by the Transfer Agent to issue (i) the Additional Commitment Shares to the Investor within five (5) Business
	Days after the date on which the Investor is entitled to receive such Additional Commitment Shares pursuant to
<U>
	Section 5(e)
</U>
	hereof and (ii) Purchase Shares to the Investor within five (5) Business Days after the applicable Purchase Date or Accelerated
	Purchase Date (as applicable) on which the Investor is entitled to receive such Purchase Shares;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(e)&#9;the
	Company breaches any representation, warranty, covenant or other term or condition under any Transaction Document if such breach
	could have a Material Adverse Effect and except, in the case of a breach of a covenant which is reasonably curable, only if such
	breach continues for a period of at least five (5) Business Days;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(f)&#9;if
	any Person commences a proceeding against the Company pursuant to or within the meaning of any Bankruptcy Law;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage110"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(g)&#9;if
	the Company, pursuant to or within the meaning of any Bankruptcy Law, (i) commences a voluntary case, (ii) consents to the entry
	of an order for relief against it in an involuntary case, (iii) consents to the appointment of a Custodian of it or for all or
	substantially all of its property, or (iv) makes a general assignment for the benefit of its creditors or is generally unable
	to pay its debts as the same become due;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(h)&#9;a
	court of competent jurisdiction enters an order or decree under any Bankruptcy Law that (i) is for relief against the Company
	in an involuntary case, (ii) appoints a Custodian of the Company or for all or substantially all of its property, or (iii) orders
	the liquidation of the Company or any Subsidiary; or
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(i)&#9;if
	at any time the Company is not eligible to transfer its Common Stock electronically as DWAC Shares.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	addition to any other rights and remedies under applicable law and this Agreement, so long as an Event of Default has occurred
	and is continuing, or if any event which, after notice and/or lapse of time, would become an Event of Default, has occurred and
	is continuing, the Company shall not deliver to the Investor any Regular Purchase Notice or Accelerated Purchase Notice.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	11.&#9;TERMINATION
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	This
	Agreement may be terminated only as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)&#9;If
	pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding
	against the Company, which is not discharged within 90 days, a Custodian is appointed for the Company or for all or substantially
	all of its property, or the Company makes a general assignment for the benefit of its creditors (any of which would be an Event
	of Default as described in
<U>
	Sections 10(f)
</U>
	,
<U>
	10(g)
</U>
	and
<U>
	10(h)
</U>
	hereof), this Agreement shall automatically terminate
	without any liability or payment to the Company (except as set forth below) without further action or notice by any Person.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(b)&#9;In
	the event that the Commencement shall not have occurred on or before July 15, 2016, due to the failure to satisfy the conditions
	set forth in
<U>
	Sections 7
</U>
	and
<U>
	8
</U>
	above with respect to the Commencement, this Agreement may be terminated by either
	party at the close of business on such date or thereafter without liability of such party to the other party (except as set forth
	below); provided, however, that the right to terminate this Agreement under this
<U>
	Section 11(b)
</U>
	shall not be available to
	any party if such party is then in breach of any covenant or agreement contained in this Agreement or any representation or warranty
	of such party contained in this Agreement fails to be true and correct such that the conditions set forth in
<U>
	Section 7(c)
</U>
	or
<U>
	Section 8(e)
</U>
	, as applicable, could not then be satisfied.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(c)&#9;
	At any time after the Commencement Date, the Company shall have the option to terminate this Agreement for any reason or for no
	reason by delivering notice (a &ldquo;
<U>
	Company Termination Notice
</U>
	&rdquo;) to the Investor electing to terminate this Agreement
	without any liability whatsoever of any party to any other party under this Agreement (except as set forth below). The Company
	Termination Notice shall not be effective until one (1) Business Day after it has been received by the Investor.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(d)&#9;This
	Agreement shall automatically terminate on the date that the Company sells and the Investor purchases the full Available Amount
	as provided herein, without any action or notice on the part of any party and without any liability whatsoever of any party to
	any other party under this Agreement (except as set forth below).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(e)&#9;If,
	for any reason or for no reason, the full Available Amount has not been purchased in accordance with
<U>
	Section&nbsp;2
</U>
	of
	this Agreement by the Maturity Date, this Agreement shall automatically terminate on the Maturity Date, without any action or
	notice on the part of any party and without any liability whatsoever of any party to any other party under this Agreement (except
	as set forth below).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage111"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Except
	as set forth in
<U>
	Sections 11(a)
</U>
	(in respect of an Event of Default under
<U>
	Sections 10(f)
</U>
	,
<U>
	10(g)
</U>
	and 10(h)),
<U>
	11(d)
</U>
	and
<U>
	11(e)
</U>
	, any termination of this Agreement pursuant to this
<U>
	Section 11
</U>
	shall be effected by written
	notice from the Company to the Investor, or the Investor to the Company, as the case may be, setting forth the basis for the termination
	hereof. The representations and warranties and covenants of the Company and the Investor contained in
<U>
	Sections 3
</U>
	,
<U>
	4
</U>
	,
<U>
	5
</U>
	, and
<U>
	6
</U>
	hereof, the indemnification provisions set forth in
<U>
	Section 9
</U>
	hereof and the agreements and covenants
	set forth in
<U>
	Sections
<B>
</B>
	10
</U>
	,
<U>
	11
</U>
	and
<U>
	12
</U>
	shall survive the Commencement and any termination of this Agreement.
	No termination of this Agreement shall (i) affect the Company&rsquo;s or the Investor&rsquo;s rights or obligations under (A)
	this Agreement with respect to pending Regular Purchases and Accelerated Purchases and the Company and the Investor shall complete
	their respective obligations with respect to any pending Regular Purchases and Accelerated Purchases under this Agreement and
	(B) the Registration Rights Agreement, which shall survive any such termination, or (ii) be deemed to release the Company or the
	Investor from any liability for intentional misrepresentation or willful breach of any of the Transaction Documents.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	12.&#9;MISCELLANEOUS.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)&#9;
<U>
	Governing
	Law; Jurisdiction; Jury Trial
</U>
	. The corporate laws of the State of Delaware shall govern all issues concerning the relative
	rights of the Company and its stockholders. All other questions concerning the construction, validity, enforcement and interpretation
	of this Agreement and the other Transaction Documents shall be governed by the internal laws of the State of Illinois, without
	giving effect to any choice of law or conflict of law provision or rule (whether of the State of Illinois or any other jurisdictions)
	that would cause the application of the laws of any jurisdictions other than the State of Illinois. Each party hereby irrevocably
	submits to the exclusive jurisdiction of the state and federal courts sitting in the State of Illinois, County of Cook, for the
	adjudication of any dispute hereunder or under the other Transaction Documents or in connection herewith or therewith, or with
	any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit,
	action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action
	or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party
	hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
	by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service
	shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit
	in any way any right to serve process in any manner permitted by law.
<B>
	EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY
	HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING
	OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(b)&#9;
<U>
	Counterparts
</U>
	.
	This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
	and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a
	facsimile signature or signature delivered by e-mail in a &ldquo;.pdf&rdquo; format data file shall be considered due execution
	and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(c)&#9;
<U>
	Headings
</U>
	.
	The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this
	Agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage112"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(d)&#9;
<U>
	Severability
</U>
	.
	If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability
	shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability
	of any provision of this Agreement in any other jurisdiction.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(e)&#9;
<U>
	Entire
	Agreement
</U>
	. The Transaction Documents supersede all other prior oral or written agreements between the Investor, the Company,
	their affiliates and Persons acting on their behalf with respect to the subject matter thereof, and this Agreement, the other
	Transaction Documents and the instruments referenced herein contain the entire understanding of the parties with respect to the
	matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Investor
	makes any representation, warranty, covenant or undertaking with respect to such matters. The Company acknowledges and agrees
	that is has not relied on, in any manner whatsoever, any representations or statements, written or oral, other than as expressly
	set forth in the Transaction Documents.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(f)&#9;
<U>
	Notices
</U>
	.
	Any notices, consents or other communications required or permitted to be given under the terms of this Agreement must be in writing
	and will be deemed to have been delivered: (i) upon receipt when delivered personally; (ii) upon receipt when sent by facsimile
	or email (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party);
	or (iii) one Business Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed
	to the party to receive the same. The addresses for such communications shall be:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	If
	to the Company:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Soligenix,
	Inc.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	29
	Emmons Drive, Suite C-10
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Princeton,
	New Jersey 08540
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Telephone:&#9;609-538-8200
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Facsimile:&#9;609-452-6467
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	E-mail:&#9;cschaber@soligenix.com
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Attention:
	&#9;Christopher J. Schaber, Ph.D., CEO
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	With
	a copy to (which shall not constitute notice or service of process):
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Duane
	Morris LLP
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	200
	South Biscayne Boulevard, Suite 3400
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Miami,
	Florida 33131-2318
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Telephone:&#9;305-960-2200
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Facsimile:&#9;305-397-1882
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	E-mail:&#9;ljcroland@duanemorris.com
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Attention:&#9;Leslie
	J. Croland, Esq.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	If
	to the Investor:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Lincoln
	Park Capital Fund, LLC
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	440
	North Wells, Suite 410
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chicago,
	IL 60654
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Telephone:&#9;312-822-9300
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Facsimile:&#9;312-822-9301
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	E-mail:&#9;jscheinfeld@lpcfunds.com/jcope@lpcfunds.com
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Attention:&#9;Josh
	Scheinfeld/Jonathan Cope
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage113"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	With
	a copy to (which shall not constitute notice or service of process):
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Greenberg
	Traurig, LLP
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	MetLife Building
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	200
	Park Avenue
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	New
	York, NY 10166
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Telephone:&#9;(212)
	801-9200
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Facsimile:
	&#9;(212) 801-6400
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	E-mail:
	marsicoa@gtlaw.com
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Attention:&#9;Anthony
	J. Marsico, Esq.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	If
	to the Transfer Agent:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	American
	Stock Transfer &amp; Trust Co.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6201
	15
<SUP>
	th
</SUP>
	Avenue, 2
<SUP>
	nd
</SUP>
	Floor
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Brooklyn,
	NY 11219
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Telephone:&#9;718-921-8360
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Facsimile:&#9;718-921-8323
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Attention:
	&#9;Angelia Brown
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	or
	at such other address and/or facsimile number and/or to the attention of such other Person as the recipient party has specified
	by written notice given to each other party three (3) Business Days prior to the effectiveness of such change. Written confirmation
	of receipt (A) given by the recipient of such notice, consent or other communication, (B) mechanically or electronically generated
	by the sender's facsimile machine or email account containing the time, date, and recipient facsimile number or email address,
	as applicable, and an image of the first page of such transmission or (C) provided by a nationally recognized overnight delivery
	service, shall be rebuttable evidence of personal service, receipt by facsimile or receipt from a nationally recognized overnight
	delivery service in accordance with clause (i), (ii) or (iii) above, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(g)&#9;
<U>
	Successors
	and Assigns
</U>
	. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors
	and assigns. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent
	of the Investor, including by merger or consolidation. The Investor may not assign its rights or obligations under this Agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(h)&#9;
<U>
	No
	Third Party Beneficiaries
</U>
	. This Agreement is intended for the benefit of the parties hereto and their respective permitted
	successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(i)&#9;
<U>
	Publicity
</U>
	.
	The Company shall afford the Investor and its counsel with the opportunity to review and comment upon, shall consult with the
	Investor and its counsel on the form and substance of, and shall give due consideration to all such comments from the Investor
	or its counsel on, any press release, SEC filing or any other public disclosure by or on behalf of the Company relating to the
	Investor, its purchases hereunder or any aspect of the Transaction Documents or the transactions contemplated thereby, not less
	than 24 hours prior to the issuance, filing or public disclosure thereof. The Investor must be provided with a final version of
	any such press release, SEC filing or other public disclosure at least 24 hours prior to any release, filing or use by the Company
	thereof. The Company agrees and acknowledges that its failure to fully comply with this provision constitutes a Material Adverse
	Effect.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(j)&#9;
<U>
	Further
	Assurances
</U>
	. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
	execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
	in order to consummate and make effective, as soon as reasonably possible, the Commencement, and to carry out the intent and accomplish
	the purposes of this Agreement and the consummation of the transactions contemplated hereby.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 27; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage114"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(k)&#9;
<U>
	No
	Financial Advisor, Placement Agent, Broker or Finder
</U>
	. The Company represents and warrants to the Investor that, except as
	disclosed in
<U>
	Schedule 4(w)
</U>
	, it has not engaged any financial advisor, placement agent, broker or finder in connection with
	the transactions contemplated hereby. The Investor represents and warrants to the Company that it has not engaged any financial
	advisor, placement agent, broker or finder in connection with the transactions contemplated hereby. The Company shall be responsible
	for the payment of any fees or commissions, if any, of any financial advisor, placement agent, broker or finder relating to or
	arising out of the transactions contemplated hereby. The Company shall pay, and hold the Investor harmless against, any liability,
	loss or expense (including, without limitation, attorneys' fees and out of pocket expenses) arising in connection with any such
	claim.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(l)&#9;
<U>
	No
	Strict Construction
</U>
	. The language used in this Agreement will be deemed to be the language chosen by the parties to express
	their mutual intent, and no rules of strict construction will be applied against any party.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(m)&#9;
<U>
	Remedies,
	Other Obligations, Breaches and Injunctive Relief
</U>
	. The Investor&rsquo;s remedies provided in this Agreement, including, without
	limitation, the Investor&rsquo;s remedies provided in Section 9, shall be cumulative and in addition to all other remedies available
	to the Investor under this Agreement, at law or in equity (including a decree of specific performance and/or other injunctive
	relief), no remedy of the Investor contained herein shall be deemed a waiver of compliance with the provisions giving rise to
	such remedy and nothing herein shall limit the Investor's right to pursue actual damages for any failure by the Company to comply
	with the terms of this Agreement. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable
	harm to the Investor and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the
	event of any such breach or threatened breach, the Investor shall be entitled, in addition to all other available remedies, to
	an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being
	required.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(n)&#9;
<U>
	Enforcement
	Costs
</U>
	. If: (i) this Agreement is placed by the Investor in the hands of an attorney for enforcement or is enforced by the
	Investor through any legal proceeding; (ii) an attorney is retained to represent the Investor in any bankruptcy, reorganization,
	receivership or other proceedings affecting creditors' rights and involving a claim under this Agreement; or (iii) an attorney
	is retained to represent the Investor in any other proceedings whatsoever in connection with this Agreement, then the Company
	shall pay to the Investor, as incurred by the Investor, all reasonable costs and expenses including attorneys' fees incurred in
	connection therewith, in addition to all other amounts due hereunder. If this Agreement is placed by the Company in the hands
	of an attorney for enforcement or is enforced by the Company through any legal proceeding, then the Investor shall pay to the
	Company, as incurred by the Company, all reasonable costs and expenses including attorneys' fees incurred in connection therewith,
	in addition to all other amounts due hereunder.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(o)&#9;
<U>
	Amendment
	and Waiver; Failure or Indulgence Not Waiver
</U>
	. No provision of this Agreement may be amended or waived by the parties from
	and after the date that is one (1) Business Day immediately preceding the filing of the initial Registration Statement with the
	SEC. Subject to the immediately preceding sentence, (i) no provision of this Agreement may be amended other than by a written
	instrument signed by both parties hereto and (ii) no provision of this Agreement may be waived other than in a written instrument
	signed by the party against whom enforcement of such waiver is sought. No failure or delay in the exercise of any power, right
	or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or
	privilege preclude other or further exercise thereof or of any other right, power or privilege.&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	*
	* * * *
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 28; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage115"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	IN
	WITNESS WHEREOF,
</B>
	the Investor and the Company have caused this Purchase Agreement to be duly executed as of the date first
	written above.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
<B>
<U>
	THE COMPANY:
</U>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 60%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%">
	&nbsp;
</TD>
<TD STYLE="PADDING: 0PT; FONT-SIZE: 10PT; TEXT-INDENT: 0PT; WIDTH: 36%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
<B>
	SOLIGENIX, INC.
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING: 0PT; FONT-SIZE: 10PT; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	By:
</TD>
<TD STYLE="PADDING-TOP: 0PT; PADDING-RIGHT: 0PT; BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING-LEFT: 0PT; FONT-SIZE: 10PT; TEXT-INDENT: 0PT">
	/s/ Christopher J. Schaber
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Name:
</TD>
<TD STYLE="PADDING: 0PT; FONT-SIZE: 10PT; TEXT-INDENT: 0PT">
	Christopher J. Schaber, Ph.D.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Title:
</TD>
<TD STYLE="PADDING: 0PT; FONT-SIZE: 10PT; TEXT-INDENT: 0PT">
	President and Chief Executive Officer
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING: 0PT; FONT-SIZE: 10PT; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
<B>
<U>
	INVESTOR:
</U>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING: 0PT; FONT-SIZE: 10PT; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2">
<B>
	LINCOLN PARK CAPITAL FUND, LLC
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<B>
	&nbsp;
</B>
</TD>
<TD>
<B>
	BY:
</B>
</TD>
<TD STYLE="PADDING: 0PT; FONT-SIZE: 10PT; TEXT-INDENT: 0PT">
<B>
	LINCOLN PARK CAPITAL, LLC
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<B>
	&nbsp;
</B>
</TD>
<TD>
<B>
	BY:
</B>
</TD>
<TD STYLE="PADDING: 0PT; FONT-SIZE: 10PT; TEXT-INDENT: 0PT">
<B>
	ROCKLEDGE CAPITAL CORPORATION
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="PADDING: 0PT; FONT-SIZE: 10PT; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	By:
</TD>
<TD STYLE="PADDING-TOP: 0PT; PADDING-RIGHT: 0PT; BORDER-BOTTOM: BLACK 1.5PT SOLID; PADDING-LEFT: 0PT; FONT-SIZE: 10PT; TEXT-INDENT: 0PT">
	/s/ Josh Scheinfeld
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Name:
</TD>
<TD STYLE="PADDING: 0PT; FONT-SIZE: 10PT; TEXT-INDENT: 0PT">
	Josh Scheinfeld
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	Title:
</TD>
<TD STYLE="PADDING: 0PT; FONT-SIZE: 10PT; TEXT-INDENT: 0PT">
	President
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 29; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage116"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<U>
	SCHEDULES
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Schedule
	4(a)&#9;Subsidiaries
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Schedule
	4(c)&#9;Capitalization
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Schedule
	4(w)&#9;Agent&rsquo;s Fees
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9;
<B>
<U>
	EXHIBITS
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 108PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -108PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Exhibit
	A&#9;Form of Company Counsel Opinion
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 108PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -108PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Exhibit
	B&#9;Form of Officer&rsquo;s Certificate
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 108PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -108PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Exhibit
	C&#9;Form of Resolutions of Board of Directors of the Company
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 108PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -108PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Exhibit
	D&#9;Form of Secretary&rsquo;s Certificate
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 108PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -108PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Exhibit
	E&#9;Form of Letter to Transfer Agent
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 30 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage117"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<U>
	DISCLOSURE
	SCHEDULES
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Schedule
	4(a) &ndash; Subsidiaries
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Schedule
	4(c) &ndash; Capitalization
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Schedule
	4(w) &ndash; Agent&rsquo;s Fees
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 31 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage118"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<U>
	EXHIBIT
	A
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	FORM
	OF COMPANY COUNSEL OPINION
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Capitalized
	terms used herein but not defined herein, have the meaning set forth in the Purchase Agreement. Based on the foregoing, and subject
	to the assumptions and qualifications set forth herein, we are of the opinion that:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.&#9;The
	Company is a corporation existing and in good standing under the laws of the State of Delaware. The Company is qualified to do
	business as a foreign corporation and is in good standing in the State of New Jersey.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2.&#9;The
	Company has the corporate power to execute and deliver, and perform its obligations under, each Transaction Document to which
	it is a party. The Company has the corporate power to conduct its business as, to the best of our knowledge, it is now conducted,
	and to own and use the properties owned and used by it.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3.&#9;The
	execution, delivery and performance by the Company of the Transaction Documents to which it is a party have been duly authorized
	by all necessary corporate action on the part of the Company. The execution and delivery of the Transaction Documents by the Company,
	the performance of the obligations of the Company thereunder and the consummation by it of the transactions contemplated therein
	have been duly authorized and approved by the Company's Board of Directors and no further consent, approval or authorization of
	the Company, its Board of Directors or its stockholders is required. The Transaction Documents to which the Company is a party
	have been duly executed and delivered by the Company and are the valid and binding obligations of the Company, enforceable against
	the Company in accordance with their terms except as such enforceability may be limited by general principles of equity or applicable
	bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting creditor&rsquo;s rights
	and remedies.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.&#9;The
	execution, delivery and performance by the Company of the Transaction Documents, the consummation by the Company of the transactions
	contemplated thereby including the offering, sale and issuance of the Commitment Shares and the Purchase Shares in accordance
	with the terms and conditions of the Purchase Agreement, and fulfillment and compliance with terms of the Transaction Documents,
	does not and shall not: (i)&nbsp;conflict with, constitute a breach of or default (or an event which, with the giving of notice
	or lapse of time or both, constitutes or could constitute a breach or a default), under (a) the Certificate of Incorporation or
	the Bylaws of the Company, (b) any material agreement, note, lease, mortgage, deed or other material instrument to which to our
	knowledge the Company is a party or by which the Company or any of its assets are bound (&ldquo;Material Agreements&rdquo;), (ii)&nbsp;result
	in any violation of any statute, law, rule or regulation applicable to the Company, or (iii) to our knowledge, violate any order,
	writ, injunction or decree applicable to the Company or any of its subsidiaries.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5.&#9;The
	issuance of the Purchase Shares and the Commitment Shares pursuant to the terms and conditions of the Transaction Documents has
	been duly authorized by all necessary corporate action on the part of the Company. The Initial Commitment Shares are validly issued,
	fully paid and non-assessable, and to our knowledge, free of all taxes, liens, charges, restrictions, rights of first refusal
	and preemptive rights. 500,000 shares of Common Stock have been properly reserved for issuance as Additional Commitment Shares
	under the Purchase Agreement. 5,000,000 shares of Common Stock have been properly reserved for issuance as Purchase Shares under
	the Purchase Agreement. When issued in accordance with the Purchase Agreement, the Additional Commitment Shares shall be validly
	issued, fully paid and non-assessable, to our knowledge, free of all taxes, liens, charges, restrictions, rights of first refusal
	and preemptive rights. When issued and paid for in accordance with the Purchase Agreement, the Purchase Shares shall be validly
	issued, fully paid and non-assessable, to our knowledge, free of all taxes, liens, charges, restrictions, rights of first refusal
	and preemptive rights. To our knowledge, the execution and delivery of the Registration Rights Agreement do not, and the performance
	by the Company of its obligations thereunder shall not, give rise to any rights of any other Person for the registration under
	the Securities Act of any shares of Common Stock or other securities of the Company which have not been waived.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 32 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage119"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6.&#9;As
	of the date hereof, the authorized capital stock of the Company consists of 50,000,000 shares of common stock, par value $0.001
	per share per share, of which to our knowledge 31,269,522 shares are issued and outstanding.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	7.&#9;Assuming
	the accuracy of the representations and your compliance with the covenants made by you in the Transaction Documents, the offering,
	sale and issuance of the Commitment Shares and the Purchase Shares to you pursuant to the Transaction Documents is exempt from
	registration under the Securities Act.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	8.&#9;Other
	than that which has been obtained and completed prior to the date hereof, no authorization, approval, consent, filing or other
	order of any federal or state governmental body, regulatory agency, or stock exchange or market, or any court, or, to our knowledge,
	any third party is required to be obtained by the Company to enter into and perform its obligations under the Transaction Documents
	or for the Company to issue and sell the Commitment Shares and the Purchase Shares as contemplated by the Transaction Documents.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	9.
	The Common Stock is registered pursuant to Section 12(g) of the Exchange Act. To our knowledge, since one year preceding the date
	of the Purchase Agreement, the Company has been in compliance with the reporting requirements of the Exchange Act applicable to
	it. To our knowledge, since one year preceding the date of the Purchase Agreement, the Company has not received any written notice
	from any Person stating that the Company has not been in compliance with any of the rules and regulations (including the requirements
	for continued listing) of the Principal Market.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.
	The Company is not, and after giving effect to the issuance of the Commitment Shares and the Purchase Shares and the application
	of the proceeds as described in the Prospectus, will not be, an &ldquo;investment company,&rdquo; as that term is defined in the
	Investment Company Act of 1940, as amended.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	11.
	Except as described in the Registration Statement and the Prospectus or the SEC Documents, none of the Material Agreements grants
	to any person the right to require the Company to file a registration statement under the Securities Act with respect to any securities
	of the Company owned or to be owned by such person or to require the Company to include such securities in the securities registered
	pursuant to the Registration Statement or in any securities being registered pursuant to any other registration statement filed
	by the Company under the Securities Act.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 33 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage120"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	[THE
	FOLLOWING MAY BE MADE IN A SEPARATE NEGATIVE ASSURANCES LETTER]
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	primary purpose of our professional engagement was not to establish or confirm factual matters or financial, quantitative , statistical
	or accounting information, and many determinations involved in the preparation of the Offering Document are of a non-legal character.
	In addition, we have not undertaken any obligation to verify independently the accuracy, completeness or fairness of any of the
	factual matters set forth in the Offering Document or in the documents incorporated by reference therein (the &ldquo;Incorporated
	Documents&rdquo;).
<SUP>
</SUP>
	Consequently, in this letter we are not passing upon and do not assume any responsibility for the
	accuracy, completeness or fairness of the statements contained or incorporated by reference in the Offering Document. Also, we
	do not make any statement herein with respect to any of the financial statements and related notes thereto, the financial statement
	schedules or the financial, statistical, quantitative or accounting data contained in, or incorporated by reference in or omitted
	from, the Offering Document.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	have reviewed the Offering Document (including the Incorporated Documents) and we have participated in conferences with representatives
	of the Company, its independent public accountants, you and your counsel, at which conferences the contents of the Offering Document
	and related matters were discussed. However, we did not participate in the preparation of the certain of Incorporated Documents.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Subject
	to the foregoing, we confirm to you that, on the basis of the information we gained in the course of performing the services referred
	to above (the &ldquo;Legal Services&rdquo;), no facts have come to the attention of the Primary Lawyer Group (as hereinafter defined)
	which cause us to believe that he Registration Statement, at the effective time thereof (including the Incorporated Documents),
	contained an untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary
	to make the statements contained therein not misleading or that the Prospectus (including any Incorporated Documents), as of its
	date and as of the date hereof, contained or contains any untrue statement of a material fact or omitted or omits to state any
	material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
	under which they were made, not misleading (in each case other than the financial statements and the related notes thereto, the
	financial statement schedules and the other financial, statistical, quantitative and accounting data included therein or which
	should be included therein, as to which we express no view). &ldquo;Primary Lawyer Group&rdquo; means any lawyer in this firm
	who (i) signs this letter on behalf of the firm or (ii) actively renders Legal Services. In connection with delivering this letter,
	the lawyers in the Primary Lawyer Group, with your consent, have not made any inquiry of other lawyers practicing law with this
	firm or any review of files maintained by this firm.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	statements made herein are set forth solely for your benefit and are addressed to you solely in your capacity as the initial purchaser
	of the Securities. Neither this letter nor any of such statements may be used or relied upon by, or assigned to, any other person
	(including any subsequent purchaser or transferee of the Securities), and neither this letter nor any copies hereof may be furnished
	to any other person, filed with a governmental agency, quoted, cited or otherwise referred to without our prior written consent.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	inform you that the Registration Statement became effective under the Securities Act on _______, 201__ and that no stop order
	suspending the effectiveness of the Registration Statement has been issued under the Securities Act.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	are not representing the Company in any pending litigation in which it is a named defendant that challenges the validity or enforceability
	of, or seeks to enjoin the performance of, the Transaction Documents.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Further,
	we confirm to you that the Registration Statement, as of its effective date, and the Prospectus, as of its date, appeared to us
	on their face to respond in all material respects to the requirements of Form S-1, except that the foregoing statement does not
	address any requirement relating to financial statements, notes or schedules and financial and accounting data or information
	contained in or omitted from the Registration Statement or the Prospectus Supplement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 34 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage121"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<U>
	EXHIBIT
	B
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	FORM
	OF OFFICER&rsquo;S CERTIFICATE
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 50.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	This
	Officer&rsquo;s Certificate (&ldquo;
<B>
	Certificate
</B>
	&rdquo;) is being delivered pursuant to
<U>
	Section 8(e)
</U>
	of that certain
	Purchase Agreement dated as of March 22, 2016, (&ldquo;
<B>
	Purchase Agreement
</B>
	&rdquo;), by and between
<B>
	SOLIGENIX, INC.
</B>
	,
	a Delaware corporation (the &ldquo;
<B>
	Company
</B>
	&rdquo;), and
<B>
	LINCOLN PARK CAPITAL FUND, LLC
</B>
	(the &ldquo;
<B>
	Investor
</B>
	&rdquo;).
	Terms used herein and not otherwise defined shall have the meanings ascribed to them in the Purchase Agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 50.4PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	undersigned, ___________, ______________ of the Company, hereby certifies as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 50.4PT 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.&#9;I
	am the _____________ of the Company and make the statements contained in this Certificate;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2.&#9;The
	representations and warranties of the Company are true and correct in all material respects (except to the extent that any of
	such representations and warranties is already qualified as to materiality in Section 4 of the Purchase Agreement, in which case,
	such representations and warranties are true and correct without further qualification) as of the date when made and as of the
	Commencement Date as though made at that time (except for representations and warranties that speak as of a specific date, in
	which case such representations and warranties are true and correct as of such date);
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3.&#9;The
	Company has performed, satisfied and complied in all material respects with covenants, agreements and conditions required by the
	Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the Commencement Date.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9;4.
	&#9;The Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to any Bankruptcy
	Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate
	involuntary bankruptcy or insolvency proceedings. The Company is financially solvent and is generally able to pay its debts as
	they become due.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 36PT 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	IN
	WITNESS WHEREOF, I have hereunder signed my name on this ___ day of ___________.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 350PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	______________________
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 350PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Name:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 350PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Title:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	undersigned as Secretary of
<B>
	SOLIGENIX, INC.
</B>
	, a Delaware corporation, hereby certifies that ___________ is the duly elected,
	appointed, qualified and acting ________ of _________ and that the signature appearing above is his genuine signature.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 216PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	___________________________________
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 216PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	Secretary
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 35 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage122"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	EXHIBIT C
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	FORM
	OF COMPANY RESOLUTIONS
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	FOR
	SIGNING PURCHASE AGREEMENT
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	UNANIMOUS
	WRITTEN CONSENT OF
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	SOLIGENIX,
	INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	accordance with the corporate laws of the State of Delaware, the undersigned, being all of the directors of
<B>
	SOLIGENIX, INC.
</B>
	,
	a Delaware corporation (the &ldquo;Corporation&rdquo;), do hereby consent to and adopt the following resolutions as the action
	of the Board of Directors for and on behalf of the Corporation and hereby direct that this Consent be filed with the minutes of
	the proceedings of the Board of Directors:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	WHEREAS,
	there has been presented to the Board of Directors of the Corporation a draft of the Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;)
	by and between the Corporation and Lincoln Park Capital Fund, LLC (&ldquo;Lincoln Park&rdquo;), providing for the purchase by
	Lincoln Park of up to Twelve Million Dollars ($12,000,000) of the Corporation&rsquo;s common stock, par value $0.001 per share
	per share (the &ldquo;Common Stock&rdquo;); and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	WHEREAS,
	after careful consideration of the Purchase Agreement, the documents incident thereto and other factors deemed relevant by the
	Board of Directors, the Board of Directors has determined that it is advisable and in the best interests of the Corporation to
	engage in the transactions contemplated by the Purchase Agreement, including, but not limited to, the issuance of up to 600,000
	shares of Common Stock to Lincoln Park as a commitment fee (the &ldquo;Commitment Shares&rdquo;) and the sale of shares of Common
	Stock to Lincoln Park up to the available amount under the Purchase Agreement (the &quot;Purchase Shares&quot;).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<U>
	Transaction
	Documents
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	NOW,
	THEREFORE, BE IT RESOLVED, that the transactions described in the Purchase Agreement are hereby approved and ________________________________________
	(the &ldquo;Authorized Officers&rdquo;) are severally authorized to execute and deliver the Purchase Agreement, and any other
	agreements or documents contemplated thereby including, without limitation, a registration rights agreement (the &ldquo;Registration
	Rights Agreement&rdquo;) providing for the registration of the shares of the Company&rsquo;s Common Stock issuable in respect
	of the Purchase Agreement on behalf of the Corporation, with such amendments, changes, additions and deletions as the Authorized
	Officers may deem to be appropriate and approve on behalf of, the Corporation, such approval to be conclusively evidenced by the
	signature of an Authorized Officer thereon; and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	FURTHER
	RESOLVED, that the terms and provisions of the Registration Rights Agreement by and among the Corporation and Lincoln Park are
	hereby approved and the Authorized Officers are authorized to execute and deliver the Registration Rights Agreement (pursuant
	to the terms of the Purchase Agreement), with such amendments, changes, additions and deletions as the Authorized Officer may
	deem appropriate and approve on behalf of, the Corporation, such approval to be conclusively evidenced by the signature of an
	Authorized Officer thereon; and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	FURTHER
	RESOLVED, that the terms and provisions of the forms of Commencement Irrevocable Transfer Agent Instructions and Notice of Effectiveness
	of Registration Statement (collectively, the &ldquo;Instructions&rdquo;) are hereby approved and the Authorized Officers are authorized
	to execute and deliver the Instructions on behalf of the Company in accordance with the Purchase Agreement, with such amendments,
	changes, additions and deletions as the Authorized Officers may deem appropriate and approve on behalf of, the Corporation, such
	approval to be conclusively evidenced by the signature of an Authorized Officer thereon; and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 36 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage123"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<U>
	Execution
	of Purchase Agreement
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	FURTHER
	RESOLVED, that the Corporation be and it hereby is authorized to execute the Purchase Agreement providing for the purchase of
	up to Twelve Million Dollars ($12,000,000) of the Corporation&rsquo;s common stock; and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<U>
	Issuance
	of Common Stock
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	FURTHER
	RESOLVED, that the Corporation is hereby authorized to issue to Lincoln Park Capital Fund, LLC, 100,000 shares of Common Stock
	as Initial Commitment Shares and that upon issuance of the Initial Commitment Shares pursuant to the Purchase Agreement the Initial
	Commitment Shares shall be duly authorized, validly issued, fully paid and nonassessable with no personal liability attaching
	to the ownership thereof; and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	FURTHER
	RESOLVED, that the Corporation is hereby authorized to issue 500,000 shares of Common Stock as Additional Commitment Shares under
	the Purchase Agreement in accordance with the terms of the Purchase Agreement and that, upon issuance of the Additional Commitment
	Shares pursuant to the Purchase Agreement, the Additional Commitment Shares will be duly authorized, validly issued, fully paid
	and nonassessable with no personal liability attaching to the ownership thereof; and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	FURTHER
	RESOLVED, that the Corporation shall reserve 500,000 shares of Common Stock for issuance as Additional Commitment Shares under
	the Purchase Agreement; and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	FURTHER
	RESOLVED, that the Corporation is hereby authorized to issue shares of Common Stock upon the purchase of Purchase Shares up to
	the Available Amount under the Purchase Agreement in accordance with the terms of the Purchase Agreement and that, upon issuance
	of the Purchase Shares pursuant to the Purchase Agreement, the Purchase Shares will be duly authorized, validly issued, fully
	paid and nonassessable with no personal liability attaching to the ownership thereof; and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	FURTHER
	RESOLVED, that the Corporation shall initially reserve 5,000,000 shares of Common Stock for issuance as Purchase Shares under
	the Purchase Agreement.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Approval
	of Actions
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	FURTHER
	RESOLVED, that, without limiting the foregoing, the Authorized Officers are, and each of them hereby is, authorized and directed
	to proceed on behalf of the Corporation and to take all such steps as deemed necessary or appropriate, with the advice and assistance
	of counsel, to cause the Corporation to consummate the agreements referred to herein and to perform its obligations under such
	agreements; and
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	FURTHER
	RESOLVED, that the Authorized Officers be, and each of them hereby is, authorized, empowered and directed on behalf of and in
	the name of the Corporation, to take or cause to be taken all such further actions and to execute and deliver or cause to be executed
	and delivered all such further agreements, amendments, documents, certificates, reports, schedules, applications, notices, letters
	and undertakings and to incur and pay all such fees and expenses as in their judgment shall be necessary, proper or desirable
	to carry into effect the purpose and intent of any and all of the foregoing resolutions, and that all actions heretofore taken
	by any officer or director of the Corporation in connection with the transactions contemplated by the agreements described herein
	are hereby approved, ratified and confirmed in all respects.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	IN
	WITNESS WHEREOF, the Board of Directors has executed and delivered this Consent effective as of __________, 2016.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	______________________
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	______________________
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	______________________
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	being
	all of the directors of
<B>
	SOLIGENIX, INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 37 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage124"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&#9;
<U>
	EXHIBIT
	D
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&#9;FORM
	OF SECRETARY&rsquo;S CERTIFICATE
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	This
	Secretary&rsquo;s Certificate (&ldquo;Certificate&rdquo;) is being delivered pursuant to
<U>
	Section 8(k)
</U>
	of that certain Purchase
	Agreement dated as of March 22, 2016 (&ldquo;Purchase Agreement&rdquo;), by and between
<B>
	SOLIGENIX, INC.
</B>
	, a Delaware corporation
	(the &ldquo;Company&rdquo;), and
<B>
	LINCOLN PARK CAPITAL FUND, LLC
</B>
	(the &ldquo;Investor&rdquo;), pursuant to which the Company
	may sell to the Investor up to Twelve Million Dollars ($12,000,000) of the Company's Common Stock, par value $0.001 per share
	per share (the &quot;Common Stock&quot;). Terms used herein and not otherwise defined shall have the meanings ascribed to them
	in the Purchase Agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	undersigned, ____________, Secretary of the Company, hereby certifies as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.&#9;I
	am the Secretary of the Company and make the statements contained in this Secretary&rsquo;s Certificate.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2.&#9;Attached
	hereto as
<U>
	Exhibit A
</U>
	and
<U>
	Exhibit B
</U>
	are true, correct and complete copies of the Company&rsquo;s bylaws (&ldquo;Bylaws&rdquo;)
	and Certificate of Incorporation (&ldquo;Charter&rdquo;), in each case, as amended through the date hereof, and no action has
	been taken by the Company, its directors, officers or stockholders, in contemplation of the filing of any further amendment relating
	to or affecting the Bylaws or Charter.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3.&#9;Attached
	hereto as
<U>
	Exhibit C
</U>
	are true, correct and complete copies of the resolutions duly adopted by the Board of Directors of
	the Company on _____________, at which a quorum was present and acting throughout. Such resolutions have not been amended, modified
	or rescinded and remain in full force and effect and such resolutions are the only resolutions adopted by the Company&rsquo;s
	Board of Directors, or any committee thereof, or the stockholders of the Company relating to or affecting (i) the entering into
	and performance of the Purchase Agreement, or the issuance, offering and sale of the Purchase Shares and the Commitment Shares
	and (ii) and the performance of the Company of its obligation under the Transaction Documents as contemplated therein.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 31.5PT 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 31.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.&#9;As
	of the date hereof, the authorized, issued and reserved capital stock of the Company is as set forth on
<U>
	Exhibit D
</U>
	hereto.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	IN
	WITNESS WHEREOF
</B>
	, I have hereunder signed my name on this ___ day of ____________.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 216PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	_________________________
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 216PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Secretary
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	undersigned as ___________ of
<B>
	SOLIGENIX, INC.
</B>
	, a Delaware corporation, hereby certifies that ____________ is the duly elected,
	appointed, qualified and acting Secretary of _________, and that the signature appearing above is his genuine signature.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 120PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	___________________________________
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 38 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage125"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<U>
	EXHIBIT
	E
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	FORM
	OF LETTER TO THE TRANSFER AGENT FOR THE ISSUANCE OF THE INITIAL COMMITMENT SHARES AT SIGNING OF THE PURCHASE AGREEMENT
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	[COMPANY
	LETTERHEAD]
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	[DATE]
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	[TRANSFER
	AGENT]
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	__________________
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	__________________
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	__________________
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Re:
	Issuance of Common Stock to Lincoln Park Capital Fund, LLC
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dear
	________,
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	behalf of
<B>
	SOLIGENIX, INC.
</B>
	, (the &ldquo;Company&rdquo;), you are hereby instructed to issue
<B>
<U>
	as soon as possible
</U>
</B>
	a share certificate representing an aggregate of 100,000 shares of our common stock in the name of
<B>
<U>
	Lincoln Park Capital
	Fund, LLC
</U>
</B>
	. The share certificate should be dated [DATE OF THE PURCHASE AGREEMENT]. I have included a true and correct
	copy of a unanimous written consent executed by all of the members of the Board of Directors of the Company adopting resolutions
	approving the issuance of these shares. The share certificate should bear the following restrictive legend:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 36PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	THE
	SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE
	STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR
	ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
	OR APPLICABLE STATE SECURITIES LAWS, UNLESS SOLD PURSUANT TO: (1) RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (2)
	AN OPINION OF HOLDER&rsquo;S COUNSEL, IN A CUSTOMARY FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE
	SECURITIES LAWS.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 39 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage126"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	share certificate should be sent
<B>
<U>
	as soon as possible via overnight mail
</U>
</B>
	to the following address:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Lincoln
	Park Capital Fund, LLC
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	440
	North Wells, Suite 410
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chicago,
	IL 60654
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Attention:
	Josh Scheinfeld/Jonathan Cope
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Thank
	you very much for your help. Please call me at ______________ if you have any questions or need anything further.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	SOLIGENIX,
	INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	BY:_____________________________
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	[name]
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	[title]
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage127"></A>
<A NAME="F10K2015EX10XXXII_SOLIGENIX_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_2"></A>
<P STYLE="MARGIN: 0PT 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<B>
	EXHIBIT 10.32
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	REGISTRATION RIGHTS AGREEMENT
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<B>
	REGISTRATION RIGHTS AGREEMENT
</B>
	(this &quot;
<U>
	Agreement
</U>
	&quot;), dated as of March 22, 2016, by and between
<B>
	SOLIGENIX, INC.,
</B>
	a Delaware corporation
	(the &quot;
<U>
	Company
</U>
	&quot;), and
<B>
	LINCOLN PARK CAPITAL FUND, LLC,
</B>
<FONT STYLE="FONT-WEIGHT: NORMAL">
	an Illinois limited
	liability company
</FONT>
	(together with it permitted assigns, the &ldquo;
<U>
	Buyer
</U>
	&rdquo;). Capitalized terms used herein and
	not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties
	hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the &quot;
<U>
	Purchase
	Agreement
</U>
	&quot;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	WHEREAS:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	The Company has agreed, upon the
	terms and subject to the conditions of the Purchase Agreement, to sell to the Buyer up to Twelve Million Dollars ($12,000,000)
	of Purchase Shares and to induce the Buyer to enter into the Purchase Agreement, the Company has agreed to provide certain registration
	rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute
	(collectively, the &quot;
<U>
	Securities Act
</U>
	&quot;), and applicable state securities laws.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<B>
	NOW, THEREFORE,
</B>
	in consideration
	of the promises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency
	of which are hereby acknowledged, the Company and the Buyer hereby agree as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	1.
<U>
	DEFINITIONS
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	As used in this Agreement, the following
	terms shall have the following meanings:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	a. &quot;
<U>
	Investor
</U>
	&quot;
	means the Buyer, any transferee or assignee thereof to whom a Buyer assigns its rights under this Agreement in accordance with
	Section 9 and who agrees to become bound by the provisions of this Agreement, and any transferee or assignee thereof to whom a
	transferee or assignee assigns its rights under this Agreement in accordance with Section 9 and who agrees to become bound by the
	provisions of this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	b. &quot;
<U>
	Person
</U>
	&quot;
	means any individual or entity including but not limited to any corporation, a limited liability company, an association, a partnership,
	an organization, a business, an individual, a governmental or political subdivision thereof or a governmental agency.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	c. &quot;
<U>
	Register
</U>
	,&quot;
	&quot;
<U>
	registered
</U>
	,&quot; and &quot;
<U>
	registration
</U>
	&quot; refer to a registration effected by preparing and filing one
	or more registration statements of the Company in compliance with the Securities Act and pursuant to Rule 415 under the Securities
	Act or any successor rule providing for offering securities on a continuous basis (&quot;
<U>
	Rule 415
</U>
	&quot;), and the declaration
	or ordering of effectiveness of such registration statement(s) by the United States Securities and Exchange Commission (the &quot;
<U>
	SEC
</U>
	&quot;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	d. &quot;
<U>
	Registrable Securities
</U>
	&quot;
	means all of the Initial Commitment Shares, all of the Additional Commitment Shares and all of the Purchase Shares that may, from
	time to time, be issued or become issuable to the Investor under the Purchase Agreement (without regard to any limitation or restriction
	on purchases), and any and all shares of capital stock issued or issuable with respect to the Purchase Shares, the Initial Commitment
	Shares or the Additional Commitment Shares
<B>
</B>
	or the Purchase Agreement as a result of any stock split, stock dividend, recapitalization,
	exchange or similar event or otherwise, without regard to any limitation on purchases under the Purchase Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage128"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	e. &quot;
<U>
	Registration Statement
</U>
	&quot;
	means one or more registration statements of the Company covering only the sale of the Registrable Securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	2.
<U>
	REGISTRATION
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	a.
<U>
	Mandatory Registration.
</U>
	The Company shall, within thirty (30) calendar days after the date hereof, file with the SEC an initial Registration Statement
	covering 5,600,000 of the Registrable Securities so as to permit the resale of such Registrable Securities by the Investor under
	Rule 415 under the Securities Act at then prevailing market prices (and not fixed prices). The initial Registration Statement shall
	register only the Registrable Securities. The Investor and its counsel shall have a reasonable opportunity to review and comment
	upon such Registration Statement and any amendment or supplement to such Registration Statement and any related prospectus prior
	to its filing with the SEC, and the Company shall give due consideration to all such comments. The Investor shall furnish all information
	reasonably requested by the Company for inclusion therein. The Company shall use its best efforts to have the Registration Statement
	and any amendment declared effective by the SEC at the earliest possible date. The Company shall use reasonable best efforts to
	keep the Registration Statement effective pursuant to Rule 415 promulgated under the Securities Act and available for the resale
	by the Investor of all of the Registrable Securities covered thereby at all times until the date on which the Investor shall have
	resold all the Registrable Securities covered thereby and no Available Amount remains under the Purchase Agreement (the &quot;
<U>
	Registration
	Period
</U>
	&quot;). The Registration Statement (including any amendments or supplements thereto and prospectuses contained therein)
	shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary
	to make the statements therein, in light of the circumstances in which they were made, not misleading.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	b.
<U>
	Rule 424 Prospectus
</U>
	.
	The Company shall, as required by applicable securities regulations, from time to time file with the SEC, pursuant to Rule 424
	promulgated under the Securities Act, the prospectus and prospectus supplements, if any, to be used in connection with sales of
	the Registrable Securities under the Registration Statement. The Investor and its counsel shall have a reasonable opportunity to
	review and comment upon such prospectus prior to its filing with the SEC, and the Company shall give due consideration to all such
	comments. The Investor shall use its reasonable best efforts to comment upon such prospectus within one (1) Business Day from the
	date the Investor receives the final pre-filing version of such prospectus.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	c.
<U>
	Sufficient Number of Shares
	Registered
</U>
	. Provided the Company&rsquo;s Certificate of Amendment, as amended, has been amended to increase the number of shares
	of Common Stock, in the event the number of shares available under the Registration Statement is insufficient to cover the Registrable
	Securities, as mutually determined by both the Company and the Investor in consultation with their respective legal counsel, the
	Company shall amend the Registration Statement or file a new Registration Statement (a &rdquo;
<U>
	New Registration Statement
</U>
	&rdquo;),
	so as to cover all of such Registrable Securities (subject to the limitations set forth in Section 2(a)) as soon as practicable,
	but in any event not later than ten (10) Business Days after the necessity therefor arises, subject to any limits that may be imposed
	by the SEC pursuant to Rule 415 under the Securities Act. The Company shall use it reasonable best efforts to cause such amendment
	and/or New Registration Statement to become effective as soon as practicable following the filing thereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage129"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	d.
<U>
	Offering
</U>
	. If the staff
	of the SEC (the &ldquo;
<U>
	Staff
</U>
	&rdquo;) or the SEC seeks to characterize any offering pursuant to a Registration Statement
	filed pursuant to this Agreement as constituting an offering of securities that does not permit such Registration Statement to
	become effective and be used for resales by the Investor under Rule 415 at then-prevailing market prices (and not fixed prices),
	or if after the filing of the initial Registration Statement with the SEC pursuant to Section 2(a), the Company is otherwise required
	by the Staff or the SEC to reduce the number of Registrable Securities included in such initial Registration Statement, then the
	Company shall reduce the number of Registrable Securities to be included in such initial Registration Statement (with the prior
	consent, which shall not be unreasonably withheld, of the Investor and its legal counsel as to the specific Registrable Securities
	to be removed therefrom) until such time as the Staff and the SEC shall so permit such Registration Statement to become effective
	and be used as aforesaid. In the event of any reduction in Registrable Securities pursuant to this paragraph, the Company shall
	file one or more New Registration Statements in accordance with Section 2(c) until such time as all Registrable Securities have
	been included in Registration Statements that have been declared effective and the prospectus contained therein is available for
	use by the Investor. Notwithstanding any provision herein or in the Purchase Agreement to the contrary, the Company&rsquo;s obligations
	to register Registrable Securities (and any related conditions to the Investor&rsquo;s obligations) shall be qualified as necessary
	to comport with any requirement of the SEC or the Staff as addressed in this Section 2(d).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	3.
<U>
	RELATED OBLIGATIONS
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	With respect to the Registration
	Statement and whenever any Registrable Securities are to be registered pursuant to Section 2 including on any New Registration
	Statement, the Company shall use its reasonable best efforts to effect the registration of the Registrable Securities in accordance
	with the intended method of disposition thereof and, pursuant thereto, the Company shall have the following obligations:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	a. The Company shall prepare
	and file with the SEC such amendments (including post-effective amendments) and supplements to any registration statement and the
	prospectus used in connection with such registration statement, which prospectus is to be filed pursuant to Rule 424 promulgated
	under the Securities Act, as may be necessary to keep the Registration Statement or any New Registration Statement effective at
	all times during the Registration Period, and, during such period, comply with the provisions of the Securities Act with respect
	to the disposition of all Registrable Securities of the Company covered by the Registration Statement or any New Registration Statement
	until such time as all of such Registrable Securities shall have been disposed of in accordance with the intended methods of disposition
	by the seller or sellers thereof as set forth in such registration statement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	b. The Company shall permit the
	Investor to review and comment upon the Registration Statement or any New Registration Statement and all amendments and supplements
	thereto at least two (2) Business Days prior to their filing with the SEC, and not file any document in a form to which Investor
	reasonably objects. The Investor shall use its reasonable best efforts to comment upon the Registration Statement or any New Registration
	Statement and any amendments or supplements thereto within two (2) Business Days from the date the Investor receives the final
	version thereof. The Company shall furnish to the Investor, without charge any correspondence from the SEC or the staff of the
	SEC to the Company or its representatives relating to the Registration Statement or any New Registration Statement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	c. Upon request of the Investor,
	the Company shall furnish to the Investor, (i) promptly after the same is prepared and filed with the SEC, at least one copy of
	such registration statement and any amendment(s) thereto, including financial statements and schedules, all documents incorporated
	therein by reference and all exhibits, (ii) upon the effectiveness of any registration statement, a copy of the prospectus included
	in such registration statement and all amendments and supplements thereto (or such other number of copies as the Investor may reasonably
	request) and (iii) such other documents, including copies of any preliminary or final prospectus, as the Investor may reasonably
	request from time to time in order to facilitate the disposition of the Registrable Securities owned by the Investor. For the avoidance
	of doubt, any filing available to the Investor via the SEC&rsquo;s live EDGAR system shall be deemed &ldquo;furnished to the Investor&rdquo;
	hereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage130"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	d. The Company shall use reasonable
	best efforts to (i) register and qualify the Registrable Securities covered by a registration statement under such other securities
	or &quot;blue sky&quot; laws of such jurisdictions in the United States as the Investor reasonably requests, (ii) prepare and file
	in those jurisdictions, such amendments (including post-effective amendments) and supplements to such registrations and qualifications
	as may be necessary to maintain the effectiveness thereof during the Registration Period, (iii) take such other actions as may
	be necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv)
	take all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions;
	provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (x) qualify to do
	business in any jurisdiction where it would not otherwise be required to qualify but for this Section 3(d), (y) subject itself
	to general taxation in any such jurisdiction, or (z) file a general consent to service of process in any such jurisdiction. The
	Company shall promptly notify the Investor who holds Registrable Securities of the receipt by the Company of any notification with
	respect to the suspension of the registration or qualification of any of the Registrable Securities for sale under the securities
	or &quot;blue sky&quot; laws of any jurisdiction in the United States or its receipt of actual notice of the initiation or threatening
	of any proceeding for such purpose.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	e. As promptly as practicable
	after becoming aware of such event or facts, the Company shall notify the Investor in writing of the happening of any event or
	existence of such facts as a result of which the prospectus included in any registration statement, as then in effect, includes
	an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the
	statements therein, in light of the circumstances under which they were made, not misleading, and promptly prepare a supplement
	or amendment to such registration statement to correct such untrue statement or omission, and deliver a copy of such supplement
	or amendment to the Investor (or such other number of copies as the Investor may reasonably request). The Company shall also promptly
	notify the Investor in writing (i) when a prospectus or any prospectus supplement or post-effective amendment has been filed, and
	when a registration statement or any post-effective amendment has become effective (notification of such effectiveness shall be
	delivered to the Investor by email or facsimile on the same day of such effectiveness and by overnight mail), (ii) of any request
	by the SEC for amendments or supplements to any registration statement or related prospectus or related information, and (iii)
	of the Company's reasonable determination that a post-effective amendment to a registration statement would be appropriate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	f. The Company shall use its
	reasonable best efforts to prevent the issuance of any stop order or other suspension of effectiveness of any registration statement,
	or the suspension of the qualification of any Registrable Securities for sale in any jurisdiction and, if such an order or suspension
	is issued, to obtain the withdrawal of such order or suspension at the earliest possible moment and to notify the Investor of the
	issuance of such order and the resolution thereof or its receipt of actual notice of the initiation or threat of any proceeding
	for such purpose.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	g. The Company shall (i) cause
	all the Registrable Securities to be listed on each securities exchange on which securities of the same class or series issued
	by the Company are then listed, if any, if the listing of such Registrable Securities is then permitted under the rules of such
	exchange, or (ii) secure designation and quotation of all the Registrable Securities on the Principal Market. The Company shall
	pay all fees and expenses in connection with satisfying its obligation under this Section.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	h. The Company shall cooperate
	with the Investor to facilitate the timely preparation and delivery of certificates (not bearing any restrictive legend) representing
	the Registrable Securities to be offered pursuant to any registration statement and enable such certificates to be in such denominations
	or amounts as the Investor may reasonably request and registered in such names as the Investor may request.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage131"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	i. The Company shall at all times
	provide a transfer agent and registrar with respect to its Common Stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	j. If reasonably requested by
	the Investor, the Company shall (i) immediately incorporate in a prospectus supplement or post-effective amendment such information
	as the Investor believes should be included therein relating to the sale and distribution of Registrable Securities, including,
	without limitation, information with respect to the number of Registrable Securities being sold, the purchase price being paid
	therefor and any other terms of the offering of the Registrable Securities; (ii) make all required filings of such prospectus supplement
	or post-effective amendment as soon as practicable upon notification of the matters to be incorporated in such prospectus supplement
	or post-effective amendment; and (iii) supplement or make amendments to any registration statement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	k. The Company shall use its
	reasonable best efforts to cause the Registrable Securities covered by any registration statement to be registered with or approved
	by such other governmental agencies or authorities as may be necessary to consummate the disposition of such Registrable Securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	l. Within one (1) Business Day
	after any registration statement which includes the Registrable Securities is ordered effective by the SEC, the Company shall deliver,
	and shall cause legal counsel for the Company to deliver, to the transfer agent for such Registrable Securities (with copies to
	the Investor) confirmation that such registration statement has been declared effective by the SEC in the form attached hereto
	as
<U>
	Exhibit A
</U>
	. Thereafter, if requested by the Buyer at any time, the Company shall require its counsel to deliver to the
	Buyer a written confirmation whether or not the effectiveness of such registration statement has lapsed at any time for any reason
	(including, without limitation, the issuance of a stop order) and whether or not the registration statement is current and available
	to the Buyer for sale of all of the Registrable Securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	m. The Company shall take all
	other reasonable actions necessary to expedite and facilitate disposition by the Investor of Registrable Securities pursuant to
	any registration statement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	4.
<U>
	OBLIGATIONS OF THE INVESTOR
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	a. The Company shall notify the
	Investor in writing of the information the Company reasonably requires from the Investor in connection with any registration statement
	hereunder. Within two (2) Business Days of the Company&rsquo;s request, the Investor shall furnish to the Company such information
	regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held
	by it as shall be reasonably required to effect the registration of such Registrable Securities and shall execute such documents
	in connection with such registration as the Company may reasonably request.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	b. The Investor agrees to cooperate
	with the Company as reasonably requested by the Company in connection with the preparation and filing of any registration statement
	hereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage132"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	c. The Investor agrees that,
	upon receipt of any notice from the Company of the happening of any event or existence of facts of the kind described in Section
	3(f) or the first sentence of Section 3(e), the Investor will immediately discontinue disposition of Registrable Securities pursuant
	to any registration statement(s) covering such Registrable Securities until the Investor's receipt of the copies of the supplemented
	or amended prospectus contemplated by Section 3(f) or the first sentence of Section 3(e). Notwithstanding anything to the contrary,
	the Company shall cause its transfer agent to promptly deliver shares of Common Stock without any restrictive legend in accordance
	with the terms of the Purchase Agreement in connection with any sale of Registrable Securities with respect to which an Investor
	has entered into a contract for sale prior to the Investor's receipt of a notice from the Company of the happening of any event
	of the kind described in Section 3(f) or the first sentence of Section 3(e) and for which the Investor has not yet settled.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	5.
<U>
	EXPENSES OF REGISTRATION
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	All reasonable expenses, other than
	sales or brokerage commissions, incurred in connection with registrations, filings or qualifications pursuant to Sections 2 and
	3, including, without limitation, all registration, listing and qualifications fees, printers and accounting fees, and fees and
	disbursements of counsel for the Company, shall be paid by the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	6.
<U>
	INDEMNIFICATION
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	a. To the fullest extent permitted
	by law, the Company will, and hereby does, indemnify, hold harmless and defend the Investor, each Person, if any, who controls
	the Investor, the members, the directors, officers, partners, employees, agents, representatives of the Investor and each Person,
	if any, who controls the Investor within the meaning of the Securities Act or the Securities Exchange Act of 1934, as amended (the
	&quot;
<U>
	Exchange Act
</U>
	&quot;) (each, an &quot;
<U>
	Indemnified Person
</U>
	&quot;), against any losses, claims, damages, liabilities,
	judgments, fines, penalties, charges, costs, attorneys' fees, amounts paid in settlement or expenses, joint or several, (collectively,
	&quot;
<U>
	Claims
</U>
	&quot;) incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation
	or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency, body or the
	SEC, whether pending or threatened, whether or not an indemnified party is or may be a party thereto (&quot;
<U>
	Indemnified Damages
</U>
	&quot;),
	to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in
	respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in the
	Registration Statement, any New Registration Statement or any post-effective amendment thereto or in any filing made in connection
	with the qualification of the offering under the securities or other &quot;blue sky&quot; laws of any jurisdiction in which Registrable
	Securities are offered (&quot;
<U>
	Blue Sky Filing
</U>
	&quot;), or the omission or alleged omission to state a material fact required
	to be stated therein or necessary to make the statements therein not misleading, (ii) any untrue statement or alleged untrue statement
	of a material fact contained in the final prospectus (as amended or supplemented, if the Company files any amendment thereof or
	supplement thereto with the SEC) or the omission or alleged omission to state therein any material fact necessary to make the statements
	made therein, in light of the circumstances under which the statements therein were made, not misleading, (iii) any violation or
	alleged violation by the Company of the Securities Act, the Exchange Act, any other law, including, without limitation, any state
	securities law, or any rule or regulation thereunder relating to the offer or sale of the Registrable Securities pursuant to the
	Registration Statement or any New Registration Statement or (iv) any material violation by the Company of this Agreement (the matters
	in the foregoing clauses (i) through (iv) being, collectively, &quot;
<U>
	Violations
</U>
	&quot;). The Company shall reimburse each
	Indemnified Person promptly as such expenses are incurred and are due and payable, for any reasonable legal fees or other reasonable
	expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary
	contained herein, the indemnification agreement contained in this Section 6(a): (i) shall not apply to a Claim by an Indemnified
	Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with information about the Investor
	furnished in writing to the Company by such Indemnified Person expressly for use in connection with the preparation of the Registration
	Statement, any New Registration Statement or any such amendment thereof or supplement thereto, if such prospectus was timely made
	available by the Company pursuant to Section 3(c) or Section 3(e); (ii) with respect to any superseded prospectus, shall not inure
	to the benefit of any such person from whom the person asserting any such Claim purchased the Registrable Securities that are the
	subject thereof (or to the benefit of any person controlling such person) if the untrue statement or omission of material fact
	contained in the superseded prospectus was corrected in the revised prospectus, as then amended or supplemented, if such revised
	prospectus was timely made available by the Company pursuant to Section 3(c) or Section 3(e), and the Indemnified Person was promptly
	advised in writing not to use the incorrect prospectus prior to the use giving rise to a violation and such Indemnified Person,
	notwithstanding such advice, used it; (iii) shall not be available to the extent such Claim is based on a failure of the Investor
	to deliver or to cause to be delivered the prospectus made available by the Company, if such prospectus was timely made available
	by the Company pursuant to Section 3(c) or Section 3(e); and (iv) shall not apply to amounts paid in settlement of any Claim if
	such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld.
	Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person
	and shall survive the transfer of the Registrable Securities by the Investor pursuant to Section 9.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage133"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	b. In connection with the Registration
	Statement or any New Registration Statement, the Investor agrees to indemnify, hold harmless and defend, to the same extent and
	in the same manner as is set forth in Section 6(a), the Company, each of its directors, each of its officers who signs the Registration
	Statement or any New Registration Statement, each Person, if any, who controls the Company within the meaning of the Securities
	Act or the Exchange Act (collectively and together with an Indemnified Person, an &quot;
<U>
	Indemnified Party
</U>
	&quot;), against
	any Claim or Indemnified Damages to which any of them may become subject, under the Securities Act, the Exchange Act or otherwise,
	insofar as such Claim or Indemnified Damages arise out of or are based upon any Violation, in each case to the extent, and only
	to the extent, that such Violation occurs in reliance upon and in conformity with written information about the Investor set forth
	on
<U>
	Exhibit B
</U>
	attached hereto and furnished to the Company by the Investor expressly for use in connection with such registration
	statement; and, subject to Section 6(d), the Investor will reimburse any legal or other expenses reasonably incurred by them in
	connection with investigating or defending any such Claim; provided, however, that the indemnity agreement contained in this Section
	6(b) and the agreement with respect to contribution contained in Section 7 shall not apply to amounts paid in settlement of any
	Claim if such settlement is effected without the prior written consent of the Investor, which consent shall not be unreasonably
	withheld; provided, further, however, that the Investor shall be liable under this Section 6(b) for only that amount of a Claim
	or Indemnified Damages as does not exceed the net proceeds to the Investor as a result of the sale of Registrable Securities pursuant
	to such registration statement. Such indemnity shall remain in full force and effect regardless of any investigation made by or
	on behalf of such Indemnified Party and shall survive the transfer of the Registrable Securities by the Investor pursuant to Section
	9.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	c. Promptly after receipt by
	an Indemnified Person or Indemnified Party under this Section 6 of notice of the commencement of any action or proceeding (including
	any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall, if a Claim in respect
	thereof is to be made against any indemnifying party under this Section 6, deliver to the indemnifying party a written notice of
	the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying
	party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel
	mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the case may be; provided,
	however, that an Indemnified Person or Indemnified Party shall have the right to retain its own counsel with the reasonable fees
	and expenses to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying party,
	the representation by such counsel of the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate
	due to actual or potential differing interests between such Indemnified Person or Indemnified Party and any other party represented
	by such counsel in such proceeding. It is understood and agreed, however, that the Indemnifying Party shall only be responsible
	to pay the reasonable fees and expenses of one law firm for all Indemnified Parties. The Indemnified Party or Indemnified Person
	shall cooperate fully with the indemnifying party in connection with any negotiation or defense of any such action or claim by
	the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnified Party
	or Indemnified Person which relates to such action or claim. The indemnifying party shall keep the Indemnified Party or Indemnified
	Person fully apprised at all times as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying
	party shall be liable for any settlement of any action, claim or proceeding effected without its written consent, provided, however,
	that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without
	the consent of the Indemnified Party or Indemnified Person, consent to entry of any judgment or enter into any settlement or other
	compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified
	Party or Indemnified Person of a release from all liability in respect to such claim or litigation. Following indemnification as
	provided for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified Person
	with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made. The failure
	to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve
	such indemnifying party of any liability to the Indemnified Person or Indemnified Party under this Section 6, except to the extent
	that the indemnifying party is prejudiced in its ability to defend such action.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage134"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	d. The indemnification required
	by this Section 6 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as
	and when bills are received or Indemnified Damages are incurred.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	e. The indemnity agreements contained
	herein shall be in addition to (i) any cause of action or similar right of the Indemnified Party or Indemnified Person against
	the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant to the law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	7.
<U>
	CONTRIBUTION
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	To the extent any indemnification
	by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect
	to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by law; provided, however,
	that: (i) no seller of Registrable Securities guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
	Securities Act) shall be entitled to contribution from any seller of Registrable Securities who was not guilty of fraudulent misrepresentation;
	and (ii) contribution by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds received
	by such seller from the sale of such Registrable Securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	8.
<U>
	REPORTS AND DISCLOSURE
	UNDER THE SECURITIES ACTS
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	With a view to making available
	to the Investor the benefits of Rule 144 promulgated under the Securities Act or any other similar rule or regulation of the SEC
	that may at any time permit the Investor to sell securities of the Company to the public without registration (&quot;
<U>
	Rule 144
</U>
	&quot;),
	the Company agrees, at the Company&rsquo;s sole expense, to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	a. make and keep public information
	available, as those terms are understood and defined in Rule 144;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage135"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	b. file with the SEC in a timely
	manner all reports and other documents required of the Company under the Securities Act and the Exchange Act so long as the Company
	remains subject to such requirements and the filing of such reports and other documents is required for the applicable provisions
	of Rule 144;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	c. furnish to the Investor so
	long as the Investor owns Registrable Securities, promptly upon request, (i) a written statement by the Company that it has complied
	with the reporting and or disclosure provisions of Rule 144, the Securities Act and the Exchange Act, (ii) a copy of the most recent
	annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information
	as may be reasonably requested to permit the Investor to sell such securities pursuant to Rule 144 without registration; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	d. take such additional action as is requested
	by the Investor to enable the Investor to sell the Registrable Securities pursuant to Rule 144, including, without limitation,
	delivering all such legal opinions, consents, certificates, resolutions and instructions to the Company&rsquo;s Transfer Agent
	as may be requested from time to time by the Investor and otherwise fully cooperate with Investor and Investor&rsquo;s broker to
	effect such sale of securities pursuant to Rule 144.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	The Company agrees that damages
	may be an inadequate remedy for any breach of the terms and provisions of this Section 8 and that Investor shall, whether or not
	it is pursuing any remedies at law, be entitled to equitable relief in the form of a preliminary or permanent injunctions, without
	having to post any bond or other security, upon any breach or threatened breach of any such terms or provisions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	9.
<U>
	ASSIGNMENT OF REGISTRATION RIGHTS
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	The Company shall not assign this
	Agreement or any rights or obligations hereunder without the prior written consent of the Investor. The Investor may not assign
	its rights under this Agreement without the written consent of the Company, other than to an affiliate of the Investor controlled
	by Jonathan Cope or Josh Scheinfeld.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	10.
<U>
	AMENDMENT OF REGISTRATION
	RIGHTS
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	No provision of this Agreement may
	be amended or waived by the parties from and after the date that is one Business Day immediately preceding the filing of the initial
	Registration Statement with the SEC. Subject to the immediately preceding sentence, no provision of this Agreement may be (i) amended
	other than by a written instrument signed by both parties hereto or (ii) waived other than in a written instrument signed by the
	party against whom enforcement of such waiver is sought. Failure of any party to exercise any right or remedy under this Agreement
	or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	11.
<U>
	MISCELLANEOUS
</U>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	a. A Person is deemed to be a
	holder of Registrable Securities whenever such Person owns or is deemed to own of record such Registrable Securities. If the Company
	receives conflicting instructions, notices or elections from two or more Persons with respect to the same Registrable Securities,
	the Company shall act upon the basis of instructions, notice or election received from the registered owner of such Registrable
	Securities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage136"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	b. Any notices, consents, waivers
	or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed
	to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile or email (provided
	confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); or (iii) one (1)
	Business Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party
	to receive the same. The addresses for such communications shall be:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY">
	If to the Company:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-INDENT: 36PT">
	Soligenix, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-INDENT: 36PT">
	29 Emmons Drive, Suite C-10
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-INDENT: 36PT">
	Princeton, New Jersey 08540
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-INDENT: 36PT">
	Telephone:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 609-538-8200
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-INDENT: 36PT">
	Facsimile:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;609-452-6467
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-INDENT: 36PT">
	E-mail:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;cschaber@soligenix.com
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-INDENT: 36PT">
	Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Christopher J. Schaber, Ph.D.,
	CEO
</P>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY">
	With a copy to (which shall not constitute
	notice or service of process):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
	Duane Morris LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
	200 South Biscayne Boulevard, Suite 3400
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
	Miami, Florida 33131-2318
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
	Telephone:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 305-960-2200
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
	Facsimile:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;305-397-1882
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
	E-mail:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ljcroland@duanemorris.com
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
	Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leslie J. Croland, Esq.
</P>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	If to the Investor:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
	Lincoln Park Capital Fund, LLC
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
	440 North Wells, Suite 410
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
	Chicago, IL 60654
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
	Telephone:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 312-822-9300
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
	Facsimile:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;312-822-9301
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
	E-mail:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;jscheinfeld@lpcfunds.com/jcope@lpcfunds.com
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY">
	Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Josh Scheinfeld/Jonathan Cope
</P>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	With a copy to (which shall not
	constitute notice or service of process):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	Greenberg Traurig, LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	The MetLife Building
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	200 Park Avenue
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	New York, NY 10166
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_36"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	Telephone:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (212) 801-9200
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	Facsimile:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(212) 801-6400
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	E-mail:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;marsicoa@gtlaw.com
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anthony J.
	Marsico, Esq.
</P>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 36PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	or at such other address and/or facsimile number and/or
	to the attention of such other person as the recipient party has specified by written notice given to each other party three (3)
	Business Days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice,
	consent, waiver or other communication, (B) mechanically or electronically generated by the sender's facsimile machine or email
	account containing the time, date, recipient facsimile number or email address, as applicable, and an image of the first page of
	such transmission or (C) provided by a nationally recognized overnight delivery service, shall be rebuttable evidence of personal
	service, receipt by facsimile or receipt from a nationally recognized overnight delivery service in accordance with clause (i),
	(ii) or (iii) above, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage137"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	c. The corporate laws of the
	State of Delaware shall govern all issues concerning the relative rights of the Company and its stockholders. All other questions
	concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws
	of the State of Illinois, without giving effect to any choice of law or conflict of law provision or rule (whether of the State
	of Illinois or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State
	of Illinois. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting the State
	of Illinois, County of Cook, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
	hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim
	that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an
	inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal
	service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such
	party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient
	service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
	in any manner permitted by law. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such
	invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction
	or the validity or enforceability of any provision of this Agreement in any other jurisdiction.
<B>
	EACH PARTY HEREBY IRREVOCABLY
	WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
	HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	d. This Agreement and the Purchase
	Agreement constitute the entire agreement among the parties hereto with respect to the subject matter hereof and thereof. There
	are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein and therein. This Agreement
	and the Purchase Agreement supersede all prior agreements and understandings among the parties hereto with respect to the subject
	matter hereof and thereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	e. Subject to the requirements
	of Section 9, this Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of
	the parties hereto.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	f. The headings in this Agreement
	are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	g. This Agreement may be executed
	in identical counterparts, each of which shall be deemed an original but all of which shall constitute one and the same agreement.
	This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile transmission or by e-mail in
	a &ldquo;.pdf&rdquo; format data file of a copy of this Agreement bearing the signature of the party so delivering this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	h. Each party shall do and perform,
	or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates,
	instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes
	of this Agreement and the consummation of the transactions contemplated hereby.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	i. The language used in this
	Agreement will be deemed to be the language chosen by the parties to express their mutual intent and no rules of strict construction
	will be applied against any party.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT">
	j. This Agreement is intended
	for the benefit of the parties hereto and their respective successors and permitted assigns, and is not for the benefit of, nor
	may any provision hereof be enforced by, any other Person.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	* * * * * *
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage138"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
<B>
	IN WITNESS WHEREOF,
</B>
	the parties have caused this Registration Rights Agreement to be duly executed as of day and year first above written.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-DECORATION: UNDERLINE; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<U>
	THE COMPANY
</U>
	:
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	SOLIGENIX, INC.
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT; WIDTH: 60%">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT; WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT; WIDTH: 34%; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Christopher J. Schaber
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	Name:
</TD>
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Christopher J. Schaber, Ph.D.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	Title:
</TD>
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	President and Chief Executive Officer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-DECORATION: UNDERLINE; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<U>
	BUYER:
</U>
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	LINCOLN PARK CAPITAL FUND, LLC
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	BY: LINCOLN PARK CAPITAL, LLC
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	BY: ROCKLEDGE CAPITAL CORPORATION
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/ Josh Scheinfeld
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	Name:
</TD>
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Josh Scheinfeld
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	Title:
</TD>
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	President
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage139"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
<U>
	EXHIBIT A
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
<U>
	TO REGISTRATION RIGHTS AGREEMENT
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	FORM OF NOTICE OF EFFECTIVENESS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	OF REGISTRATION STATEMENT
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	[Date]
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	[TRANSFER AGENT]
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	___________________
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	___________________
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Re: [__________]
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Ladies and Gentlemen:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 40.5PT">
	We are counsel to Soligenix, Inc.,
	a Delaware corporation (the &ldquo;
<U>
	Company
</U>
	&rdquo;), and have represented the Company in connection with that certain Purchase
	Agreement, dated as of March 22, 2016 (the &ldquo;
<U>
	Purchase Agreement
</U>
	&rdquo;), entered into by and between the Company and
	Lincoln Park Capital Fund, LLC (the &ldquo;
<U>
	Buyer
</U>
	&rdquo;) pursuant to which the Company has agreed to issue to the Buyer
	shares of the Company's Common Stock, par value $0.001 per share (the &ldquo;
<U>
	Common Stock
</U>
	&rdquo;), in an amount up to Twelve
	Million Dollars ($12,000,000) (the &ldquo;
<U>
	Purchase Shares
</U>
	&rdquo;), in accordance with the terms of the Purchase Agreement.
	In connection with the transactions contemplated by the
<B>
</B>
	Purchase Agreement, the Company has registered with the U.S. Securities
	&amp; Exchange Commission the following shares of Common Stock:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -36PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 36PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-TOP: 0PT; PADDING-BOTTOM: 0PT">
</TD>
<TD STYLE="WIDTH: 36PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-TOP: 0PT; PADDING-BOTTOM: 0PT">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-TOP: 0PT; PADDING-BOTTOM: 0PT">
	5,000,000 shares of Common Stock to be issued to the Buyer upon purchase from the Company by the
	Buyer from time to time (the
<B>
</B>
	&ldquo;
<U>
	Purchase Shares
</U>
	&rdquo;).
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -36PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 36PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-TOP: 0PT; PADDING-BOTTOM: 0PT">
</TD>
<TD STYLE="WIDTH: 36PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-TOP: 0PT; PADDING-BOTTOM: 0PT">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-TOP: 0PT; PADDING-BOTTOM: 0PT">
	100,000 shares of Common Stock that have been issued to the Buyer as a commitment fee (the &ldquo;
<U>
	Initial
	Commitment Shares
</U>
	&rdquo;).
<B>
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 72PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -36PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 36PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-TOP: 0PT; PADDING-BOTTOM: 0PT">
</TD>
<TD STYLE="WIDTH: 36PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-TOP: 0PT; PADDING-BOTTOM: 0PT">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-TOP: 0PT; PADDING-BOTTOM: 0PT">
	500,000 shares of Common Stock that may be issued to the Buyer as a commitment fee from time to
	time (the &ldquo;
<U>
	Additional Commitment Shares
</U>
	&rdquo; and, collectively with the Initial Commitment Shares, the &ldquo;
<U>
	Commitment
	Shares
</U>
	&rdquo;).
<B>
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Pursuant to the Purchase Agreement, the Company also
	has entered into a Registration Rights Agreement, dated as of March 22, 2016 with the Buyer (the &ldquo;
<U>
	Registration Rights
	Agreement
</U>
	&rdquo;) pursuant to which the Company agreed, among other things, to register the Purchase Shares and the Commitment
	Shares under the Securities Act of 1933, as amended (the &ldquo;
<U>
	Securities Act
</U>
	&rdquo;). In connection with the Company's
	obligations under the Purchase Agreement and the Registration Rights Agreement, on [_____________], 2016, the Company filed a Registration
	Statement (File No. 333-[_________]) (the &ldquo;
<U>
	Registration Statement
</U>
	&rdquo;) with the Securities and Exchange Commission
	(the &ldquo;
<U>
	SEC
</U>
	&rdquo;) relating to the resale of the Purchase Shares and the Commitment Shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	In connection with
	the foregoing, we advise you that a member of the SEC's staff has advised us by telephone that the SEC has entered an order declaring
	the Registration Statement effective under the Securities Act at [_____] [A.M./P.M.] on [__________], 201[__] and we have no knowledge,
	after telephonic inquiry of a member of the SEC's staff, that any stop order suspending its effectiveness has been issued or that
	any proceedings for that purpose are pending before, or threatened by, the SEC and the Purchase Shares and the Commitment Shares
	are available for resale under the Securities Act pursuant to the Registration Statement and may be issued without any restrictive
	legend.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Very truly yours,
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT">
	[Company Counsel]
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT; WIDTH: 60%">
	&nbsp;
</TD>
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT; WIDTH: 4%">
<FONT STYLE="FONT-SIZE: 10PT">
	By:
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0PT; PADDING-LEFT: 0PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: 0PT; WIDTH: 36%; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	cc:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lincoln
	Park Capital Fund, LLC
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 13 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1.5PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage140"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<U>
	EXHIBIT B
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
<U>
	TO REGISTRATION RIGHTS AGREEMENT
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Information About The Investor Furnished To The Company
	By The Investor
</B>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Expressly For Use In Connection With The Registration
	Statement
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Information With Respect to Lincoln Park Capital
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As of the date of the Purchase Agreement,
	Lincoln Park Capital Fund, LLC, beneficially owned 100,000 shares of our common stock. Josh Scheinfeld and Jonathan Cope, the
	Managing Members of Lincoln Park Capital, LLC, the manager of Lincoln Park Capital Fund, LLC, are deemed to be beneficial owners
	of all of the shares of common stock owned by Lincoln Park Capital Fund, LLC. Messrs. Cope and Scheinfeld have shared voting and
	investment power over the shares being offered under the prospectus filed with the SEC in connection with the transactions contemplated
	under the Purchase Agreement. Lincoln Park Capital, LLC is not a licensed broker dealer or an affiliate of a licensed broker dealer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.5PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage141"></A>
<A NAME="F10K2015EX21I_SOLIGENIX_HTM"></A>
<EFX_EXHIBIT_21>
<A NAME="FIS_EXHIBIT_21"></A>
<EFX_SUBSIDIARIES>
<A NAME="FIS_SUBSIDIARIES"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	EXHIBIT 21.1
</B>
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	SUBSIDIARIES
	OF SOLIGENIX, INC.
</FONT>
</P>
<P STYLE="FONT: BOLD 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	following represents a list of Soligenix, Inc.&rsquo;s subsidiaries:
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Name
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	Ownership
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.5PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.5PT SOLID">
	State of Incorporation
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 76%; TEXT-ALIGN: LEFT">
	Enteron Pharmaceuticals, Inc.
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	100.00
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: CENTER">
	Delaware
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Orasomal Technologies Inc.
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	75.30
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	Delaware
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	DOR BioDefense Corp.
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	Delaware
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Soligenix BioPharma Canada Incorporated
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	Canada
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Soligenix UK Limited
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	United&nbsp;Kingdom
</TD>
</TR>
</TABLE>
</EFX_SUBSIDIARIES>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_21>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage142"></A>
<A NAME="F10K2015EX23I_SOLIGENIX_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	EXHIBIT
	23.1
</B>
</FONT>
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	CONSENT
	OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</B>
</FONT>
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	We
	consent to the incorporation by reference in the Registration Statements of Soligenix, Inc. on Form S-8 (Nos.
	333-130801, 333-196941 and 333-208515) of our report dated March 24, 2016, on our audits of the consolidated financial statements
	as of December 31, 2015 and 2014 and for each of the years then ended, which report is included in this Annual Report on Form
	10-K to be filed on or about March 24, 2016.
</FONT>
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/ EisnerAmper LLP&nbsp;
</FONT>
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Philadelphia,
	Pennsylvania
</FONT>
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	March
	24, 2016
</FONT>
</P>
</EFX_EXPERTS_CONSENT>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage143"></A>
<A NAME="F10K2015EX31I_SOLIGENIX_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	EXHIBIT 31.1
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	OF THE SECURITIES EXCHANGE ACT OF
	1934
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	I, Christopher J. Schaber, Ph.D., certify that:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 98%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	I have reviewed this Form 10-K of the Soligenix, Inc. for the fiscal year ended December 31, 2015;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 98%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 98%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 98%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	a.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	b.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	c.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	d.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 98%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	a.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	b.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 65%; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	March 24, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 35%; BORDER-BOTTOM: BLACK 1.5PT SOLID; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	/s/ Christopher J. Schaber
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Christopher J. Schaber, Ph.D.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	President and Chief Executive Officer
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage144"></A>
<A NAME="F10K2015EX31II_SOLIGENIX_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	EXHIBIT 31.2
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	OF THE SECURITIES EXCHANGE ACT OF
	1934
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	I, Joseph M. Warusz, certify that:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 98%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	I have reviewed this Form 10-K of the Soligenix, Inc. for the fiscal year ended December 31, 2015;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 98%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 98%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 98%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	a.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	b.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	c.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	d.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 98%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	a.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	b.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 65%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	March 24, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 35%; BORDER-BOTTOM: BLACK 1.5PT SOLID; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	/s/ Joseph M. Warusz
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Joseph M. Warusz, CPA
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Vice Presient of Finance,&nbsp; Acting
	Chief Financial Officer and Corporate Secretary
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage145"></A>
<A NAME="F10K2015EX32I_SOLIGENIX_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	EXHIBIT 32.1
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION PURSUANT TO 18 U.S.C.
	SECTION 1350, AS ADOPTED
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY
	ACT OF 2002
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In connection with this Form 10-K of
	Soligenix, Inc. (the &ldquo;Company&rdquo;) for the fiscal year ended December 31, 2015, as filed with the Securities and Exchange
	Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350,
	that:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 98%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 98%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 65%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	March 24, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 35%; BORDER-BOTTOM: BLACK 1.5PT SOLID; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	/s/ Christopher J. Schaber
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Christopher J. Schaber, Ph.D.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	President and Chief Executive Officer
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT/107% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 8PT">
	&nbsp;
</P>
</EFX_EXHIBIT_32>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage146"></A>
<A NAME="F10K2015EX32II_SOLIGENIX_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32_2"></A>
<P STYLE="FONT: 10PT/107% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	EXHIBIT 32.2
</B>
</P>
<P STYLE="FONT: 10PT/107% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_4"></A>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATION PURSUANT TO 18 U.S.C.
	SECTION 1350, AS ADOPTED
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY
	ACT OF 2002
</B>
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	In connection with this Form 10-K of
	Soligenix, Inc. (the &ldquo;Company&rdquo;) for the fiscal year ended December 31, 2015, as filed with the Securities and Exchange
	Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350,
	that:
</P>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 98%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2.&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 98%; TEXT-ALIGN: JUSTIFY; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 65%; LINE-HEIGHT: 107%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	March 24, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 35%; BORDER-BOTTOM: BLACK 1.5PT SOLID; LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	/s/ Joseph M. Warusz
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Joseph M. Warusz, CPA
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD STYLE="LINE-HEIGHT: 107%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Vice Presient of Finance,&nbsp;Acting
	Chief Financial Officer and Corporate Secretary
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="LINE-HEIGHT: 107%">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT: 10PT/NORMAL TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/107% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 8PT">
	&nbsp;
</P>
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
